NCT01975389,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,AL,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,AL,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT02164513,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT02182830,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02528253,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01663402,Sanofi,False,AL,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01652872,Amgen,False,AL,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,AL,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT02573311,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT02573311,True,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],"January 25, 2016",18,9223372036854775807,Male,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02487446,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,AL,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT01968967,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01272037,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02590432,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02367456,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02367456,True,"A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients",Myelodysplastic Syndrome,Drug:PF-04449913; Drug:Azacitidine; Drug:PF-04449913 Placebo,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02343458,"Pearl Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02343458,True,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",COPD,Drug:GFF MDI (PT003); Drug:FF MDI (PT005); Drug:GP MDI (PT001); Drug:Placebo MDI,[],"September 28, 2015",40,80,Both,False
NCT02258542,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02194699,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02092467,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,AL,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,AL,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01751906,Abbott Vascular,False,AL,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,AL,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,AL,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01546038,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00547469,Dynogen Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT00547469,True,A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females,Irritable Bowel Syndrome,Drug:DDP733,[],"April 7, 2008",18,65,Female,False
NCT02674386,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02640612,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02638129,Takeda,False,AL,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02607865,Novo Nordisk A/S,False,AL,https://ClinicalTrials.gov/show/NCT02607865,True,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:sitagliptin; Drug:placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02584660,"Janssen Scientific Affairs, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02584660,True,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,Pulmonary Embolism,Drug:Rivaroxaban; Drug:Standard-of-care,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02557100,Bristol-Myers Squibb,False,AL,https://ClinicalTrials.gov/show/NCT02557100,True,Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Adalimumab; Drug:Methotrexate,"[u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Integral Rheumatology & Immunology Specialists', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Altoona Center For Clinical Research', u'Local Institution', u'Local Institution']","January 26, 2016",18,9223372036854775807,Both,False
NCT02552212,UCB BIOSCIENCES GmbH,False,AL,https://ClinicalTrials.gov/show/NCT02552212,True,Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS,Axial Spondyloarthritis; Nonradiographic Axial Spondyloarthritis; Nr-axSpA,Biological:Certolizumab Pegol; Other:Placebo,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02536508,"Pearl Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02536508,True,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COPD,Drug:BGF MDI (PT010) 320/14.4/9.6 g; Drug:GFF MDI (PT003) 14.4/9.6 g; Drug:BFF MDI (PT009) 320/9.6 g,[],"January 6, 2016",40,80,Both,False
NCT02528188,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02470585,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02373813,Amgen,False,AL,https://ClinicalTrials.gov/show/NCT02373813,True,Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission,Rheumatoid Arthritis,Drug:etanercept pre-filled syringe sq injection; Drug:Oral methotrexate; Drug:Placebo for etanercept sq injection; Drug:Placebo for methotrexate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02364999,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02364999,True,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02342548,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02342548,True,"Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021",Huntington's Disease,Drug:20 mg BID of PF-02545920,[],"January 19, 2016",30,66,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02197130,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02197130,True,"Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease",Huntington's Disease,Drug:PF-02545920; Drug:PF-02545920; Other:Placebo,[],"January 19, 2016",30,65,Both,False
NCT02173379,Abbott Vascular,False,AL,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02138916,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02104817,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02089217,"Thomas G. Brott, M.D.",False,AL,https://ClinicalTrials.gov/show/NCT02089217,True,Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial,Carotid Stenosis,Procedure:Carotid endarterectomy; Device:Carotid stenting,[],"January 27, 2016",35,9223372036854775807,Both,False
NCT02025751,Evoke Pharma,False,AL,https://ClinicalTrials.gov/show/NCT02025751,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Male,False
NCT02025725,Evoke Pharma,False,AL,https://ClinicalTrials.gov/show/NCT02025725,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Female,False
NCT01897532,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01705977,"Human Genome Sciences Inc., a GSK Company",False,AL,https://ClinicalTrials.gov/show/NCT01705977,True,Belimumab Assessment of Safety in SLE,Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Other:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01274338,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01163253,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00736749,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT00351611,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),True,AL,https://ClinicalTrials.gov/show/NCT00042289,True,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],"September 2, 2015",0,9223372036854775807,Female,False
NCT02672111,Braeburn Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02672111,True,Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder,Opioid Use Disorder,Drug:CAM2038 (buprenorphine FluidCrystal once-weekly injection depot); Drug:CAM2038 (buprenorphine FluidCrystal once-monthly injection depot),[],"February 3, 2016",18,65,Both,True
NCT02671981,Radiation Therapy Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02651584,Braeburn Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02651584,True,"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence",Opioid Use Disorders,Drug:CAM2038 subcutaneous injection; Drug:SL BPN tablets; Drug:placebo subcutaneous (SC) injections; Drug:SL placebo tablets,[],"February 3, 2016",18,65,Both,True
NCT02638805,Intarcia Therapeutics,False,AL,https://ClinicalTrials.gov/show/NCT02638805,True,Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide,"Diabetes Mellitus, Type 2",Drug:ITCA 650 20/60 mcg/day; Drug:ITCA 650 60 mcg/day,[],"February 3, 2016",18,80,Both,False
NCT02604680,Braintree Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT02604680,True,A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris,Acne Vulgaris,Drug:BLI1100-1; Drug:BLI1100-2; Drug:BLI1100-3; Drug:Control group; Drug:Placebo,[],"November 12, 2015",12,45,Both,False
NCT02574520,Durect,False,AL,https://ClinicalTrials.gov/show/NCT02574520,True,Trial of Extended Release Bupivacaine for Pain Relief After Surgery,Post Operative Pain,Drug:SABER-Bupivacaine; Drug:Placebo (Saline),"[u'Durect Study Site 04', u'Durect Study Site 03', u'Durect Study Site 08', u'DURECT Study Site 01']","December 16, 2015",18,9223372036854775807,Both,False
NCT02536404,Arena Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02536404,True,Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis,Drug:APD334; Drug:Placebo,[],"December 23, 2015",18,80,Both,False
NCT02511184,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02511184,True,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,ALK-positive Advanced NSCLC,Drug:Crizotinib; Drug:Pembrolizumab,"[u'University of Alabama', u'University of Alabama at Birmingham', u'City of Hope National Medical Center', u'University Of California / San Diego Moores Cancer Center', u'UC San Diego Medical Center - La Jolla(Thornton Hospital)', u'UC San Diego Moores Cancer Center - IDS', u'UC San Diego Medical Center - Hillcrest', u'Emory University Hospital Midtown', u'Emory University Hospital', u'The Emory Clinic', u'Winship Cancer Institute, Emory University', u'University of Minnesota', u'University Of Minnesota Fairview Pharmacy Services', u'University of Minnesota Medical Center, Fairview', u'The Cleveland Clinic Foundation', u'Swedish Cancer Institute', u'Swedish Medical Center']","January 4, 2016",18,99,Both,False
NCT02510014,Indivior Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02510014,True,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Opioid Use Disorder; Opioid-related Disorders,Drug:SUBOXONE sublingual film; Drug:high dose RBP-6000; Drug:low dose RBP-6000,[],"December 10, 2015",18,65,Both,False
NCT02504268,Bristol-Myers Squibb,False,AL,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02465515,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02461589,Novo Nordisk A/S,False,AL,https://ClinicalTrials.gov/show/NCT02461589,True,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:liraglutide; Drug:placebo,[],"October 29, 2015",18,9223372036854775807,Both,False
NCT02447302,Arena Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02447302,True,Safety and Efficacy of APD334 in Patients With Ulcerative Colitis,Ulcerative Colitis,Drug:APD334; Drug:Placebo,[],"December 23, 2015",18,80,Both,False
NCT02445807,"Promius Pharma, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02445807,True,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Chronic Stable Plaque Psoriasis,Drug:DFD06-Cream; Drug:Vehicle Cream,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02436239,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT02436239,True,A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Vilazodone,[],"December 23, 2015",7,17,Both,False
NCT02427802,Innocoll,False,AL,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02412917,"ContraVir Pharmaceuticals, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02412917,True,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],"September 1, 2015",50,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02400905,Veryan Medical Ltd.,False,AL,https://ClinicalTrials.gov/show/NCT02400905,True,Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System,Peripheral Arterial Disease,Device:BioMimics 3D Stent System,[],"January 21, 2016",19,85,Both,False
NCT02387762,Acerta Pharma BV,False,AL,https://ClinicalTrials.gov/show/NCT02387762,True,ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate,Rheumatoid Arthritis,Drug:ACP-196; Drug:Placebo; Drug:Methotrexate,"[u'', u'', u'', u'', u'', u'', u'', u'', u'']","November 4, 2015",18,75,Both,False
NCT02372799,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT02372799,True,Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22),Major Depressive Disorder,Drug:Vilazodone; Drug:Placebo; Drug:Fluoxetine,[],"December 17, 2015",7,17,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02336425,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02336425,True,Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma,Asthma,Drug:QGE031; Drug:Placebo,[],"December 18, 2015",18,75,Both,False
NCT02326454,Light Sciences Oncology,False,AL,https://ClinicalTrials.gov/show/NCT02326454,True,A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug:talaporfin sodium; Drug:Saline; Device:Drug Activator 100 J/cm; Device:Drug Activator 200 J/cm,[],"February 1, 2016",40,9223372036854775807,Male,False
NCT02320487,"Genentech, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02320487,True,A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Drug:Bendamustine; Drug:Obinutuzumab,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02299414,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02299414,True,Chronic Hypertension and Pregnancy (CHAP) Project,Hypertension,Other:Anti-hypertensive therapy; Other:No anti-hypertensive therapy (unless BP is severe),[],"November 5, 2015",12,9223372036854775807,Female,False
NCT02294227,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02294227,True,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","Arthritis, Psoriatic",Biological:Secukinumab; Biological:Secukinumab; Biological:Placebo,[],"September 18, 2015",18,9223372036854775807,Both,False
NCT02282020,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02282020,True,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Drug:OLAPARIB; Drug:Single agent chemotherapy,[],"January 25, 2016",18,96,Female,False
NCT02271022,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02271022,True,Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry,Acute Coronary Syndromes,Other:Non-Interventional Study,[],"January 21, 2016",18,99,Both,False
NCT02264990,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT02264990,True,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,Non-squamous Non-small Cell Lung Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Cisplatin; Drug:Pemetrexed,[],"January 18, 2016",18,99,Both,False
NCT02264288,Celgene Corporation,False,AL,https://ClinicalTrials.gov/show/NCT02264288,True,Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease,Peripheral Arterial Disease; Diabetic Foot,Biological:3 x 10^6 cells; Biological:10 x 10^6 cells; Biological:30 x 10^6 cells; Other:Placebo,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02257567,Hoffmann-La Roche,False,AL,https://ClinicalTrials.gov/show/NCT02257567,True,A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,"Diffuse Large B-Cell Lymphoma, Lymphoma, Non Hodgkin, Lymphoma, Follicular",Drug:bendamustine; Drug:obinutuzumab; Drug:polatuzumab vedotin; Drug:rituximab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02243293,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT02243293,True,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],"February 4, 2016",18,100,Both,False
NCT02237950,Starpharma Pty Ltd,False,AL,https://ClinicalTrials.gov/show/NCT02237950,True,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Bacterial Vaginosis,Drug:Metronidazole oral tablets 500mg; Drug:1% SPL7013 Gel; Drug:Placebo gel,[],"May 18, 2015",16,45,Female,False
NCT02234583,Daiichi Sankyo Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02226120,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02226120,True,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,Chronic Heart Failure With Reduced Ejection Fraction.,Drug:LCZ696,[],"October 14, 2015",0,9223372036854775807,Both,False
NCT02221869,Jazz Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02221869,True,A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy,Narcolepsy With Cataplexy,Drug:Xyrem,[],"November 12, 2015",7,17,Both,False
NCT02194738,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02187471,Daiichi Sankyo Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02187471,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02165215,Hoffmann-La Roche,False,AL,https://ClinicalTrials.gov/show/NCT02165215,True,A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug:Etrolizumab; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02153502,Avanir Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02153502,True,"Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","Depressive Disorder, Treatment-Resistant",Drug:AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination); Drug:Placebo,[],"January 28, 2015",18,9223372036854775807,Both,False
NCT02143973,Trevi Therapeutics,False,AL,https://ClinicalTrials.gov/show/NCT02143973,True,Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus,Uremic Pruritus; Pruritus,Drug:nalbuphine HCl ER 60mg BID; Drug:nalbuphine HCl ER 90mg BID; Drug:nalbuphine HCl ER 120mg BID,[],"May 14, 2015",18,9223372036854775807,Both,False
NCT02126943,Actelion,False,AL,https://ClinicalTrials.gov/show/NCT02126943,True,OPsumit USers Registry,Pulmonary Arterial Hypertension; PAH,Drug:Opsumit (macitentan),[],"February 24, 2015",0,9223372036854775807,Both,False
NCT02118584,Hoffmann-La Roche,False,AL,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02109939,Assurex Health Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02109939,True,Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic,Major Depressive Disorder (MDD),Genetic:GeneSight Psychotropic,[],"December 4, 2015",18,9223372036854775807,Both,False
NCT02100514,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02065570,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT02065570,True,Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease,Crohn's Disease,Drug:Adalimumab,[],"January 27, 2016",18,75,Both,False
NCT02059135,rEVO Biologics,False,AL,https://ClinicalTrials.gov/show/NCT02059135,True,"Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia",Preeclampsia,Biological:Recombinant human antithrombin (ATryn); Other:Normal Saline 0.9%,[],"November 2, 2015",16,9223372036854775807,Female,False
NCT02043678,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02032004,Teva Pharmaceutical Industries,False,AL,https://ClinicalTrials.gov/show/NCT02032004,True,The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure.,Chronic Heart Failure,Biological:Allogeneic Mesenchymal Precursor Cells (MPC); Other:Sham Comparator,[],"February 4, 2016",18,80,Both,False
NCT01993862,St. Jude Medical,False,AL,https://ClinicalTrials.gov/show/NCT01993862,True,Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant,Heart Failure; Coronary Artery Disease,Other:Same Day Discharge; Device:Merlin.net,[],"August 7, 2015",18,9223372036854775807,Both,False
NCT01976364,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01976364,True,Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis,"Arthritis, Psoriatic",Drug:Tofacitinib; Drug:Tofacitinib,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01975090,Novate Medical,True,AL,https://ClinicalTrials.gov/show/NCT01975090,True,The SENTRY Clinical Study,Pulmonary Embolism; Deep Vein Thrombosis,Device:SENTRY IVC Filter,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949116,"National Institute of Allergy and Infectious Disease (NIAID), National Heart, Lung, and Blood Institute (NHLBI)",False,AL,https://ClinicalTrials.gov/show/NCT01949116,True,Evaluating Safety and Effectiveness of Low-Dose Methotrexate at Reducing Inflammation in HIV-Infected Adults Taking Antiretroviral Medications,HIV Infections,Drug:Methotrexate (MTX); Drug:Placebo; Dietary Supplement:Folic acid,[],"February 2, 2016",40,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01917968,Boston Scientific Corporation,False,AL,https://ClinicalTrials.gov/show/NCT01917968,True,Multi-center Study of Uphold LITE Versus Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse,Pelvic Organ Prolapse,Device:Uphold Lightweight Vaginal Support System; Procedure:Traditional native tissue repair,[],"October 27, 2015",18,100,Female,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,AL,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01872975,NSABP Foundation Inc,False,AL,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01864174,Bristol-Myers Squibb,False,AL,https://ClinicalTrials.gov/show/NCT01864174,True,Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug:Metformin XR; Drug:Metformin IR; Drug:Placebo matching with Metformin XR; Drug:Placebo matching with Metformin IR,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01839487,Halozyme Therapeutics,False,AL,https://ClinicalTrials.gov/show/NCT01839487,True,PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug:PEGPH20+nab-paclitaxel+gemcitabine; Drug:nab-paclitaxel + gemcitabine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01836471,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT01836471,True,A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients,Asthma,Drug:QAW039; Drug:Placebo; Drug:Inhaled corticosteroid (ICS),[],"November 3, 2014",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01799993,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT01799993,True,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin Inhalation Solution (BAY41-6551); Drug:Aerosolized Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01786096,"Seattle Genetics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT01786096,True,A Safety Study of SGN-CD19A for Leukemia and Lymphoma,Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma,Drug:SGN-CD19A,"[u""Children's Hospital of Alabama / University of Alabama at Birmingham"", u'University of Alabama at Birmingham', u'Mayo Clinic Arizona', u'City of Hope National Medical Center', u'Mayo Clinic Florida', u""All Children's Hospital"", u'H. Lee Moffitt Cancer Center & Research Institute', u""Children's Healthcare of Atlanta / Emory University"", u'Massachusetts General Hospital', u""Boston Children's Hospital"", u'Dana Farber Cancer Institute', u'Memorial Sloan Kettering Cancer Center', u""Cincinnati Children's Hospital Medical Center""]","January 28, 2016",1,9223372036854775807,Both,False
NCT01776424,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT01776424,True,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,Prevention & Control,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Aspirin; Drug:Aspirin placebo; Drug:Rivaroxaban placebo; Drug:Pantoprazole",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01632241,"Human Genome Sciences Inc., a GSK Company",False,AL,https://ClinicalTrials.gov/show/NCT01632241,True,Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Drug:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01621243,"Momenta Pharmaceuticals, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT01621243,True,M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug:nab-paclitaxel; Drug:gemcitabine; Drug:placebo; Drug:Necuparanib,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01602666,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01602666,True,Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors,Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma,Procedure:therapeutic conventional surgery; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Drug:carboplatin; Drug:etoposide; Drug:ifosfamide,[],"October 20, 2015",3,21,Both,False
NCT01598831,Asahi Kasei Pharma America Corporation,False,AL,https://ClinicalTrials.gov/show/NCT01598831,True,Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy,Severe Sepsis; Coagulopathy,Drug:ART-123; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT01584557,Cardiovascular Clinical Science Foundation,False,AL,https://ClinicalTrials.gov/show/NCT01584557,True,"Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management",Heart Failure,Drug:Tolvaptan or Samsca; Drug:placebo or sugar pill,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT01503632,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01485614,Merck Sharp & Dohme Corp.,False,AL,https://ClinicalTrials.gov/show/NCT01485614,True,Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083),Diabetes Mellitus; Type 2 Diabetes,Drug:Sitagliptin; Drug:Metformin; Drug:Placebo to sitagliptin; Drug:Placebo to metformin; Drug:Glycemic Rescue 1; Drug:Glycemic Rescue 2; Biological:Glycemic Rescue 3,[],"February 2, 2016",10,17,Both,False
NCT01470612,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01458574,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01307579,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01236547,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01096368,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT00980954,Radiation Therapy Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00955708,Boston Scientific Corporation,False,AL,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00858364,Amgen,False,AL,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00772200,Children's Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00719303,Gynecologic Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,AL,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02674503,VA Office of Research and Development,False,AL,https://ClinicalTrials.gov/show/NCT02674503,True,Impact of a Mobility Program,Hospitalization,Behavioral:Walking; Behavioral:Friendly visit,"[u'Birmingham VA Medical Center, Birmingham, AL']","February 3, 2016",50,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02666664,Esperion Therapeutics,True,AL,https://ClinicalTrials.gov/show/NCT02666664,True,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk,Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases,Drug:ETC-1002; Drug:Placebo,"[u'', u'', u'', u'', u'', u'']","January 25, 2016",18,9223372036854775807,Both,False
NCT02665468,VA Office of Research and Development,False,AL,https://ClinicalTrials.gov/show/NCT02665468,True,eHealth Partnered Evaluation Initiative,Non-secure Message Senders,Behavioral:Supported adoption intervention; Behavioral:Active comparator control,"[u'Birmingham VA Medical Center, Birmingham, AL', u'Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA', u'VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA', u'VA Salt Lake City Health Care System, Salt Lake City, UT']","January 22, 2016",18,99,Both,True
NCT02663908,Ferring Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02663908,True,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,Prostate Cancer,Drug:Degarelix; Drug:Leuprolide,[],"January 22, 2016",0,9223372036854775807,Male,False
NCT02663219,HIV Prevention Trials Network,False,AL,https://ClinicalTrials.gov/show/NCT02663219,True,"Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States",HIV,Behavioral:Intervention,"[u'Alabama CRS', u'Ponce de Leon CRS', u'Johns Hopkins Baltimore CRS', u'Fenway Health CRS']","January 21, 2016",16,9223372036854775807,Male,True
NCT02659800,Sidney Kimmel Comprehensive Cancer Center,False,AL,https://ClinicalTrials.gov/show/NCT02659800,True,IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas,Lymphopenia; Malignant Glioma,Other:Laboratory Biomarker Analysis; Biological:Glycosylated Recombinant Human Interleukin-7; Other:Placebo,"[u'UAB Comprehensive Cancer Center', u'Jonsson Comprehensive Cancer Center at UCLA', u'UCSF Comprehensive Cancer Center', u'Johns Hopkins Oncology Center', u'Dana Farber Cancer Institute', u'Josephine Ford Cancer Center at Henry Ford Hospital', u'Washington University', u'Memorial Sloan-Kettering Cancer Center', u'Wake Forest University Comprehensive Cancer Center', u'Cleveland Clinic Taussig Cancer Center', u'Abrams Cancer Center of the University of Pennsylvania', u'Hillman Cancer Center at University of Pittsburgh Cancer Institute']","January 15, 2016",18,9223372036854775807,Both,False
NCT02658981,Sidney Kimmel Comprehensive Cancer Center,False,AL,https://ClinicalTrials.gov/show/NCT02658981,True,Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma,Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Biological:Anti-LAG-3 Monoclonal Antibody BMS 986016; Biological:Anti-PD-1; Other:Pharmacological Study; Other:Laboratory Biomarker Analysis; Biological:Anti-CD137,"[u'UAB Comprehensive Cancer Center', u'Jonsson Comprehensive Cancer Center at UCLA', u'University of California San Francisco Medical Center', u'Johns Hopkins Oncology Center', u'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', u'Memorial Sloan-Kettering Cancer Center', u'Wake Forest University Comprehensive Cancer Center', u'Cleveland Clinic Taussig Cancer Center', u'Abrams Cancer Center of the University of Pennsylvania', u'Hillman Cancer Center at University of Pittsburgh Cancer Institute']","January 19, 2016",18,9223372036854775807,Both,False
NCT02658916,Bristol-Myers Squibb,False,AL,https://ClinicalTrials.gov/show/NCT02658916,True,Extension Study of BMS-986168 in Patients With Progressive Supranuclear Palsy Who Participated in CN002003,Progressive Supranuclear Palsy,Drug:BMS-986168,"[u'The University of Alabama at Birmingham', u'David Geffen School of Medicine at UCLA', u'University of California San Diego', u'University of California, San Francisco, Medical Center at Parnassus', u'Parkinsons Disease and Movement Disorders Center of Boca Raton', u'University of Florida College of Medicine', u'University of South Florida', u""Parkinson's & Movement Disorders Center of Maryland"", u'University of Minnesota Medical School', u'Robert Wood Johnson Medical School', u'Columbia University Medical Center', u'Hospital of the University of Pennsylvania', u'The University of Texas Southwestern Medical Center']","January 19, 2016",41,86,Both,False
NCT02656303,"TG Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02656303,True,An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,Chronic Lymphocytic Leukemia,Biological:ublituximab; Drug:TGR-1202,"[u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site']","January 13, 2016",18,9223372036854775807,Both,False
NCT02652429,Bellerophon Pulse Technologies,False,AL,https://ClinicalTrials.gov/show/NCT02652429,True,Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH,Pulmonary Arterial Hypertension,Drug:Inhaled Nitric Oxide,"[u'University of Alabama at Birmingham', u'West Los Angeles VA Healthcare Center', u'University of Colorado Denver', u'Cleveland Clinic Florida', u'University of Maryland Medical Center', u'Mount Sinai Beth Israel', u'Duke University Medical Center', u'UC Health University of Cincinnati', u'Cleveland Clinic', u'Ohio State University, Wexner Medical Center', u'Allegheny General Hospital', u'Intermountain Medical Center', u'Peter Lougheed Centre', u'University of Alberta Hospitals - MAHI', u'Lawson Clinical Research Services', u'University Health Network']","January 8, 2016",0,9223372036854775807,Both,False
NCT02648204,Novo Nordisk A/S,False,AL,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02640157,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT02640157,True,A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection,Chronic Hepatitis C; Hepatitis C Virus; Genotype 3 Hepatitis C Virus,Drug:ABT-493/ABT-530; Drug:sofosbuvir; Drug:daclatasvir; Drug:daclatasvir,[],"January 26, 2016",18,100,Both,False
NCT02636868,"Discovery Laboratories, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02636868,True,Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age,Respiratory Distress Syndrome,Drug:Lucinactant delivered via investigational delivery device; Drug:nCPAP,"[u'University of Alabama at Birmingham', u'Loma Linda University Medical Center', u'Sharp Mary Birch Hospital for Women and Newborns', u'Christiana Care Health System', u'University of Miami', u'Mid Atlantic Neonatology Associates', u'Duke University Medical Center', u'Providence St. Vincent Medical Center']","December 28, 2015",26,32,Both,False
NCT02636569,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02636569,True,Topical Chemoprevention of Skin Cancer Biomarkers,Non-melanoma Skin Cancer,Drug:topical DFMO+diclofenac twice daily; Drug:placebo,[u'University of Alabama at Birmingham Kirklin Clinic'],"February 3, 2016",18,9223372036854775807,Both,True
NCT02633969,"Iroko Pharmaceuticals, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02633969,True,Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age,"Pain, Postoperative",Drug:Indomethacin Capsules low dose; Drug:Indomethacin Capsules high dose,"[u'', u'']","December 15, 2015",6,16,Both,False
NCT02632045,Kevin Kalinsky,False,AL,https://ClinicalTrials.gov/show/NCT02632045,True,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,Metastatic Breast Cancer; Breast Carcinoma,Drug:LEE-011; Drug:Fulvestrant; Drug:Placebo,"[u'University of Alabama at Birmingham (UAB)', u'Northwestern Medical Hospital', u'Albert Einstein University / Montefiore Medical Center', u'NYU Langone Medical Center', u'Mount Sinai Medical Center', u'Weill Cornell Medical Center', u'Columbia University Medical Center', u'Vanderbilt-Ingham Cancer Center', u'University of Wisconsin School of Medicine']","December 15, 2015",18,9223372036854775807,Both,False
NCT02631850,Ohio State University,False,AL,https://ClinicalTrials.gov/show/NCT02631850,True,Effectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity Rehabilitation,Stroke; Hemiparesis,Behavioral:Traditional CI Therapy; Behavioral:Gaming CI Therapy; Behavioral:Gaming CI Therapy with Additional Contact via Video Conference; Behavioral:Traditional Occupational Therapy/Physical Therapy,"[u'University of Alabama at Birmingham', u'The Ohio State University, 2154 Dodd Hall', u'OhioHealth Rehabilitation', u'Providence Medford Medical Center']","January 15, 2016",18,9223372036854775807,Both,False
NCT02629159,AbbVie,False,AL,https://ClinicalTrials.gov/show/NCT02629159,True,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],"December 10, 2015",18,99,Both,False
NCT02628795,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02628795,True,Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement,Osteoarthritis,Behavioral:PRT + FM; Other:Usual Care,[u'UAB Center for Exercise Medicine'],"December 11, 2015",40,80,Both,False
NCT02627235,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02627235,True,The Deep South IVR-based Active Lifestyle Study,Physical Activity,Behavioral:DIAL; Behavioral:Wait List Control,[u'University of Alabama at Birmingham'],"December 8, 2015",21,9223372036854775807,Both,True
NCT02620449,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02620449,True,Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults,Healthy; Chronic Kidney Disease,Other:Diet,[u'University of Alabama'],"November 30, 2015",18,9223372036854775807,Both,True
NCT02617589,Bristol-Myers Squibb,False,AL,https://ClinicalTrials.gov/show/NCT02617589,True,"Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",Brain Cancer,Drug:Nivolumab; Drug:Temozolomide; Radiation:Radiotherapy,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02616302,Takeda,False,AL,https://ClinicalTrials.gov/show/NCT02616302,True,A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years,Gastroesophageal Reflux,Drug:Dexlansoprazole,[],"December 14, 2015",1,11,Both,False
NCT02615184,Takeda,False,AL,https://ClinicalTrials.gov/show/NCT02615184,True,"A Phase 2, Double Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Participants",Erosive Esophagitis,Drug:Dexlansoprazole; Drug:Placebo,[],"December 14, 2015",1,11,Both,False
NCT02614170,"Fujirebio Diagnostics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02614170,True,A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals,Diabetes,Other:Prospective Blood Draw,[u'Fundamental Research LLC'],"November 24, 2015",18,9223372036854775807,Both,True
NCT02613949,Cerephex Corporation,True,AL,https://ClinicalTrials.gov/show/NCT02613949,True,Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 202,Fibromyalgia,Device:RINCE,"[u'Achieve Clinical Research, LLC', u'Superior Research LLC', u'Chicago Research Center', u'Upstate Clinical Research Associates']","November 23, 2015",22,75,Both,False
NCT02613065,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02613065,True,The Role of Protein in Regulating Ad Libitum Energy Intake in Humans,Energy Balance,Dietary Supplement:Consumption of NOW Foods eggwhite protein shake; Dietary Supplement:Consumption of NOW Foods maltodextrin shake,[u'University of Alabama at Birmingham'],"November 30, 2015",30,50,Both,True
NCT02612779,Bristol-Myers Squibb,False,AL,https://ClinicalTrials.gov/show/NCT02612779,True,A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,Multiple Myeloma,Drug:Elotuzumab; Drug:Pomalidomide; Drug:Dexamethasone,"[u'Local Institution', u'Local Institution', u'Local Institution', u'Rocky Mountain Cancer Centers', u'Local Institution', u'Local Institution', u'Local Institution', u'Bay Hematology Oncology', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Cancer Care Centers Of South Texas', u'Virginia Cancer Specialists, Pc', u'Local Institution', u'Local Institution']","January 26, 2016",18,9223372036854775807,Both,False
NCT02612311,"TG Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02612311,True,Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Biological:Obinutuzumab; Biological:Ublituximab; Drug:TGR-1202; Drug:Chlorambucil,"[u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site']","February 1, 2016",18,9223372036854775807,Both,False
NCT02610517,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT02610517,True,ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment,HIV; Alcoholism,Behavioral:Provider Training; Behavioral:Patient Intervention,"[u'University of Alabama at Birmingham', u'Johns Hopkins University', u'University of Washington']","November 18, 2015",18,9223372036854775807,Both,False
NCT02610296,Quark Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02610296,True,QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant,Delayed Graft Function,Drug:QPI-1002; Other:Placebo,"[u'University of Alabama at Birmingham', u'Yale University School of Medicine', u'Tampa General Hospital', u'Medical University of South Carolina']","December 11, 2015",18,9223372036854775807,Both,False
NCT02608697,Catabasis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02608697,True,A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia,Hypercholesterolemia,Drug:CAT-2054; Drug:Placebo; Drug:Atorvastatin,[],"December 23, 2015",18,74,Both,False
NCT02488967,NRG Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01272037,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01856192,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01620190,University of Washington,False,AK,https://ClinicalTrials.gov/show/NCT01620190,True,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'Bozeman Deaconess Hospital', u'Kadlec Clinic Hematology and Oncology', u'Skagit Valley Hospital', u'Olympic Medical Center', u'Group Health Cooperative', u'Fred Hutch/University of Washington Cancer Consortium', u'Spokane Valley Cancer Center-Mission', u'Multicare Health System', u'Wenatchee Valley Hospital and Clinics']","January 29, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02152982,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01908101,University of Washington,False,AK,https://ClinicalTrials.gov/show/NCT01908101,True,Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer,Recurrent Breast Carcinoma; Stage IV Breast Cancer,Drug:Eribulin Mesylate; Other:Laboratory Biomarker Analysis,"[u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'The University of Arizona Medical Center-University Campus', u'Bozeman Deaconess Hospital', u'Bend Memorial Clinic', u'Kadlec Clinic Hematology and Oncology', u'Skagit Valley Hospital', u'Olympic Medical Center', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium', u'Group Health Cooperative-Seattle', u'Multicare Health System', u'Wenatchee Valley Hospital and Clinics']","November 12, 2015",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02663908,Ferring Pharmaceuticals,False,AK,https://ClinicalTrials.gov/show/NCT02663908,True,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,Prostate Cancer,Drug:Degarelix; Drug:Leuprolide,[],"January 22, 2016",0,9223372036854775807,Male,False
NCT02614183,Eli Lilly and Company,False,AK,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02477020,Takeda,False,AK,https://ClinicalTrials.gov/show/NCT02477020,True,A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia,Schizophrenia,Drug:TAK-063 20 mg; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 18, 2016",18,65,Both,False
NCT02470585,AbbVie,False,AK,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02451137,Sanofi,False,AK,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02443688,"Celtaxsys, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02443688,True,"EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients",Cystic Fibrosis,Drug:CTX-4430; Drug:Placebo,"[u'University of Alabama', u'Providence Health and Services', u'Banner University of Arizona Medical Center', u'Pediatric Pulmonary and Cystic Fibrosis Clinic, Stanford University', u'University of California Davis Medical Center', u'National Jewish Health', u'University of Florida', u'Central Florida Pulmonary Group', u'Emory University', u'University of Chicago', u'Massachusetts General Hospital', u'University of Michigan', u'Spectrum Health Butterworth Campus', u'University of New Mexico', u'Hershey Medical Center', u""Children's Hospital of Pittsburgh of UPMC"", u'Universiy of Tennessee Medical Center UHS']","February 1, 2016",18,30,Both,False
NCT02431611,Mayo Clinic,False,AK,https://ClinicalTrials.gov/show/NCT02431611,True,Biomarker Feedback to Motivate Cessation in Pregnancy,Nicotine Dependence; Pregnancy,Behavioral:Biomarker feedback (phone based smoking cessation counseling); Behavioral:Control condition (phone based smoking cessation counseling),[u'Alaska Native Tribal Health Consortium'],"January 12, 2016",18,45,Female,True
NCT02406677,AstraZeneca,False,AK,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02365818,"Cold Genesys, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02365818,True,Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,Bladder Cancer,Drug:CG0070,"[u'Alaska Clinical Research Center', u'BCG Oncology', u'Institute of Urologic Oncology at UCLA', u'Tower Urology', u'UC Irvine Medical Center', u'UF Health Cancer Center', u'University of Chicago', u'Michigan Institute of Urology, P.C.', u'Adult Pediatric Urology and Urogynecology, PC', u'Premier Urology Group, LLC.', u'Premier Medical Group of the Hudson Valley', u'Wake Forest University School of Medicine', u'The Urology Group', u'Erlanger Institute for Clinical Research', u'Vanderbilt University Medical Center, Dept. of Urologic Surgery']","February 1, 2016",18,9223372036854775807,Both,False
NCT02326454,Light Sciences Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02326454,True,A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug:talaporfin sodium; Drug:Saline; Device:Drug Activator 100 J/cm; Device:Drug Activator 200 J/cm,[],"February 1, 2016",40,9223372036854775807,Male,False
NCT02319837,"Medivation, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02319837,True,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Drug:Enzalutamide; Drug:Placebo; Drug:Leuprolide,[],"December 1, 2015",18,9223372036854775807,Male,False
NCT02315469,NRG Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02277990,Medtronic Cardiac Rhythm Disease Management,False,AK,https://ClinicalTrials.gov/show/NCT02277990,True,World-wide Randomized Antibiotic Envelope Infection Prevention Trial,CIED Related Infection,Device:TYRX Absorbable Antibacterial Envelope,[],"August 27, 2015",18,9223372036854775807,Both,True
NCT02264288,Celgene Corporation,False,AK,https://ClinicalTrials.gov/show/NCT02264288,True,Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease,Peripheral Arterial Disease; Diabetic Foot,Biological:3 x 10^6 cells; Biological:10 x 10^6 cells; Biological:30 x 10^6 cells; Other:Placebo,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02200614,Bayer,False,AK,https://ClinicalTrials.gov/show/NCT02200614,True,Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS),Prostate Cancer Non-Metastatic; Castration-Resistant,Drug:BAY1841788 (ODM-201); Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02187783,Novartis Pharmaceuticals,False,AK,https://ClinicalTrials.gov/show/NCT02187783,True,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),Tumors With CDK4/6 Pathway Activation,Drug:LEE011,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02164916,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02141438,Bayer,False,AK,https://ClinicalTrials.gov/show/NCT02141438,True,Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer,Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223)",[],"February 4, 2016",18,9223372036854775807,Male,False
NCT02138734,Altor Bioscience Corporation,False,AK,https://ClinicalTrials.gov/show/NCT02138734,True,A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer,Non-muscle Invasive Bladder Cancer,Biological:BCG+ALT-803; Biological:BCG,"[u'University of Alabama at Birmingham', u'Alaska Clinical Research Center', u'UCLA Department of Urology', u'University of Hawaii Cancer Center', u'Dartmouth-Hitchcock Medical Center', u'Winthrop University Hospital']","October 21, 2015",18,9223372036854775807,Both,False
NCT02137902,Stanford University,False,AK,https://ClinicalTrials.gov/show/NCT02137902,True,Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study,Tobacco Dependence,Behavioral:Counselor intervention for tobacco/physical activity; Drug:Nicotine replacement therapy; Behavioral:Intervention for managing hypertension/hypercholesterolemia,"[u'Norton Sound Health Corporation', u'Stanford Hospital and Clinics']","October 22, 2015",19,9223372036854775807,Both,True
NCT02112916,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02109757,United States Air Force,False,AK,https://ClinicalTrials.gov/show/NCT02109757,True,Evaluation of Hearing Protection Fit Testing Program,Hearing Loss,Other:Software intervention and education; Other:Education only,"[u'Elmendorf Air Force Base', u'Wright-Patterson Air Force Base']","April 7, 2014",0,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02097121,Allergan,False,AK,https://ClinicalTrials.gov/show/NCT02097121,True,OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients,"Urinary Incontinence; Urinary Bladder, Overactive",Biological:OnabotulinumtoxinA,[],"January 19, 2016",12,17,Both,False
NCT02083081,Mayo Clinic,False,AK,https://ClinicalTrials.gov/show/NCT02083081,True,Community Intervention to Reduce Tobacco Use in Pregnant Women,Nicotine Dependence,Behavioral:Community level intervention,[u'Yukon Kuskokwim Health Corporation'],"January 12, 2016",18,55,Female,True
NCT02080689,GenomeDx Biosciences Corp,True,AK,https://ClinicalTrials.gov/show/NCT02080689,True,Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery,Prostate Cancer,Other:Decipher,"[u'Alaska Urology Institute Alaska Clinical Research Center', u'Cedars-Sinai Medical Center', u'University of Colorado, Denver Medical Campus', u'The Urology Center of Colorado', u'Urological Research Network', u'Lakeland Regional Health Systems', u'University of Miami Miller School of Medicine', u""Brigham and Women's Hospital"", u'Spectrum Health Medical Group', u'Delaware Valley Urology, LLC', u'Carolina Urology Partners', u'Lancaster Urology', u'Thomas Jefferson University', u'Fox Chase Cancer Center', u'UT Southwestern Medical Center', u'Huntsman Cancer Hospital', u'University of Vermont Medical Center', u'Virginia Urology', u'University of Washington']","September 18, 2015",0,9223372036854775807,Male,False
NCT02054156,Bonnie Ramsey,False,AK,https://ClinicalTrials.gov/show/NCT02054156,True,OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis,Cystic Fibrosis,Drug:azithromycin; Drug:placebo; Drug:Tobramycin solution for inhalation,[],"September 25, 2015",6,18,Both,False
NCT02043678,Bayer,False,AK,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02032823,AstraZeneca,False,AK,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02019264,Eisai Inc.,False,AK,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01975389,Pfizer,False,AK,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,AK,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01970501,"ARCA Biopharma, Inc.",True,AK,https://ClinicalTrials.gov/show/NCT01970501,True,Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure,Current or Recent History of Atrial Fibrillation,Drug:bucindolol hydrochloride; Drug:metoprolol succinate,[],"February 1, 2016",18,120,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01891344,"Clovis Oncology, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT01891344,True,"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Drug:Oral rucaparib,[],"January 18, 2016",18,9223372036854775807,Female,False
NCT01877915,"Janssen Research & Development, LLC",False,AK,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01872975,NSABP Foundation Inc,False,AK,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01858519,AbbVie,False,AK,https://ClinicalTrials.gov/show/NCT01858519,True,Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy,Cystic Fibrosis,Biological:pancrelipase,[],"December 14, 2015",2,99,Both,False
NCT01822496,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01772472,Hoffmann-La Roche,False,AK,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01660451,Bayer,False,AK,https://ClinicalTrials.gov/show/NCT01660451,True,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","Lymphoma, Non-Hodgkin",Drug:Copanlisib (BAY80-6946),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01446965,"University of California, San Francisco",False,AK,https://ClinicalTrials.gov/show/NCT01446965,True,Vest Prevention of Early Sudden Death Trial and VEST Registry,Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation,Device:wearable defibrillator,[],"April 7, 2015",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01359592,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01345669,Boehringer Ingelheim,False,AK,https://ClinicalTrials.gov/show/NCT01345669,True,LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,Head and Neck Neoplasms,Drug:Placebo; Drug:Afatinib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01200589,GlaxoSmithKline,False,AK,https://ClinicalTrials.gov/show/NCT01200589,True,Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy,Non-Hodgkin's Lymphoma,Biological:Ofatumumab; Biological:Rituximab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01120249,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT00980954,Radiation Therapy Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00955708,Boston Scientific Corporation,False,AK,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00858364,Amgen,False,AK,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00244686,GlaxoSmithKline,False,AK,https://ClinicalTrials.gov/show/NCT00244686,True,Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES),Hypereosinophilic Syndrome,Drug:mepolizumab,[],"January 28, 2016",12,9223372036854775807,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01966107,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01594333,Brigham and Women's Hospital,False,AZ,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,AZ,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01975376,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,AZ,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02301234,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02301234,True,"Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg; Drug:Celecoxib 100 mg; Drug:Celecoxib 100 mg Matching Placebo,[],"January 20, 2016",18,99,Both,False
NCT02019264,Eisai Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02674386,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01652872,Amgen,False,AZ,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02504268,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02451137,Sanofi,False,AZ,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02412917,"ContraVir Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02412917,True,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],"September 1, 2015",50,9223372036854775807,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,AZ,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,AZ,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01953601,Merck Sharp & Dohme Corp.,False,AZ,https://ClinicalTrials.gov/show/NCT01953601,True,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],"December 31, 2015",50,85,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01901900,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01901900,True,Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.,Rheumatoid Arthritis,Biological:Secukinumab (AIN457),[],"January 12, 2015",18,9223372036854775807,Both,False
NCT01885078,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,AZ,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,AZ,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02640612,Boehringer Ingelheim,False,AZ,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02629159,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT02629159,True,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],"December 10, 2015",18,99,Both,False
NCT02551874,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02551874,True,"A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy",Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glargine insulin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02528253,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02505542,UCB BIOSCIENCES GmbH,False,AZ,https://ClinicalTrials.gov/show/NCT02505542,True,Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo,Axial Spondyloarthrithis; Ankylosing Spondylitis,Biological:Certolizumab Pegol; Other:Placebo,[],"February 2, 2016",18,45,Both,False
NCT02487446,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02403401,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02373813,Amgen,False,AZ,https://ClinicalTrials.gov/show/NCT02373813,True,Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission,Rheumatoid Arthritis,Drug:etanercept pre-filled syringe sq injection; Drug:Oral methotrexate; Drug:Placebo for etanercept sq injection; Drug:Placebo for methotrexate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02283320,BIND Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02283320,True,A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer,KRAS Positive Patients With Non-small Cell Lung Cancer; Squamous Cell Non-small Cell Lung Cancer,Drug:BIND-014 (Docetaxel Nanoparticles for Injectable Suspension),[],"December 17, 2015",18,9223372036854775807,Both,False
NCT02187471,Daiichi Sankyo Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT02187471,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02156843,"NephroGenex, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02156843,True,Pyridorin in Diabetic Nephropathy,Diabetic Nephropathy; Diabetic Kidney Disease,Drug:Pyridorin; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02111577,Sotio a.s.,False,AZ,https://ClinicalTrials.gov/show/NCT02111577,True,Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,Metastatic Castrate Resistant Prostate Cancer,Biological:Dendritic Cells DCVAC; Biological:Placebo; Drug:Docetaxel; Drug:Taxotere,[],"January 5, 2016",18,9223372036854775807,Male,False
NCT02066636,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02043678,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,AZ,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,AZ,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01888120,Jazz Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01846611,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT01846611,True,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms,Drug:Trabectedin; Drug:DOXIL; Drug:Dexamethasone; Drug:DOXIL,[],"January 19, 2016",18,9223372036854775807,Female,False
NCT01797185,Sun Pharma Advanced Research Company Limited,False,AZ,https://ClinicalTrials.gov/show/NCT01797185,True,"A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial",Spasticity,Drug:Baclofen,[],"September 15, 2015",18,90,Both,False
NCT01751906,Abbott Vascular,False,AZ,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01705977,"Human Genome Sciences Inc., a GSK Company",False,AZ,https://ClinicalTrials.gov/show/NCT01705977,True,Belimumab Assessment of Safety in SLE,Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Other:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01546571,Polynoma LLC,False,AZ,https://ClinicalTrials.gov/show/NCT01546571,True,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",Melanoma,Biological:POL-103A; Biological:POL-103A without API,[],"December 8, 2015",18,80,Both,False
NCT01471340,Merck Sharp & Dohme Corp.,False,AZ,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,AZ,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00628498,Jazz Pharmaceuticals,True,AZ,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT02675426,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT02675426,True,A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,99,Both,False
NCT02670083,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02663674,National Institute of Allergy and Infectious Diseases (NIAID),False,AZ,https://ClinicalTrials.gov/show/NCT02663674,True,Early Fluconazole Treatment for Coccidiodomycosis Pneumonia,Coccidioidomycosis,Drug:Fluconazole; Other:Placebo,"[u'Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix', u'Mayo Clinic, Scottsdale - Infectious Diseases', u'The University of Arizona - Banner University Medical Center Tucson Campus - Tucson', u'Kaiser Permanente Chester Avenue Medical Offices - Pulmonology', u'Kern Medical Center - Medicine', u'Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases']","February 4, 2016",18,99,Both,False
NCT02584855,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT02584855,True,A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02584660,"Janssen Scientific Affairs, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02584660,True,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,Pulmonary Embolism,Drug:Rivaroxaban; Drug:Standard-of-care,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02574078,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02574078,True,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02516046,Avid Radiopharmaceuticals,True,AZ,https://ClinicalTrials.gov/show/NCT02516046,True,18F-AV-1451 Autopsy Study,Alzheimer's Disease,Drug:18F-AV-1451,"[u'Xenoscience', u""Banner Alzheimer's Institute"", u""St. Joseph's Hospital and Medical Center"", u'Hoag Memorial Hospital Presbyterian', u'Pacific Research Network', u'Neuropsychiatric Research Center of Southwest Florida', u'Galiz Research', u'Miami Jewish Health Systems', u'Compass Research', u'Emory University Brain Health Center', u""Alzheimer's Disease Center"", u'Steinberg Diagnostics', u'Las Vegas Medical Research', u'Duke University Medical Center', u'Wake Forest School of Medicine', u'Valley Medical Primary Care', u'American Clinical Trials, LLC (Site 1216)', u'Rhode Island Hospital', u'University of Washington Medicine']","January 27, 2016",50,9223372036854775807,Both,False
NCT02501161,Novo Nordisk A/S,False,AZ,https://ClinicalTrials.gov/show/NCT02501161,True,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec/liraglutide; Drug:insulin glargine,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02484547,Biogen,False,AZ,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02480153,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02480153,True,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02470585,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02446912,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT02446912,True,Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus,Active Systemic Lupus Erythematosus,Biological:Anifrolumab; Drug:Placebo,[],"November 9, 2015",18,70,Both,False
NCT02445807,"Promius Pharma, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02445807,True,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Chronic Stable Plaque Psoriasis,Drug:DFD06-Cream; Drug:Vehicle Cream,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02438787,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02438787,True,A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis,Axial Spondyloarthritis,Drug:Placebo; Drug:Ustekinumab 45 mg; Drug:Ustekinumab 90 mg; Drug:Golimumab 50 mg,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02437890,Ablynx,False,AZ,https://ClinicalTrials.gov/show/NCT02437890,True,A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus,"Lupus Erythematosus, Systemic",Biological:ALX-0061; Biological:Placebo,[],"January 26, 2016",18,64,Both,False
NCT02422615,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02422615,True,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,"Breast Neoplasms; Breast Diseases; Neoplasms; Neoplasms by Site; Fulvestrant; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Therapeutic Use",Drug:Ribociclib; Drug:fulvestrant; Drug:Ribociclib placebo,[],"September 14, 2015",18,9223372036854775807,Female,False
NCT02419612,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02419612,True,"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone",Diabetes,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glimepiride; Other:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02414854,Sanofi,False,AZ,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02366143,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02365597,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02365597,True,An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer,Urothelial Cancer,"Drug:JNJ-42756493, 10 mg; Drug:JNJ-42756493, 6 mg",[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02349295,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT02349295,True,A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02320487,"Genentech, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02320487,True,A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Drug:Bendamustine; Drug:Obinutuzumab,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT02313909,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02313909,True,Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS),Stroke,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Aspirin (Acetylsalicylic acid, BAY1019036); Other:Rivaroxaban-Placebo; Other:Aspirin-Placebo",[],"February 3, 2016",50,9223372036854775807,Both,False
NCT02311881,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT02311881,True,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Pain,Drug:Paracetamol 1000 mg SR tablets; Drug:Paracetamol 665 mg SR tablets; Drug:Placebo,[],"September 24, 2015",40,80,Both,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02264288,Celgene Corporation,False,AZ,https://ClinicalTrials.gov/show/NCT02264288,True,Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease,Peripheral Arterial Disease; Diabetic Foot,Biological:3 x 10^6 cells; Biological:10 x 10^6 cells; Biological:30 x 10^6 cells; Other:Placebo,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02242487,Acorda Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02242487,True,Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Drug:CVT-301,[],"December 21, 2015",30,80,Both,False
NCT02240121,"Valeant Pharmaceuticals International, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02240121,True,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02240108,"Valeant Pharmaceuticals International, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02240108,True,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02240030,Acorda Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02240030,True,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Drug:CVT-301,[],"November 12, 2015",30,85,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02202551,"Adamas Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02202551,True,Open-Label Safety Study of ADS-5102 in PD Patients With LID,Dyskinesia; Levodopa Induced Dyskinesia (LID); Parkinson's Disease (PD),Drug:ADS-5102,[],"October 1, 2015",30,85,Both,False
NCT02194738,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02181673,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02181673,True,A Study of Golimumab in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Placebo; Drug:Golimumab,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02177695,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,AZ,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02145468,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02104583,Gilead Sciences,False,AZ,https://ClinicalTrials.gov/show/NCT02104583,True,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],"January 8, 2016",18,80,Both,False
NCT02092467,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02080364,vTv Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02080364,True,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02051608,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02051608,True,A Study of Gantenerumab in Patients With Mild Alzheimer Disease,Alzheimer Disease,Drug:florbetapir; Drug:gantenerumab; Drug:placebo,[],"February 1, 2016",50,90,Both,False
NCT02034552,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02034552,True,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo,BAY88-8223); Drug:Abiraterone acetate; Drug:Prednisone; Drug:Enzalutamide",[],"January 4, 2016",18,9223372036854775807,Male,False
NCT02032277,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT02032004,Teva Pharmaceutical Industries,False,AZ,https://ClinicalTrials.gov/show/NCT02032004,True,The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure.,Chronic Heart Failure,Biological:Allogeneic Mesenchymal Precursor Cells (MPC); Other:Sham Comparator,[],"February 4, 2016",18,80,Both,False
NCT02027428,Celgene Corporation,False,AZ,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02008357,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT02008357,True,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,Cognition Disorders,Drug:Solanezumab; Drug:Placebo,[],"January 12, 2016",65,85,Both,True
NCT01968031,"Kyowa Hakko Kirin Pharma, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01968031,True,A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease,Idiopathic Parkinson's Disease,Drug:Istradefylline 40 mg; Drug:Istradefylline 20 mg; Drug:Placebo,[],"November 13, 2015",30,9223372036854775807,Both,False
NCT01947608,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01947608,True,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:LDK378,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,AZ,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01877915,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01872689,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT01872689,True,A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Drug:lebrikizumab; Drug:pirfenidone; Drug:placebo,[],"February 1, 2016",40,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01839487,Halozyme Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT01839487,True,PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug:PEGPH20+nab-paclitaxel+gemcitabine; Drug:nab-paclitaxel + gemcitabine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,AZ,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01762085,Association of Extremity Nerve Surgeons,True,AZ,https://ClinicalTrials.gov/show/NCT01762085,True,Nerve Decompression for Ulcer Recurrence Avoidance (DURA),Diabetic Ulcer of Plantar Aspect of Left Foot; Diabetic Ulcer of Plantar Aspect of Right Foot; Diabetic Polyneuropathy,Procedure:nerve decompression,"[u'Barrett Foot & Ankle Institute', u'Richard P. Jacoby', u'Southern Arizona Limb Salvage Alliance,', u'Andrew Rader, DPM', u'Damien Dauphinee', u'Maria Buitrago, DPM']","June 25, 2015",18,80,Both,False
NCT01727154,Dendreon,False,AZ,https://ClinicalTrials.gov/show/NCT01727154,True,Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T,Prostate Cancer,Biological:Sipuleucel-T,[],"December 18, 2015",18,9223372036854775807,Male,False
NCT01672892,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01656603,New York Blood Center,False,AZ,https://ClinicalTrials.gov/show/NCT01656603,True,"Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation",Infusion Reactions,Biological:unlicensed CBU,[],"March 6, 2015",0,9223372036854775807,Both,False
NCT01645891,"Electrochemical Oxygen Concepts, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01645891,True,"A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers",Diabetic Foot Ulcer,Device:CDO electrochemical tissue oxygenation system; Device:Moist Wound Therapy,"[u'Clinical Trials of Texas, Inc., dba Clinical Trials of Arizona, Inc.', u'Associated Foot and Ankle Specialists', u'Southern Arizona VA Health Care System', u'Roy O. Kroeker, DPM , Inc.', u'Doctors Research Network', u'Foot and Ankle Specialists of the Mid-Atlantic', u'Foot and Ankle Specialists of the Mid-Atlantic', u'Foot and Ankle Specialists of the Mid-Atlantic', u'PMG Research of Wilmington, LLC', u'Richard C. Galperin, DPM, PA', u'William Blake Partners, LLC', u'Complete Family Foot Care', u'Alamo Clinical Research', u'Clinical Trials of Texas', u'The University of Texas Health Science Center at San Antonio']","August 9, 2013",30,90,Both,False
NCT01575548,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01529034,Upsher-Smith Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT01529034,True,Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters,Epilepsy,Drug:USL261,[],"January 20, 2016",12,9223372036854775807,Both,False
NCT01518374,Avid Radiopharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01518374,True,Clinical Evaluation of Florbetapir F 18 (18F-AV-45),Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases,Drug:Florbetapir F 18,[],"January 27, 2016",18,9223372036854775807,Both,True
NCT01492361,Amarin Pharma Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01470612,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01457352,Sun Pharma Advanced Research Company Limited,False,AZ,https://ClinicalTrials.gov/show/NCT01457352,True,Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen ER Capsules; Drug:Placebo GRS,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01390220,Upsher-Smith Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT01390220,True,Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters,Epilepsy,Drug:USL261; Drug:Placebo,[],"January 19, 2016",12,9223372036854775807,Both,False
NCT01367002,Yale University,True,AZ,https://ClinicalTrials.gov/show/NCT01367002,True,Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,Endometrial Cancer,Drug:Carboplatin/Paclitaxel; Drug:Trastuzumab,"[u""St. Joseph's Hospital and Medical Center"", u'University of Arizona Cancer Center', u'University of Arizona Cancer Center', u'John Muir Clinical Research Center', u'University of California at Los Angeles', u'Penrose St. Francis Hospital', u'The Hospital of Central Connecticut', u'Smilow Cancer Hospital at Yale New Haven', u'The University of Chicago Medicine', u'Greater Baltimore Medical Center', u'Walter Reed National Military Medical Center', u'University of Maryland Medical Center', u'Holy Cross Hospital', u'Jersey Shore University Medical Center', u'Montefiore Medical Center', u'Duke University School of Medicine', u'The Ohio State University']","August 20, 2015",0,9223372036854775807,Female,False
NCT01236547,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01227967,National Institute of Allergy and Infectious Diseases (NIAID),True,AZ,https://ClinicalTrials.gov/show/NCT01227967,True,"Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications",Influenza,"Drug:Amantadine, Ribavirin, Oseltamivir; Drug:Oseltamivir",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01120249,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00955708,Boston Scientific Corporation,False,AZ,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00511147,Grifols Biologicals Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT00511147,True,IGIV Study for Chronic ITP Patients Ages 3-70,Idiopathic Thrombocytopenic Purpura,Biological:IGIV3I Grifols 10%,[],"May 7, 2015",3,70,Both,False
NCT00351611,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02649959,Curemark,True,AZ,https://ClinicalTrials.gov/show/NCT02649959,True,An Open Label Study of CM-AT for the Treatment of Children With Autism,Autism,Drug:CM-AT,[],"January 6, 2016",3,8,Both,False
NCT02648204,Novo Nordisk A/S,False,AZ,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02643251,BioDelivery Sciences International,False,AZ,https://ClinicalTrials.gov/show/NCT02643251,True,"The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy",Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,"Drug:Clonidine Hydrochloride Topical Gel, 0.1%; Drug:Clonidine Hydrochloride Gel Comparator",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02635204,"Promius Pharma, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02635204,True,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Psoriasis,Drug:DFD06 Cream; Drug:Vehicle Cream,[],"December 21, 2015",18,9223372036854775807,Both,False
NCT02616302,Takeda,False,AZ,https://ClinicalTrials.gov/show/NCT02616302,True,A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years,Gastroesophageal Reflux,Drug:Dexlansoprazole,[],"December 14, 2015",1,11,Both,False
NCT02615184,Takeda,False,AZ,https://ClinicalTrials.gov/show/NCT02615184,True,"A Phase 2, Double Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Participants",Erosive Esophagitis,Drug:Dexlansoprazole; Drug:Placebo,[],"December 14, 2015",1,11,Both,False
NCT02615002,Neurim Pharmaceuticals Ltd.,False,AZ,https://ClinicalTrials.gov/show/NCT02615002,True,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug:Piromelatine; Drug:Placebo,[],"January 26, 2016",60,85,Both,False
NCT02614261,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT02614261,True,Evaluation of LY2951742 in the Prevention of Chronic Migraine,Chronic Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02614196,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT02614196,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-2 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02614183,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02589717,"Genentech, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02589717,True,An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy,Urothelial Carcinoma,Drug:Atezolizumab,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02571738,Osiris Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02571738,True,Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers,Chronic Diabetic Foot Ulcers,Biological:CHAM; Other:Control,"[u'', u'', u'ILD Research Center', u'', u'MedStar Georgetown University Hospital', u'Barry University Clinical Research', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'Spartanburg Regional Healthcare System', u'North Texas Podiatric Medicine and Surgery Associates', u'Texas Gulf Coast Medical Group']","February 1, 2016",18,80,Both,False
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02557100,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02557100,True,Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Adalimumab; Drug:Methotrexate,"[u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Integral Rheumatology & Immunology Specialists', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Altoona Center For Clinical Research', u'Local Institution', u'Local Institution']","January 26, 2016",18,9223372036854775807,Both,False
NCT02547922,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT02547922,True,Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis,Lupus Nephritis,Biological:Anifrolumab; Drug:Placebo,[],"December 17, 2015",18,70,Both,False
NCT02545049,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02542215,Sucampo AG,False,AZ,https://ClinicalTrials.gov/show/NCT02542215,True,Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer,Oral Mucositis,Drug:Cobiprostone; Drug:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02536833,Samumed LLC,False,AZ,https://ClinicalTrials.gov/show/NCT02536833,True,"A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects",Osteoarthritis,Drug:SM04690; Drug:Placebo,[],"January 12, 2016",40,80,Both,False
NCT02536508,"Pearl Therapeutics, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02536508,True,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COPD,Drug:BGF MDI (PT010) 320/14.4/9.6 g; Drug:GFF MDI (PT003) 14.4/9.6 g; Drug:BFF MDI (PT009) 320/9.6 g,[],"January 6, 2016",40,80,Both,False
NCT02532855,Merck Sharp & Dohme Corp.,False,AZ,https://ClinicalTrials.gov/show/NCT02532855,True,A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838),Type 2 Diabetes Mellitus,Drug:Sitagliptin; Drug:Dapagliflozin; Drug:Metformin; Drug:Matching placebo to sitagliptin; Drug:Matching placebo to dapagliflozin,[],"February 2, 2016",25,9223372036854775807,Both,False
NCT02531516,"Aragon Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02531516,True,An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS,Prostatic Neoplasms,Drug:JNJ-56021927; Drug:Bicalutamide; Drug:Bicalutamide Placebo; Drug:JNJ-56021927 Placebo; Drug:GnRH (agonist); Radiation:74-80 Grays (units of radiation),[],"January 27, 2016",18,9223372036854775807,Male,False
NCT02510794,"Genentech, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02510794,True,Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration,Macular Degeneration,Drug:Ranibizumab ITV injection; Drug:Ranibizumab through RPDS Implant,[],"December 31, 2015",50,9223372036854775807,Both,False
NCT02501902,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02501902,True,Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,Metastatic Pancreatic Ductal Adenocarcinoma,Drug:Palbociclib; Drug:Nab-Paclitaxel,"[u'Scottsdale Healthcare Hospitals DBA HonorHealth', u'Virginia G. Piper Cancer Pharmacy', u'Oncology Investigational Drug Services (Drug Shipment Only)', u'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', u'John Hopkins Hospital', u'Siteman Cancer Center - West County', u'Siteman Cancer Center - South County', u'Barnes-Jewish Hospital', u'Washington University Infusion Center Pharmacy', u'Washington University School of Medicine, Siteman Cancer Center', u'Siteman Cancer Center', u""Hospital Universitari Vall D'Hebron""]","January 4, 2016",18,9223372036854775807,Both,False
NCT02495545,"St. Joseph's Hospital and Medical Center, Phoenix",True,AZ,https://ClinicalTrials.gov/show/NCT02495545,True,Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury,Acute Traumatic Spinal Cord Injury,Procedure:CSFD and elevation of MAP; Procedure:Maintenance of MAP,"[u'University of Alabama School of Medicine Department of Neurosurgery', u""Barrow Neurological Institute St. Joseph's Hospital and Medical Center"", u'University of Arizona Department of Surgery Division of Neurosurgery']","October 2, 2015",18,75,Both,False
NCT02492763,Merck Sharp & Dohme Corp.,False,AZ,https://ClinicalTrials.gov/show/NCT02492763,True,A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004),Type II Diabetes Mellitus,Drug:MK-8521; Drug:Placebo; Drug:Liraglutide; Drug:Metformin,[],"February 2, 2016",21,65,Both,False
NCT02489318,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02489318,True,A Study of JNJ-56021927 (ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,Prostate Cancer,Drug:JNJ-56021927; Drug:Placebo; Drug:Androgen Deprivation Therapy (ADT),[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02486718,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02477800,Biogen,False,AZ,https://ClinicalTrials.gov/show/NCT02477800,True,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02477618,Sage Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02469090,Cynapsus Therapeutics Inc,False,AZ,https://ClinicalTrials.gov/show/NCT02469090,True,"A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease",Parkinson Disease,Drug:APL-130277; Drug:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02440022,C. R. Bard,False,AZ,https://ClinicalTrials.gov/show/NCT02440022,True,Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae,Arteriovenous Fistula,Device:Lutonix DCB; Device:Standard Balloon Angioplasty Catheter,[],"February 2, 2016",21,9223372036854775807,Both,False
NCT02438007,Tokai Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02438007,True,A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,Prostate Cancer,Drug:Galeterone; Drug:Enzalutamide,[],"January 22, 2016",18,9223372036854775807,Male,False
NCT02425891,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02425891,True,A Study of Atezolizumab (MPDL3280A) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130),Metastatic Breast Cancer,Drug:Atezolizumab; Drug:Nab-Paclitaxel; Drug:Placebo,[],"December 31, 2015",18,9223372036854775807,Female,False
NCT02418754,Regeneron Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02418754,True,"Study of Intravitreal REGN2176-3 in Patients With Neovascular (""Wet"") Age-Related Macular Degeneration (AMD)",Neovascular Age-Related Macular Degeneration,Drug:REGN2176-3; Drug:Intravitreal Aflibercept Injection (IAI),[],"January 14, 2016",50,9223372036854775807,Both,False
NCT02415400,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02414841,Proteon Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02414841,True,A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2),Chronic Kidney Disease,Drug:vonapanitase; Drug:Placebo,[],"February 4, 2016",18,100,Both,False
NCT02410902,Curemark,True,AZ,https://ClinicalTrials.gov/show/NCT02410902,True,A Trial of CM-AT in Children With Autism With All Levels of FCT,Autism,Drug:CM-AT; Drug:PLACEBO,[],"January 6, 2016",3,8,Both,True
NCT02405260,vTv Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02405260,True,Add Glucokinase Activator to Target A1c,"Diabetes Mellitus, Type 2",Drug:TTP399 400 mg; Drug:TTP399 800 mg; Drug:Sitagliptin 100 mg; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","December 3, 2015",18,75,Both,False
NCT02392234,Vertex Pharmaceuticals Incorporated,False,AZ,https://ClinicalTrials.gov/show/NCT02392234,True,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug:VX-661/ivacaftor; Drug:ivacaftor; Drug:VX-661/ ivacaftor placebo; Drug:ivacaftor placebo,[],"December 2, 2015",12,9223372036854775807,Both,False
NCT02390050,Theracos,True,AZ,https://ClinicalTrials.gov/show/NCT02390050,True,A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Bexagliflozin tablets,[],"January 6, 2016",20,9223372036854775807,Both,False
NCT02387398,University of Arizona,False,AZ,https://ClinicalTrials.gov/show/NCT02387398,True,Early Coronary Angiography Versus Delayed Coronary Angiography,Out-of-Hospital Cardiac Arrest; Hypothermia; Cardiac Arrest,Procedure:Early Angiography,"[u'Banner University Medical Center-South Campus', u'Banner University Medical Center-Tucson Campus']","January 29, 2016",18,9223372036854775807,Both,False
NCT02376790,Amgen,False,AZ,https://ClinicalTrials.gov/show/NCT02376790,True,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Drug:Etanercept + Oral Methotrexate; Drug:Etanercept + Placebo for Methotrexate; Drug:Oral Methotrexate + Placebo for Etanercept,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02374099,Celgene Corporation,False,AZ,https://ClinicalTrials.gov/show/NCT02374099,True,Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,Breast Neoplasms,Drug:CC-486; Drug:Fulvestrant,[],"January 26, 2016",18,9223372036854775807,Female,False
NCT02367820,Nektar Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02367794,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02362672,Nektar Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT02362672,True,Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181; Drug:Placebo,[],"September 10, 2015",18,75,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02354586,"Tesaro, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02354586,True,A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,Ovarian Cancer,Drug:Niraparib,[],"January 26, 2016",18,9223372036854775807,Female,False
NCT02352948,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02348606,Jazz Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02348606,True,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Obstructive Sleep Apnea,Drug:JZP-110,[],"January 8, 2016",18,75,Both,False
NCT02348593,Jazz Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02348593,True,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Narcolepsy,Drug:JZP-110,[],"January 29, 2016",18,75,Both,False
NCT02343003,Halyard Health,False,AZ,https://ClinicalTrials.gov/show/NCT02343003,True,Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain,Osteoarthritis of the Knee,Device:Cooled Radiofrequency; Drug:Corticosteroid injection,"[u'Valley Anesthesiology Consultants - Estrella', u'Valley Anesthesiology Consultants/Valley Pain Consultants', u'Orthopedic Pain Specialists', u'Rush University Medical Center', u'MAPS Applied Research Center, Inc.', u'Ainsworth Institute of Pain Management', u'Center for Clinical Research', u'Drexel University', u'Piedmont Comprehensive Pain Management', u'Virginia iSpine Physicians', u'Advanced Pain Management']","January 7, 2016",21,9223372036854775807,Both,False
NCT02342548,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02342548,True,"Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021",Huntington's Disease,Drug:20 mg BID of PF-02545920,[],"January 19, 2016",30,66,Both,False
NCT02340221,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT02340221,True,SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,Breast Cancer,Drug:fulvestrant; Drug:placebo; Drug:taselisib,[],"February 1, 2016",18,9223372036854775807,Female,False
NCT00351611,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02150577,University of Arkansas,True,AR,https://ClinicalTrials.gov/show/NCT02150577,True,Implementation Trial of Evidence Based Practices for Mood Disorders,Bipolar Disorder; Treatment Resistant Depression,Behavioral:Evidence Based Quality Improvement,"[u'Mainline Health Systems Inc.', u'Boston Mountain Rural Health Center', u'Lee County Cooperative Clinic', u'ARcare', u'Jefferson Comprehensive Care System', u'East Arkansas Family Health Center']","October 14, 2015",18,100,Both,False
NCT01274338,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00858364,Amgen,False,AR,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,AR,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02427802,Innocoll,False,AR,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02406677,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02164864,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01888120,Jazz Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02528253,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02431806,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02431806,True,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],"December 23, 2015",12,17,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02240121,"Valeant Pharmaceuticals International, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02240121,True,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02075047,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT02048813,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01970865,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT01970865,True,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug:PF-06463922; Drug:Crizotinib,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01968876,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT01968876,True,Is a Smartphone Application Effective as an Oral Medication Adherence Aid,Hypertension; Diabetes; Dyslipidemia,Other:Medication Adherence Smartphone App,"[u'Internal Medicine Clinic North; University of Arkansas for Medical Sciences', u'Remedy Drug', u'Internal Medicine Clinic West; University of Arkansas for Medical Sciences']","November 12, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01828112,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT01828112,True,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,AR,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01546571,Polynoma LLC,False,AR,https://ClinicalTrials.gov/show/NCT01546571,True,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",Melanoma,Biological:POL-103A; Biological:POL-103A without API,[],"December 8, 2015",18,80,Both,False
NCT01120249,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01101035,Takeda,True,AR,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02638129,Takeda,False,AR,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02592434,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02592434,True,Efficacy Study Of Tofacitinib In Pediatric JIA Population,Juvenile Idiopathic Arthritis,"Drug:CP-690,550 (tofacitinib); Other:placebo","[u""Arkansas Children's Hospital - Attention: Billy Furgerson (IP Shipment Address)"", u""Arkansas Children's Hospital"", u'Tufts Medical Center, Inc.', u'Tufts Medical Center', u'Montefiore Medical Center (Drug Shipment)', u'Montefiore Medical Center', u""Cohen Children's Medical Center of NY"", u""Cohen Children's Medical Center of New York (Drug Shipment Address)"", u""Randall Children's Hospital at Legacy Emanuel""]","January 11, 2016",2,17,Both,False
NCT02590432,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02580305,Suven Life Sciences Limited,False,AR,https://ClinicalTrials.gov/show/NCT02580305,True,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,Alzheimer's Disease,Drug:SUVN-502; Drug:Placebo,"[u'Woodland International Research Group, LLC', u'Woodland Research Northwest', u'ATP Clinical Research, Inc.', u'Neuro-Pain Medical Center Inc', u'Senior Clinical Trials, Inc.', u'Jacksonville Center for Clinical Research', u'Premier Clinical Research Institute Inc', u'Miami Research Associates, LLC', u'The Roskamp Institute, Inc.', u'Neurology Clinical Research, Inc.', u'Axiom Clinical Research of Florida', u'Stedman Clinical Trials', u'Radiant Research', u'Sheppard Pratt Health System', u'AdvanceMed Research', u'Advanced Memory Research Institute', u'Biobehavioral Health', u'Integrative Clinical Trials, LLC', u'Eastside Comprehensive Medical Center, LLC', u'Valley Medical Research', u'IPS Research Company', u'Tulsa Clinical Research, LLC', u'Radiant Research, Inc.', u'Universal Research Group, LLC']","January 18, 2016",50,85,Both,False
NCT02580058,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02580058,True,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),Ovarian Cancer,Biological:avelumab; Drug:PLD,"[u'Highlands Oncology Group', u'Highlands Oncology Group', u'Cabrini Health Limited', u'Cabrini Health Limited']","January 13, 2016",18,9223372036854775807,Female,False
NCT02544152,Sucampo AG,False,AR,https://ClinicalTrials.gov/show/NCT02544152,True,Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome,Irritable Bowel Syndrome,Drug:Lubiprostone; Drug:Placebo,"[u'Gastroenterology Associates,P.A.', u'Arkansas Gastroenterology', u'GW Research Inc.', u'Therapeutic Research Institute of Orange County', u'The Regents of the University of California / Los Angeles Campus', u'Advanced Gastroenterology Associates, LLC', u'Digestive Care Physicians', u'Meritus Center for Clinical Research', u'Mayo Clinic', u'Cumberland Research Associates, LLC', u'Wake Research Associates, LLC', u'Clinical Research Solutions', u'Nashville Medical Research Institute', u'Houston Endoscopy Research Center']","January 4, 2016",18,9223372036854775807,Both,False
NCT02504268,Bristol-Myers Squibb,False,AR,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,AR,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,AR,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02452190,"Teva Branded Pharmaceutical Products, R&D Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02452190,True,Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Drug:Reslizumab; Drug:Placebo,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02445040,"Draeger Medical Systems, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02445040,True,Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates,Respiratory Distress Syndrome In Premature Infants,Device:Babylog VN500 in HFOV Mode,"[u""Arkansas Children's Hospital"", u'University of Arkansas for Medical Sciences', u'Sharp Mary Birch Hospital for Women and Newborns', u'University of Iowa Hospitals and Clinics', u""Children's Hospitals and Clinics of Minnesota"", u""St. Paul Children's Hospital"", u'New Hanover Regional Medical Center', u'Women & Infants Hospital of Rhode Island', u'Medical University of South Carolina', u'University of Texas Health Science Center at San Antonio', u'University of Utah Health Science Center']","January 25, 2016",23,30,Both,False
NCT02403401,Bayer,False,AR,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02369874,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT02369874,True,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN).,Drug:MEDI4736; Drug:MEDI4736 + Tremelimumab; Drug:Standard of Care,[],"January 18, 2016",18,96,Both,False
NCT02367794,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02367781,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02281773,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT02281773,True,"A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.",Schizophrenia,Drug:BI 409306 100 mg QD; Drug:BI 498306 50 mg QD; Drug:Placebo; Drug:BI 498306 25 mg QD; Drug:BI 409306 10 mg QD,[],"January 11, 2016",18,55,Both,False
NCT02229084,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02229084,True,Vaccination of High Risk Breast Cancer Patients,Breast Neoplasms,Biological:Chemovax,"[u'Highlands Oncology Group', u'University of Arkansas for Medical Sciences']","January 21, 2016",18,9223372036854775807,Female,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02165215,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02165215,True,A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug:Etrolizumab; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02161718,"Alkermes, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02161718,True,A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder,Schizophrenia; Alcohol Use Disorder,Drug:Samidorphan + olanzapine (ALKS 3831); Drug:Placebo,[],"February 3, 2016",18,65,Both,False
NCT02154490,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02152631,Eli Lilly and Company,False,AR,https://ClinicalTrials.gov/show/NCT02152631,True,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,Non Small Cell Lung Cancer,Drug:Abemaciclib; Drug:Erlotinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02145468,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02125461,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT02125461,True,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Drug:MEDI4736; Other:PLACEBO,[],"January 11, 2016",18,130,Both,False
NCT02100514,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02092467,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02025751,Evoke Pharma,False,AR,https://ClinicalTrials.gov/show/NCT02025751,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Male,False
NCT02025725,Evoke Pharma,False,AR,https://ClinicalTrials.gov/show/NCT02025725,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Female,False
NCT01991795,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,AR,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,AR,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,AR,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01807637,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT01807637,True,Transcranial Direct Current Stimulation for Improving Gait Training in Stroke,Stroke; Cerebral Vascular Accident,Device:transcranial direct current stim,"[u'University of Central Arkansas', u'University of Arkansas for Medical Sciences']","October 28, 2015",30,9223372036854775807,Both,False
NCT01741194,"Accera, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT01741194,True,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,Alzheimer's Disease,Drug:AC-1204; Drug:Placebo,[],"November 23, 2015",66,90,Both,False
NCT01715805,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01710709,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT01710709,True,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Bipolar I,Drug:Aripiprazole,[],"October 7, 2015",18,65,Both,False
NCT01674140,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01387932,"Merit Medical Systems, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT01387932,True,HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer,Hepatocellular Carcinoma,"Device:HepaSphere/QuadraSphere Microspheres; Procedure:PVA, lipiodol, doxorubicin",[],"October 20, 2015",18,9223372036854775807,Both,False
NCT01371656,Children's Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01371656,True,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,Acute Leukemias of Ambiguous Lineage; Bacterial Infection; Diarrhea; Fungal Infection; Musculoskeletal Complications; Neutropenia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:levofloxacin,[],"August 28, 2015",6,21,Both,False
NCT01349881,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01321541,CTI BioPharma,False,AR,https://ClinicalTrials.gov/show/NCT01321541,True,Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant,Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma,Drug:Pixantrone + Rituximab; Drug:Gemcitabine + Rituximab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01307579,Children's Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01190930,Children's Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00955708,Boston Scientific Corporation,False,AR,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00736749,Children's Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02656303,"TG Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02656303,True,An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,Chronic Lymphocytic Leukemia,Biological:ublituximab; Drug:TGR-1202,"[u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site']","January 13, 2016",18,9223372036854775807,Both,False
NCT02649959,Curemark,True,AR,https://ClinicalTrials.gov/show/NCT02649959,True,An Open Label Study of CM-AT for the Treatment of Children With Autism,Autism,Drug:CM-AT,[],"January 6, 2016",3,8,Both,False
NCT02648269,"Selecta Biosciences, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02648269,True,Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels,Gout,Drug:SEL-110; Biological:SEL-212; Biological:SEL-037,"[u'Baptist Health Center for Clinical Research', u'Miami Research Associates', u'Orlando Clinical Research Center, Inc.', u'SNBL Clinical Pharmacology Center Inc.', u'Davita Clinical Research', u'Altoona Center for Clincal Research']","January 6, 2016",21,70,Both,False
NCT02647086,Regeneron Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02647086,True,"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",Atopic Dermatitis,Drug:Dupilumab; Drug:Cytochrome P450 Substrates,"[u'Regeneron Study Site', u'Regeneron Study Site', u'Regeneron Study Site', u'Regeneron Study Site', u'Regeneron Study Site', u'Regeneron Study Site']","January 4, 2016",18,9223372036854775807,Both,False
NCT02639546,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02639546,True,iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,Solid or Brain Tumor With Evidence of RAS/RAF/MEK/ERK Activation,Drug:Cobimetinib,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","February 1, 2016",6,30,Both,False
NCT02638805,Intarcia Therapeutics,False,AR,https://ClinicalTrials.gov/show/NCT02638805,True,Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide,"Diabetes Mellitus, Type 2",Drug:ITCA 650 20/60 mcg/day; Drug:ITCA 650 60 mcg/day,[],"February 3, 2016",18,80,Both,False
NCT02636946,Allergan,False,AR,https://ClinicalTrials.gov/show/NCT02636946,True,A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension,Glaucoma; Open-Angle Ocular Hypertension,Drug:Bimatoprost SR; Drug:Sham Bimatoprost SR; Procedure:Selective Laser Trabeculoplasty; Procedure:Sham Selective Laser Trabeculoplasty,"[u'', u'', u'', u'', u'', u'']","December 18, 2015",18,9223372036854775807,Both,False
NCT02636699,DBV Technologies,False,AR,https://ClinicalTrials.gov/show/NCT02636699,True,Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy,Peanut Allergy,Biological:Viaskin Peanut 250mcg; Biological:Placebo,[],"February 2, 2016",4,11,Both,False
NCT02634346,"Alkermes, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02634346,True,A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study),"Schizophrenia,",Drug:ALK3831; Drug:Olanzapine; Drug:Placebo,"[u'Alkermes Investigational Site', u'Alkermes Investigational Site', u'Akermes Investigational Site', u'Alkermes Investigational Site']","January 11, 2016",18,70,Both,False
NCT02634320,"Alkermes, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02634320,True,A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia,Schizophrenia,Drug:Aripiprazole Lauroxil,"[u'Alkermes Investigational Site', u'Alkermes Investigational Site']","December 16, 2015",18,65,Both,False
NCT02625545,"NeoTract, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02625545,True,Study of Median Lobe Prostatic UroLift Procedure,Benign Prostatic Hyperplasia (BPH),Device:UroLift System procedure,"[u'Arkansas Urology', u'Chesapeake Urology', u'Adult Pediatric Urology and Urogynecology', u'Urology of Virginia', u'Sound Urology Associates']","February 4, 2016",50,9223372036854775807,Male,False
NCT02618915,Dimension Therapeutics,False,AR,https://ClinicalTrials.gov/show/NCT02618915,True,Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B,Hemophilia B,Genetic:AAVrh10FIX; Genetic:AAVrh10FIX; Genetic:AAVrh10FIX; Genetic:AAVrh10FIX,"[u""Arkansas Children's Hospital"", u""Boston Children's Hospital"", u'University of Michigan Hospital and Health Systems, Michigan Clinical Research Unit', u'The Hemophilia Center of Western Pennsylvania']","December 21, 2015",18,9223372036854775807,Male,False
NCT02616640,Celgene Corporation,False,AR,https://ClinicalTrials.gov/show/NCT02616640,True,A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,Multiple Myeloma,Drug:Durvalumab; Drug:Pomalidomide; Drug:Dexamethasone,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02612922,Romark Laboratories L.C.,False,AR,https://ClinicalTrials.gov/show/NCT02612922,True,Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza,Influenza,Drug:Nitazoxanide; Drug:Placebo,"[u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site', u'Influence Study Site']","January 26, 2016",12,65,Both,False
NCT02612311,"TG Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02612311,True,Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Biological:Obinutuzumab; Biological:Ublituximab; Drug:TGR-1202; Drug:Chlorambucil,"[u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site', u'TG Therapeutics Investigational Trial Site']","February 1, 2016",18,9223372036854775807,Both,False
NCT02608450,Cassiopea SpA,False,AR,https://ClinicalTrials.gov/show/NCT02608450,True,"A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)",Acne Vulgaris,"Drug:CB-03-01 cream, 1%; Drug:Vehicle cream",[],"January 20, 2016",9,9223372036854775807,Both,False
NCT02607774,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02607774,True,Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis,Moderate to Severe Plaque Psoriasis,Drug:Midazolam; Drug:AIN457,"[u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site']","January 28, 2016",18,9223372036854775807,Both,False
NCT02605837,Shire,False,AR,https://ClinicalTrials.gov/show/NCT02605837,True,A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved,Eosinophilic Esophagitis (EoE) Dysphagia,Drug:Oral Budesonide Suspension; Drug:Placebo,"[u'Arkansas Gastroenterology', u'GW Research, Inc.', u'Accord Clinical Research LLC', u'Gastroenterology Associates LLC', u'Louisiana Research Center LLC']","November 24, 2015",11,55,Both,False
NCT02605356,Bayer,False,AR,https://ClinicalTrials.gov/show/NCT02605356,True,Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,Multiple Myeloma,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Placebo; Drug:Bortezomib; Drug:Dexamethasone",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02604680,Braintree Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02604680,True,A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris,Acne Vulgaris,Drug:BLI1100-1; Drug:BLI1100-2; Drug:BLI1100-3; Drug:Control group; Drug:Placebo,[],"November 12, 2015",12,45,Both,False
NCT02601209,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02597738,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02597738,True,A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine,Lung Cancer,Other:Fresh tissue biopsy and blood collection; Other:Blood Sample Collection,[u'University of Arkansas for Medical Sciences'],"January 26, 2016",18,99,Both,True
NCT02597504,"ImPACT Applications, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02597504,True,Development of a Neurocognitive Screening Test,Brain Concussion; Mild Cognitive Impairment,Other:Pen and paper neuropsychological test; Device:Quick Test,"[u'FastMed Urgent Care', u'University of Arkansas', u'Heads Up Pediatrics']","November 5, 2015",6,75,Both,True
NCT02589847,Rebiotix Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02589847,True,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,Clostridium Difficile Infection,Biological:RBX2660,"[u'', u'', u'', u'', u'', u'', u'', u'', u'']","November 23, 2015",18,9223372036854775807,Both,False
NCT02584933,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02584933,True,Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study,ALK Positive Malignancies,Drug:ceritinib,"[u'Highlands Oncology Group SC-3', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site', u'Novartis Investigative Site']","January 24, 2016",18,9223372036854775807,Both,False
NCT02578121,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02578121,True,UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination,Multiple Myeloma,Drug:Ixazomib; Drug:Pomalidomide; Drug:Dexamethasone,[u'University of Arkansas for Medical Science'],"October 14, 2015",18,9223372036854775807,Both,False
NCT02576860,"Cutanea Life Sciences, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02576860,True,Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle,Rosacea,Drug:Omiganan; Drug:Vehicle,[],"December 23, 2015",18,9223372036854775807,Both,True
NCT02573324,AbbVie,False,AR,https://ClinicalTrials.gov/show/NCT02573324,True,A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,Glioblastoma; Gliosarcoma,Drug:ABT-414; Radiation:Radiation; Drug:Temozolomide; Drug:Placebo for ABT-414,[],"January 23, 2016",18,99,Both,False
NCT02572817,National Institute of Allergy and Infectious Diseases (NIAID),False,AR,https://ClinicalTrials.gov/show/NCT02572817,True,Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A,Influenza A Virus Infection,Biological:High-titer anti-influenza plasma; Biological:Low-titer (control) anti-influenza plasma,"[u""Arkansas Children's Hospital"", u'University of Iowa Hospitals & Clinics', u'Johns Hopkins University', u'NIH Clinical Center', u'Massachusetts General Hospital', u'University of Massachusetts Medical School', u'University of Michigan']","February 3, 2016",0,9223372036854775807,Both,False
NCT02563106,Synthetic Biologics Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02563106,True,A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI,Clostridium Difficile; Clostridium Infections,Drug:SYN-004; Drug:Placebo,"[u'', u'', u'', u'', u'']","November 16, 2015",50,9223372036854775807,Both,False
NCT02559817,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02559817,True,"A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation",Irritable Bowel Syndrome With Constipation,Drug:Linaclotide Dose A; Drug:Linaclotide Dose B; Drug:Linaclotide Dose C; Drug:Linaclotide Approved Adult Dose; Drug:Matching Placebo,[],"October 30, 2015",7,17,Both,False
NCT02559778,Giselle Sholler,False,AR,https://ClinicalTrials.gov/show/NCT02559778,True,Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,Neuroblastoma,Drug:bortezomib; Drug:crizotinib; Drug:dasatinib; Drug:lapatinib; Drug:sorafenib; Drug:vorinostat; Drug:DFMO,"[u""Arkansas Children's Hospital"", u""Rady Children's Hospital"", u""Connecticut Children's Hospital"", u'Arnold Palmer Hospital for Children', u'Kapiolani Medical Center for Women and Children', u""Helen DeVos Children's Hospital"", u""Children's Hospital and Clinics on Minnesota"", u""Cardinal Glennon Children's Medical Center"", u""Levine Children's Hospital"", u""Penn State Milton S. Hershey Medical Center and Children's Hospital"", u'Medical University of South Carolina', u""Dell Children's Blood and Cancer Center""]","January 18, 2016",12,21,Both,False
NCT02559570,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02559570,True,A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC),Functional Constipation in Children Ages 6-17 Years,Drug:Linaclotide Dose A; Drug:Linaclotide Dose B; Drug:Linaclotide Dose C; Drug:Linaclotide Approved Adult Dose; Drug:Matching Placebo,[],"October 30, 2015",6,17,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02558296,Theracos,True,AR,https://ClinicalTrials.gov/show/NCT02558296,True,Bexagliflozin Efficacy and Safety Trial (BEST),Type 2 Diabetes Mellitus,Drug:Bexagliflozin; Drug:Placebo,[],"January 7, 2016",40,9223372036854775807,Both,False
NCT02556567,Arkansas Children's Hospital Research Institute,True,AR,https://ClinicalTrials.gov/show/NCT02556567,True,Exploring the Effects of Sleep Patterns and Physical Activity on Asthma in Adolescents With Wrist-worn Smart Devices,Asthma,Other:Fitbit Charge HR wristband,"[u""Arkansas Children's Hospital Research Institute""]","December 18, 2015",14,17,Both,True
NCT02555709,"Vitae Pharmaceuticals, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02555709,True,An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients,Psoriasis,Drug:VTP-43742; Drug:Placebo 1; Drug:Placebo 2,"[u'Patient Site 5', u'Patient Site 1', u'Patient Site 8', u'Patient Site 4', u'Healthy Volunteer Site 1', u'Patient Site 2', u'Patient Site 9', u'Patient Site 6', u'Patient Site 3', u'Patient Site 10', u'Patient Site 11', u'Patient Site 7']","January 7, 2016",18,75,Both,True
NCT02553798,"Dermira, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02553798,True,Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis,Hyperhidrosis,Drug:DRM04 Topical Wipes,[],"January 21, 2016",9,9223372036854775807,Both,False
NCT02552212,UCB BIOSCIENCES GmbH,False,AR,https://ClinicalTrials.gov/show/NCT02552212,True,Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS,Axial Spondyloarthritis; Nonradiographic Axial Spondyloarthritis; Nr-axSpA,Biological:Certolizumab Pegol; Other:Placebo,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02551874,Bristol-Myers Squibb,False,AR,https://ClinicalTrials.gov/show/NCT02551874,True,"A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy",Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glargine insulin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02538965,Celgene Corporation,False,AR,https://ClinicalTrials.gov/show/NCT02538965,True,A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia,"Leukemia, Myeloid",Drug:Lenalidomide,"[u""Arkansas Children's Hospital"", u""Miller Children's Hospital"", u""All Children's Hospital"", u'Riley Hospital For Children at IU Health', u'University of Michigan', u'University of Mississippi Medical Center', u""Children's Specialty Center of Nevada"", u'Hackensack University Medical Center', u'Morristown Memorial Hosp', u'Cancer Institute of New Jersey', u'New York Medical College', u'University of North Carolina', u'Legacy Emanuel Hospital and Health Center', u""Texas Children's Cancer Center"", u""Seattle Children's Hospital""]","December 11, 2015",1,18,Both,False
NCT02535091,SK Life Science,False,AR,https://ClinicalTrials.gov/show/NCT02535091,True,Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures,Partial Epilepsy,Drug:YKP3089,"[u'Clinical Trials, Inc.', u'Mid-Atlantic Epilepsy and Sleep Center', u'Austin Epilepsy Care Center']","November 24, 2015",18,70,Both,False
NCT02532855,Merck Sharp & Dohme Corp.,False,AR,https://ClinicalTrials.gov/show/NCT02532855,True,A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838),Type 2 Diabetes Mellitus,Drug:Sitagliptin; Drug:Dapagliflozin; Drug:Metformin; Drug:Matching placebo to sitagliptin; Drug:Matching placebo to dapagliflozin,[],"February 2, 2016",25,9223372036854775807,Both,False
NCT02531373,Merck Sharp & Dohme Corp.,False,AR,https://ClinicalTrials.gov/show/NCT02531373,True,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)",Pneumococcal Infections,Biological:V114 Medium Dose; Biological:V114 High Dose; Biological:V114 Medium Dose with Alternative Carrier Protein; Biological:V114 High Dose with Alternative Carrier Protein; Biological:Prevnar 13,"[u'Call for Information (Investigational Site 0016)', u'Call for Information (Investigational Site 0021)', u'Call for Information (Investigational Site 0010)', u'Call for Information (Investigational Site 0012)', u'Call for Information (Investigational Site 0018)', u'Call for Information (Investigational Site 0027)', u'Call for Information (Investigational Site 0028)', u'Call for Information (Investigational Site 0024)', u'Call for Information (Investigational Site 0026)', u'Call for Information (Investigational Site 0025)', u'Call for Information (Investigational Site 0011)', u'Call for Information (Investigational Site 0008)', u'Call for Information (Investigational Site 0009)', u'Call for Information (Investigational Site 0017)', u'Call for Information (Investigational Site 0004)', u'Call for Information (Investigational Site 0001)', u'Call for Information (Investigational Site 0015)', u'Call for Information (Investigational Site 0029)']","February 4, 2016",2,49,Both,True
NCT02531126,"Receptos, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02531126,True,Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Drug:RPC1063,"[u'Receptos Study Site 144', u'Receptos Study Site 212', u'Receptos Study Site 198', u'Receptos Study Site 207', u'Receptos Study Site 211', u'Receptos Study Site 112', u'Receptos Study Site 201', u'Receptos Study Site 106', u'Receptos Study Site 179', u'Receptos Study Site 265']","January 20, 2016",18,75,Both,False
NCT02530294,"Dermira, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02530294,True,Study of DRM04 in Subjects With Axillary Hyperhidrosis,Hyperhidrosis,Drug:DRM04 Topical Wipes; Other:Placebo,"[u'Northwest Arkansas Clinical Trials Center, PLLC', u'Dermatology Research Associates', u'Clinical Science Institute', u'Colorado Medical Research Center, Inc.', u'Shideler Clinical Research Center', u'Lawrence J Green, MD LLC', u'Zel Skin & Laser Specialist', u'MediSearch Clinical Trials', u'Clinical Studies Group, LLC', u'Academic Dermatology Associates', u'Schweiger Dermatology Group', u'Skin Search of Rochester, Inc.', u'Oregon Dermatology and Research Center', u'Clinical Research Associates, Inc.', u'Modern Research Associates', u'The University of Texas Dermatology Clinical Research Center', u'Dermatology Research Center, Inc.', u'Jordan Valley Dermatology Center', u'Dermatology Associates', u'Premier Clinical Research']","February 2, 2016",9,9223372036854775807,Both,False
NCT02524171,VA Office of Research and Development,False,AR,https://ClinicalTrials.gov/show/NCT02524171,True,Justice-Involved Veterans and Moral Reconation Therapy,Antisocial Personality Disorder; Substance Use Disorder,Behavioral:Moral Reconation Therapy (MRT),"[u'Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR', u'VA Palo Alto Health Care System, Palo Alto, CA', u'Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA']","January 28, 2016",0,9223372036854775807,Both,False
NCT02514447,"G1 Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02514447,True,Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,Small Cell Lung Cancer,Drug:G1T28 + Topotecan,"[u'Genesis Cancer Center', u'Rocky Mountain Cancer Centers', u'University of Colorado Health, Oncology Clinical Research Northern Region', u'Florida Cancer Specialists - South', u'Florida Cancer Specialists - North', u'Florida Cancer Specialists - East', u'University Cancer and Blood Center, LLC', u'Emory University', u'Northside Hospital - Georgia Cancer Specialists', u'North Shore Hematology Oncology Associates PC', u'Lineberger Comprehensive Cancer Center', u'Oklahoma University - Peggy and Charles Stephenson Cancer Center', u'Greenville Health System', u'Gibbs Cancer Center', u'Meharry Medical College', u'Sarah Cannon Research Institute', u'Texas Oncology- Baylor Charles A. Sammons Cancer Center', u'M.D. Anderson', u'Texas Oncology', u'Virginia Cancer Specialists', u'Virginia Oncology Associates', u'Northwest Cancer Specialists, P.C.']","November 30, 2015",18,9223372036854775807,Both,False
NCT02510014,Indivior Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02510014,True,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Opioid Use Disorder; Opioid-related Disorders,Drug:SUBOXONE sublingual film; Drug:high dose RBP-6000; Drug:low dose RBP-6000,[],"December 10, 2015",18,65,Both,False
NCT02504008,"Axsome Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02504008,True,A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1,Complex Regional Pain Syndrome - Type 1; Reflex Sympathetic Dystrophy,Drug:AXS-02 (oral zoledronate); Drug:Placebo,"[u'HealthStar Physicians of Hot Springs', u'UCSD Physical Medicine and Rehabilitation', u'University of Southern California Pain Center', u'American Spine and Pain MedGroup', u'Orthopedic Pain Specialists', u'University of South Florida', u'North Georgia Medical Associates', u'Rush University Medical Center', u'Great Lakes Clinical Trials', u'University of Louisville', u'Ainsworth Institute of Pain Management', u'The Center for Clinical Research', u'Hunter Clinical Research', u'The Menzies Institute for Medical Research at the University of Tasmania', u'Royal Liverpool University Hospital', u""St. Thomas' Hospital"", u'Norfolk and Norwich University Hospital', u'Gartnavel General Hospital']","February 2, 2016",18,9223372036854775807,Both,False
NCT02502669,"Elorac, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02502669,True,Finasteride Treatment of Severe Nodulocystic Acne,NODULOCYSTIC ACNE,Drug:Finasteride 23.5 mg tablets; Drug:Finasteride 33.5 mg tablets; Drug:Placebo tablets,[],"February 3, 2016",18,35,Male,True
NCT02500719,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02500719,True,Real-time Functional MRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD,"Stress Disorders, Post-Traumatic",Other:Fitted Q Learning Algorithm,[u'University of Arkansas for Medical Sciences'],"October 1, 2015",21,50,Female,True
NCT02499770,"G1 Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02499770,True,G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),Small Cell Lung Cancer,Drug:G1T28 + carboplatin/ etoposide; Drug:Placebo + carboplatin/ etoposide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02499081,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02499081,True,UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment,Multiple Myeloma,Drug:Ixazomib,[u'University of Arkansas for Medical Science'],"September 15, 2015",18,75,Both,False
NCT02497716,Bayer,False,AR,https://ClinicalTrials.gov/show/NCT02497716,True,Phase I Study on Rivaroxaban Dry Powder Suspension in Children,Thrombosis,"Drug:Rivaroxaban (Xarelto, BAY59-7939",[],"January 5, 2016",6,12,Both,False
NCT02497469,Takeda,False,AR,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02493868,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02493868,True,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 2, 2016",18,64,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02487498,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02487498,True,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol ); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02487446,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02485964,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02485964,True,A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine,Prostate Cancer,Other:Blood draw,[u'University of Arkansas for Medical Sciences'],"August 14, 2015",18,9223372036854775807,Male,False
NCT02483975,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT02483975,True,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Asthma,Drug:FF; Drug:Placebo; Drug:Montelukast; Drug:Albuterol/Salbutamol,[u'GSK Investigational Site'],"December 3, 2015",5,11,Both,False
NCT02482311,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT02482311,True,"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","Ovarian Cancer, TNBC, SqNSCLC, and Other Solid Tumours",Drug:AZD 1775,"[u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site']","January 7, 2016",18,99,Both,False
NCT02481830,Bristol-Myers Squibb,False,AR,https://ClinicalTrials.gov/show/NCT02481830,True,Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,Lung Cancer,Drug:Nivolumab; Drug:Topotecan; Drug:Amrubicin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02481414,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02481414,True,A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions,Cervical Intraepithelial Neoplasia,Biological:Pepcan+Candin; Biological:Candin,[u'University of Arkansas for Medical Sciences'],"December 15, 2015",18,50,Female,False
NCT02477943,"BrainScope Company, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02477943,True,Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization,"Brain Injuries, Traumatic; Brain Injury Without Open Intracranial Wound",Device:BrainScope Battery; Device:Advanced MRI Neuroimaging,"[u'University of Arkansas', u'University of Connecticut', u'SUNY Upstate Medical University', u'University of South Carolina', u'University of Texas - Austin', u'Baylor College of Medicine', u'Houston Methodist Hospital']","September 18, 2015",18,30,Both,False
NCT02477891,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02477891,True,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02477618,Sage Therapeutics,False,AR,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02477332,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02477332,True,Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU,Chronic Spontaneous Urticaria,Biological:QGE031; Biological:Omalizumab; Other:Placebo,[],"January 5, 2016",18,75,Both,False
NCT02475876,Michael Cohen-Wolkowiez,False,AR,https://ClinicalTrials.gov/show/NCT02475876,True,PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children,Bacterial Infections,Drug:Clindamycin; Drug:trimethoprim-sulfamethoxazole,"[u""Arkansas Children's Hospital"", u""Ann & Robert H. Lurie Children's Hospital of Chicago"", u""University of Michigan C.S. Mott Children's Hospital""]","January 4, 2016",1,16,Both,False
NCT02469532,"Mercator MedSystems, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02469532,True,DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes,Peripheral Arterial Disease,Device:Balloon Angioplasty; Device:Atherectomy System,"[u'Arkansas Heart Hospital', u'Endovascular Technologies (Willis Knighton Medical Center)', u'Hattiesburg Clinic', u'Mission Research Institute', u'Palestine Regional Medical Center']","January 13, 2016",18,9223372036854775807,Both,False
NCT02454348,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02454348,True,NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock,"Shock, Septic",Drug:Vasopressin; Drug:Norepinephrine,[u'University of Arkansas for Medical Sciences'],"November 30, 2015",18,9223372036854775807,Both,False
NCT02450539,Eli Lilly and Company,False,AR,https://ClinicalTrials.gov/show/NCT02450539,True,A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,Non-Small Cell Lung Cancer Stage IV,Drug:Abemaciclib; Drug:Docetaxel,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02436239,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02436239,True,A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Vilazodone,[],"December 23, 2015",7,17,Both,False
NCT02435992,"Receptos, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02435992,True,Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Drug:RPC1063; Drug:Placebo,[],"January 20, 2016",18,75,Both,False
NCT02431702,"Janssen Scientific Affairs, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02431702,True,A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform,Schizophrenia; Psychotic Disorders,Drug:Aripiprazole; Drug:Haloperidol; Drug:Olanzapine; Drug:Paliperidone ER; Drug:Perphenazine; Drug:Quetiapine; Drug:Risperidone; Drug:Paliperidone Palmitate Injection (PP1M); Drug:Paliperidone Palmitate Injection (PP3M),[],"January 12, 2016",18,35,Both,True
NCT02426125,Eli Lilly and Company,False,AR,https://ClinicalTrials.gov/show/NCT02426125,True,A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,Urothelial Carcinoma,Drug:Ramucirumab; Drug:Docetaxel; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02424578,"Iroko Pharmaceuticals, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02424578,True,Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age,"Pain, Postoperative",Drug:Diclofenac Capsules low dose; Drug:Diclofenac Capsules high dose,"[u'', u'', u'', u'', u'']","September 16, 2015",6,16,Both,False
NCT02422615,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02422615,True,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,"Breast Neoplasms; Breast Diseases; Neoplasms; Neoplasms by Site; Fulvestrant; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Therapeutic Use",Drug:Ribociclib; Drug:fulvestrant; Drug:Ribociclib placebo,[],"September 14, 2015",18,9223372036854775807,Female,False
NCT02417064,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02417064,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 3, 2016",18,64,Both,False
NCT02415400,Bristol-Myers Squibb,False,AR,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02411695,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02411695,True,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia",Schizophrenia,Drug:Brexpiprazole (OPC-34712),"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 7, 2016",13,17,Both,False
NCT02410902,Curemark,True,AR,https://ClinicalTrials.gov/show/NCT02410902,True,A Trial of CM-AT in Children With Autism With All Levels of FCT,Autism,Drug:CM-AT; Drug:PLACEBO,[],"January 6, 2016",3,8,Both,True
NCT02410278,Biogen,False,AR,https://ClinicalTrials.gov/show/NCT02410278,True,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,Multiple Sclerosis,Drug:dimethyl fumarate; Drug:montelukast; Drug:Placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02408523,"UCB BIOSCIENCES, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02408523,True,A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications,Epilepsy,Drug:Lacosamide Tablet; Drug:Lasosamide Oral Solution; Other:Placebo Tablet; Other:Placebo Oral Solution,[],"January 8, 2016",4,9223372036854775807,Both,False
NCT02407314,Arkansas Heart Hospital,False,AR,https://ClinicalTrials.gov/show/NCT02407314,True,Ticagrelor and Peripheral Arterial Disease,Peripheral Arterial Disease,Procedure:Percutaneous Peripheral Intervention; Device:Optical Coherence Tomography; Other:Ankle Brachial Index; Other:Six minute walk distance assessment; Drug:Aspirin; Drug:Aspirin + Ticagrelor,[u'Arkansas Heart Hospital'],"January 6, 2016",18,9223372036854775807,Both,False
NCT02407132,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02407132,True,Family Model of Diabetes Self-Management Education in the Marshallese Community,Diabetes,Behavioral:Family Model DSME,[u'University of Arkansas for Medical Sciences Northwest'],"October 14, 2015",18,9223372036854775807,Both,True
NCT02407054,Eli Lilly and Company,False,AR,https://ClinicalTrials.gov/show/NCT02407054,True,A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,Prostate Cancer Metastatic,Drug:LY3023414; Drug:Enzalutamide; Drug:Placebo,"[u'Urology Centers of Alabama, P.C.', u'Pinnacle Oncology Hematology', u'Highlands Oncology Group', u'Florida Cancer Specialists', u'Florida Cancer Specialists North', u'Florida Cancer Specialists East', u'Ingalls Memorial Hospital', u'Fort Wayne Oncology and Hematology', u'Indiana Cancer Pavilion', u'Tulane University School of Medicine', u'Dana Farber Cancer Institute', u'Hudson Valley Urology', u'Oncology Hematology Care Inc.', u'Carolina Urologic Research Center', u'Urology Associates', u'Tennessee Oncology PLLC', u'SMO Sarah Cannon Research Inst.', u'Southwestern Medical Center - Dallas', u'University of Virginia Health System', u'Swedish Medical Center']","December 22, 2015",18,9223372036854775807,Male,False
NCT02403323,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02397096,Merck Sharp & Dohme Corp.,False,AR,https://ClinicalTrials.gov/show/NCT02397096,True,Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024),HIV-1 Infection,Drug:MK-1439A; Drug:Baseline regimen of ritonavir-boosted protease inhibitor; Drug:Baseline regimen of two nucleoside reverse transcriptase inhibitors,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02396238,Cytori Therapeutics,False,AR,https://ClinicalTrials.gov/show/NCT02396238,True,Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR),Scleroderma; Systemic Sclerosis; Raynaud Phenomena; Raynaud's Disease,Device:Celution Device; Other:Placebo,"[u'Arizona Arthritis and Rheumatology Research, PLLC', u'Baptist Health Center for Clinical Research', u'Arthritis Associates of Southern California', u'UCLA David Geffen School of Medicine', u'Georgetown University Hospital', u'Northwestern University', u'Heartland Research Associates', u'Central Kentucky Research Associates, Inc.', u'Boston University Medical Center', u'University of Michigan', u'West Michigan Rheumatology, PLLC', u'Robert Wood Johnson Medical School', u'Hospital for Special Surgery', u'Duke University Medical Center', u'Cleveland Clinic', u'University of Pennsylvania', u'University of Pittsburgh', u'University of Texas Houston Medical School']","December 4, 2015",18,70,Both,False
NCT02394028,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02393417,"Nielsen BioSciences, Inc.",True,AR,https://ClinicalTrials.gov/show/NCT02393417,True,Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris),Warts,Biological:CANDIN; Other:Placebo,"[u'Johnson Dermatology', u'California Dermatology and Clinical Research Institute', u'Silverberg MD Inc.', u'BayState Clinical Trials', u'Hamzavi Dermatology Clinical Trials', u'Austin Institute for Clinical Research Inc.', u'DermResearch Inc.', u'Texas Dermatology and Laser Specialists', u'The Education and Research Foundation, Inc.']","November 9, 2015",18,65,Both,False
NCT02392507,Eli Lilly and Company,False,AR,https://ClinicalTrials.gov/show/NCT02392507,True,A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,"Carcinoma, Non-small-Cell Lung",Drug:Necitumumab; Drug:Nab-Paclitaxel; Drug:Carboplatin,"[u'Clopton Clinic', u'Summit Cancer Care', u'Rush University Medical Center', u'Cancer Center of Kansas, P.A.', u'Wake Forest Baptist Univ CAR', u'University of Pittsburgh Medical Center', u'South Carolina Oncology Associates', u'University of Tennessee Medical Center', u'Cancer Care Northwest', u'University of Wisconsin-Madison Hospital and Health Clinic']","January 8, 2016",18,9223372036854775807,Both,False
NCT02389127,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02389127,True,Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis,"Cirrhosis; Diabetes Mellitus, Type 2","Device:Continuous glucose monitor (Dexcom, San Diego, CA)",[u'University of Arkansas for Medical Sciences'],"October 12, 2015",18,9223372036854775807,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02382614,"Spiration, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02382614,True,Spiration Valves Against Standard Therapy,Pulmonary Air Leaks,Device:Spiration Valve System,"[u'University of Alabama at Birmingham', u'Sparks Regional Medical Center', u'California Pacific Medical Center', u'Washington Hospital Center', u'University of South Florida', u'University of Chicago', u'St. Vincent Hospital', u'University of Kentucky', u'Dartmouth Mary Hitchcock Memorial Hospital', u'Cooper University Hospital', u'University of Cincinnati', u'Penn State Hershey Medical Center', u'University of Texas Southwestern']","February 2, 2016",18,9223372036854775807,Both,False
NCT02378220,Genelex Corporation,False,AR,https://ClinicalTrials.gov/show/NCT02378220,True,Pharmacogenetic Testing Among Home Health Patients,"Adverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED; Drug Metabolism, Poor, CYP2C19-RELATED; Cytochrome P450 Enzyme Deficiency; Cytochrome P450 CYP2D6 Enzyme Deficiency; Cytochrome P450 CYP2C9 Enzyme Deficiency; Cytochrome P450 CYP2C19 Enzyme Deficiency; Cytochrome P450 CYP3A Enzyme Deficiency; Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant; Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant",Genetic:Pharmacogenetic testing,[u'White County Medical Center Home Health'],"September 10, 2015",50,9223372036854775807,Both,False
NCT02376790,Amgen,False,AR,https://ClinicalTrials.gov/show/NCT02376790,True,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Drug:Etanercept + Oral Methotrexate; Drug:Etanercept + Placebo for Methotrexate; Drug:Oral Methotrexate + Placebo for Etanercept,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02374099,Celgene Corporation,False,AR,https://ClinicalTrials.gov/show/NCT02374099,True,Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,Breast Neoplasms,Drug:CC-486; Drug:Fulvestrant,[],"January 26, 2016",18,9223372036854775807,Female,False
NCT02372799,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02372799,True,Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22),Major Depressive Disorder,Drug:Vilazodone; Drug:Placebo; Drug:Fluoxetine,[],"December 17, 2015",7,17,Both,False
NCT02367820,Nektar Therapeutics,False,AR,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02365909,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT02365909,True,Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH),Postdural Puncture Headache,Drug:0.5% bupivacaine; Drug:normal saline,[u'University of Arkansas for Medical Sciences'],"September 2, 2015",18,9223372036854775807,Both,True
NCT02364999,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02364999,True,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02349295,Eli Lilly and Company,False,AR,https://ClinicalTrials.gov/show/NCT02349295,True,A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02348723,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT02348723,True,Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT),Atrial Fibrillation,Drug:Warfarin; Drug:Dabigatran Etexilate 150mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02348606,Jazz Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02348606,True,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Obstructive Sleep Apnea,Drug:JZP-110,[],"January 8, 2016",18,75,Both,False
NCT02348593,Jazz Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02348593,True,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Narcolepsy,Drug:JZP-110,[],"January 29, 2016",18,75,Both,False
NCT02347657,Vertex Pharmaceuticals Incorporated,False,AR,https://ClinicalTrials.gov/show/NCT02347657,True,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Cystic Fibrosis,Drug:VX-661/ ivacaftor; Drug:ivacaftor; Drug:VX-661/ ivacaftor placebo; Drug:ivacaftor placebo,[],"September 30, 2015",12,9223372036854775807,Both,False
NCT02346201,Johns Hopkins Bloomberg School of Public Health,False,AR,https://ClinicalTrials.gov/show/NCT02346201,True,Apathy in Dementia Methylphenidate Trial 2,Apathy; Alzheimer's Disease,Drug:Methylphenidate; Drug:Placebo,"[u""Banner Alzheimer's Institute"", u'University of Arkansas', u""Yale Alzheimer's Disease Research Unit"", u'Emory', u'Johns Hopkins University', u'University of Rochester', u'Wake Forest', u'University Hospitals- Case Medical Center', u'Roper-St. Francis Healthcare', u'Sunnybrook Health Sciences Centre']","January 28, 2016",0,9223372036854775807,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02333331,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT02333331,True,Dose Range Finding Study in Sarcopenia,Sarcopenia,Drug:bimagrumab; Other:placebo,[],"February 3, 2016",70,9223372036854775807,Both,False
NCT02327312,Glaukos Corporation,False,AR,https://ClinicalTrials.gov/show/NCT02327312,True,Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty,Primary Open-Angle Glaucoma,Device:Stents; Procedure:Laser; Device:Laser Trabeculoplasty,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","June 16, 2015",35,9223372036854775807,Both,False
NCT02322866,Warner Chilcott,False,AR,https://ClinicalTrials.gov/show/NCT02322866,True,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Acne Vulgaris,Drug:Sarecycline; Drug:Placebo,[],"December 23, 2015",9,45,Both,False
NCT02320487,"Genentech, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02320487,True,A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Drug:Bendamustine; Drug:Obinutuzumab,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT02319044,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT02319044,True,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck,Drug:MEDI4736; Drug:Tremelimumab; Drug:MEDI4736 + Tremelimumab,[],"January 18, 2016",18,96,Both,False
NCT02316847,Acorda Therapeutics,False,AR,https://ClinicalTrials.gov/show/NCT02316847,True,"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures",Epilepsy,Drug:diazepam nasal spray,[],"January 13, 2016",12,65,Both,False
NCT02674386,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02601209,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02540993,Bayer,False,CA,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,CA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,CA,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02315469,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,CA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02135042,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02135042,True,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02092467,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02019264,Eisai Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01991795,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,CA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01903811,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01872975,NSABP Foundation Inc,False,CA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01870778,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,CA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,CA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01856192,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01808573,"Puma Biotechnology, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,CA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01667419,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT01667419,True,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,Malignant Melanoma,Drug:Placebo; Drug:Vemurafenib,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,CA,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01652872,Amgen,False,CA,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01649089,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01622868,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,CA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01535066,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01535066,True,"S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer",Breast Cancer; Pain,Procedure:acupuncture therapy; Procedure:sham acupuncture,[],"September 25, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,CA,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01349881,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01190930,Children's Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01101451,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,CA,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00858364,Amgen,False,CA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02671981,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT01897532,Boehringer Ingelheim,False,CA,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,CA,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528253,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02060630,New England Research Institutes,False,CA,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,CA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT00736749,Children's Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT01968967,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,CA,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01610284,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01610284,True,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,Breast Cancer,Drug:BKM120 Matching placebo; Drug:Fulvestrant; Drug:BKM120,[],"January 20, 2016",18,9223372036854775807,Female,False
NCT01416688,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01169337,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02670083,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02291861,Teva Pharmaceutical Industries,False,CA,https://ClinicalTrials.gov/show/NCT02291861,True,Addressing Involuntary Movements in Tardive Dyskinesia,Tardive Dyskinesia,Drug:SD-809; Drug:Placebo,[],"January 13, 2016",18,75,Both,False
NCT02250651,Allergan,False,CA,https://ClinicalTrials.gov/show/NCT02250651,True,Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Drug:Bimatoprost sustained-release; Other:Sham; Drug:Timolol; Drug:Timolol Vehicle (placebo),[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02198794,Teva Pharmaceutical Industries,False,CA,https://ClinicalTrials.gov/show/NCT02198794,True,Reducing Involuntary Movements in Tardive Dyskinesia,Tardive Dyskinesia,Drug:SD-809,[],"January 13, 2016",18,75,Both,False
NCT02187055,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02187055,True,An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate,Rhematoid Arthritis,Drug:Tofacitinib with methotrexate; Drug:Tofacitinib without methotrexate; Biological:Adalimumab with methotrexate,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02135991,RAND,False,CA,https://ClinicalTrials.gov/show/NCT02135991,True,Preparing to Run Effective Prevention,Implementation of Evidence Based Programs,Behavioral:Getting To Outcomes; Behavioral:Project CHOICE,"[u'BGC of Buena Park', u'BGC of Burbank and Greater E Valley', u'BGC of Carson', u'BGC of South Bay', u'BGC of Santa Ana', u'Challengers Boys and Girls Club', u'BGC of East LA', u'BGC of Santa Monica', u'BGC of West Valley', u'East Valley Boys and Girls Club', u'Salesian BGC', u'BGC of LA Harbor', u'BGC Stanton', u'BGC of Westminster', u'BGC of Whittier']","May 5, 2015",10,14,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01810913,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,CA,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT02243293,AbbVie,False,CA,https://ClinicalTrials.gov/show/NCT02243293,True,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],"February 4, 2016",18,100,Both,False
NCT02194699,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02187471,Daiichi Sankyo Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02187471,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02101853,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT01950390,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01732913,Gilead Sciences,False,CA,https://ClinicalTrials.gov/show/NCT01732913,True,Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,Indolent Non-Hodgkin's Lymphomas,Drug:Idelalisib; Drug:Rituximab; Drug:Placebo to match idelalisib,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01471340,Merck Sharp & Dohme Corp.,False,CA,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01242800,Eastern Cooperative Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02596451,Glenmark Pharmaceuticals Ltd. India,False,CA,https://ClinicalTrials.gov/show/NCT02596451,True,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Osteoarthritis,"Drug:Diclofenac Sodium gel, 1%; Drug:Voltaren Gel; Drug:Placebo",[],"December 11, 2015",35,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,CA,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02414854,Sanofi,False,CA,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02400476,"Puma Biotechnology, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02400476,True,A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,Early Stage HER2+ Breast Cancer,Drug:Neratinib; Drug:Loperamide,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02254278,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02254278,True,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma,Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,CA,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02161718,"Alkermes, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02161718,True,A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder,Schizophrenia; Alcohol Use Disorder,Drug:Samidorphan + olanzapine (ALKS 3831); Drug:Placebo,[],"February 3, 2016",18,65,Both,False
NCT02155660,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02138916,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02111577,Sotio a.s.,False,CA,https://ClinicalTrials.gov/show/NCT02111577,True,Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,Metastatic Castrate Resistant Prostate Cancer,Biological:Dendritic Cells DCVAC; Biological:Placebo; Drug:Docetaxel; Drug:Taxotere,[],"January 5, 2016",18,9223372036854775807,Male,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,CA,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01805076,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01741194,"Accera, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01741194,True,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,Alzheimer's Disease,Drug:AC-1204; Drug:Placebo,[],"November 23, 2015",66,90,Both,False
NCT01715805,Forest Laboratories,False,CA,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01458574,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT00955708,Boston Scientific Corporation,False,CA,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00628498,Jazz Pharmaceuticals,True,CA,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT02614183,Eli Lilly and Company,False,CA,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02561078,Eli Lilly and Company,False,CA,https://ClinicalTrials.gov/show/NCT02561078,True,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug:Human regular U-500 insulin (CSII); Drug:Human regular U-500 insulin (MDI),[],"January 7, 2016",18,85,Both,False
NCT02487888,"Proove Bioscience, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02487888,True,A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care,"Pain; Chronic Pain; Mental Disorders; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Arthritis",Other:Unblinded to Genetic Testing Results; Other:Blinded to Genetic Testing Results,[],"July 21, 2015",18,9223372036854775807,Both,False
NCT02484547,Biogen,False,CA,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02427802,Innocoll,False,CA,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02269917,Janssen R&D Ireland,False,CA,https://ClinicalTrials.gov/show/NCT02269917,True,"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants",Human Immunodeficiency Virus Type 1,Drug:D/C/F/TAF; Drug:Boosted Protease Inhibitor (bPI); Drug:FTC/TDF,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02247804,Allergan,False,CA,https://ClinicalTrials.gov/show/NCT02247804,True,Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Drug:Bimatoprost sustained-release; Other:Sham; Drug:Timolol; Drug:Timolol Vehicle (placebo),[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,CA,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02186301,"Clovis Oncology, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02186301,True,TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,Non-Small Cell Lung Cancer,Drug:Rociletinib Mono-Therapy; Drug:Erlotinib Mono-Therapy,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT01945775,"Medivation, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01945775,True,"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",Breast Neoplasms; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation,Drug:talazoparib; Drug:Physician's-Choice,[],"December 15, 2015",18,9223372036854775807,Both,False
NCT01836471,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01836471,True,A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients,Asthma,Drug:QAW039; Drug:Placebo; Drug:Inhaled corticosteroid (ICS),[],"November 3, 2014",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01236547,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01096368,Children's Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT02648204,Novo Nordisk A/S,False,CA,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02547935,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02547935,True,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabestes and CKD3","Type 2 Diabetes Mellitus, CKD3 and Albuminuria",Drug:Dapagliflozin 10 mg; Drug:Dapagliflozin 10mg+Saxagliptin 2.5mg; Drug:Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,[],"December 16, 2015",18,74,Both,False
NCT02504216,Bayer,False,CA,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02465515,GlaxoSmithKline,False,CA,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02433834,"Pearl Therapeutics, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02433834,True,Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma,Asthma,Drug:Glycopyrronium MDI; Drug:Serevent Diskus 50 g; Drug:Placebo,[],"May 4, 2015",18,70,Both,False
NCT02388165,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02367794,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02352948,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02322281,"Clovis Oncology, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02322281,True,"TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",Non-small Cell Lung Cancer,Drug:Rociletinib; Drug:Pemetrexed or gemcitabine or paclitaxel or docetaxel,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02320721,Sanofi,False,CA,https://ClinicalTrials.gov/show/NCT02320721,True,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Drug:Insulin glargine U300 HOE901; Drug:Insulin glargine HOE901,[],"February 3, 2016",65,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02273726,FibroGen,False,CA,https://ClinicalTrials.gov/show/NCT02273726,True,Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects,CKD Anemia in Stable Dialysis Patients,Drug:Epoetin Alfa; Drug:FG-4592,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,CA,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02100696,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02100696,True,A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors,Ulcerative Colitis,Drug:etrozulimab; Drug:placebo,[],"February 1, 2016",18,80,Both,False
NCT02080364,vTv Therapeutics,False,CA,https://ClinicalTrials.gov/show/NCT02080364,True,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02066636,Bristol-Myers Squibb,False,CA,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01828112,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01828112,True,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT01710709,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01710709,True,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Bipolar I,Drug:Aripiprazole,[],"October 7, 2015",18,65,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01546038,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01470612,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01307579,Children's Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01307267,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01307267,True,A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,"Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell of Head and Neck",Drug:PF-05082566; Drug:rituximab; Drug:PF-05082566,"[u'For Drug Shipment: Moores UC San Diego Cancer Center - Investigational Drug Services', u'UC San Diego Medical Center - La Jolla (Thornton Hospital)', u'Moores UC San Diego Cancer Center', u'Research Administration Office: Clinical Research Unit', u'Ronald Reagan UCLA Medical Center, Drug Information Center', u'UCLA Bowyer Clinic', u'UCLA Hematology-Oncology Clinic', u'Stanford University Medical Center', u'UC San Diego Medical Center - Hillcrest', u'Stanford University Medical Center', u'Stanford University Medical Center', u'Drug Shipment Address and Pharmacist Designees', u'Georgetown University Hospital', u'Barnes-Jewish Hospital', u'Barnes-Jewish Hospital', u'Washington University Infusion Center Pharmacy', u'Washington University School of Medicine', u'Memorial Sloan-Kettering Cancer Center', u'Memorial Sloan-Kettering Cancer Center', u'University of Washington/Seattle Cancer Care Alliance', u""Centre d'investigation clinique"", u'National Cancer Center Hospital East']","January 20, 2016",18,9223372036854775807,Both,False
NCT01163253,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00772200,Children's Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00131313,East Valley Hematology and Oncology Medical Group,False,CA,https://ClinicalTrials.gov/show/NCT00131313,True,"Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.",Chronic Lymphocytic Leukemia,"Drug:Nipent, Cytoxan, Rituxan",[],"August 17, 2005",18,9223372036854775807,Both,False
NCT02601703,Glenmark Pharmaceuticals Ltd. India,False,CA,https://ClinicalTrials.gov/show/NCT02601703,True,"To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)",Atopic Dermatitis,"Drug:Tacrolimus Ointment 0.1%; Drug:Protopic ointment, 0.1%; Drug:Placebo of Tacrolimus Ointment",[],"December 11, 2015",18,9223372036854775807,Both,False
NCT02551874,Bristol-Myers Squibb,False,CA,https://ClinicalTrials.gov/show/NCT02551874,True,"A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy",Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glargine insulin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02456740,Amgen,False,CA,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02426918,Debiopharm International SA,False,CA,https://ClinicalTrials.gov/show/NCT02426918,True,Study of Debio 1450 for Bacterial Skin Infections,Bacterial Infections,Drug:Debio 1450 IV; Drug:Debio 1450 Oral; Drug:Linezolid; Drug:Debio 1450 Oral Placebo; Drug:Linezolid Placebo; Drug:Vancomycin IV,[],"January 14, 2016",18,70,Both,False
NCT02420262,Novo Nordisk A/S,False,CA,https://ClinicalTrials.gov/show/NCT02420262,True,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec/liraglutide; Drug:insulin glargine; Drug:insulin aspart,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02418585,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02418585,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 27, 2016",18,64,Both,False
NCT02417064,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02417064,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 3, 2016",18,64,Both,False
NCT02367781,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02258542,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02247531,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02247531,True,A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02207530,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02207530,True,Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck (SCCHN),Drug:MEDI4736,[],"January 25, 2016",18,130,Both,False
NCT02187159,Daiichi Sankyo Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02187159,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,CA,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02174731,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02174731,True,"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis",Anemia,Drug:Roxadustat; Drug:Epoetin alfa,[],"February 2, 2016",18,130,Both,False
NCT02152631,Eli Lilly and Company,False,CA,https://ClinicalTrials.gov/show/NCT02152631,True,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,Non Small Cell Lung Cancer,Drug:Abemaciclib; Drug:Erlotinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02150343,Circassia Limited,False,CA,https://ClinicalTrials.gov/show/NCT02150343,True,Phase II HDM-SPIRE Safety and Efficacy Study,Rhinoconjunctivitis,Drug:HDM-SPIRE; Drug:Placebo,[],"June 11, 2015",18,65,Both,False
NCT02118584,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02008357,Eli Lilly and Company,False,CA,https://ClinicalTrials.gov/show/NCT02008357,True,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,Cognition Disorders,Drug:Solanezumab; Drug:Placebo,[],"January 12, 2016",65,85,Both,True
NCT01997333,Celldex Therapeutics,False,CA,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01953601,Merck Sharp & Dohme Corp.,False,CA,https://ClinicalTrials.gov/show/NCT01953601,True,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],"December 31, 2015",50,85,Both,False
NCT01852110,Merck Sharp & Dohme Corp.,False,CA,https://ClinicalTrials.gov/show/NCT01852110,True,Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),Alzheimer's Disease,Drug:MK-7622; Drug:Placebo; Drug:AChEI,[],"January 22, 2016",55,85,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01757535,Celgene Corporation,False,CA,https://ClinicalTrials.gov/show/NCT01757535,True,Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission,"Leukemia, Myeloid, Acute",Drug:300 mg Oral Azacitidine; Drug:Placebo,[],"January 20, 2016",55,9223372036854775807,Both,False
NCT01693133,"MiMedx Group, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01693133,True,Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers,Diabetic Foot Ulcer,Other:Standard of Care: Moist Wound Therapy and Offloading; Other:EpiFix plus Standard of Care,"[u'Stockdale Podiatry Group', u'Center for Clinical Research Inc', u'Valley Vascular Surgery Associates', u'Limb Preservation Platform', u'Novak Urgent Care and Family Practice', u'Loma Linda VA Medical Center', u'Foot & Ankle Clinic', u'Palmtree Clinical Research, Inc.', u'Center for Clinical Research, Inc.', u'Center for Clinical Research', u'MetroWest Medical Center', u'South Shore Hospital', u'Jobst Vascular Institute, Promedica Toledo Hospital', u'Center for Clinical Research, Inc.', u'IMC Wound Care', u'LDS Hospital', u'Coastal Podiatry, Inc.']","February 4, 2016",18,9223372036854775807,Both,False
NCT01471522,New York University School of Medicine,True,CA,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02488967,NRG Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,CO,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01216683,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,CO,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,CO,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,CO,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT01966107,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,CO,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02671981,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,CO,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,CO,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01975376,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,CO,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01220583,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01220583,True,Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery,Head and Neck Cancer,Drug:cisplatin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT01975389,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01808573,"Puma Biotechnology, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02614183,Eli Lilly and Company,False,CO,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02509078,Massachusetts General Hospital,False,CO,https://ClinicalTrials.gov/show/NCT02509078,True,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02180867,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01822496,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01695382,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT01695382,True,Apoyo Con Carino: Patient Navigation for Palliative Care,Cancer,Behavioral:Navigation,"[u'San Luis Valley Regional Medical Center', u'University of Colorado Cancer Center', u'Denver Health and Hospital Authority', u'Shaw Cancer Center', u'Valley View Medical Center']","December 9, 2015",18,90,Both,False
NCT01185132,Rocky Mountain Cancer Centers,False,CO,https://ClinicalTrials.gov/show/NCT01185132,True,Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy,Breast Cancer,Radiation:accelerated partial breast irradiation - 3D-conformal planning; Radiation:accelerated partial breast irradiation - IMRT planning,"[u'Rocky Mountain Cancer Centers - Aurora', u'Rocky Mountain Cancer Centers - Boulder', u'Rocky Mountain Cancer Centers - Lakewood', u'Rocky Mountain Cancer Centers - Littleton', u'Rocky Mountain Cancer Centers - Thornton']","June 24, 2014",40,9223372036854775807,Both,False
NCT02412917,"ContraVir Pharmaceuticals, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02412917,True,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],"September 1, 2015",50,9223372036854775807,Both,False
NCT02317965,"Progenity, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02317965,True,Non-Invasive Screening for Fetal Aneuploidy,Down Syndrome; Edwards Syndrome,Other:Maternal Blood Draw,"[u'Obstetrix Medical Group of California', u'Long Beach Memorial Medical Ctr - 2nd Floor Perinatal', u""OBX Med. Group. of Colorado - Pres/St Luke's Clinic"", u'OBX Med. Group. of Colorado - Antepartum Testing Unit @ Rose Medical Center', u'OBX Med. Group. of Colorado - Perinatal Resource Ctr @ Swedish Med Ctr.', u'OBX Med. Group. of Colorado - Skyridge', u'Maryland Perinatal Associates', u'Regional Obstetrical Consultants', u'Obstetrix Medical Group of Texas', u'Obstetrix, Medical Group of Washington, Inc. - Swedish Medical Center']","October 19, 2015",18,54,Female,False
NCT02239120,Boehringer Ingelheim,False,CO,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02164513,GlaxoSmithKline,False,CO,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT01947608,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01947608,True,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:LDK378,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01898962,Rocky Mountain Cancer Centers,False,CO,https://ClinicalTrials.gov/show/NCT01898962,True,Definitive Therapy for Oligometastatic Solid Malignancies,Stage IV or Recurrent Carcinoma or Sarcoma,Procedure:Complete Surgical Removal; Radiation:Stereotactic Radiosurgery; Radiation:Ablative external beam radiation dose; Procedure:Subtotal surgical removal plus ablative radiation dose; Radiation:Radioembolization,"[u'Rocky Mountain Cancer Centers - Aurora', u'Rocky Mountain Cancer Centers - Boulder', u'Rocky Mountain Cancer Centers - Littleton', u'Rocky Mountain Cancer Centers - Thornton']","July 10, 2013",18,9223372036854775807,Both,False
NCT01898494,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01898494,True,Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,Human Papilloma Virus Infection; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Oropharynx,Procedure:therapeutic conventional surgery; Radiation:intensity-modulated radiation therapy; Drug:cisplatin; Drug:carboplatin; Radiation:intensity-modulated radiation therapy; Other:laboratory biomarker analysis; Other:quality-of-life assessment,[],"November 19, 2015",18,9223372036854775807,Both,False
NCT01875003,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT01875003,True,A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication,Asthma,Drug:Lebrikizumab; Drug:Lebrikizumab; Drug:Placebo,[],"February 1, 2016",12,17,Both,False
NCT01772472,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01576406,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01576406,True,Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,Advanced Cancer,Drug:crizotinib; Drug:crizotinib; Drug:crizotinib; Drug:crizotinib; Drug:crizotinib,"[u'Keck Hospital of the University of Southern California', u'Los Angeles County/University of Southern California Medical Center', u'USC/Norris Comprehensive Cancer / Investigational Drug Services', u'USC/Norris Comprehensive Cancer Center', u'Drug Shipment: Anschutz Cancer Pavilion, Room 2224, c/o Melinda Friesleben, Pharm D', u'University of Colorado Denver - Clinical Translational Research Center', u'University of Colorado Hospital, Anschutz Inpatient Pavilion', u'University of Colorado Hospital', u'Drug Shipment Address: Investigational Drug Service: The Emory Clinic Bldg A', u'Emory University Hospital', u'The Emory Clinic', u'Winship Cancer Institute', u'University Hospital East', u'Investigational Drug Services (Drug Management Only)', u'James Cancer Hospital', u'The Ohio State University, Wexner Medical Center', u'Martha Morehouse Medical Plaza', u'Cancer Therapy & Research Center at UTHSCSA', u'Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio']","January 6, 2016",18,9223372036854775807,Both,False
NCT00387218,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),False,CO,https://ClinicalTrials.gov/show/NCT00387218,True,Exercise Study For People With Parkinson's Disease,Parkinson's Disease,"Behavioral:Exercise, Physical therapy","[u""Waldron's Peak Physical Therapy"", u'Penrose Hospital', u'University of Colorado at Denver and Health Sciences Center', u'Carmody Recreation Center']","May 21, 2008",30,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02528253,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02426125,Eli Lilly and Company,False,CO,https://ClinicalTrials.gov/show/NCT02426125,True,A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,Urothelial Carcinoma,Drug:Ramucirumab; Drug:Docetaxel; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02414854,Sanofi,False,CO,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,CO,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02397096,Merck Sharp & Dohme Corp.,False,CO,https://ClinicalTrials.gov/show/NCT02397096,True,Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024),HIV-1 Infection,Drug:MK-1439A; Drug:Baseline regimen of ritonavir-boosted protease inhibitor; Drug:Baseline regimen of two nucleoside reverse transcriptase inhibitors,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02379819,Cochlear,False,CO,https://ClinicalTrials.gov/show/NCT02379819,True,Hybrid L24 New Enrollment Post Approval Study,High Frequency Sensorineural Hearing Loss,Device:Nucleus Hybrid L24 Implant,"[u'Arizona Ear Center', u'University of Colorado Hospitals', u'Denver Ear Associates', u'Rocky Mountain Ear Center', u'University of Miami', u'NorthShore University Health System', u'Greater Baltimore Medical Center', u'Lahey Hospital and Medical Center', u'University of Michigan', u'Michigan Ear Institute', u'Midwest Ear Institute', u'The University of Cincinnati', u'The Ohio State University', u'Ohio Ear Institute', u'Hospital of the University of Pennsylvania', u'University of Pittsburgh Medical Center', u'Carolina Eye Ear Nose and Throat', u'Vanderbilt University Medical Center', u'Ear Institute of Texas', u'University of Washington']","October 30, 2015",18,9223372036854775807,Both,False
NCT02374541,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT02374541,True,Screening and Linkage to Services for Autism,Autism Spectrum Disorders,Behavioral:Patient Navigation,"[u'Colorado School of Public Health, University of Colorado Denver', u'University of Colorado', u'Denver Health and Hospital Authority']","September 14, 2015",16,32,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02258542,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02247531,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02247531,True,A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02200614,Bayer,False,CO,https://ClinicalTrials.gov/show/NCT02200614,True,Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS),Prostate Cancer Non-Metastatic; Castration-Resistant,Drug:BAY1841788 (ODM-201); Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02194699,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02164864,Boehringer Ingelheim,False,CO,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02156843,"NephroGenex, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02156843,True,Pyridorin in Diabetic Nephropathy,Diabetic Nephropathy; Diabetic Kidney Disease,Drug:Pyridorin; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02122146,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02122146,True,A Study Of PF-06664178 In Patients With Advanced Solid Tumors,Neoplasms,Drug:PF-06664178; Drug:PF-06664178,"[u'USC/Norris Comprehensive Cancer Center', u'Lac & Usc Medical Center', u'Keck Hospital of USC', u'Anschutz Cancer Pavilion', u'University of Colorado Denver CTO (CTRC)', u'University of Colorado Hospital', u'University of Washington Medical Center', u'Swedish Medical Center', u'Seattle Cancer Care Alliance (Drug Shipment Address)', u'Seattle Cancer Care Alliance']","January 4, 2016",18,9223372036854775807,Both,False
NCT02118584,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02100514,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02066636,Bristol-Myers Squibb,False,CO,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02026102,"University of Colorado, Denver",True,CO,https://ClinicalTrials.gov/show/NCT02026102,True,A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs),Systolic Heart Failure; Sudden Cardiac Death,Behavioral:ICD Decision Aid Toolkit,"[u'University of Colorado Hospital (UCH)', u'Kaiser Permanente of Colorado', u'Denver VA Medical Center']","November 23, 2015",18,9223372036854775807,Both,False
NCT02012309,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT02012309,True,Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses,HIV; Pneumococcal Infections; Pneumococcal Vaccines,Biological:PCV-13; Biological:PPSV-23,"[u'University of Colorado-Denver', u'Denver Health and Hospitals', u'Denver VA Medical Center']","December 10, 2015",18,55,Both,True
NCT01996865,Celgene Corporation,False,CO,https://ClinicalTrials.gov/show/NCT01996865,True,"Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.","Lymphoma, Non-Hodgkin",Drug:Lenalidomide; Drug:Rituximab,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01970865,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01970865,True,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug:PF-06463922; Drug:Crizotinib,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01920061,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01920061,True,A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,Neoplasm,Drug:PF-05212384; Drug:Docetaxel; Drug:PF-05212384; Drug:Cisplatin; Drug:PF-05212384; Drug:Dacomitinib,"[u'Drug Shipping Address: Ronald Reagan UCLA Medical Center', u'Ronald Reagan UCLA Medical Center', u'UCLA Hematology Oncology', u'Westwood Bowyer Clinic', u'Administrative Address: UCLA Hematology/Oncology', u'UCLA Hematology Oncology', u'Santa Monica UCLA Medical Center & Orthopaedic Hospital', u'Drug Shipment Address: Anschutz Cancer Pavilion', u'University of Colorado Denver CTO (CTRC)', u'University of Colorado Hospital', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Harper Professional Building', u'Karmanos Cancer Institute', u'Fox Chase Cancer Center', u'Medical University of South Carolina', u'MUSC Health East Cooper', u'MUSC Specialty Care-North', u'British Columbia Cancer Agency - Vancouver Centre', u'Princess Margaret Cancer Centre', u'Istituto Europeo di Oncologia - Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative', u'Istituto Regina Elena Struttura Complessa Oncologia Medica A', u""Hospital Universitari Vall d'Hebron"", u'Hospital Universitario 12 De Octubre', u'University College London Hospital, NIHR/Wellcome UCLH Clinical Research Facility', u'Oxford Cancer Centre']","January 6, 2016",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,CO,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01870778,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01864174,Bristol-Myers Squibb,False,CO,https://ClinicalTrials.gov/show/NCT01864174,True,Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug:Metformin XR; Drug:Metformin IR; Drug:Placebo matching with Metformin XR; Drug:Placebo matching with Metformin IR,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01836471,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01836471,True,A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients,Asthma,Drug:QAW039; Drug:Placebo; Drug:Inhaled corticosteroid (ICS),[],"November 3, 2014",18,9223372036854775807,Both,False
NCT01828112,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01828112,True,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT01797185,Sun Pharma Advanced Research Company Limited,False,CO,https://ClinicalTrials.gov/show/NCT01797185,True,"A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial",Spasticity,Drug:Baclofen,[],"September 15, 2015",18,90,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,CO,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01741194,"Accera, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT01741194,True,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,Alzheimer's Disease,Drug:AC-1204; Drug:Placebo,[],"November 23, 2015",66,90,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,CO,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01663402,Sanofi,False,CO,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01660451,Bayer,False,CO,https://ClinicalTrials.gov/show/NCT01660451,True,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","Lymphoma, Non-Hodgkin",Drug:Copanlisib (BAY80-6946),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01610284,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT01610284,True,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,Breast Cancer,Drug:BKM120 Matching placebo; Drug:Fulvestrant; Drug:BKM120,[],"January 20, 2016",18,9223372036854775807,Female,False
NCT01594333,Brigham and Women's Hospital,False,CO,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01546571,Polynoma LLC,False,CO,https://ClinicalTrials.gov/show/NCT01546571,True,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",Melanoma,Biological:POL-103A; Biological:POL-103A without API,[],"December 8, 2015",18,80,Both,False
NCT01546038,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,CO,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01457352,Sun Pharma Advanced Research Company Limited,False,CO,https://ClinicalTrials.gov/show/NCT01457352,True,Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen ER Capsules; Drug:Placebo GRS,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01410864,Integra LifeSciences Corporation,False,CO,https://ClinicalTrials.gov/show/NCT01410864,True,DuraSeal Exact Spine Sealant System Post-Approval Study,Dural Sealing,Device:DuraSeal Exact Spine Sealant System; Other:Control,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01358266,Santen Inc.,False,CO,https://ClinicalTrials.gov/show/NCT01358266,True,Study Assessing Double-masked Uveitis Treatment,"Uvea; Posterior, Disorder",Drug:DE-109; Drug:DE-109; Drug:DE-109,[],"January 21, 2015",18,9223372036854775807,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,CO,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01321541,CTI BioPharma,False,CO,https://ClinicalTrials.gov/show/NCT01321541,True,Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant,Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma,Drug:Pixantrone + Rituximab; Drug:Gemcitabine + Rituximab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01312909,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT01312909,True,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],"February 3, 2016",12,19,Both,False
NCT00858364,Amgen,False,CO,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02650921,Q-Med AB,False,CO,https://ClinicalTrials.gov/show/NCT02650921,True,Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand,Volume Deficit in the Hand,Device:Restylane Lyft with Lidocaine,"[u'', u'', u'', u'', u'', u'', u'']","January 6, 2016",22,9223372036854775807,Both,True
NCT02639338,Gilead Sciences,False,CO,https://ClinicalTrials.gov/show/NCT02639338,True,Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Hepatitis C Virus Infection,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02639247,Gilead Sciences,False,CO,https://ClinicalTrials.gov/show/NCT02639247,True,Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Hepatitis C Virus Infection,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02636530,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT02636530,True,Effect of Two Exercise Programs on Bone Strength and Architecture,Osteoporosis,Behavioral:Ground Reaction Forces; Behavioral:Joint Reaction Forces,"[u'University of Colorado Anschutz Medical Campus', u""Veteran's Affairs Eastern Colorado Healthcare System""]","December 18, 2015",60,75,Both,True
NCT02614261,Eli Lilly and Company,False,CO,https://ClinicalTrials.gov/show/NCT02614261,True,Evaluation of LY2951742 in the Prevention of Chronic Migraine,Chronic Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02612779,Bristol-Myers Squibb,False,CO,https://ClinicalTrials.gov/show/NCT02612779,True,A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,Multiple Myeloma,Drug:Elotuzumab; Drug:Pomalidomide; Drug:Dexamethasone,"[u'Local Institution', u'Local Institution', u'Local Institution', u'Rocky Mountain Cancer Centers', u'Local Institution', u'Local Institution', u'Local Institution', u'Bay Hematology Oncology', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Cancer Care Centers Of South Texas', u'Virginia Cancer Specialists, Pc', u'Local Institution', u'Local Institution']","January 26, 2016",18,9223372036854775807,Both,False
NCT02612610,"Afferent Pharmaceuticals, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02612610,True,A 12-Week Study in Subjects With Refractory Chronic Cough,Refractory Chronic Cough,Drug:AF-219; Drug:Placebo (for AF-219),"[u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site', u'Afferent Investigative Site']","December 17, 2015",18,80,Both,False
NCT02607800,Gilead Sciences,False,CO,https://ClinicalTrials.gov/show/NCT02607800,True,Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 18, 2016",18,9223372036854775807,Both,False
NCT02607735,Gilead Sciences,False,CO,https://ClinicalTrials.gov/show/NCT02607735,True,Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Drug:SOF/VEL/GS-9857; Drug:Placebo,[],"January 18, 2016",18,9223372036854775807,Both,False
NCT02604680,Braintree Laboratories,False,CO,https://ClinicalTrials.gov/show/NCT02604680,True,A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris,Acne Vulgaris,Drug:BLI1100-1; Drug:BLI1100-2; Drug:BLI1100-3; Drug:Control group; Drug:Placebo,[],"November 12, 2015",12,45,Both,False
NCT02596893,Celgene Corporation,False,CO,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02584959,Shire,False,CO,https://ClinicalTrials.gov/show/NCT02584959,True,Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema,Hereditary Angioedema (HAE),Drug:C1 esterase inhibitor [human] liquid,"[u'Bay Area Allergy', u'IMMUNOe Research Centers', u'Asthma and Allergy Associates PC', u'Institute For Asthma and Allergy', u'Clinical Research of Charlotte', u'Premier Clinical Research']","January 21, 2016",12,9223372036854775807,Both,False
NCT02531516,"Aragon Pharmaceuticals, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02531516,True,An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS,Prostatic Neoplasms,Drug:JNJ-56021927; Drug:Bicalutamide; Drug:Bicalutamide Placebo; Drug:JNJ-56021927 Placebo; Drug:GnRH (agonist); Radiation:74-80 Grays (units of radiation),[],"January 27, 2016",18,9223372036854775807,Male,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02520518,Christopher Bell,False,CO,https://ClinicalTrials.gov/show/NCT02520518,True,Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?,Weight Loss,Drug:Dapagliflozin; Drug:Placebo; Behavioral:Weight maintenance; Behavioral:Ad libitum dietary intake; Behavioral:Dietary restriction,"[u'Colorado State University, Dept. of Health and Exercise Science', u'Colorado State University, Dept. of Health and Exercise Science']","January 26, 2016",18,65,Both,True
NCT02516462,National Foundation for Fertility Research,False,CO,https://ClinicalTrials.gov/show/NCT02516462,True,In Vitro Maturation of Human Eggs,"Infertility; Reproductive Techniques, Assisted",Device:IVM media; Drug:Follicle Stimulating Hormone (FSH),"[u'Fertility Laboratories of Colorado', u'National Foundation for Fertility Research']","August 3, 2015",35,45,Female,False
NCT02514447,"G1 Therapeutics, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02514447,True,Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,Small Cell Lung Cancer,Drug:G1T28 + Topotecan,"[u'Genesis Cancer Center', u'Rocky Mountain Cancer Centers', u'University of Colorado Health, Oncology Clinical Research Northern Region', u'Florida Cancer Specialists - South', u'Florida Cancer Specialists - North', u'Florida Cancer Specialists - East', u'University Cancer and Blood Center, LLC', u'Emory University', u'Northside Hospital - Georgia Cancer Specialists', u'North Shore Hematology Oncology Associates PC', u'Lineberger Comprehensive Cancer Center', u'Oklahoma University - Peggy and Charles Stephenson Cancer Center', u'Greenville Health System', u'Gibbs Cancer Center', u'Meharry Medical College', u'Sarah Cannon Research Institute', u'Texas Oncology- Baylor Charles A. Sammons Cancer Center', u'M.D. Anderson', u'Texas Oncology', u'Virginia Cancer Specialists', u'Virginia Oncology Associates', u'Northwest Cancer Specialists, P.C.']","November 30, 2015",18,9223372036854775807,Both,False
NCT02510794,"Genentech, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02510794,True,Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration,Macular Degeneration,Drug:Ranibizumab ITV injection; Drug:Ranibizumab through RPDS Implant,[],"December 31, 2015",50,9223372036854775807,Both,False
NCT02508194,MedImmune LLC,False,CO,https://ClinicalTrials.gov/show/NCT02508194,True,A Study to Evaluate the Efficacy of MEDI7510 in Older Adults,Respiratory Syncytial Virus (RSV),Biological:MEDI7510; Biological:IIV; Other:Placebo,[],"January 22, 2016",60,99,Both,True
NCT02504216,Bayer,False,CO,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02499770,"G1 Therapeutics, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02499770,True,G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),Small Cell Lung Cancer,Drug:G1T28 + carboplatin/ etoposide; Drug:Placebo + carboplatin/ etoposide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02496598,National Foundation for Fertility Research,True,CO,https://ClinicalTrials.gov/show/NCT02496598,True,In Vitro Follicle Activation,Primary Ovarian Insufficiency; Infertility,Procedure:In Vitro Follicle Activation (IVA); Drug:Follicle Activation,"[u'Fertility Laboratories of Colorado', u'National Foundation for Fertility Research']","July 9, 2015",18,45,Female,False
NCT02487446,Novartis Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02484690,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02484690,True,AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD),"Macular Degeneration, Choroidal Neovascularization",Drug:RG7716; Drug:Ranibizumab,[],"September 9, 2015",50,9223372036854775807,Both,False
NCT02484547,Biogen,False,CO,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02483988,Active Implants,True,CO,https://ClinicalTrials.gov/show/NCT02483988,True,The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant),"Post-Meniscectomy Pain Syndrome; Osteoarthritis, Knee",Device:NUsurface Meniscus Implant,"[u'TOCA (The Orthopaedic Clinic Association PC)', u'Long Beach Memorial Medical Center', u""St Mary's Medical Center"", u'CU Sports Medicine', u'Advanced Orthopaedics & Sports Medicine Specialists', u'Baton Rouge Orthopaedic Clinic', u'Sports Medicine Oregon', u'Arlington Orthopedic Associates, PA', u'Comprehensive Orthopaedics & Sports Medicine']","January 29, 2016",30,75,Both,False
NCT02477319,University of Alabama at Birmingham,False,CO,https://ClinicalTrials.gov/show/NCT02477319,True,A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT),Cystic Fibrosis,Other:Observational,[],"November 30, 2015",12,9223372036854775807,Both,True
NCT02441946,Eli Lilly and Company,False,CO,https://ClinicalTrials.gov/show/NCT02441946,True,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma,Drug:Abemaciclib; Drug:Loperamide; Drug:Anastrozole,[],"January 28, 2016",18,9223372036854775807,Female,False
NCT02439762,University of Michigan,False,CO,https://ClinicalTrials.gov/show/NCT02439762,True,Intervening to Reduce Suicide Risk in Veterans With Substance Use Disorders,Suicide; Suicidal Ideation; Substance-Related Disorders,Behavioral:Cognitive Behavioral Therapy (CBT); Behavioral:Supportive Psycho-education (SPC),"[u'Colorado Springs, Colorado Community-Based Outpatient Clinic', u'VA Eastern Colorado Health Care System', u'VA Ann Arbor Healthcare System', u'John D. Dingell VA Medical Center']","September 25, 2015",18,9223372036854775807,Both,False
NCT02438007,Tokai Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT02438007,True,A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,Prostate Cancer,Drug:Galeterone; Drug:Enzalutamide,[],"January 22, 2016",18,9223372036854775807,Male,False
NCT02420821,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02420821,True,"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]",Renal Cell Carcinoma,Drug:Atezolizumab; Drug:Bevacizumab; Drug:Sunitinib,[],"December 31, 2015",18,9223372036854775807,Both,False
NCT02410278,Biogen,False,CO,https://ClinicalTrials.gov/show/NCT02410278,True,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,Multiple Sclerosis,Drug:dimethyl fumarate; Drug:montelukast; Drug:Placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02405260,vTv Therapeutics,False,CO,https://ClinicalTrials.gov/show/NCT02405260,True,Add Glucokinase Activator to Target A1c,"Diabetes Mellitus, Type 2",Drug:TTP399 400 mg; Drug:TTP399 800 mg; Drug:Sitagliptin 100 mg; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","December 3, 2015",18,75,Both,False
NCT02403401,Bayer,False,CO,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02403323,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02398461,Acorda Therapeutics,False,CO,https://ClinicalTrials.gov/show/NCT02398461,True,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse,"Multiple Sclerosis, Acute Relapsing",Drug:rHIgM22; Drug:Placebo,"[u'Acorda Site #12', u'Acorda Site #3', u'Acorda Site #7', u'Acorda Site #15', u'Acorda Site #11', u'Acorda Site #16', u'Acorda Site #5', u'Acorda Site #14', u'Acorda Site #19', u'Acorda Site #10', u'Acorda Site #17', u'Acorda Site #18', u'Acorda Site #2', u'Acorda Site #6']","January 19, 2016",18,70,Both,False
NCT02394028,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02393560,"Ardea Biosciences, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02393560,True,DECT Study in Allopurinol-Treated Gout Patients,Gout,Procedure:DECT scan,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 26, 2016",18,85,Both,False
NCT02392624,"Genentech, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02392624,True,A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU),Chronic Idiopathic Urticaria,Drug:Omalizumab,[],"September 1, 2015",12,75,Both,False
NCT02392234,Vertex Pharmaceuticals Incorporated,False,CO,https://ClinicalTrials.gov/show/NCT02392234,True,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug:VX-661/ivacaftor; Drug:ivacaftor; Drug:VX-661/ ivacaftor placebo; Drug:ivacaftor placebo,[],"December 2, 2015",12,9223372036854775807,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,CO,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02369874,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02369874,True,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN).,Drug:MEDI4736; Drug:MEDI4736 + Tremelimumab; Drug:Standard of Care,[],"January 18, 2016",18,96,Both,False
NCT02367313,"Biota Pharmaceuticals, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02367313,True,A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection,Asthma,Drug:Vapendavir; Drug:Vapendavir; Drug:Placebo,[],"October 16, 2015",18,70,Both,False
NCT02366143,Hoffmann-La Roche,False,CO,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02364557,NRG Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02364557,True,Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer,Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer,Radiation:Stereotactic Radiosurgery; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,"[u'University of Alabama at Birmingham Cancer Center', u'UC San Diego Moores Cancer Center', u'University of California Irvine Health', u'Permanente Medical Group - Roseville Radiation Oncology', u'Kaiser Permanente Cancer Treatment Center', u'University of Colorado Cancer Center - Anschutz Cancer Pavilion', u'Memorial Hospital Colorado Springs', u'Emory University Hospital Midtown', u'Piedmont Hospital', u'Emory University/Winship Cancer Institute', u'Northwestern University', u'University of Illinois', u'Decatur Memorial Hospital', u'Loyola University Medical Center', u'Northwestern Medicine Cancer Center Warrenville', u'Saint Vincent Anderson Regional Hospital/Cancer Center', u'Parkview Hospital', u'Memorial Hospital of South Bend', u'Lahey Hosptial and Medical Center', u'NRG Oncology', u'Jewish General Hospital']","December 22, 2015",18,9223372036854775807,Both,False
NCT02352948,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02348359,Tyrogenex,False,CO,https://ClinicalTrials.gov/show/NCT02348359,True,X-82 to Treat Age-related Macular Degeneration,"Age-Related Macular Degeneration (AMD); Macular Degeneration; Exudative Age-related Macular Degeneration; AMD; Macular Degeneration, Age-related, 10; Eye Diseases; Retinal Degeneration; Retinal Diseases",Drug:X-82; Drug:Aflibercept; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","May 15, 2015",50,9223372036854775807,Both,False
NCT02344290,National Institute of Allergy and Infectious Diseases (NIAID),False,CO,https://ClinicalTrials.gov/show/NCT02344290,True,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,HIV Infections; Cardiovascular Diseases,Drug:Pitavastatin; Drug:Placebo,[],"February 1, 2016",40,75,Both,False
NCT02343406,AbbVie,False,CO,https://ClinicalTrials.gov/show/NCT02343406,True,ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,Glioblastoma Multiforme,Drug:ABT-414; Drug:Lomustine; Drug:Temozolomide,[],"January 7, 2016",18,99,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,CO,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02339064,US WorldMeds LLC,False,CO,https://ClinicalTrials.gov/show/NCT02339064,True,Infusion of Apomorphine: Long-term Safety Study,Idiopathic Parkinson's Disease,Drug:apomorphine infusion,"[u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 29, 2016",30,80,Both,False
NCT02332720,Merck Sharp & Dohme Corp.,False,CO,https://ClinicalTrials.gov/show/NCT02332720,True,Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012),Hepatitis C,Drug:Grazoprevir; Drug:MK-3682; Drug:Elbasvir; Drug:MK-8408; Drug:MK-3682B; Drug:RBV,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02320487,"Genentech, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02320487,True,A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Drug:Bendamustine; Drug:Obinutuzumab,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT02320149,Warner Chilcott,False,CO,https://ClinicalTrials.gov/show/NCT02320149,True,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Drug:Sarecycline; Drug:Placebo,[],"December 23, 2015",9,45,Both,False
NCT02319044,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02319044,True,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck,Drug:MEDI4736; Drug:Tremelimumab; Drug:MEDI4736 + Tremelimumab,[],"January 18, 2016",18,96,Both,False
NCT02308046,"Curatek Pharmaceuticals, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02308046,True,Multi-Center Study of New Medications to Treat Vaginal Infections,Vaginal Infection,Drug:Terconazole; Drug:Placebo,[],"November 17, 2015",12,9223372036854775807,Female,False
NCT02308033,"Curatek Pharmaceuticals, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02308033,True,Multi-Center Study of New Medications to Treat Vaginal Infections,Vaginal Infection,Drug:Metronidazole; Drug:Gel vehicle,[],"November 17, 2015",12,9223372036854775807,Female,False
NCT02308007,"Curatek Pharmaceuticals, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02308007,True,Multi-Center Study of New Medications to Treat Vaginal Infections,Vaginal Infection,Drug:Terconazole; Drug:Metronidazole; Drug:Terconazole/metronidazole,[],"November 17, 2015",12,9223372036854775807,Female,False
NCT02293395,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02293395,True,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:Acetylsalicylic acid; Drug:Rivaroxaban; Drug:Clopidogrel; Drug:Ticagrelor,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02282020,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02282020,True,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Drug:OLAPARIB; Drug:Single agent chemotherapy,[],"January 25, 2016",18,96,Female,False
NCT02281877,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT02281877,True,Alterations in Muscle After Total Knee Arthroplasty,Knee Osteoarthritis,Procedure:Neuromuscular electrical stimulation (NMES); Behavioral:Standard Rehabilitation Protocol,"[u'Univeristy of Colorado Anschutz Medical Campus', u'University of Colorado School of Medicine']","December 3, 2015",50,75,Both,False
NCT02268214,Bristol-Myers Squibb,False,CO,https://ClinicalTrials.gov/show/NCT02268214,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Drug:Dapagliflozin; Drug:Placebo for Dapagliflozin,[],"January 26, 2016",18,75,Both,False
NCT02257736,"Janssen Research & Development, LLC",False,CO,https://ClinicalTrials.gov/show/NCT02257736,True,An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),Prostatic Neoplasms,Drug:JNJ56021927; Drug:Abiraterone acetate; Drug:Prednisone; Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02255383,"Zimmer, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02255383,True,Persona Total Knee Arthroplasty Outcomes Study,Severe Knee Pain; Severe Knee Disability; Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis; Polyarthritis,Device:Zimmer Persona Total Knee System,"[u'Colorado Joint Replacement', u'Denver-Vail Orthopedics', u'Rockford Orthopedic Associates', u'Henry County Orthopedics and Sports Medicine', u'OrthoCarolina', u'Raleigh Orthopaedic Clinic', u'Lindner Research Center', u'SportsMedicine Grant & Orthopaedic Associates', u'University of Pennsylvania', u'Tennessee Orthopaedic Foundation for Education and Research', u'Texas Tech University Health Sciences Center']","December 28, 2015",18,75,Both,False
NCT02250651,Allergan,False,CO,https://ClinicalTrials.gov/show/NCT02250651,True,Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Drug:Bimatoprost sustained-release; Other:Sham; Drug:Timolol; Drug:Timolol Vehicle (placebo),[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02240680,Boehringer Ingelheim,False,CO,https://ClinicalTrials.gov/show/NCT02240680,True,Linagliptin as Add on to Basal Insulin in the Elderly,"Diabetes Mellitus, Type 2",Drug:placebo; Drug:linagliptin,[],"January 26, 2016",60,9223372036854775807,Both,False
NCT02237950,Starpharma Pty Ltd,False,CO,https://ClinicalTrials.gov/show/NCT02237950,True,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Bacterial Vaginosis,Drug:Metronidazole oral tablets 500mg; Drug:1% SPL7013 Gel; Drug:Placebo gel,[],"May 18, 2015",16,45,Female,False
NCT02230969,Biogen,False,CO,https://ClinicalTrials.gov/show/NCT02230969,True,Plegridy Observational Program,Relapsing Forms of Multiple Sclerosis,Drug:peginterferon beta-1a,[],"September 10, 2015",18,9223372036854775807,Both,False
NCT02230202,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT02230202,True,Endothelial Microparticles: A Novel Marker of Vascular Dysfunction,Chronic Kidney Disease,Other:Flow-mediated dilation; Other:single blood draw,"[u'University of Colorado Anschutz Medical Campus; CTRC', u'University of Colorado School of Medicine']","December 2, 2015",18,100,Both,True
NCT02224664,Pfizer,False,CO,https://ClinicalTrials.gov/show/NCT02224664,True,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease",Parkinson`s Disease,Drug:PF-06649751; Drug:PF-06649751; Drug:PF-06649751; Drug:PF-06649751,"[u'Orange Coast Memorial Medical Center', u""The Parkinson's and Movement Disorder Institute"", u'Collaborative Neuroscience Network, LLC', u'Rocky Mountain Movement Disorders Center', u'Davita Clinical Research Center', u'MD Clinical', u'Compass Research, LLC', u'Atlanta Center for Medical Research', u'SNBL Clinical Pharmacology Center (Pharmacy Shipping Address)', u'SNBL Clinical Pharmacology Center', u""Parkinson's and Movement Disorders Center of Maryland"", u'Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY', u'Massachusetts General Hospital', u'QUEST Research Institute', u'PRA International', u'Carolina Phase I Research, LLC', u'Lynn Health Science Institute', u'Neurology Consultants of Dallas, PA', u'Walnut Hill Medical Center']","February 1, 2016",30,80,Both,False
NCT02221869,Jazz Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT02221869,True,A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy,Narcolepsy With Cataplexy,Drug:Xyrem,[],"November 12, 2015",7,17,Both,False
NCT02213744,Merrimack Pharmaceuticals,False,CO,https://ClinicalTrials.gov/show/NCT02213744,True,MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,Breast Cancer; HER2 Positive Breast Cancer,Drug:MM-302; Drug:Gemcitabine; Drug:Capecitabine; Drug:Vinorelbine; Drug:Trastuzumab,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02209636,VA Office of Research and Development,False,CO,https://ClinicalTrials.gov/show/NCT02209636,True,Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease,Chronic Kidney Disease; Cardiovascular Disease,Drug:Lanthanum carbonate; Drug:placebo; Drug:Ascorbic Acid; Drug:Nitroglycerin; Procedure:Flow-mediated dilation measurement; Procedure:Aortic pulse-wave velocity; Procedure:Endothelial cell collection,"[u'University of Colorado Denver', u'VA Eastern Colorado Health Care System, Denver, CO']","February 3, 2016",40,79,Both,False
NCT02205359,Medtronic Cardiac Rhythm Disease Management,False,CO,https://ClinicalTrials.gov/show/NCT02205359,True,AdaptResponse Clinical Trial,Heart Failure With Left Bundle Branch Block,Device:aCRT ON; Device:aCRT OFF,[],"October 16, 2015",18,9223372036854775807,Both,False
NCT02174731,AstraZeneca,False,CO,https://ClinicalTrials.gov/show/NCT02174731,True,"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis",Anemia,Drug:Roxadustat; Drug:Epoetin alfa,[],"February 2, 2016",18,130,Both,False
NCT01272037,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,CT,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01668719,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01349881,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,CT,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01470612,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,CT,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00807768,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01274338,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,CT,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01975389,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01458574,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00565851,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02406677,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT01991795,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00351611,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02459925,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02459925,True,MOMS Hubs- CT Dept of Social Services Block Grant,Depression,Behavioral:CBT- Mental Health Program; Behavioral:MOMS GROW,"[u'Boys & Girls Club of New Haven', u'Center for Wellbeing of Women and Mothers, Dept. of Psychiatry, Yale University', u'Stop & Shop', u""West Rock Author's Academy""]","February 1, 2016",18,9223372036854775807,Female,False
NCT02358031,Merck Sharp & Dohme Corp.,False,CT,https://ClinicalTrials.gov/show/NCT02358031,True,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer,Biological:Pembrolizumab; Drug:Cisplatin; Drug:Carboplatin; Drug:5-FU; Biological:Cetuximab,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,CT,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02271217,Acorda Therapeutics,False,CT,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01920711,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,CT,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01771809,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01771809,True,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],"January 16, 2016",18,65,Both,False
NCT01414608,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01107626,Eastern Cooperative Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,CT,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00888615,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00843882,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02671981,Radiation Therapy Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02670083,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02615002,Neurim Pharmaceuticals Ltd.,False,CT,https://ClinicalTrials.gov/show/NCT02615002,True,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug:Piromelatine; Drug:Placebo,[],"January 26, 2016",60,85,Both,False
NCT02528253,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02484547,Biogen,False,CT,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02456740,Amgen,False,CT,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02436668,Pharmacyclics,False,CT,https://ClinicalTrials.gov/show/NCT02436668,True,"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)",Metastatic Pancreatic Adenocarcinoma,Drug:Ibrutinib; Drug:Gemcitabine; Drug:Nab-paclitaxel,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02425891,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02425891,True,A Study of Atezolizumab (MPDL3280A) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130),Metastatic Breast Cancer,Drug:Atezolizumab; Drug:Nab-Paclitaxel; Drug:Placebo,[],"December 31, 2015",18,9223372036854775807,Female,False
NCT02422940,Acorda Therapeutics,False,CT,https://ClinicalTrials.gov/show/NCT02422940,True,"An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study",Post-ischemic Stroke,Drug:dalfampridine-ER 7.5 mg; Drug:dalfampridine-ER 10 mg,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02179918,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02179918,True,A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),Advanced Solid Tumors,Drug:PF-05082566; Drug:MK-3475,"[u'UCLA Bowyer Clinic', u'Ronald Reagan UCLA Medical Center, Drug Information Center', u'UCLA Hematology-Oncology Clinic', u'UCLA Department of Medicine, Division of Hematology/Oncology', u'Yale University School of Medicine', u'Smilow Cancer Hospital at Yale-New Haven', u'Smilow CNCR CTR. Yale New Haven HOSP Drug Shipment Address', u'South Texas Accelerated Research Therapeutics, LLC (START)', u'Seattle Cancer Care Alliance (Drug Shipment Address)', u'Seattle Cancer Care Alliance', u'University of Washington Medical Center']","January 6, 2016",18,9223372036854775807,Both,False
NCT02143063,University of Connecticut Health Center,False,CT,https://ClinicalTrials.gov/show/NCT02143063,True,Extending Long-term Outcomes Through an Adaptive Aftercare Intervention,Cocaine Use Disorder; Contingency Management,Behavioral:prize contingency management on a traditional twice weekly schedule for cocaine abstinence; Behavioral:prize contingency management on a variable interval schedule for cocaine abstinence; Behavioral:standard care,"[u'Regional Network of Programs, Inc.', u'Alcohol and Drug Recovery Centers, Inc.', u'The Hospital of Central Connecticut at New Britain General', u'Behavioral Health Network, Inc.']","December 7, 2015",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02043210,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02043210,True,CBT for Spanish Speakers,Substance Use,Behavioral:Standard Treatment as Usual; Behavioral:CBT4CBT plus Standard treatment as usual,"[u'MAAS', u'Hispanic Clinic', u'Substance Abuse Treatment Unit (SATU)']","January 15, 2016",18,65,Both,False
NCT02038764,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02038764,True,A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Drug:Placebo; Biological:PF-06342674 Dose A; Biological:PF-06342674 Dose B; Biological:PF-06342674 Dose C; Biological:PF-06342674 Dose D,"[u'VA San Diego Healthcare System (Drug Shipment)', u'Veterans Administration San Diego Healthcare System', u'UCSF Gateway Medical Building', u'Barbara Davis Center for Childhood Diabetes', u'Yale University School of Medicine', u'Yale New Haven Hospital - Investigational Drug Services', u'Yale New Haven Hospital', u'Atlanta Diabetes Associates', u'Duchossois Center for Advanced Medicine', u'The University of Chicago Medical Center', u'University of Chicago Clinical Resource Center', u'University of Chicago Medical Center', u'UMass Medical School', u'University Of Minnesota Fairview Pharmacy Services', u'University Of Minnesota Medical School', u'(drug shipment only) Barnes- Jewish HOSP Att: Kathryn Vehe', u'Washington University (study supplies shipping only)', u'Washington University - Center for Advanced Medicine', u'Washington University', u'Duke Clinical Research Unit']","February 4, 2016",18,9223372036854775807,Both,False
NCT02008292,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02008292,True,"Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors",Smoking; Schizophrenia,Drug:Physostigmine,"[u'Connecticut Mental Health Center', u'Yale Magnetic Resonance Research Center', u'Yale PET Center']","July 14, 2015",18,60,Both,True
NCT01996865,Celgene Corporation,False,CT,https://ClinicalTrials.gov/show/NCT01996865,True,"Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.","Lymphoma, Non-Hodgkin",Drug:Lenalidomide; Drug:Rituximab,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01950390,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01855750,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,CT,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01852110,Merck Sharp & Dohme Corp.,False,CT,https://ClinicalTrials.gov/show/NCT01852110,True,Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),Alzheimer's Disease,Drug:MK-7622; Drug:Placebo; Drug:AChEI,[],"January 22, 2016",55,85,Both,False
NCT01846611,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT01846611,True,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms,Drug:Trabectedin; Drug:DOXIL; Drug:Dexamethasone; Drug:DOXIL,[],"January 19, 2016",18,9223372036854775807,Female,False
NCT01845025,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01817660,Boston University,False,CT,https://ClinicalTrials.gov/show/NCT01817660,True,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u'Massachusetts General Hospital', u'BI-Deaconess Hospital', u'Boston Medical Center', u""Brigham and Women's Hospital"", u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']","March 28, 2013",35,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01799993,Bayer,False,CT,https://ClinicalTrials.gov/show/NCT01799993,True,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin Inhalation Solution (BAY41-6551); Drug:Aerosolized Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01776424,Bayer,False,CT,https://ClinicalTrials.gov/show/NCT01776424,True,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,Prevention & Control,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Aspirin; Drug:Aspirin placebo; Drug:Rivaroxaban placebo; Drug:Pantoprazole",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01691092,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT01691092,True,PET Imaging of mGLuR5 With Drug Challenge,Major Depressive Disorder; Post-Traumatic Stress Disorder (PTSD),Drug:Ketamine,"[u'Connecticut Mental Health Center', u'Yale University Magnetic Resonance Research Center (MRRC)', u'Yale University PET Center']","October 19, 2015",18,65,Both,True
NCT01652872,Amgen,False,CT,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,CT,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01542528,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT01542528,True,"Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)",Attention Deficit Hyperactivity Disorder (ADHD),Behavioral:IBBS,"[u'PAXIS Institute', u'Hamden Public Schools', u'Department of Psychiatry, Yale University', u'Yale Child Study Center', u'Capital Medical University', u'Peking University']","July 20, 2015",5,8,Both,False
NCT01372787,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01312909,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01312909,True,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],"February 3, 2016",12,19,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00897442,Gynecologic Oncology Group,True,CT,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02661425,"Entera Health, Inc",False,CT,https://ClinicalTrials.gov/show/NCT02661425,True,Retrospective Study of IBS-D Patients Previously Receiving SBI,Diarrhoea Predominant Irritable Bowel Syndrome,Other:EnteraGam,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 25, 2016",18,9223372036854775807,Both,False
NCT02638649,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02638649,True,Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath,Pneumonia; Pulmonary Edema; Dyspnea,Procedure:Lung ultrasound; Device:ultrasound,"[u'Yale-New Haven Hospital\u2014Saint Raphael Campus', u'Yale New Haven Hospital']","December 22, 2015",18,9223372036854775807,Both,False
NCT02629081,Loren Laine,False,CT,https://ClinicalTrials.gov/show/NCT02629081,True,Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease,GERD,Other:Controls & Cases,"[u'Yale New Haven Hospital', u'VACHS']","December 10, 2015",21,75,Both,False
NCT02601209,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,CT,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02589717,"Genentech, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02589717,True,An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy,Urothelial Carcinoma,Drug:Atezolizumab,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02585934,Axovant Sciences Ltd.,False,CT,https://ClinicalTrials.gov/show/NCT02585934,True,Study Evaluating RVT-101 in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil Treatment: MINDSET Study,Alzheimer's Disease,Drug:RVT-101; Drug:Placebo,[],"January 19, 2016",50,85,Both,False
NCT02579928,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT02579928,True,Ketamine Infusion for Adolescent Depression,Major Depressive Disorder,Drug:Ketamine; Drug:Midazolam,"[u'Hospital Research Unit at the Yale New Haven Hospital', u'Yale Child Study Center']","October 19, 2015",13,17,Both,False
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,CT,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,CT,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02537691,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02537691,True,Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers,Asthma,Other:Laboratory biomarker analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02508298,VA Connecticut Healthcare System,False,CT,https://ClinicalTrials.gov/show/NCT02508298,True,Surrogate Markers of Portal Pressure,Portal Hypertension; Cirrhosis,Procedure:HVPG; Drug:Indocyanine Green Retention test; Device:Liver stiffness measurement; Device:Spleen stiffness measurement,"[u'Yale-New Haven Hospital', u'VA Connecticut Healthcare System']","July 22, 2015",18,85,Both,False
NCT02504216,Bayer,False,CT,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02497287,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02497287,True,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Duloxetine; Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02482441,"OncoMed Pharmaceuticals, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02482441,True,"A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",Advanced Relapsed Tumors; Refractory Solid Tumors,Drug:OMP-131R10; Drug:FOLFIRI,"[u'UCSF', u'University of Colorado Hospital Anschulz Cancer Pavilion', u'Smilow Cancer Hospital at Yale-New Haven', u'Yale', u'The Sarah Cannon Research Institute', u'M.D. Anderson Cancer Center']","August 28, 2015",18,9223372036854775807,Both,False
NCT02474160,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02446899,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02446899,True,Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus,Active Systemic Lupus Erythematosus,Biological:Anifrolumab; Drug:Placebo,[],"November 9, 2015",18,70,Both,False
NCT02438722,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02422186,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02422186,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral Antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (New Antidepressant),[],"February 4, 2016",65,9223372036854775807,Both,False
NCT02409355,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02409355,True,A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Cisplatin; Drug:Gemcitabine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,CT,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02366143,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02364999,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02364999,True,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02344290,National Institute of Allergy and Infectious Diseases (NIAID),False,CT,https://ClinicalTrials.gov/show/NCT02344290,True,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,HIV Infections; Cardiovascular Diseases,Drug:Pitavastatin; Drug:Placebo,[],"February 1, 2016",40,75,Both,False
NCT02340273,"ZetrOZ, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02340273,True,Long Duration Therapeutic Ultrasound on Tendon Injuries,Tendon Injuries; Musculoskeletal Pain,Device:Therapeutic ultrasound; Device:Placebo therapeutic ultrasound,"[u'Clinical Research Consulting', u'Zetroz, Inc']","February 2, 2015",18,70,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02319018,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02319018,True,Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,Malignant Digestive System Neoplasm,Drug:Alisertib; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,"[u'Smilow Cancer Center/Yale-New Haven Hospital', u'Yale University', u'Johns Hopkins University/Sidney Kimmel Cancer Center', u'Wayne State University/Karmanos Cancer Institute', u'Vanderbilt University/Ingram Cancer Center']","February 4, 2016",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,CT,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02301156,"TG Therapeutics, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02289248,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02289248,True,Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine,Depression,Drug:Ketamine; Behavioral:Cognitive Behavioral Therapy (CBT),"[u'Connecticut Mental Health Center', u'Yale Psychiatric Hospital']","June 4, 2015",18,65,Both,False
NCT02279394,Dana-Farber Cancer Institute,False,CT,https://ClinicalTrials.gov/show/NCT02279394,True,Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,Smoldering Myeloma; Smoldering Multiple Myeloma,Drug:Elotuzumab; Drug:Lenalidomide; Drug:Dexamethasone,"[u'Colorado Blood Cancer Institute', u'St Francis Hospital and Medical Center', u'Lawrence and Memorial Hospital', u'Eastern Maine Medical Center', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Newton-Wellesley Hospital', u'Barbara Ann Karmanos Cancer Institute']","October 22, 2015",18,9223372036854775807,Both,False
NCT02275533,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02275533,True,Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,Adult Acute Myeloid Leukemia in Remission,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,"[u'City of Hope Comprehensive Cancer Center', u'University of California Davis Comprehensive Cancer Center', u'Smilow Cancer Center/Yale-New Haven Hospital', u'Yale University', u'University of Chicago Comprehensive Cancer Center P2C', u'University of Chicago Comprehensive Cancer Center', u'Decatur Memorial Hospital', u'UC Comprehensive Cancer Center at Silver Cross', u'Illinois CancerCare-Peoria', u'Indiana University/Melvin and Bren Simon Cancer Center', u'University of Maryland/Greenebaum Cancer Center', u'National Institutes of Health Clinical Center', u'NCI - Center for Cancer Research', u'Wayne State University/Karmanos Cancer Institute', u'Case Western Reserve University', u'Penn State Milton S Hershey Medical Center', u'Virginia Commonwealth University/Massey Cancer Center', u'University Health Network-Princess Margaret Hospital']","January 11, 2016",18,9223372036854775807,Both,False
NCT02271022,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02271022,True,Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry,Acute Coronary Syndromes,Other:Non-Interventional Study,[],"January 21, 2016",18,99,Both,False
NCT02267694,University of Connecticut Health Center,False,CT,https://ClinicalTrials.gov/show/NCT02267694,True,Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis,Ulcerative Colitis,Drug:Freeze-dried black raspberry powder,"[u'University of Connecticut Health Center', u'University of Connecticut Health Center']","October 14, 2014",18,90,Both,False
NCT02265744,Bristol-Myers Squibb,False,CT,https://ClinicalTrials.gov/show/NCT02265744,True,Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus,Lupus,Drug:BMS-931699; Drug:Placebo matching BMS-931699,[],"January 26, 2016",18,70,Both,False
NCT02263742,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02263742,True,Project Wellness Enhancement: Increasing Health Care Choice and Outcomes for People With Mental Illness,"Mental Health Wellness 1; Mental Illnesses; Other Diagnoses, Comorbidities, and Complications | Patient",Behavioral:Peer whole health intervention; Behavioral:EBPs at Wellness Center,"[u'CT Mental Health Center', u'Yale University Program for Recovery and Community Health']","October 7, 2014",18,9223372036854775807,Both,True
NCT02258542,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02247531,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT02247531,True,A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02240121,"Valeant Pharmaceuticals International, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02240121,True,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,CT,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194699,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02194062,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT02194062,True,Comparison of Nasal Steroids After FESS in CRSwNP,Sinusitis; Nasal Polyps,Drug:fluticasone nasal spray; Drug:Budesonide; Drug:Budesonide,"[u'Yale Physicians Bldg', u'Yale ENT Stratford']","January 21, 2015",18,9223372036854775807,Both,False
NCT02187783,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT02187783,True,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),Tumors With CDK4/6 Pathway Activation,Drug:LEE011,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02175225,Beth Israel Deaconess Medical Center,True,CT,https://ClinicalTrials.gov/show/NCT02175225,True,Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial,Intracerebral Hemorrhage,Drug:Deferoxamine Mesylate; Drug:Placebo (for Deferoxamine Mesylate),[],"July 20, 2015",18,80,Both,False
NCT02173379,Abbott Vascular,False,CT,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02164864,Boehringer Ingelheim,False,CT,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02149108,Boehringer Ingelheim,False,CT,https://ClinicalTrials.gov/show/NCT02149108,True,Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer,Colorectal Neoplasms,Drug:Nindetanib (BIBF 1120); Drug:Placebo; Drug:BSC; Drug:BSC,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02148575,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02148575,True,Integrating Palliative Care Into Self-Management of Breast Cancer,Breast Cancer,Behavioral:Self-Management Group; Behavioral:Symptom Management Group,"[u'Yale-New Haven Hospital', u'Yale School of Nursing']","July 14, 2015",21,9223372036854775807,Female,False
NCT02143037,University of Connecticut Health Center,False,CT,https://ClinicalTrials.gov/show/NCT02143037,True,CM Treatment for Alcohol Dependence Using New Technology,Alcohol Use Disorder; Contingency Management,Behavioral:prize contingency management for attending treatment; Behavioral:usual care; Device:The Secure Continuous Remote Alcohol Monitor (SCRAMx),"[u'Regional Network of Programs, Inc.', u'Alcohol and Drug Recovery Centers, Inc.']","December 7, 2015",18,9223372036854775807,Both,False
NCT02138916,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02135237,University of Connecticut Health Center,False,CT,https://ClinicalTrials.gov/show/NCT02135237,True,Contingency Management for Alcohol Use Disorders,Alcohol Use Disorder; Contingency Management,Behavioral:Prize Contingency Management for Alcohol Abstinence; Behavioral:Standard Care,"[u'The Hospital of Central Connecticut at New Britain General', u'Farrell Treatment Center', u'Behavioral Health Network, Inc.']","December 7, 2015",18,9223372036854775807,Both,False
NCT02119650,Incyte Corporation,False,CT,https://ClinicalTrials.gov/show/NCT02119650,True,Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,"Carcinoma, Non-Small-Cell Lung",Drug:Ruxolitinib; Drug:Placebo; Drug:Pemetrexed; Drug:Cisplatin,[],"May 28, 2015",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02102100,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02102100,True,The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users,Nicotine Dependence,Drug:IV nicotine; Drug:Tobacco Flavor; Drug:Low dose Menthol; Drug:High Dose Menthol,"[u'Connecticut VA Healthcare System', u'VA Connecticut Health Care System']","January 8, 2016",18,30,Both,True
NCT02101853,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02100228,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02100228,True,"Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",Atrial Fibrillation,Drug:Apixaban; Drug:Parenteral heparin and/or oral Vitamin K antagonist,[],"January 16, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02075047,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT02072226,"Genentech, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02072226,True,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02048852,University of Connecticut Health Center,False,CT,https://ClinicalTrials.gov/show/NCT02048852,True,Manipulating Tobacco Constituents in Female Menthol Smokers,Nicotine Dependence,Other:Reduced Nicotine Content- Non Menthol; Other:Reduced Nicotine Content- Menthol; Other:Conventional Nicotine Content- Menthol; Other:Conventional Nicotine Content- Non Menthol,"[u'UCONN Health Center', u'Hartford Hospital']","June 5, 2015",18,45,Female,True
NCT02047097,Biogen,False,CT,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02037347,Brett King,False,CT,https://ClinicalTrials.gov/show/NCT02037347,True,Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis,Toxic Epidermal Necrolysis; Stevens-Johnson Syndrome,Drug:Palifermin,"[u'Bridgeport Hospital', u'Yale-New Haven Hospital']","January 13, 2014",18,9223372036854775807,Both,False
NCT02025621,"Tenax Therapeutics, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT02025621,True,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,Coronary Artery Bypass Grafting; Mitral Valve Surgery; Low Cardiac Output Syndrome,Drug:Levosimendan; Drug:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02006654,H. Lundbeck A/S,False,CT,https://ClinicalTrials.gov/show/NCT02006654,True,Lu AE58054 in Patients With Mild to Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Alzheimer's Disease,Drug:Placebo; Drug:Lu AE58054,[],"December 10, 2015",50,9223372036854775807,Both,False
NCT02006641,H. Lundbeck A/S,False,CT,https://ClinicalTrials.gov/show/NCT02006641,True,Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Drug:Placebo; Drug:Lu AE58054,[],"December 10, 2015",50,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01970865,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01970865,True,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug:PF-06463922; Drug:Crizotinib,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01970007,Cook,False,CT,https://ClinicalTrials.gov/show/NCT01970007,True,VIVO Clinical Study,Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein,Device:Zilver Vena Venous Stent,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01947608,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01947608,True,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:LDK378,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,CT,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01903811,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,CT,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01885078,Eli Lilly and Company,False,CT,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01870778,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01859741,"OncoMed Pharmaceuticals, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT01859741,True,A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),Stage IV Small Cell Lung Cancer,Drug:OMP-59R5; Drug:Etoposide; Drug:Placebo; Drug:Cisplatin or Carboplatin,[],"January 27, 2016",18,90,Both,False
NCT01858532,AbbVie,False,CT,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01858519,AbbVie,False,CT,https://ClinicalTrials.gov/show/NCT01858519,True,Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy,Cystic Fibrosis,Biological:pancrelipase,[],"December 14, 2015",2,99,Both,False
NCT01856192,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,CT,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01828112,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01828112,True,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01817075,Children's Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01817075,True,Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant,Bacterial Infection; Benign Neoplasm; Malignant Neoplasm; Methicillin-Resistant Staphylococcus Aureus Infection; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Untreated Childhood Myeloid Neoplasm,Drug:Chlorhexidine Gluconate; Procedure:Wound Care Management; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"August 13, 2015",2,21,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01799889,Gilead Sciences,False,CT,https://ClinicalTrials.gov/show/NCT01799889,True,Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies,Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Non-FL Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma,Drug:Entospletinib; Drug:Entospletinib SDD,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT01797185,Sun Pharma Advanced Research Company Limited,False,CT,https://ClinicalTrials.gov/show/NCT01797185,True,"A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial",Spasticity,Drug:Baclofen,[],"September 15, 2015",18,90,Both,False
NCT01772472,Hoffmann-La Roche,False,CT,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01760759,University of Connecticut Health Center,False,CT,https://ClinicalTrials.gov/show/NCT01760759,True,Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus,HIV,Drug:antiretroviral therapy; Behavioral:cell phone reminders; Behavioral:contingency management for adherence,"[u'University of Connecticut Health Center', u'Nathan Smith Clinic, Yale-New Haven Hospital']","December 7, 2015",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,CT,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,CT,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01711515,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01711515,True,Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage IIIB Cervical Cancer; Stage IVA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,"[u'Los Angeles County-USC Medical Center', u'USC / Norris Comprehensive Cancer Center', u'UC Irvine Health/Chao Family Comprehensive Cancer Center', u'University of California Davis Comprehensive Cancer Center', u'Hartford Hospital', u'The Hospital of Central Connecticut', u'Georgia Regents University Medical Center', u'University of New Mexico Cancer Center', u'Montefiore Medical Center-Einstein Campus', u'Cleveland Clinic Foundation', u'Case Western Reserve University', u'University of Oklahoma Health Sciences Center', u'Thomas Jefferson University Hospital', u'Fox Chase Cancer Center', u'Women and Infants Hospital', u'Virginia Commonwealth University/Massey Cancer Center']","January 28, 2016",18,9223372036854775807,Female,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,CT,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01663402,Sanofi,False,CT,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01659411,Actelion,False,CT,https://ClinicalTrials.gov/show/NCT01659411,True,Adult Congenital Heart Disease Registry (QuERI),Pulmonary Arterial Hypertension; Congenital Heart Disease,Other:observational,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01644656,VA Connecticut Healthcare System,False,CT,https://ClinicalTrials.gov/show/NCT01644656,True,Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI),Portal Hypertension; Chronic Liver Disease,Device:ARFI ultrasound,"[u'Yale-New Haven Hospital', u'VA Connecticut Healthcare System']","July 22, 2015",18,85,Both,False
NCT01633112,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01626079,Evalve,False,CT,https://ClinicalTrials.gov/show/NCT01626079,True,COAPT Clinical Trial,Mitral Regurgitation; Mitral Valve Regurgitation,Device:MitraClip System,[],"October 9, 2015",18,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01602666,Children's Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01602666,True,Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors,Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma,Procedure:therapeutic conventional surgery; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Drug:carboplatin; Drug:etoposide; Drug:ifosfamide,[],"October 20, 2015",3,21,Both,False
NCT01595061,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01592630,Stamford Hospital,True,CT,https://ClinicalTrials.gov/show/NCT01592630,True,Effectiveness of Transverse Abdominus Plane Catheter Blocks to Patient-controlled Analgesia in Laparoscopic Colon Resections,Colorectal Disorders; Observation of Neuromuscular Block,Drug:0.2% ropivacaine; Drug:Saline,"[u'Colon and Rectal Surgery', u'Stamford Hospital']","May 3, 2012",18,9223372036854775807,Both,False
NCT01590277,VA Office of Research and Development,False,CT,https://ClinicalTrials.gov/show/NCT01590277,True,"Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans",Active Ethanol and Active Iomazenil; Active Ethanol and Placebo Iomazenil; Placebo Ethanol and Placebo Iomazenil; Placebo Ethanol and Active Iomazenil,Drug:Ethanol; Drug:Iomazenil,"[u'CERC (VISN1, West Haven, CT)', u'VA Connecticut Healthcare System West Haven Campus, West Haven, CT']","January 21, 2016",21,35,Both,True
NCT01589796,"Stamford Anesthesiology Services, PC",True,CT,https://ClinicalTrials.gov/show/NCT01589796,True,Medial Versus Traditional Approach to US-guided TAP Blocks for Open Inguinal Hernia Repair,"Abdominal Muscles/Ultrasonography; Adult; Ambulatory Surgical Procedures; Anesthetics, Local/Administration & Dosage; Ropivacaine/Administration & Dosage; Ropivacaine/Analogs & Derivatives; Hernia, Inguinal/Surgery; Humans; Nerve Block/Methods; Pain Measurement/Methods; Pain, Postoperative/Prevention & Control; Ultrasonography, Interventional",Procedure:TAP block,"[u'Tully Health Center', u'Stamford Hospital']","April 30, 2012",18,75,Both,False
NCT01535053,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01492361,Amarin Pharma Inc.,False,CT,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01457352,Sun Pharma Advanced Research Company Limited,False,CT,https://ClinicalTrials.gov/show/NCT01457352,True,Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen ER Capsules; Drug:Placebo GRS,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01367002,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT01367002,True,Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,Endometrial Cancer,Drug:Carboplatin/Paclitaxel; Drug:Trastuzumab,"[u""St. Joseph's Hospital and Medical Center"", u'University of Arizona Cancer Center', u'University of Arizona Cancer Center', u'John Muir Clinical Research Center', u'University of California at Los Angeles', u'Penrose St. Francis Hospital', u'The Hospital of Central Connecticut', u'Smilow Cancer Hospital at Yale New Haven', u'The University of Chicago Medicine', u'Greater Baltimore Medical Center', u'Walter Reed National Military Medical Center', u'University of Maryland Medical Center', u'Holy Cross Hospital', u'Jersey Shore University Medical Center', u'Montefiore Medical Center', u'Duke University School of Medicine', u'The Ohio State University']","August 20, 2015",0,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01307579,Children's Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01246401,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT01246401,True,Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations,HIV; AIDS; Opioid Dependence; Drug Dependence,Drug:Extended-Release Naltrexone,"[u'Yale University', u'Yale University', u'Baystate Medical Center']","July 29, 2015",18,9223372036854775807,Both,True
NCT01240993,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT01240993,True,Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers,Parenting Capacities of Substance Abusing Mothers,Behavioral:Mentalization-Based Therapy for Substance Abusing Mothers; Behavioral:Parent Education,"[u""The Moms 'n' Kids Program at the APT Foundation"", u'Yale Psychosocial Substance Abuse Research Unit']","January 23, 2014",21,45,Female,False
NCT01200589,GlaxoSmithKline,False,CT,https://ClinicalTrials.gov/show/NCT01200589,True,Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy,Non-Hodgkin's Lymphoma,Biological:Ofatumumab; Biological:Rituximab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01163253,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01096368,Children's Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02601209,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,DE,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,DE,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01622868,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01595061,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01575548,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01415752,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01013649,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01236547,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT02474160,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT01439711,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01439711,True,Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:letrozole; Procedure:MRI; Procedure:conventional surgery,[],"September 18, 2015",18,9223372036854775807,Female,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,DE,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,DE,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01959581,University of Delaware,False,DE,https://ClinicalTrials.gov/show/NCT01959581,True,Movement Enhancing Device for Children,Upper Extremity Dysfunction,Device:Movement Enhancing Device,"[u'Christiana Care Health Services', u'University of Delaware', u'Nemours Foundation']","December 11, 2014",1,6,Both,True
NCT01809691,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02336685,"Janssen Research & Development, LLC",False,DE,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02047097,Biogen,False,DE,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01960075,University of Virginia,False,DE,https://ClinicalTrials.gov/show/NCT01960075,True,Established Status Epilepticus Treatment Trial,Benzodiazepine Refractory Status Epilepticus,Drug:Fosphenytoin; Drug:Levetiracetam; Drug:Valproic acid,[],"October 30, 2015",2,9223372036854775807,Both,False
NCT01888120,Jazz Pharmaceuticals,False,DE,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01805076,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,DE,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01492361,Amarin Pharma Inc.,False,DE,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00897767,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00888615,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00807768,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00499330,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT00499330,True,Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer,Lung Cancer,Procedure:lobectomy; Procedure:segmentectomy or wedge resection,[],"August 28, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00074282,Eastern Cooperative Oncology Group,True,DE,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,DE,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02656641,Christiana Care Health Services,True,DE,https://ClinicalTrials.gov/show/NCT02656641,True,Using the PHQ-9 and GAD-7 as Feedback Instruments in Brief Psychotherapy,"Depressive Symptoms; Anxiety States, Neurotic",Behavioral:Continuous Client Feedback; Behavioral:Continuous Self Feedback,[u'Christiana Care Health System - Adult Bridge Program'],"January 13, 2016",18,64,Both,False
NCT02638129,Takeda,False,DE,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02636868,"Discovery Laboratories, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02636868,True,Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age,Respiratory Distress Syndrome,Drug:Lucinactant delivered via investigational delivery device; Drug:nCPAP,"[u'University of Alabama at Birmingham', u'Loma Linda University Medical Center', u'Sharp Mary Birch Hospital for Women and Newborns', u'Christiana Care Health System', u'University of Miami', u'Mid Atlantic Neonatology Associates', u'Duke University Medical Center', u'Providence St. Vincent Medical Center']","December 28, 2015",26,32,Both,False
NCT02629159,AbbVie,False,DE,https://ClinicalTrials.gov/show/NCT02629159,True,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],"December 10, 2015",18,99,Both,False
NCT02582957,University of Minnesota - Clinical and Translational Science Institute,False,DE,https://ClinicalTrials.gov/show/NCT02582957,True,Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome,Other:Sigh breaths,"[u'UCSF Fresno Community Regional Medical Center', u'University of Southern California (LA County)', u'Stanford University', u'Christiana Care Health System', u'University of Maryland Medical System Shock Trauma Center', u'University of Michigan', u'Washington University in St. Louis', u'University Medical Center Brackenridge', u'UT Southwestern (Parkland)', u'University of Utah']","October 23, 2015",18,89,Both,False
NCT02556632,Gary Morrow,False,DE,https://ClinicalTrials.gov/show/NCT02556632,True,Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis,Breast Carcinoma; Pain; Radiation-Induced Dermatitis; Stage 0 Breast Cancer,Drug:Curcumin-based Gel; Drug:HPR Plus; Drug:Placebo; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,"[u'Delaware/Christiana Care NCORP', u'Heartland NCORP', u'Metro Minnesota NCORP', u'URCC NCORP Research Base', u'Columbus NCORP', u'Dayton Community Oncology Program']","November 2, 2015",21,120,Female,False
NCT02552238,"Bracco Diagnostics, Inc",False,DE,https://ClinicalTrials.gov/show/NCT02552238,True,Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142,Coronary Artery Disease,Drug:sulphur hexafluoride lipid-type A microspheres,[u'Alfieri Cardiology'],"November 2, 2015",18,9223372036854775807,Both,False
NCT02533011,Christiana Care Health Services,True,DE,https://ClinicalTrials.gov/show/NCT02533011,True,Evaluation of the Heparin Binding Protein Levels in Sepsis,Sepsis; Infection; Septic Shock,Other:HBP lab test,[u'Christiana Care Health System'],"August 24, 2015",18,9223372036854775807,Both,False
NCT02532244,Nemours Children's Clinic,False,DE,https://ClinicalTrials.gov/show/NCT02532244,True,Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases,Spinal Muscular Atrophy; Charcot-Marie-Tooth Disease; Muscular Dystrophy; Spinal Muscular Atrophy With Respiratory Distress 1; Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Neuromuscular Disease; Peroneal Muscular Atrophy; Fragile X Syndrome,Other:sample collection,"[u'Alfred I. duPont Hospital for Children', u""Nemours Children's Specialty Care, Jacksonville"", u""Nemours Children's Hospital""]","August 24, 2015",6,9223372036854775807,Both,True
NCT02528318,"Discovery Laboratories, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02528318,True,Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA,Respiratory Distress Syndrome,Drug:Lucinactant for inhalation; Device:nCPAP alone,"[u'Loma Linda University Medical Center', u'Sharp Mary Birch Hospital for Women and Newborns', u'Christiana Care Health System', u'University of Miami', u'University of Louisville', u'Mid Atlantic Neonatology Associates', u'Providence St. Vincent Medical Center']","November 19, 2015",26,28,Both,False
NCT02521493,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02521493,True,Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,Childhood Acute Myeloid Leukemia; Childhood Myelodysplastic Syndrome; Cytopenia; Down Syndrome; Myeloid Leukemia Associated With Down Syndrome; Myeloproliferative Neoplasm,Drug:Asparaginase; Drug:Asparaginase Erwinia chrysanthemi; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mitoxantrone Hydrochloride; Drug:Thioguanine,[],"January 26, 2016",91,3,Both,False
NCT02514473,Vertex Pharmaceuticals Incorporated,False,DE,https://ClinicalTrials.gov/show/NCT02514473,True,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug:VX-809; Drug:Placebo; Drug:VX-770,[],"September 1, 2015",6,11,Both,False
NCT02504216,Bayer,False,DE,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02503787,MedtronicNeuro,False,DE,https://ClinicalTrials.gov/show/NCT02503787,True,OPTIONS Spinal Cord Stimulation Programming Parameters,"Pain, Intractable",Device:RestoreSensor SureScan MRI Rechargeable Neurostimulator,"[u'Valley Pain Consultants-North Scottsdale', u'Synovation Medical Group', u'Center for Interventional Pain Spine', u'Pain Care LLC', u'Millennium Pain Center', u'Mayo Clinic', u'The Center for Clinical Research', u'University Hospitals Case Medical Center', u""St. Luke's Neurosurgical Associates"", u'Precision Spine Care', u'Virginia Commonwealth University Medical Center', u'Swedish Pain Services', u'Northwest Pain Care']","December 24, 2015",18,9223372036854775807,Both,False
NCT02485795,"Proove Bioscience, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02485795,True,Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management,"Pain; Chronic Pain; Back Pain; Nociceptive Pain; Neuropathic Pain; Musculoskeletal Pain; Neck Pain; Pain, Intractable",Other:Observational,"[u'Medical Clinic - Steven J. Waltrip M.D. Inc.', u'Coastal Pain & Spinal Diagnostics - Yogesh Patel, M.D.', u'Regional Pain Treatment Medical Center', u'The Helm Center for Pain Management', u'Remedy Pain Solutions', u'Back Bay Medical', u'Pain Management Associates of CT, PC', u'Center for Interventional Pain & Spine', u'Neurospine Institute, LLC', u'South Florida Pain & Wellness Institute', u'Coastal Pain & Neurology', u'Perimeter Orthopedics', u'OrthoGeorgia', u'Roswell Pain Specialists', u'Optim Orthopedics', u'Medical Clinic - Dr. Robert Rust', u'The Kahan Center For Pain Management', u'Medical Centre Pain Mgmt', u'Spine Specialists (Texas Spine & Joint Hospital)', u'National Spine And Pain Centers', u'Northwest Spine and Pain Medicine']","July 21, 2015",18,9223372036854775807,Both,False
NCT02480153,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT02480153,True,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02470091,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02470091,True,Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma,Childhood Osteosarcoma; Metastatic Osteosarcoma; Recurrent Osteosarcoma,Biological:Denosumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,"[u'Alfred I duPont Hospital for Children', u""Children's National Medical Center"", u""Nemours Children's Hospital"", u""All Children's Hospital"", u""Lurie Children's Hospital-Chicago"", u'Ochsner Medical Center Jefferson', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Saint John Hospital and Medical Center', u'Albany Medical Center', u""Children's Hospital of Philadelphia"", u""Children's Oncology Group"", u""St. Jude Children's Research Hospital"", u""Childrens Hospital-King's Daughters""]","January 7, 2016",11,49,Both,False
NCT02469857,Atox Bio Ltd,False,DE,https://ClinicalTrials.gov/show/NCT02469857,True,Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections,Necrotizing Soft Tissue Infections; Necrotizing Fasciitis; Fournier's Gangrene,Drug:AB103 0.5 mg/kg; Other:NaCl 0.9%,[],"December 12, 2015",12,9223372036854775807,Both,False
NCT02465099,Ethicon Endo-Surgery,False,DE,https://ClinicalTrials.gov/show/NCT02465099,True,Posterior Spinal Fusion With Two Energy Dissection Techniques,Scoliosis,Device:Ultrasonic Dissection (UD); Device:Electrocautery Dissection (ED),"[u""Valley Children's Hospital"", u'Nemours/Alfred I. duPont Hospital for Children', u""Cincinnati Children's Hospital Medical Center"", u'Shriners Hospitals for Children-Philadelphia']","August 3, 2015",10,21,Both,False
NCT02460978,Bristol-Myers Squibb,False,DE,https://ClinicalTrials.gov/show/NCT02460978,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Diabetes,Drug:Dapagliflozin; Drug:Insulin; Other:Placebo,[],"January 26, 2016",18,75,Both,False
NCT02440022,C. R. Bard,False,DE,https://ClinicalTrials.gov/show/NCT02440022,True,Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae,Arteriovenous Fistula,Device:Lutonix DCB; Device:Standard Balloon Angioplasty Catheter,[],"February 2, 2016",21,9223372036854775807,Both,False
NCT02415400,Bristol-Myers Squibb,False,DE,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02412371,AbbVie,False,DE,https://ClinicalTrials.gov/show/NCT02412371,True,A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Stage III,Drug:Veliparib; Drug:Paclitaxel; Drug:Carboplatin; Radiation:Radiotherapy; Other:Placebo for Veliparib,"[u'Site Reference ID/Investigator# 133037', u'Site Reference ID/Investigator# 133486', u'Site Reference ID/Investigator# 133828', u'Site Reference ID/Investigator# 132944', u'Site Reference ID/Investigator# 133494', u'Site Reference ID/Investigator# 133492', u'Site Reference ID/Investigator# 134438', u'Site Reference ID/Investigator# 133496', u'Site Reference ID/Investigator# 133497', u'Site Reference ID/Investigator# 134608', u'Site Reference ID/Investigator# 133493', u'Site Reference ID/Investigator# 133910', u'Site Reference ID/Investigator# 141321', u'Site Reference ID/Investigator# 133495']","January 18, 2016",18,99,Both,False
NCT02410356,"Teva Pharmaceutical Industries, Ltd.",False,DE,https://ClinicalTrials.gov/show/NCT02410356,True,Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD),Growth Hormone Deficiency,Drug:TV-1106; Drug:dGH,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02409615,Nemours Children's Clinic,True,DE,https://ClinicalTrials.gov/show/NCT02409615,True,Complementary Therapies in Spinal Fusion Patients,Idiopathic Scoliosis,Other:Hypnosis Therapy; Other:Healing Touch Therapy,[u'Nemours / A I duPont Hospital for Children'],"April 6, 2015",12,17,Female,True
NCT02406677,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02405546,Nemours Children's Clinic,True,DE,https://ClinicalTrials.gov/show/NCT02405546,True,ETT Rotation During Nasal Fiberoptic Intubation,Dental Caries,Other:Pre-Rotated (Group R),[u'Nemours DuPont Hospital for Children'],"March 27, 2015",2,17,Both,True
NCT02405091,Neurocrine Biosciences,False,DE,https://ClinicalTrials.gov/show/NCT02405091,True,Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia,Drug:NBI-98854,[],"January 7, 2016",18,85,Both,False
NCT02369874,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT02369874,True,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN).,Drug:MEDI4736; Drug:MEDI4736 + Tremelimumab; Drug:Standard of Care,[],"January 18, 2016",18,96,Both,False
NCT02369653,Bristol-Myers Squibb,False,DE,https://ClinicalTrials.gov/show/NCT02369653,True,Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase,Lymphoma; Acute Lymphoblastic Leukemia,Drug:Apixaban; Other:No systemic anticoagulant prophylaxis,[],"January 26, 2016",1,17,Both,False
NCT02364648,University of Delaware,False,DE,https://ClinicalTrials.gov/show/NCT02364648,True,Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease,Chronic Kidney Disease,Dietary Supplement:MitoQ; Dietary Supplement:Placebo,"[u'Department of Kinesiology and Applied Physiology, University of Delaware']","February 4, 2016",18,9223372036854775807,Both,False
NCT02352753,Amgen,False,DE,https://ClinicalTrials.gov/show/NCT02352753,True,"Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI",Osteogenesis Imperfecta,Drug:Denosumab,[],"January 27, 2016",2,17,Both,False
NCT02340585,Stryker Neurovascular,False,DE,https://ClinicalTrials.gov/show/NCT02340585,True,Neuroform ATLAS IDE Study,Intracranial Aneurysm,Device:Next Generation Neuroform Stent System,"[u'Radiology Imaging Associates', u'Christiana Care Health Services', u'Lyerly Neurosurgery', u'WellStar Kennestone Hospital', u'Tufts Medical Center', u'Beth Israel Deaconess Medical Center', u'University of Massachusetts Medical School', u'SSM DePaul Health Center', u'University at Buffalo Neurosurgery/Gates Vascular Institute', u'The Cleveland Clinic Foundation', u'Hospital of the University of Pennsylvania', u'University of Pittsburgh Medical Center', u'Medical University of South Carolina', u'Methodist Healthcare - Memphis Hospitals', u'Houston Methodist Hospital', u'Virginia Commonwealth University', u'Harborview Medical Center']","December 9, 2015",18,80,Both,False
NCT02322320,"National Heart, Lung, and Blood Institute (NHLBI)",False,DE,https://ClinicalTrials.gov/show/NCT02322320,True,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",Multiple Myeloma,Drug:Lenalidomide,[],"December 17, 2015",18,70,Both,False
NCT02312037,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT02312037,True,Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy,CD33 Positive Acute Myelogenous Leukemia,Biological:Antibody Drug Conjugate Chemotherapeutic,[],"January 5, 2016",3,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02299414,University of Alabama at Birmingham,False,DE,https://ClinicalTrials.gov/show/NCT02299414,True,Chronic Hypertension and Pregnancy (CHAP) Project,Hypertension,Other:Anti-hypertensive therapy; Other:No anti-hypertensive therapy (unless BP is severe),[],"November 5, 2015",12,9223372036854775807,Female,False
NCT02273115,Christiana Care Health Services,True,DE,https://ClinicalTrials.gov/show/NCT02273115,True,Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor,"Labor; Forced or Induced, Affecting Fetus or Newborn",Drug:Oxytocin; Device:Transcervical Foley catheter,"[u'Christiana Care Health Services', u'Thomas Jefferson University Hospital']","January 14, 2016",18,9223372036854775807,Female,True
NCT02268786,"Illumina, Inc.",True,DE,https://ClinicalTrials.gov/show/NCT02268786,True,Single Embryo TrAnsfeR of Euploid Embryo,Infertility; Aneuploidy,Other:Preimplantation Genetic Screening by NGS,[],"November 14, 2015",25,40,Female,False
NCT02259231,"Reata Pharmaceuticals, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02259231,True,RTA 408 Capsules in Patients With Melanoma - REVEAL,Melanoma; Unresectable (Stage III) Melanoma; Metastatic (Stage IV) Melanoma,Drug:Omaveloxolone Capsules (2.5 mg/capsule); Drug:Ipilimumab (3 mg/kg); Drug:Nivolumab (3 mg/kg),"[u'Southern Cancer Center', u'Highlands Oncology Group', u'Christiana Hospital Helen F. Graham Cancer Center', u'H. Lee Moffitt Cancer Center & Research Institute', u'Dana Farber Cancer Institute', u'Atlantic Melanoma Center', u'Duke Cancer Institute', u'MD Anderson Cancer Center']","February 3, 2016",18,9223372036854775807,Both,False
NCT02254278,NRG Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02254278,True,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma,Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02235909,"Arbor Pharmaceuticals, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02235909,True,An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension,Hypertension,Drug:Azilsartan Medoxomil; Drug:Losartan; Drug:Placebo for Azilsartan Medoxomil; Drug:Placebo for Losartan,[],"January 25, 2016",6,18,Both,False
NCT02230969,Biogen,False,DE,https://ClinicalTrials.gov/show/NCT02230969,True,Plegridy Observational Program,Relapsing Forms of Multiple Sclerosis,Drug:peginterferon beta-1a,[],"September 10, 2015",18,9223372036854775807,Both,False
NCT02228174,Gynesonics,False,DE,https://ClinicalTrials.gov/show/NCT02228174,True,Sonography Guided Transcervical Ablation of Uterine Fibroids,Menorrhagia,Device:Intrauterine Ultrasound-Guided Radiofrequency Ablation System,[],"January 25, 2016",25,50,Female,False
NCT02193841,The Hospital for Sick Children,True,DE,https://ClinicalTrials.gov/show/NCT02193841,True,Simple Bone Cysts in Kids,Bone Cyst,Procedure:Curettage with puncture (C & P); Device:Curette; Device:Vitoss morsels,[],"September 4, 2015",2,21,Both,False
NCT02190981,WellSpan Health,True,DE,https://ClinicalTrials.gov/show/NCT02190981,True,Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department,Small Bowel Obstruction,Device:Ultrasound for Small Bowel Obstruction,"[u'University of California Irvine Medical Center', u'Christana Hospital', u'Wellspan Health York Hospital']","December 8, 2015",18,9223372036854775807,Both,False
NCT02186847,NRG Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,DE,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02159521,EKOS Corporation,False,DE,https://ClinicalTrials.gov/show/NCT02159521,True,Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic Endovascular System,Deep Vein Thrombosis; Post-thrombotic Syndrome,Device:EkoSonic Endovascular System,"[u'Pima Vascular, Tucson Medical Center', u'UCLA Medical Center', u'Yale-New haven Hospital', u'Christiana Hospital', u'Florida Hospital at Tampa', u'Tampa General Hospital', u'Medical Center of Central Georgia', u'St. Vincent Hospital', u'University of Louisville Research Foundation', u'Maine Medical Center', u'University of Michigan Medical Center', u'Hackensack Medical Center', u'Saint Barnabas Medical Center', u'Holy Name Medical Center', u'Aultman Hospital', u'Fairfield Medical Center', u'Oregon Health & Science University', u'DFW Vascular Group/ Methodist Dallas Medical Ctr', u'Inova Alexandria Hospital', u'Sentara Norfolk General Hospital']","January 26, 2015",18,75,Both,False
NCT02152631,Eli Lilly and Company,False,DE,https://ClinicalTrials.gov/show/NCT02152631,True,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,Non Small Cell Lung Cancer,Drug:Abemaciclib; Drug:Erlotinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02138838,Amgen,False,DE,https://ClinicalTrials.gov/show/NCT02138838,True,A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",Drug:Cinacalcet HCl; Dietary Supplement:Standard of Care,[],"January 19, 2016",6,17,Both,False
NCT02134327,Nemours Children's Clinic,False,DE,https://ClinicalTrials.gov/show/NCT02134327,True,Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion,Pre Operative Sedation; Mask Acceptance; Post Operative Delerium,Drug:Combination of Dexmedetomidine with Midazolam,[u'A.I. Dupont Hospital for Children'],"May 7, 2014",6,4,Both,True
NCT02132195,Emory University,False,DE,https://ClinicalTrials.gov/show/NCT02132195,True,Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome,Nephrotic Syndrome,Drug:ACTH,"[u'Pediatric Nephrology of Alabama, PC.', u'University of California, Los Angeles', u'Nemours/AI duPont Hospital for Children', u""Nemours Children's Hospital"", u'Emory University', u'Riley Hospital for Children', u""Helen DeVos Children's Hospital at Spectrum Health"", u'Mayo Clinic', u""Children's Hospital at Montefiore"", u""Duke Children's Health Center"", u'East Carolina University', u""Cincinnati Children's Hospital Medical Center"", u""Texas Children's Hospital"", u""Children's Hospital of Richmond at VCU""]","December 13, 2015",2,20,Both,False
NCT02112916,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,DE,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02107443,Gary Morrow,False,DE,https://ClinicalTrials.gov/show/NCT02107443,True,Improving Communication in Older Cancer Patients and Their Caregivers,Adult Solid Neoplasm; Lymphoma,Other:Informational Intervention; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,"[u'City of Hope Comprehensive Cancer Center', u'Delaware/Christiana Care NCORP', u'University of Chicago Comprehensive Cancer Center', u'Heartland NCORP', u'Kansas City NCORP', u'Wichita NCORP', u'Metro-Minnesota NCORP', u'Nevada NCORP', u'North Shore LIJ Health System NCORP', u'University of Rochester', u'Southeast Clinical ONcology Research Consortium', u'Columbus NCORP', u'Dayton NCORP', u'Pacific Cancer Research Consortium Ncorp', u'Geisinger Cancer Institute NCORP', u'Greenville NCORP', u'Northwest NCORP', u'Wisconsin NCORP', u'Aurora NCORP']","November 2, 2015",70,9223372036854775807,Both,True
NCT02104583,Gilead Sciences,False,DE,https://ClinicalTrials.gov/show/NCT02104583,True,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],"January 8, 2016",18,80,Both,False
NCT02101853,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02093221,Grifols Therapeutics Inc.,False,DE,https://ClinicalTrials.gov/show/NCT02093221,True,Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Biological:180 mg/kg Alpha1-PI; Biological:90 mg/kg Alpha1-PI; Biological:Placebo,[],"September 17, 2015",6,35,Both,False
NCT02072226,"Genentech, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT02072226,True,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02069899,NovImmune SA,False,DE,https://ClinicalTrials.gov/show/NCT02069899,True,"Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody",Hemophagocytic Lymphohistiocytosis,Drug:NI-0501,"[u'Alfred I. duPont Hospital for Children Nemours Center for Cancer and Blood Disorders', u'Dana-Farber Cancer Institute (DFCI)', u""Cincinnati Children's Hospital - Division of Immunobiology"", u""Texas Children's Cancer Center"", u""St. Anna Children's Hospital Dept. Outpatient Hematology/Oncology"", u'Charles University Prague University Hospital Motol Department of Pediatric Hematology and Oncology', u""University Children's Hospital M\xfcnster Department of Pediatric Hematology and Oncology"", u'Azienda Ospedaliero-Universitaria Meyer', u'Istituto Giannina Gaslini - Emato-Oncologia Pediatrica', u'Azienda Ospedaliera San Gerardo - Centro di Emato-Oncologia Pediatrica', u'Azienda Ospedaliera Santobono Pausilipon', u'Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica', u""Ospedale Pediatrico Bambino Gesu'"", u'A.O. Regina Margherita / S. Anna - Unit\xe0 di Oncoematologia', u""Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia"", u'Hospital Sant Joan de D\xe9u Secci\xf3n de Alergia e Inmunolog\xeda Cl\xednica', u'Hospital Universitario Cruces Servicio de Pediatria', u'Hospital Universitario Ni\xf1o Jes\xfas Servicio de Hemato-Oncolog\xeda Pedi\xe1trica']","April 13, 2015",0,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02054741,Gary Morrow,False,DE,https://ClinicalTrials.gov/show/NCT02054741,True,Geriatric Assessment Intervention for Reducing Chemotherapy Toxicity in Older Patients With Advanced Cancer,Adult Solid Neoplasm; Chemotherapeutic Agent Toxicity; Lymphoma,Other:Comprehensive Geriatric Assessment; Other:Quality-of-Life Assessment; Other:Survey Administration,[],"November 2, 2015",70,9223372036854775807,Both,False
NCT02050035,University of Delaware,False,DE,https://ClinicalTrials.gov/show/NCT02050035,True,Exercise and Vascular Function in Chronic Kidney Disease,Chronic Renal Insufficiency,Other:Aerobic Exercise Training,"[u'Department of Kinesiology and Applied Physiology, University of Delaware']","December 11, 2014",18,9223372036854775807,Both,True
NCT02043678,Bayer,False,DE,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02037529,Academic and Community Cancer Research United,False,DE,https://ClinicalTrials.gov/show/NCT02037529,True,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Drug:Eribulin; Drug:Paclitaxel,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02034552,Bayer,False,DE,https://ClinicalTrials.gov/show/NCT02034552,True,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo,BAY88-8223); Drug:Abiraterone acetate; Drug:Prednisone; Drug:Enzalutamide",[],"January 4, 2016",18,9223372036854775807,Male,False
NCT02032329,customKYnetics,False,DE,https://ClinicalTrials.gov/show/NCT02032329,True,FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device,Stroke; Gait,Device:FastFES,[u'University of Delaware - STAR Campus'],"January 8, 2014",21,80,Both,False
NCT02032277,AbbVie,False,DE,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT01991795,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01976728,Ferring Pharmaceuticals,False,DE,https://ClinicalTrials.gov/show/NCT01976728,True,LutrePulse Hypogonadotropic Hypogonadism,Primary Amenorrhea With Hypogonadotropic Hypogonadism,Drug:Gonadorelin acetate 10g/pulse; Drug:Gonadorelin acetate 15g/pulse; Drug:Gonadorelin acetate 20g/pulse; Drug:Placebo,[],"October 8, 2015",18,40,Female,False
NCT01973036,Geisinger Clinic,True,DE,https://ClinicalTrials.gov/show/NCT01973036,True,FOLCROM Trial: Foley Catheter in Rupture of Membranes,Premature Rupture of Membranes; Cervical Ripening,Device:Foley Catheter; Drug:Oxytocin,"[u'Banner Good Samaritan Regional Medical Center', u'Christiana Care Health System CCHS', u'Abington Hospital', u'Lehigh Valley Hospital', u'Geisinger Medical Center', u'Geisinger Wyoming Valley']","March 9, 2015",18,70,Female,True
NCT01970007,Cook,False,DE,https://ClinicalTrials.gov/show/NCT01970007,True,VIVO Clinical Study,Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein,Device:Zilver Vena Venous Stent,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01954992,Eleison Pharmaceuticals LLC.,False,DE,https://ClinicalTrials.gov/show/NCT01954992,True,Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug:Glufosfamide; Drug:Fluorouracil,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01892345,Alexion Pharmaceuticals,True,DE,https://ClinicalTrials.gov/show/NCT01892345,True,A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study),Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder,Drug:Eculizumab,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01885078,Eli Lilly and Company,False,DE,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01881711,NeuroDx Development,False,DE,https://ClinicalTrials.gov/show/NCT01881711,True,ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study,Suspected CSF Shunt Obstruction,Device:ShuntCheck-Micro-Pumper (SCMP); Device:Imaging,"[u'A I dePont Hospital for Children', u""Children's National Medical Center"", u""University of Chicago Comer Children's Hospital"", u'Johns Hopkins Hospital', u""Boston Children's Hospital"", u'Stony Brook Medical Center', u""Nationwide Children's Hospital"", u""Children's Hospital of Philadelphia"", u""Children's Hospital of Pittsburgh"", u'Rhode Island Hospital', u""University of Texas-Houston/Children's Memorial Hermann Hospital""]","June 22, 2015",35,29,Both,False
NCT01870778,Novartis Pharmaceuticals,False,DE,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,DE,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01835639,Children's Hospital of Philadelphia,False,DE,https://ClinicalTrials.gov/show/NCT01835639,True,Vitamin D Supplementation in Glomerular Disease,Focal Segmental Glomerulosclerosis (FSGS),"Dietary Supplement:Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks","[u'Nemours/Alfred I. duPont Hospital for Children', u'Johns Hopkins University,Division of Pediatric Nephrology', u'North Shore-Long Island Jewish Health System', u""Children's Hospital of Philadelphia"", u'The Hospital of the University of Pennsylvania']","August 17, 2015",5,30,Both,False
NCT01822496,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01817075,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01817075,True,Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant,Bacterial Infection; Benign Neoplasm; Malignant Neoplasm; Methicillin-Resistant Staphylococcus Aureus Infection; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Untreated Childhood Myeloid Neoplasm,Drug:Chlorhexidine Gluconate; Procedure:Wound Care Management; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"August 13, 2015",2,21,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01799993,Bayer,False,DE,https://ClinicalTrials.gov/show/NCT01799993,True,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin Inhalation Solution (BAY41-6551); Drug:Aerosolized Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01780129,Neptunus Pharmaceuticals Inc.,False,DE,https://ClinicalTrials.gov/show/NCT01780129,True,Polydatin Injectable (HW6) for Shock Treatment,"Shock, Hemorrhagic; Shock, Traumatic; Shock, Septic",Drug:Polydatin Injectable,[u'Christiana Care'],"January 29, 2013",18,80,Both,False
NCT01773317,Lynn Snyder-Mackler,False,DE,https://ClinicalTrials.gov/show/NCT01773317,True,Can Neuromuscular Training Alter Movement Patterns,Acute Injury of Anterior Cruciate Ligament,Other:Perturbation,"[u'University of Delaware, Physical Therapy Department']","October 6, 2015",14,40,Both,False
NCT01751906,Abbott Vascular,False,DE,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01737814,"Mast Therapeutics, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT01737814,True,Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC),Vaso-occlusive Crisis; Sickle Cell Disease,Drug:Saline; Drug:MST-188,[],"January 9, 2016",4,65,Both,False
NCT01728207,"Immunomedics, Inc.",True,DE,https://ClinicalTrials.gov/show/NCT01728207,True,Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL,Non-hodgkin's Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:IMMU-114,"[u'Helen F Graham Cancer Center', u'Nancy N. and J.C. Lewis Cancer and Research Pavilion', u'Indiana University Health Goshen Hospital', u'The Ohio State University Comprehensive Cancer Center', u'Huntsman Cancer Institute, Univ. Utah']","January 28, 2016",18,9223372036854775807,Both,False
NCT01727297,Medtronic Cardiac Rhythm Disease Management,False,DE,https://ClinicalTrials.gov/show/NCT01727297,True,REVEAL AF: Incidence of AF in High Risk Patients,Atrial Fibrillation,Device:REVEAL Implantable cardiac monitor,[],"December 3, 2013",18,9223372036854775807,Both,False
NCT01713894,Christiana Care Health Services,False,DE,https://ClinicalTrials.gov/show/NCT01713894,True,Decision Aid - Extreme Prematurity,Prematurity; Decision Support,Other:Decision Aid; Other:Standard,[u'Christiana Care Health System'],"January 14, 2016",18,70,Both,True
NCT01665092,University of Mississippi Medical Center,False,DE,https://ClinicalTrials.gov/show/NCT01665092,True,Rapid Administration of Carnitine in sEpsis,Septic Shock,Drug:Levo-Carnitine; Drug:placebo,"[u'University of Alabama Birmingham', u'Univeristy of California Davis', u'Christiana Care Health Services', u'University of Florida', u'Northwestern University', u'Indiana University', u'BIDMC', u'BWH', u'MGH', u'Wayne State University', u'University of Mississippi Medical Center', u'Cooper University Hospital', u'Carolinas Medical Center']","June 16, 2015",18,9223372036854775807,Both,False
NCT01656603,New York Blood Center,False,DE,https://ClinicalTrials.gov/show/NCT01656603,True,"Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation",Infusion Reactions,Biological:unlicensed CBU,[],"March 6, 2015",0,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,DE,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01631552,"Immunomedics, Inc.",False,DE,https://ClinicalTrials.gov/show/NCT01631552,True,Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers,Colorectal Cancer; Gastric Adenocarcinoma; Esophageal Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Ovarian Epithelial Cancer; Carcinoma Breast Stage IV; Hormone-refractory Prostate Cancer; Pancreatic Ductal Adenocarcinoma; Head and Neck Cancers- Squamous Cell; Renal Cell Cancer; Urinary Bladder Neoplasms; Cervical Cancer; Endometrial Cancer; Follicular Thyroid Cancer; Glioblastoma Multiforme,Drug:IMMU-132,"[u'University of Colorado Anschutz Medical Campus', u'Yale University School of Medicine', u'Helen F. Graham Cancer Center', u'MD Anderson Cancer Center Orlando (UF Health Cancer Center)', u'IU Health Goshen Cancer Center', u'Massachusettes General Hospital', u'Weill Cornell/New York Presbyterian Hospital', u'Columbia University Herbert Irving Cancer Center', u'Vanderbilt-Ingram Cancer Center', u'Texas Oncology Sammons Cancer Center', u'Virginia Mason Cancer Center']","December 9, 2015",18,9223372036854775807,Both,False
NCT01605318,"Immunomedics, Inc.",True,DE,https://ClinicalTrials.gov/show/NCT01605318,True,Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer,Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer,Drug:IMMU-130,"[u'UCLA Jonsson Comprehensive Cancer Center', u'University of Colorado Anschutz Medical Campus', u'Helen F. Graham Cancer Center-Christiana Care', u'IUHealth Goshen Center for Cancer Care', u'The Ohio State University Comprehensive Cancer Center', u'Fox Chase', u'Vanderbilt-Ingram Cancer Center']","October 9, 2015",18,9223372036854775807,Both,False
NCT01598831,Asahi Kasei Pharma America Corporation,False,DE,https://ClinicalTrials.gov/show/NCT01598831,True,Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy,Severe Sepsis; Coagulopathy,Drug:ART-123; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,DE,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01541215,Novo Nordisk A/S,False,DE,https://ClinicalTrials.gov/show/NCT01541215,True,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","Diabetes; Diabetes Mellitus, Type 2",Drug:liraglutide; Drug:placebo; Drug:metformin,[],"February 3, 2016",10,16,Both,False
NCT01528046,H. Lee Moffitt Cancer Center and Research Institute,False,DE,https://ClinicalTrials.gov/show/NCT01528046,True,Metformin in Children With Relapsed or Refractory Solid Tumors,Solid Tumors; Primary Brain Tumors,Drug:Vincristine; Drug:Irinotecan; Drug:Temozolomide; Drug:Metformin,"[u""Connecticut Children's Medical Center"", u'Nemours/Alfred I. duPont Hospital for Children, Delaware', u'University of Florida', u""Nemours Children's Clinic"", u'University of Miami', u""All Children's Hospital"", u'Tampa General Hospital', u""The Children's Hospital at Montefiore"", u""Primary Children's Medical Center/Utah""]","February 4, 2016",1,18,Both,False
NCT01503632,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01503515,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01503515,True,"Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant",Fungal Infection; Hematopoietic/Lymphoid Cancer,Drug:caspofungin acetate; Drug:fluconazole; Drug:voriconazole; Other:laboratory biomarker analysis,[],"August 12, 2015",3,20,Both,False
NCT01471522,New York University School of Medicine,True,DE,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT01446965,"University of California, San Francisco",False,DE,https://ClinicalTrials.gov/show/NCT01446965,True,Vest Prevention of Early Sudden Death Trial and VEST Registry,Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation,Device:wearable defibrillator,[],"April 7, 2015",18,9223372036854775807,Both,False
NCT01442194,Novartis,False,DE,https://ClinicalTrials.gov/show/NCT01442194,True,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,Multiple Sclerosis,Drug:Fingolimod; Drug:other disease-modifying therapy,[],"January 15, 2016",0,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01407952,Northwestern University,False,DE,https://ClinicalTrials.gov/show/NCT01407952,True,Hydrogel Endovascular Aneurysm Treatment Trial,Cerebral Aneurysm,Device:HydroCoil Embolic System; Device:Control (bare platinum coils),[],"July 10, 2015",18,75,Both,False
NCT01406756,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01372774,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01372774,True,Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery,"Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Radiation Toxicity; Unspecified Adult Solid Tumor, Protocol Specific",Radiation:stereotactic radiosurgery; Radiation:whole-brain radiation therapy,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT01371656,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01371656,True,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,Acute Leukemias of Ambiguous Lineage; Bacterial Infection; Diarrhea; Fungal Infection; Musculoskeletal Complications; Neutropenia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:levofloxacin,[],"August 28, 2015",6,21,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,DE,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01346267,University of South Florida,False,DE,https://ClinicalTrials.gov/show/NCT01346267,True,Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy,"Central Nervous System Tumor, Pediatric; Chemotherapy-induced Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific",Procedure:Real Acupressure Band; Procedure:Placebo Acupressure Band,[],"July 7, 2015",4,18,Both,False
NCT01324180,H. Lee Moffitt Cancer Center and Research Institute,False,DE,https://ClinicalTrials.gov/show/NCT01324180,True,"Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",Acute Lymphoblastic Leukemia,Drug:Metformin; Drug:Vincristine; Drug:Dexamethasone; Drug:PEG-asparaginase; Drug:Doxorubicin; Drug:Intrathecal chemotherapy,"[u""Connecticut Children's Medical Center"", u'Nemours/Alfred I. duPont Hospital for Children', u'University of Florida Shands Cancer Center', u""Nemours Children's Clinic"", u""Holtz Children's Hospital University of Miami Miller School of Medicine"", u'Arnold Palmer Hospital for Children', u""All Children's Hospital"", u'Tampa General Hospital', u""Montefiore Medical Center, The Children's Hospital at Montefiore""]","October 9, 2015",1,30,Both,False
NCT01307579,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01220583,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01220583,True,Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery,Head and Neck Cancer,Drug:cisplatin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01118026,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01118026,True,Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma,Lymphoma,Drug:ABVD; Drug:BEACOPP; Radiation:radiation therapy,[],"August 25, 2015",18,60,Both,False
NCT01096368,Children's Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT01073475,NICHD Global Network for Women's and Children's Health,False,DE,https://ClinicalTrials.gov/show/NCT01073475,True,Maternal Newborn Health Registry,Pregnancy Outcome Trends in Low-resource Geographic Areas,Other:There is no intervention associated with this study.,"[u'University of Alabama at Birmingham', u'University of Colorado Denver', u'Christiana Care', u'Indiana University School of Medicine', u'Tufts University School of Medicine', u'Drexel University College of Medicine', u'Institute for Nutrition of Central America and Panama (INCAP & FANCAP)', u'Jawaharlal Nehru Medical College', u'Indira Gandhi Government Medical College', u'Moi University School of Medicine', u'The Aga Khan University', u'University Teaching Hospital']","October 28, 2015",0,9223372036854775807,Both,True
NCT02674386,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,FL,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02427802,Innocoll,False,FL,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02406677,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,FL,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02138916,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02100514,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02092467,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02049515,"Infinity Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02049515,True,A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:IPI-145 (duvelisib); Drug:Ofatumumab,[],"November 16, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01897532,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,FL,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01858532,AbbVie,False,FL,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01674140,Southwest Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,FL,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01652872,Amgen,False,FL,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,FL,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,FL,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00867815,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT00867815,True,PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION),Anterior Ischemic Optic Neuropathy,Drug:Diagnostic procedures,[],"January 25, 2016",40,9223372036854775807,Male,False
NCT00858364,Amgen,False,FL,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT01767311,Eisai Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01767311,True,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Alzheimer's Disease,Drug:BAN2401 2.5 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg,[],"November 29, 2015",50,90,Both,False
NCT01406756,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01190930,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT02601703,Glenmark Pharmaceuticals Ltd. India,False,FL,https://ClinicalTrials.gov/show/NCT02601703,True,"To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)",Atopic Dermatitis,"Drug:Tacrolimus Ointment 0.1%; Drug:Protopic ointment, 0.1%; Drug:Placebo of Tacrolimus Ointment",[],"December 11, 2015",18,9223372036854775807,Both,False
NCT02528253,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02504216,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02365636,"Teva Branded Pharmaceutical Products, R&D Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02365636,True,A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN),Postherpetic Neuralgia,Drug:TV-45070; Drug:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02187471,Daiichi Sankyo Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02187471,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02670083,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02638129,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,FL,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT02415400,Bristol-Myers Squibb,False,FL,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02240108,"Valeant Pharmaceuticals International, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02240108,True,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02080364,vTv Therapeutics,False,FL,https://ClinicalTrials.gov/show/NCT02080364,True,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT02551874,Bristol-Myers Squibb,False,FL,https://ClinicalTrials.gov/show/NCT02551874,True,"A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy",Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glargine insulin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02403323,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02394028,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02194738,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT02118584,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01715805,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01307579,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT00772200,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00736749,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT02615002,Neurim Pharmaceuticals Ltd.,False,FL,https://ClinicalTrials.gov/show/NCT02615002,True,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug:Piromelatine; Drug:Placebo,[],"January 26, 2016",60,85,Both,False
NCT02421601,Seikagaku Corporation,False,FL,https://ClinicalTrials.gov/show/NCT02421601,True,A Study of SI-6603 in Patients With Lumbar Disc Herniation,Intervertebral Disc Disease; Lumbar Disc Disease,Drug:Condoliase,[],"January 7, 2016",30,70,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02258542,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02112916,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01741194,"Accera, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01741194,True,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,Alzheimer's Disease,Drug:AC-1204; Drug:Placebo,[],"November 23, 2015",66,90,Both,False
NCT02640612,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02477800,Biogen,False,FL,https://ClinicalTrials.gov/show/NCT02477800,True,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02452190,"Teva Branded Pharmaceutical Products, R&D Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02452190,True,Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Drug:Reslizumab; Drug:Placebo,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02239120,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02194699,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02187055,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02187055,True,An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate,Rhematoid Arthritis,Drug:Tofacitinib with methotrexate; Drug:Tofacitinib without methotrexate; Biological:Adalimumab with methotrexate,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02054624,University of Florida,False,FL,https://ClinicalTrials.gov/show/NCT02054624,True,Rural Lifestyle Eating and Activity Program (Rural LEAP),Obesity,Behavioral:Lifestyle intervention; Behavioral:Health education control; Behavioral:Individual; Behavioral:All Groups,"[u'Levy County', u'Flagler County', u'Dixie County', u'Hamilton County', u'Union County', u'Columbia County', u'Suwannee County', u'Baker County', u'Lafayette County', u'Putnam County', u'Taylor County', u'Bradford County', u'Gilchrist County']","August 18, 2015",21,75,Both,False
NCT01870778,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01862640,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01862640,True,A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases,"Drug:Brexpiprazole, OPC-34712",[],"April 20, 2015",55,90,Both,False
NCT01852110,Merck Sharp & Dohme Corp.,False,FL,https://ClinicalTrials.gov/show/NCT01852110,True,Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),Alzheimer's Disease,Drug:MK-7622; Drug:Placebo; Drug:AChEI,[],"January 22, 2016",55,85,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,FL,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,FL,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01458574,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01096368,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02497469,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02431806,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT02431806,True,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],"December 23, 2015",12,17,Both,False
NCT02372578,"Astellas Pharma Global Development, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02372578,True,Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy,Painful Diabetic Peripheral Neuropathy (PDPN),Drug:ASP3662; Drug:pregabalin; Drug:ASP3662 placebo; Drug:pregabalin placebo,[],"January 29, 2016",18,75,Both,False
NCT02311881,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT02311881,True,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Pain,Drug:Paracetamol 1000 mg SR tablets; Drug:Paracetamol 665 mg SR tablets; Drug:Placebo,[],"September 24, 2015",40,80,Both,False
NCT02240121,"Valeant Pharmaceuticals International, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02240121,True,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02187159,Daiichi Sankyo Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02187159,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,FL,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02066636,Bristol-Myers Squibb,False,FL,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01503632,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01471340,Merck Sharp & Dohme Corp.,False,FL,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01470612,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01470599,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01470599,True,"A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease",Crohn's Disease,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,76,Both,False
NCT01442194,Novartis,False,FL,https://ClinicalTrials.gov/show/NCT01442194,True,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,Multiple Sclerosis,Drug:Fingolimod; Drug:other disease-modifying therapy,[],"January 15, 2016",0,9223372036854775807,Both,False
NCT02629159,AbbVie,False,FL,https://ClinicalTrials.gov/show/NCT02629159,True,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],"December 10, 2015",18,99,Both,False
NCT02614183,Eli Lilly and Company,False,FL,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02604680,Braintree Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT02604680,True,A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris,Acne Vulgaris,Drug:BLI1100-1; Drug:BLI1100-2; Drug:BLI1100-3; Drug:Control group; Drug:Placebo,[],"November 12, 2015",12,45,Both,False
NCT02603120,Gilead Sciences,False,FL,https://ClinicalTrials.gov/show/NCT02603120,True,Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to GS-9883/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed,HIV-1 Infection,Drug:ABC/DTG/3TC; Drug:GS-9883/F/TAF Placebo; Drug:ABC/DTG/3TC Placebo; Drug:GS-9883/F/TAF,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02410356,"Teva Pharmaceutical Industries, Ltd.",False,FL,https://ClinicalTrials.gov/show/NCT02410356,True,Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD),Growth Hormone Deficiency,Drug:TV-1106; Drug:dGH,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02403401,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02365649,AbbVie,False,FL,https://ClinicalTrials.gov/show/NCT02365649,True,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Anti-TNF Therapy (Celest Study)",Crohn's Disease,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,75,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02271217,Acorda Therapeutics,False,FL,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02240680,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT02240680,True,Linagliptin as Add on to Basal Insulin in the Elderly,"Diabetes Mellitus, Type 2",Drug:placebo; Drug:linagliptin,[],"January 26, 2016",60,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02051608,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02051608,True,A Study of Gantenerumab in Patients With Mild Alzheimer Disease,Alzheimer Disease,Drug:florbetapir; Drug:gantenerumab; Drug:placebo,[],"February 1, 2016",50,90,Both,False
NCT01953601,Merck Sharp & Dohme Corp.,False,FL,https://ClinicalTrials.gov/show/NCT01953601,True,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],"December 31, 2015",50,85,Both,False
NCT01872975,NSABP Foundation Inc,False,FL,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01797185,Sun Pharma Advanced Research Company Limited,False,FL,https://ClinicalTrials.gov/show/NCT01797185,True,"A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial",Spasticity,Drug:Baclofen,[],"September 15, 2015",18,90,Both,False
NCT01457352,Sun Pharma Advanced Research Company Limited,False,FL,https://ClinicalTrials.gov/show/NCT01457352,True,Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen ER Capsules; Drug:Placebo GRS,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00672139,"Valeant Pharmaceuticals International, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT00672139,True,Study Evaluating The Safety Of Subcutaneous Methylnaltrexone In Treatment Of Opioid-Induced Constipation,Opioid-Induced Constipation,Drug:Methylnaltrexone bromide,[],"June 27, 2012",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,FL,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02596451,Glenmark Pharmaceuticals Ltd. India,False,FL,https://ClinicalTrials.gov/show/NCT02596451,True,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Osteoarthritis,"Drug:Diclofenac Sodium gel, 1%; Drug:Voltaren Gel; Drug:Placebo",[],"December 11, 2015",35,9223372036854775807,Both,False
NCT02585934,Axovant Sciences Ltd.,False,FL,https://ClinicalTrials.gov/show/NCT02585934,True,Study Evaluating RVT-101 in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil Treatment: MINDSET Study,Alzheimer's Disease,Drug:RVT-101; Drug:Placebo,[],"January 19, 2016",50,85,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02484547,Biogen,False,FL,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02446912,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02446912,True,Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus,Active Systemic Lupus Erythematosus,Biological:Anifrolumab; Drug:Placebo,[],"November 9, 2015",18,70,Both,False
NCT02414854,Sanofi,False,FL,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02165215,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02165215,True,A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug:Etrolizumab; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02006641,H. Lundbeck A/S,False,FL,https://ClinicalTrials.gov/show/NCT02006641,True,Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Drug:Placebo; Drug:Lu AE58054,[],"December 10, 2015",50,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01914393,Sunovion,False,FL,https://ClinicalTrials.gov/show/NCT01914393,True,Pediatric Open-Label Extension Study,Schizophrenia; Autism; Bipolar Depression,"Drug:Lurasidone 20, 40, 60, 80 mg, flexibly dosed",[],"January 12, 2016",6,17,Both,False
NCT01909791,Diabetic Retinopathy Clinical Research Network,False,FL,https://ClinicalTrials.gov/show/NCT01909791,True,Treatment for CI-DME in Eyes With Very Good VA Study,Diabetic Macular Edema,Procedure:Prompt Laser; Drug:Prompt aflibercept; Procedure:Deferred laser; Drug:Deferred aflibercept,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT01888120,Jazz Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01727726,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01727726,True,"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders",Drug:Brexpiprazole; Drug:Seroquel XR; Drug:Placebo,[],"April 1, 2015",18,65,Both,False
NCT01621178,Eli Lilly and Company,False,FL,https://ClinicalTrials.gov/show/NCT01621178,True,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes; Chronic Kidney Disease,Drug:Dulaglutide; Drug:Insulin glargine; Drug:Insulin lispro,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT01381718,University of South Florida,False,FL,https://ClinicalTrials.gov/show/NCT01381718,True,Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor,Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment,Drug:modafinil; Other:placebo,[],"July 15, 2015",6,19,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,FL,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02501629,"Teva Branded Pharmaceutical Products, R&D Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02501629,True,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma; Elevated Blood Eosinophils,Drug:Reslizumab; Drug:Placebo,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02493868,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02493868,True,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 2, 2016",18,64,Both,False
NCT02487446,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02480153,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02480153,True,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02460978,Bristol-Myers Squibb,False,FL,https://ClinicalTrials.gov/show/NCT02460978,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Diabetes,Drug:Dapagliflozin; Drug:Insulin; Other:Placebo,[],"January 26, 2016",18,75,Both,False
NCT02412917,"ContraVir Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02412917,True,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],"September 1, 2015",50,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02371980,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT02371980,True,"Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder",Major Depressive Disorder,Drug:Vortioxetine; Drug:Placebo,[],"November 24, 2015",18,75,Both,False
NCT02367820,Nektar Therapeutics,False,FL,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02343458,"Pearl Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02343458,True,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",COPD,Drug:GFF MDI (PT003); Drug:FF MDI (PT005); Drug:GP MDI (PT001); Drug:Placebo MDI,[],"September 28, 2015",40,80,Both,False
NCT02322866,Warner Chilcott,False,FL,https://ClinicalTrials.gov/show/NCT02322866,True,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Acne Vulgaris,Drug:Sarecycline; Drug:Placebo,[],"December 23, 2015",9,45,Both,False
NCT02301234,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02301234,True,"Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg; Drug:Celecoxib 100 mg; Drug:Celecoxib 100 mg Matching Placebo,[],"January 20, 2016",18,99,Both,False
NCT02276209,Sunovion,False,FL,https://ClinicalTrials.gov/show/NCT02276209,True,Dasotraline Adult ADHD Study,Adult Attention Hyperactivity Disorder,Drug:Dasotraline; Drug:Dasotraline; Other:Placebo,[],"January 12, 2016",18,55,Both,False
NCT02269917,Janssen R&D Ireland,False,FL,https://ClinicalTrials.gov/show/NCT02269917,True,"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants",Human Immunodeficiency Virus Type 1,Drug:D/C/F/TAF; Drug:Boosted Protease Inhibitor (bPI); Drug:FTC/TDF,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02264288,Celgene Corporation,False,FL,https://ClinicalTrials.gov/show/NCT02264288,True,Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease,Peripheral Arterial Disease; Diabetic Foot,Biological:3 x 10^6 cells; Biological:10 x 10^6 cells; Biological:30 x 10^6 cells; Other:Placebo,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02240030,Acorda Therapeutics,False,FL,https://ClinicalTrials.gov/show/NCT02240030,True,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Drug:CVT-301,[],"November 12, 2015",30,85,Both,False
NCT02202551,"Adamas Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02202551,True,Open-Label Safety Study of ADS-5102 in PD Patients With LID,Dyskinesia; Levodopa Induced Dyskinesia (LID); Parkinson's Disease (PD),Drug:ADS-5102,[],"October 1, 2015",30,85,Both,False
NCT02164916,Southwest Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02161718,"Alkermes, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02161718,True,A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder,Schizophrenia; Alcohol Use Disorder,Drug:Samidorphan + olanzapine (ALKS 3831); Drug:Placebo,[],"February 3, 2016",18,65,Both,False
NCT02152982,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02145468,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02126943,Actelion,False,FL,https://ClinicalTrials.gov/show/NCT02126943,True,OPsumit USers Registry,Pulmonary Arterial Hypertension; PAH,Drug:Opsumit (macitentan),[],"February 24, 2015",0,9223372036854775807,Both,False
NCT02100696,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02100696,True,A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors,Ulcerative Colitis,Drug:etrozulimab; Drug:placebo,[],"February 1, 2016",18,80,Both,False
NCT02027428,Celgene Corporation,False,FL,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT01901900,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01901900,True,Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.,Rheumatoid Arthritis,Biological:Secukinumab (AIN457),[],"January 12, 2015",18,9223372036854775807,Both,False
NCT01885078,Eli Lilly and Company,False,FL,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01771809,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01771809,True,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],"January 16, 2016",18,65,Both,False
NCT01594762,"Dipexium Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01594762,True,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Drug:Topical pexiganan cream 0.8%; Drug:Topical placebo cream; Other:Standard wound care,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,FL,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01163253,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00906308,Bionovo,False,FL,https://ClinicalTrials.gov/show/NCT00906308,True,A Study of MF101 in Postmenopausal Women,Hot Flushes; Vasomotor Symptoms,Drug:MF101 5 g/day; Drug:Placebo; Drug:MF101 10 g/day,[],"February 6, 2012",40,65,Female,True
NCT02675426,AbbVie,False,FL,https://ClinicalTrials.gov/show/NCT02675426,True,A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,99,Both,False
NCT02648204,Novo Nordisk A/S,False,FL,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02607956,Gilead Sciences,False,FL,https://ClinicalTrials.gov/show/NCT02607956,True,"Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV-1 Infection,Drug:DTG; Drug:F/TAF; Drug:GS-9883/F/TAF Placebo; Drug:DTG Placebo; Drug:F/TAF Placebo; Drug:GS-9883/F/TAF,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02604407,Shire,False,FL,https://ClinicalTrials.gov/show/NCT02604407,True,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),"Drug:SHP465 12.5mg capsules (one capsule daily); Other:Placebo; Drug:SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)",[],"December 8, 2015",18,55,Both,False
NCT02547818,"AZTherapies, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02547818,True,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,Alzheimer's Disease,Drug:ALZT-OP1a; Drug:ALZT-OP1b; Other:Placebo ALZT-OP1a; Other:Placebo ALZT-OP1b,"[u'Xenoscience', u'Asclepes Research Center', u'Sonoma West Medical Research Foundation', u'MD Clinical', u'Compass Research', u'IMIC, Inc.', u'Panax', u'Anchor Clinic', u'Laslo Mate MD', u'Neurostudies, Inc.', u'Stedman Clinical Trials', u'Precise Clinical Research', u'Memory Enhancement Center of America', u'AdvancedMed Research', u'Albuquerque Neuroscience', u'Manhattan Behavioral Medicine', u'Winifred Masterson Burke Medical Research Institute', u""ANI Neurology, PLLC Alzheimer's Memory Center"", u'Cutting Edge Research Group', u'Tulsa Clinical Research, Inc.', u'Thomas Jefferson University', u'Grayline Clinical Drug Trials', u'Summit Research Network (Seattle), Inc.']","January 28, 2016",55,79,Both,False
NCT02536508,"Pearl Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02536508,True,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COPD,Drug:BGF MDI (PT010) 320/14.4/9.6 g; Drug:GFF MDI (PT003) 14.4/9.6 g; Drug:BFF MDI (PT009) 320/9.6 g,[],"January 6, 2016",40,80,Both,False
NCT02520388,"Ironshore Pharmaceuticals and Development, Inc",False,FL,https://ClinicalTrials.gov/show/NCT02520388,True,A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting,Attention Deficit Hyperactivity Disorder,Drug:HLD200 methylphenidate hydrochloride (MPH) Capsules; Drug:Placebo,"[u'Florida Clinical Research Center, LLC', u'Sarkis Clinical Trials', u'Clinical Neuroscience Solutions, Inc', u'Florida Clinical Research Center, LLC', u'Scientific Clinical Research, Inc.', u'Medical Research Group of Central Florida', u'Clinical Neuroscience Solutions, Inc.', u'QPS MRA, dba Miami Research Associates, LLC', u'Pedia Research, LLC', u'IPS Research Company', u'Clinical Neuroscience Solutions, Inc.', u'Red Oak Psychiatry Associates, PA', u'Bayou City Research, Ltd', u'Westex Clinical Investigations', u'Ericksen Research and Development']","August 24, 2015",6,12,Both,False
NCT02510014,Indivior Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02510014,True,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Opioid Use Disorder; Opioid-related Disorders,Drug:SUBOXONE sublingual film; Drug:high dose RBP-6000; Drug:low dose RBP-6000,[],"December 10, 2015",18,65,Both,False
NCT02456740,Amgen,False,FL,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02436096,"Tonix Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02436096,True,A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia,Fibromyalgia; Myofascial Pain Syndromes; Muscular Diseases; Musculoskeletal Diseases; Nervous System Diseases; Neuromuscular Diseases; Rheumatic Diseases,"Drug:TNX-102 SL Tablet, 2.8mg; Drug:Placebo SL Tablet",[],"October 18, 2015",18,75,Both,False
NCT02419612,Bristol-Myers Squibb,False,FL,https://ClinicalTrials.gov/show/NCT02419612,True,"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone",Diabetes,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glimepiride; Other:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02418754,Regeneron Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT02418754,True,"Study of Intravitreal REGN2176-3 in Patients With Neovascular (""Wet"") Age-Related Macular Degeneration (AMD)",Neovascular Age-Related Macular Degeneration,Drug:REGN2176-3; Drug:Intravitreal Aflibercept Injection (IAI),[],"January 14, 2016",50,9223372036854775807,Both,False
NCT02417064,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02417064,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 3, 2016",18,64,Both,False
NCT02410343,"Teva Pharmaceutical Industries, Ltd.",False,FL,https://ClinicalTrials.gov/show/NCT02410343,True,Study of TV-1106 in Growth Hormone-Deficient Adults,Growth Hormone Deficiency,Drug:TV-1106; Drug:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02362672,Nektar Therapeutics,False,FL,https://ClinicalTrials.gov/show/NCT02362672,True,Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181; Drug:Placebo,[],"September 10, 2015",18,75,Both,False
NCT02360319,Vanguard Research Group,False,FL,https://ClinicalTrials.gov/show/NCT02360319,True,Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics,Schizophrenia,Drug:Any FDA approved antipsychotic agent; Drug:aripiprazole long acting injectable formulation,[],"December 7, 2015",18,35,Both,False
NCT02344004,Insmed Incorporated,False,FL,https://ClinicalTrials.gov/show/NCT02344004,True,Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone,"Mycobacterium Infections, Nontuberculous",Drug:Liposomal Amikacin for Inhalation,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02247479,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT02247479,True,A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02451137,Sanofi,False,GA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01966107,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT02194738,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01975376,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,GA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,GA,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT01359592,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,GA,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,GA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01274338,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02003209,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02674386,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02528188,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02187003,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02187003,True,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug:Rivipansel; Other:Placebo,[],"January 8, 2016",6,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,GA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,GA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02528253,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,GA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01845025,Novartis Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,GA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02465567,"Pearl Therapeutics, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02138916,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02066636,Bristol-Myers Squibb,False,GA,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,GA,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01870778,Novartis Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,GA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01674140,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01632241,"Human Genome Sciences Inc., a GSK Company",False,GA,https://ClinicalTrials.gov/show/NCT01632241,True,Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Drug:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,GA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02648204,Novo Nordisk A/S,False,GA,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02403323,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02118584,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01920711,Novartis Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01663402,Sanofi,False,GA,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01458574,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02584634,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02584634,True,"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",Non-Small Cell Lung Cancer,Drug:Avelumab; Drug:PF-06463922; Drug:Crizotinib,"[u'Emory University Hospital Midtown', u'Emory Investigational Drug Service', u'Emory University Hospital', u'The Emory Clinic', u'Winship Cancer Institute, Emory University', u'Tennessee Oncology, PLLC', u'The Sarah Cannon Research Institute']","January 25, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,GA,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02536508,"Pearl Therapeutics, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02536508,True,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COPD,Drug:BGF MDI (PT010) 320/14.4/9.6 g; Drug:GFF MDI (PT003) 14.4/9.6 g; Drug:BFF MDI (PT009) 320/9.6 g,[],"January 6, 2016",40,80,Both,False
NCT02497469,Takeda,False,GA,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02488967,NRG Oncology,False,GA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02470585,AbbVie,False,GA,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02394028,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02367794,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02367781,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02293395,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02293395,True,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:Acetylsalicylic acid; Drug:Rivaroxaban; Drug:Clopidogrel; Drug:Ticagrelor,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02282397,"DexCom, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02282397,True,Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes,Diabetes Mellitus,Device:Continuous Glucose Monitor; Other:Continuous Subcutaneous insulin infusion,[],"December 17, 2015",25,9223372036854775807,Both,False
NCT02276209,Sunovion,False,GA,https://ClinicalTrials.gov/show/NCT02276209,True,Dasotraline Adult ADHD Study,Adult Attention Hyperactivity Disorder,Drug:Dasotraline; Drug:Dasotraline; Other:Placebo,[],"January 12, 2016",18,55,Both,False
NCT02254278,NRG Oncology,False,GA,https://ClinicalTrials.gov/show/NCT02254278,True,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma,Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02187159,Daiichi Sankyo Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02187159,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,GA,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02025751,Evoke Pharma,False,GA,https://ClinicalTrials.gov/show/NCT02025751,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Male,False
NCT02025725,Evoke Pharma,False,GA,https://ClinicalTrials.gov/show/NCT02025725,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Female,False
NCT01997333,Celldex Therapeutics,False,GA,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01652872,Amgen,False,GA,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,GA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT00980954,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00956007,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,GA,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02657382,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02657382,True,Mental Stress Ischemia: Biofeedback Study,Cardiovascular Disease; Coronary Artery Disease,Behavioral:Heart Rate Variability (HRV) Biofeedback (BF); Other:Mental Stress Protocol,"[u'Emory University Hospital', u'Emory University', u'Rollins School of Public Health', u'The Emory Clinic']","January 20, 2016",18,9223372036854775807,Both,False
NCT02607956,Gilead Sciences,False,GA,https://ClinicalTrials.gov/show/NCT02607956,True,"Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV-1 Infection,Drug:DTG; Drug:F/TAF; Drug:GS-9883/F/TAF Placebo; Drug:DTG Placebo; Drug:F/TAF Placebo; Drug:GS-9883/F/TAF,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02603120,Gilead Sciences,False,GA,https://ClinicalTrials.gov/show/NCT02603120,True,Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to GS-9883/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed,HIV-1 Infection,Drug:ABC/DTG/3TC; Drug:GS-9883/F/TAF Placebo; Drug:ABC/DTG/3TC Placebo; Drug:GS-9883/F/TAF,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,GA,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02529618,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02529618,True,Field Implementation of iDETECT,Concussion; Brain Trauma,Device:integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT); Device:Riddell High Impact Technology (HIT) System; Device:i1 Biometrics Vector Mouth Guard,"[u'Westminster High School', u'Woodward Academy', u'Marietta High School', u'Blessed Trinity Catholic High School']","August 19, 2015",14,9223372036854775807,Both,True
NCT02511184,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02511184,True,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,ALK-positive Advanced NSCLC,Drug:Crizotinib; Drug:Pembrolizumab,"[u'University of Alabama', u'University of Alabama at Birmingham', u'City of Hope National Medical Center', u'UC San Diego Moores Cancer Center - IDS', u'UC San Diego Medical Center - La Jolla(Thornton Hospital)', u'University Of California / San Diego Moores Cancer Center', u'UC San Diego Medical Center - Hillcrest', u'The Emory Clinic', u'Emory University Hospital', u'Winship Cancer Institute, Emory University', u'Emory University Hospital Midtown', u'University Of Minnesota Fairview Pharmacy Services', u'University of Minnesota Medical Center, Fairview', u'University of Minnesota', u'The Cleveland Clinic Foundation', u'Swedish Medical Center', u'Swedish Cancer Institute']","January 4, 2016",18,99,Both,False
NCT02486718,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02485795,"Proove Bioscience, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02485795,True,Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management,"Pain; Chronic Pain; Back Pain; Nociceptive Pain; Neuropathic Pain; Musculoskeletal Pain; Neck Pain; Pain, Intractable",Other:Observational,"[u'Medical Clinic - Steven J. Waltrip M.D. Inc.', u'Coastal Pain & Spinal Diagnostics - Yogesh Patel, M.D.', u'Regional Pain Treatment Medical Center', u'The Helm Center for Pain Management', u'Remedy Pain Solutions', u'Back Bay Medical', u'Pain Management Associates of CT, PC', u'Center for Interventional Pain & Spine', u'Neurospine Institute, LLC', u'South Florida Pain & Wellness Institute', u'Coastal Pain & Neurology', u'Perimeter Orthopedics', u'OrthoGeorgia', u'Roswell Pain Specialists', u'Optim Orthopedics', u'Medical Clinic - Dr. Robert Rust', u'The Kahan Center For Pain Management', u'Medical Centre Pain Mgmt', u'Spine Specialists (Texas Spine & Joint Hospital)', u'National Spine And Pain Centers', u'Northwest Spine and Pain Medicine']","July 21, 2015",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02409056,University of Georgia,False,GA,https://ClinicalTrials.gov/show/NCT02409056,True,Putting CDSMP to Work,Chronic Disease; Cardiovascular Diseases,Behavioral:Workplace-tailored CDSMP; Behavioral:Chronic Disease Self-Management Program,"[u'City of Moultrie', u'Colquitt County Government', u'Colquitt Regional Medical Center', u'Turning Point Hospital']","December 1, 2015",18,70,Both,True
NCT02407236,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02367820,Nektar Therapeutics,False,GA,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02357368,Lisa Haddad,False,GA,https://ClinicalTrials.gov/show/NCT02357368,True,Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk,HIV; Contraception,Drug:Depot medroxyprogesterone acetate (DMPA); Drug:Etonogestrel implant (Eng-Implant); Device:Levonorgestrel intrauterine device (Lng-IUD),"[u'Grady Health System', u'The Ponce de Leon Center of the Grady Health System', u'Emory Clinic', u'Emory University Clinical Research Network']","August 18, 2015",18,45,Female,True
NCT02332707,Merck Sharp & Dohme Corp.,False,GA,https://ClinicalTrials.gov/show/NCT02332707,True,Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011),Hepatitis C,Drug:Grazoprevir; Drug:MK-3682; Drug:Elbasvir; Drug:MK-8408; Drug:MK-3682B; Drug:Ribavirin,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02312037,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02312037,True,Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy,CD33 Positive Acute Myelogenous Leukemia,Biological:Antibody Drug Conjugate Chemotherapeutic,[],"January 5, 2016",3,9223372036854775807,Both,False
NCT02296125,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02296125,True,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,Drug:AZD9291 80 mg/40 mg + placebo; Drug:Placebo Erlotinib 150/100mg; Drug:Placebo Gefitinib 250 mg; Drug:Erlotinib 150/100 mg; Drug:Gefitinib 250 mg; Drug:Placebo AZD9291 80 mg/ 40 mg,[],"January 18, 2016",18,130,Both,False
NCT02258542,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02240108,"Valeant Pharmaceuticals International, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02240108,True,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02226172,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02226172,True,Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib,Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis,Drug:Glasdegib (PF-04449913); Drug:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02203331,Bayer,False,GA,https://ClinicalTrials.gov/show/NCT02203331,True,"Bay98-7196, Dose Finding / POC Study",Endometriosis,Drug:Placebo; Drug:Levonorgestrel; Drug:Anastrozole + Levonorgestrel (BAY 98-7196); Drug:Anastrozole + Levonorgestrel (BAY 98-7196); Drug:Anastrozole + Levonorgestrel (BAY 98-7196); Drug:Lupron / Leuprolide acetate,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02194699,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02191137,Bayer,False,GA,https://ClinicalTrials.gov/show/NCT02191137,True,"MOTION, Measuring Outcomes in Treatment Naive Patients",Pulmonary,"Drug:Riociguat (Adempas,BAY63-2521)",[],"January 22, 2016",18,80,Both,False
NCT02164916,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02125461,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02125461,True,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Drug:MEDI4736; Other:PLACEBO,[],"January 11, 2016",18,130,Both,False
NCT02119663,Incyte Corporation,False,GA,https://ClinicalTrials.gov/show/NCT02119663,True,A Study of Ruxolitinib in Pancreatic Cancer Patients,Metastatic Pancreatic Adenocarcinoma That is Recurrent,Drug:Ruxolitinib; Drug:Placebo; Drug:Capecitabine,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT02109939,Assurex Health Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02109939,True,Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic,Major Depressive Disorder (MDD),Genetic:GeneSight Psychotropic,[],"December 4, 2015",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02100696,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02100696,True,A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors,Ulcerative Colitis,Drug:etrozulimab; Drug:placebo,[],"February 1, 2016",18,80,Both,False
NCT02061969,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02061969,True,ADA Linagliptin in Long Term Care,Diabetes,Drug:linagliptin; Drug:insulin glargine,"[u'Crestvew Nursing Home', u'Budd Terrace Nursing Home', u'Wesley Woods Nursing Home', u'VA Nursing Home']","October 28, 2015",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,GA,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01846611,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT01846611,True,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms,Drug:Trabectedin; Drug:DOXIL; Drug:Dexamethasone; Drug:DOXIL,[],"January 19, 2016",18,9223372036854775807,Female,False
NCT01822496,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01811550,Temple University,False,GA,https://ClinicalTrials.gov/show/NCT01811550,True,Study of Procoagulation Markers in Stroke Patients,Stroke; Hyperglycemia; Procoagulation Markers,Other:Glycemic Control,[],"August 24, 2015",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01767311,Eisai Inc.,False,GA,https://ClinicalTrials.gov/show/NCT01767311,True,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Alzheimer's Disease,Drug:BAN2401 2.5 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg,[],"November 29, 2015",50,90,Both,False
NCT01715805,Forest Laboratories,False,GA,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01693120,Medtronic Atrial Fibrillation Solutions,False,GA,https://ClinicalTrials.gov/show/NCT01693120,True,Evaluation of the Phased Radio Frequency Ablation System,Persistent Atrial Fibrillation,Device:Medtronic Phased RF Ablation System,[],"December 3, 2015",18,75,Both,False
NCT01576406,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01576406,True,Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,Advanced Cancer,Drug:crizotinib; Drug:crizotinib; Drug:crizotinib; Drug:crizotinib; Drug:crizotinib,"[u'Keck Hospital of the University of Southern California', u'Los Angeles County/University of Southern California Medical Center', u'USC/Norris Comprehensive Cancer / Investigational Drug Services', u'USC/Norris Comprehensive Cancer Center', u'University of Colorado Hospital, Anschutz Inpatient Pavilion', u'University of Colorado Denver - Clinical Translational Research Center', u'University of Colorado Hospital', u'Drug Shipment: Anschutz Cancer Pavilion, Room 2224, c/o Melinda Friesleben, Pharm D', u'Drug Shipment Address: Investigational Drug Service: The Emory Clinic Bldg A', u'Emory University Hospital', u'The Emory Clinic', u'Winship Cancer Institute', u'Martha Morehouse Medical Plaza', u'University Hospital East', u'James Cancer Hospital', u'The Ohio State University, Wexner Medical Center', u'Investigational Drug Services (Drug Management Only)', u'Cancer Therapy & Research Center at UTHSCSA', u'Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio']","January 6, 2016",18,9223372036854775807,Both,False
NCT01546038,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,GA,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01470612,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01369069,University of Virginia,False,GA,https://ClinicalTrials.gov/show/NCT01369069,True,Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial,Acute Ischemic Stroke; Diabetes; Hyperglycemia,Drug:IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug:Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL,[],"December 1, 2014",18,9223372036854775807,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,GA,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01042522,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01042522,True,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00955708,Boston Scientific Corporation,False,GA,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00858364,Amgen,False,GA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02661828,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02661828,True,Tapering Off Antidepressants,Major Depressive Disorder; Anxiety Disorder; Obsessive Compulsive Disorder; Post-Traumatic Stress Disorder,Other:Two-Week Antidepressant Taper Regimen; Other:One-Week Antidepressant Taper Regimen,"[u'Emory University', u'The Emory Clinic', u'12 Executive Park Drive, 3rd floor']","January 20, 2016",18,75,Both,False
NCT02639338,Gilead Sciences,False,GA,https://ClinicalTrials.gov/show/NCT02639338,True,Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Hepatitis C Virus Infection,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02639247,Gilead Sciences,False,GA,https://ClinicalTrials.gov/show/NCT02639247,True,Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Hepatitis C Virus Infection,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,GA,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,GA,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02585934,Axovant Sciences Ltd.,False,GA,https://ClinicalTrials.gov/show/NCT02585934,True,Study Evaluating RVT-101 in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil Treatment: MINDSET Study,Alzheimer's Disease,Drug:RVT-101; Drug:Placebo,[],"January 19, 2016",50,85,Both,False
NCT02573311,Boehringer Ingelheim,False,GA,https://ClinicalTrials.gov/show/NCT02573311,True,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],"January 25, 2016",18,9223372036854775807,Male,False
NCT02572648,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02572648,True,"A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls",Heart Failure,Other:Brain Imaging (Neuroimaging); Other:Cognitive Function Assessment,"[u'Emory University Hospital Midtown', u'The Emory Clinic', u""Emory St. Joseph's Hospital""]","December 3, 2015",40,75,Both,True
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02556918,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02556918,True,Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery,Hyperglycemia,Drug:Sitagliptin; Drug:Placebo; Drug:Regular Human Insulin; Drug:Insulin glargine; Drug:Supplemental insulin (Insulin lispro); Drug:Supplemental insulin (Insulin aspart),"[u'Grady Health System', u'Emory Univeristy Hospital Midtown', u'Emory University Hospital']","January 26, 2016",18,80,Both,False
NCT02548351,Intercept Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT02548351,True,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment,Non Alcoholic Steatohepatitis (NASH),Drug:Obeticholic Acid; Drug:Placebo,[],"November 2, 2015",18,85,Both,False
NCT02544503,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02544503,True,Customized Cortical Stimulation Therapy in the Rehabilitation of Stroke Patients,Stroke,Device:Single-pulse Transcranial Magnetic Stimulation (TMS); Device:Paired-pulse Transcranial Magnetic Stimulation (ppTMS); Device:Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS); Device:Sham Motor Cortex Stimulation,"[u'Center for Rehabilitation Medicine', u'Emory University Hospital', u'Emory University School of Medicine']","November 16, 2015",50,80,Both,True
NCT02536170,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02536170,True,Arginine Therapy for Sickle Cell Disease Pain,Sickle Cell Disease; Vaso-occlusive Pain Event,Drug:L-arginine; Drug:L-arginine Loading Dose; Other:Placebo,"[u""Children's Healthcare of Atlanta at Hugh Spalding"", u""Children's Healthcare of Atlanta at Egleston"", u""Children's Healthcare of Atlanta at Scottish Rite""]","August 27, 2015",3,21,Both,False
NCT02525978,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02525978,True,Heart Rate Variability in Depression,Major Depressive Disorder,Behavioral:Video Task; Other:Imaginal Task,"[u'Emory University Hospital', u'12 Executive Park Drive', u'Emory University at Wesley Woods Hospital']","November 19, 2015",18,65,Both,True
NCT02514447,"G1 Therapeutics, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02514447,True,Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,Small Cell Lung Cancer,Drug:G1T28 + Topotecan,"[u'Genesis Cancer Center', u'Rocky Mountain Cancer Centers', u'University of Colorado Health, Oncology Clinical Research Northern Region', u'Florida Cancer Specialists - South', u'Florida Cancer Specialists - North', u'Florida Cancer Specialists - East', u'University Cancer and Blood Center, LLC', u'Emory University', u'Northside Hospital - Georgia Cancer Specialists', u'North Shore Hematology Oncology Associates PC', u'Lineberger Comprehensive Cancer Center', u'Oklahoma University - Peggy and Charles Stephenson Cancer Center', u'Greenville Health System', u'Gibbs Cancer Center', u'Meharry Medical College', u'Sarah Cannon Research Institute', u'Texas Oncology- Baylor Charles A. Sammons Cancer Center', u'M.D. Anderson', u'Texas Oncology', u'Virginia Cancer Specialists', u'Virginia Oncology Associates', u'Northwest Cancer Specialists, P.C.']","November 30, 2015",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,GA,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02499770,"G1 Therapeutics, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02499770,True,G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),Small Cell Lung Cancer,Drug:G1T28 + carboplatin/ etoposide; Drug:Placebo + carboplatin/ etoposide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02487446,Novartis Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02484547,Biogen,False,GA,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02477618,Sage Therapeutics,False,GA,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,GA,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02460978,Bristol-Myers Squibb,False,GA,https://ClinicalTrials.gov/show/NCT02460978,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Diabetes,Drug:Dapagliflozin; Drug:Insulin; Other:Placebo,[],"January 26, 2016",18,75,Both,False
NCT02460354,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02460354,True,Metformin and Congenital Nephrogenic Diabetes Insipidus,Diabetes Insipidus,Drug:Metformin,"[u""Childen's Healthcare of Atlanta"", u'Emory University Hospital - Atlanta Clinical and Translational Science Institute (ACTSI)', u'Emory University Hospital']","October 11, 2015",18,9223372036854775807,Male,False
NCT02446912,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02446912,True,Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus,Active Systemic Lupus Erythematosus,Biological:Anifrolumab; Drug:Placebo,[],"November 9, 2015",18,70,Both,False
NCT02443402,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02443402,True,Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery,Coronary Artery Disease,Drug:Sitagliptin; Drug:Placebo; Drug:Regular Human Insulin; Drug:Insulin glargine; Drug:Supplemental insulin (Insulin lispro); Drug:Supplemental insulin (Insulin aspart),"[u'Grady Health System', u'Emory University Hospital - Midtown', u'Emory University Hospital']","January 26, 2016",18,80,Both,False
NCT02436239,Forest Laboratories,False,GA,https://ClinicalTrials.gov/show/NCT02436239,True,A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Vilazodone,[],"December 23, 2015",7,17,Both,False
NCT02436096,"Tonix Pharmaceuticals, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02436096,True,A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia,Fibromyalgia; Myofascial Pain Syndromes; Muscular Diseases; Musculoskeletal Diseases; Nervous System Diseases; Neuromuscular Diseases; Rheumatic Diseases,"Drug:TNX-102 SL Tablet, 2.8mg; Drug:Placebo SL Tablet",[],"October 18, 2015",18,75,Both,False
NCT02427802,Innocoll,False,GA,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02420821,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02420821,True,"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]",Renal Cell Carcinoma,Drug:Atezolizumab; Drug:Bevacizumab; Drug:Sunitinib,[],"December 31, 2015",18,9223372036854775807,Both,False
NCT02415400,Bristol-Myers Squibb,False,GA,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02372799,Forest Laboratories,False,GA,https://ClinicalTrials.gov/show/NCT02372799,True,Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22),Major Depressive Disorder,Drug:Vilazodone; Drug:Placebo; Drug:Fluoxetine,[],"December 17, 2015",7,17,Both,False
NCT02366143,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02365649,AbbVie,False,GA,https://ClinicalTrials.gov/show/NCT02365649,True,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Anti-TNF Therapy (Celest Study)",Crohn's Disease,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,75,Both,False
NCT02364557,NRG Oncology,False,GA,https://ClinicalTrials.gov/show/NCT02364557,True,Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer,Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer,Radiation:Stereotactic Radiosurgery; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,"[u'University of Alabama at Birmingham Cancer Center', u'UC San Diego Moores Cancer Center', u'University of California Irvine Health', u'Permanente Medical Group - Roseville Radiation Oncology', u'Kaiser Permanente Cancer Treatment Center', u'University of Colorado Cancer Center - Anschutz Cancer Pavilion', u'Memorial Hospital Colorado Springs', u'Emory University Hospital Midtown', u'Piedmont Hospital', u'Emory University/Winship Cancer Institute', u'Northwestern University', u'University of Illinois', u'Decatur Memorial Hospital', u'Loyola University Medical Center', u'Northwestern Medicine Cancer Center Warrenville', u'Saint Vincent Anderson Regional Hospital/Cancer Center', u'Parkview Hospital', u'Memorial Hospital of South Bend', u'Lahey Hosptial and Medical Center', u'NRG Oncology', u'Jewish General Hospital']","December 22, 2015",18,9223372036854775807,Both,False
NCT02362672,Nektar Therapeutics,False,GA,https://ClinicalTrials.gov/show/NCT02362672,True,Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181; Drug:Placebo,[],"September 10, 2015",18,75,Both,False
NCT02362503,Bristol-Myers Squibb,False,GA,https://ClinicalTrials.gov/show/NCT02362503,True,Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients,HIV/AIDS,Drug:BMS-663068; Other:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02360319,Vanguard Research Group,False,GA,https://ClinicalTrials.gov/show/NCT02360319,True,Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics,Schizophrenia,Drug:Any FDA approved antipsychotic agent; Drug:aripiprazole long acting injectable formulation,[],"December 7, 2015",18,35,Both,False
NCT02352948,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02352363,Acorda Therapeutics,False,GA,https://ClinicalTrials.gov/show/NCT02352363,True,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,Idiopathic Parkinson's Disease,Drug:CVT-301; Other:Observational cohort,[],"November 17, 2015",30,85,Both,False
NCT02348593,Jazz Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT02348593,True,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Narcolepsy,Drug:JZP-110,[],"January 29, 2016",18,75,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,GA,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02320721,Sanofi,False,GA,https://ClinicalTrials.gov/show/NCT02320721,True,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Drug:Insulin glargine U300 HOE901; Drug:Insulin glargine HOE901,[],"February 3, 2016",65,9223372036854775807,Both,False
NCT02320487,"Genentech, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02320487,True,A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Drug:Bendamustine; Drug:Obinutuzumab,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT02319044,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02319044,True,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck,Drug:MEDI4736; Drug:Tremelimumab; Drug:MEDI4736 + Tremelimumab,[],"January 18, 2016",18,96,Both,False
NCT02315742,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02315742,True,Hearts and Minds in HIV,HIV,Behavioral:Let's Move Program,"[u'The Ponce de Leon Center of the Grady Health System', u'AbsoluteCARE, Inc.', u'Emory Hospital Infectious Diseases Clinic']","December 3, 2015",50,9223372036854775807,Both,False
NCT02308111,Intercept Pharmaceuticals,True,GA,https://ClinicalTrials.gov/show/NCT02308111,True,Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis,"Liver Cirrhosis, Biliary",Drug:Obeticholic Acid (OCA); Drug:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02301234,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT02301234,True,"Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg; Drug:Celecoxib 100 mg; Drug:Celecoxib 100 mg Matching Placebo,[],"January 20, 2016",18,99,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02289950,Morphotek,False,GA,https://ClinicalTrials.gov/show/NCT02289950,True,A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,Platinum-Sensitive Ovarian Cancer in First Relapse,Drug:Farletuzumab; Drug:Placebo,[],"January 8, 2016",18,9223372036854775807,Female,False
NCT02269670,Emory University,False,GA,https://ClinicalTrials.gov/show/NCT02269670,True,Phase II Study of Everolimus Beyond Progression,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:everolimus; Drug:anastrozole; Drug:letrozole; Drug:tamoxifen citrate; Drug:fulvestrant; Drug:megestrol acetate,"[u'Grady Memorial Hospital', u'Emory University Hospital Midtown', u'Emory University/Winship Cancer Institute']","October 2, 2015",19,9223372036854775807,Female,False
NCT02267525,"Theravance Biopharma R & D, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02267525,True,"The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study",Gastroparesis,Drug:Velusetrag; Drug:Placebo,[],"December 10, 2015",18,75,Both,False
NCT02243293,AbbVie,False,GA,https://ClinicalTrials.gov/show/NCT02243293,True,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],"February 4, 2016",18,100,Both,False
NCT02239120,Boehringer Ingelheim,False,GA,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02206334,NRG Oncology,False,GA,https://ClinicalTrials.gov/show/NCT02206334,True,"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",Male Breast Carcinoma; Prostate Adenocarcinoma; Recurrent Breast Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Prostate Carcinoma; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Prostate Cancer,Radiation:Stereotactic Radiosurgery,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02187471,Daiichi Sankyo Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02187471,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02186847,NRG Oncology,False,GA,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02185599,DySIS Medical Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02185599,True,IMproved PRactice Outcomes and Value Excellence in Colposcopy,High Grade Cervical Intraepithelial Neoplasia,Device:DySIS,[],"November 23, 2015",21,9223372036854775807,Female,False
NCT02185040,Celgene Corporation,False,GA,https://ClinicalTrials.gov/show/NCT02185040,True,A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.,Systemic Lupus Erythematosus,Drug:CC-220; Drug:CC-220; Drug:CC-220; Drug:CC-220; Drug:Placebo,[],"October 5, 2015",18,9223372036854775807,Both,False
NCT02167685,Chimerix,False,GA,https://ClinicalTrials.gov/show/NCT02167685,True,The Chimerix CMX001 Registry,Outcomes; Survival Rates,Drug:CMX001,[],"December 21, 2015",6,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT02161718,"Alkermes, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02161718,True,A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder,Schizophrenia; Alcohol Use Disorder,Drug:Samidorphan + olanzapine (ALKS 3831); Drug:Placebo,[],"February 3, 2016",18,65,Both,False
NCT02152982,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02135042,NRG Oncology,False,GA,https://ClinicalTrials.gov/show/NCT02135042,True,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02092467,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02091141,"Genentech, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02091141,True,"A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients",Neoplasms,Drug:Erlotinib [Tarceva]; Drug:Pertuzumab [Perjeta]; Drug:Trastuzumab [Herceptin]; Drug:Vemurafenib [Zelboraf]; Drug:Vismodegib [Erivedge],[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02075047,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT02065570,AbbVie,False,GA,https://ClinicalTrials.gov/show/NCT02065570,True,Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease,Crohn's Disease,Drug:Adalimumab,[],"January 27, 2016",18,75,Both,False
NCT02059265,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02052648,NewLink Genetics Corporation,False,GA,https://ClinicalTrials.gov/show/NCT02052648,True,Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,Glioblastoma Multiforme; Glioma; Gliosarcoma; Malignant Brain Tumor,Drug:Indoximod; Drug:Temozolomide; Drug:Bevacizumab; Radiation:Stereotactic Radiation,"[u'Cedars-Sinai Medical Center', u'Moffitt Cancer Center', u'University Cancer and Blood Center', u""Children's Healthcare of Atlanta"", u'Georgia Regents University', u'University of Chicago', u'University of Iowa Hospitals and Clinics', u'John Nasseff Neuroscience Institute', u'Penn State Hershey Medical Center', u'Texas Oncology', u'Huntsman Cancer Center', u'Virginia Cancer Specialists']","February 2, 2016",16,9223372036854775807,Both,False
NCT02047097,Biogen,False,GA,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02006641,H. Lundbeck A/S,False,GA,https://ClinicalTrials.gov/show/NCT02006641,True,Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Drug:Placebo; Drug:Lu AE58054,[],"December 10, 2015",50,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02194738,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02177695,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,HI,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,HI,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00700882,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01595061,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01414608,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02186847,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,HI,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01190930,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00807768,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02451943,Eli Lilly and Company,False,HI,https://ClinicalTrials.gov/show/NCT02451943,True,A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,Soft Tissue Sarcoma,Drug:Olaratumab; Drug:Doxorubicin; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02135042,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02135042,True,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,HI,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01822496,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01790152,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01790152,True,Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment,Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma; Refractory Childhood Hodgkin Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult T-Cell Leukemia/Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-Cell Leukemia/Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult T-Cell Leukemia/Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult T-Cell Leukemia/Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Other:Anthropometry; Other:Serum Biomarkers; Other:Diagnostic/symptom checklist; Procedure:Echocardiogram; Other:6 minute walk test (6MWT); Behavioral:Participant Questionnaires (ages >14 years only),[],"September 11, 2015",0,9223372036854775807,Both,False
NCT01248117,Retina Consultants of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT01248117,True,Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy,Polypoidal Choroidal Vasculopathy,Drug:ranibizumab 2.0mg,"[u'Retina Consultants of Hawaii', u'Retina Consultants of Hawaii, Inc']","November 24, 2010",25,9223372036854775807,Both,True
NCT01101451,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00980954,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00736749,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT02674386,Pfizer,False,HI,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02648919,University of Hawaii,True,HI,https://ClinicalTrials.gov/show/NCT02648919,True,Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer,Prostate Cancer,Drug:Noni extract,[u'University of Hawaii Cancer Center'],"January 6, 2016",60,9223372036854775807,Male,False
NCT02643251,BioDelivery Sciences International,False,HI,https://ClinicalTrials.gov/show/NCT02643251,True,"The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy",Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,"Drug:Clonidine Hydrochloride Topical Gel, 0.1%; Drug:Clonidine Hydrochloride Gel Comparator",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,HI,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02620709,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02620709,True,The KaHOLO Project: Preventing Cardiovascular Disease in Native Hawaiians,Hypertension,Behavioral:Hula intervention,"[u'University of Hawaii, John A Burns School of Medicine, Department of Native Hawaiian Health']","November 30, 2015",21,9223372036854775807,Both,False
NCT02607865,Novo Nordisk A/S,False,HI,https://ClinicalTrials.gov/show/NCT02607865,True,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:sitagliptin; Drug:placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02602418,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02602418,True,Neural Correlates of Working Memory Training for HIV Patients,HIV Infection,Device:CogMedTM Training,[u'University of Hawaii'],"November 10, 2015",18,85,Both,True
NCT02590146,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02590146,True,Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion,Pregnancy Termination; Pain Management,Behavioral:Non-pharmacologic pain control adjuncts,[u'University of Hawaii'],"November 30, 2015",18,9223372036854775807,Female,False
NCT02562716,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02559778,Giselle Sholler,False,HI,https://ClinicalTrials.gov/show/NCT02559778,True,Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,Neuroblastoma,Drug:bortezomib; Drug:crizotinib; Drug:dasatinib; Drug:lapatinib; Drug:sorafenib; Drug:vorinostat; Drug:DFMO,"[u""Arkansas Children's Hospital"", u""Rady Children's Hospital"", u""Connecticut Children's Hospital"", u'Arnold Palmer Hospital for Children', u'Kapiolani Medical Center for Women and Children', u""Helen DeVos Children's Hospital"", u""Children's Hospital and Clinics on Minnesota"", u""Cardinal Glennon Children's Medical Center"", u""Levine Children's Hospital"", u""Penn State Milton S. Hershey Medical Center and Children's Hospital"", u'Medical University of South Carolina', u""Dell Children's Blood and Cancer Center""]","January 18, 2016",12,21,Both,False
NCT02559674,Altor Bioscience Corporation,False,HI,https://ClinicalTrials.gov/show/NCT02559674,True,ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,Advanced Pancreatic Cancer,Biological:Gemcitabine; Biological:Nab-paclitaxel; Biological:ALT-803,[u'University of Hawaii Cancer Center'],"September 23, 2015",18,9223372036854775807,Both,False
NCT02559193,"First Vitals Health and Wellness, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT02559193,True,Pharmacogenomic Testing for Medication Management.,Pharmacogenomic Testing for Medication Management.,"Other:Observational study, data collection only trial.","[u'Southland Clinical Research Center', u'Emerald Coast Orthopedics', u'Laurie Tom, MD', u'Sports Medicine North, LLC', u'Emergency MD']","November 15, 2015",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,HI,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,HI,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02514174,Boehringer Ingelheim,False,HI,https://ClinicalTrials.gov/show/NCT02514174,True,Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,"Carcinoma, Non-Small-Cell Lung; ErbB Receptors",Drug:Afatinib,"[u'1200.209.20029 Boehringer Ingelheim Investigational Site', u'1200.209.20007 Boehringer Ingelheim Investigational Site', u'1200.209.20001 Boehringer Ingelheim Investigational Site', u'1200.209.20018 Boehringer Ingelheim Investigational Site', u'1200.209.20033 Boehringer Ingelheim Investigational Site', u'1200.209.20035 Boehringer Ingelheim Investigational Site', u'1200.209.20002 Boehringer Ingelheim Investigational Site', u'1200.209.20015 Boehringer Ingelheim Investigational Site', u'1200.209.20024 Boehringer Ingelheim Investigational Site', u'1200.209.20022 Boehringer Ingelheim Investigational Site', u'1200.209.20034 Boehringer Ingelheim Investigational Site', u'1200.209.20037 Boehringer Ingelheim Investigational Site', u'1200.209.20023 Boehringer Ingelheim Investigational Site', u'1200.209.20014 Boehringer Ingelheim Investigational Site', u'1200.209.20028 Boehringer Ingelheim Investigational Site', u'1200.209.20026 Boehringer Ingelheim Investigational Site', u'1200.209.20016 Boehringer Ingelheim Investigational Site', u'1200.209.20030 Boehringer Ingelheim Investigational Site', u'1200.209.20006 Boehringer Ingelheim Investigational Site', u'1200.209.20017 Boehringer Ingelheim Investigational Site', u'1200.209.20005 Boehringer Ingelheim Investigational Site']","January 26, 2016",70,9223372036854775807,Both,False
NCT02511106,AstraZeneca,False,HI,https://ClinicalTrials.gov/show/NCT02511106,True,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",Stage IB-IIIA Non-small Cell Lung Carcinoma,Drug:AZD9291 80 mg/40 mg; Drug:Placebo AZD9291 80 mg/40 mg,[],"January 29, 2016",18,130,Both,False
NCT02497105,Shriners Hospitals for Children,True,HI,https://ClinicalTrials.gov/show/NCT02497105,True,Ketogenic Diet Program for Epilepsy,Epilepsy,Other:Ketogenic Diet,[u'Shriners Hospitals for Children - Honolulu'],"July 13, 2015",6,18,Both,True
NCT02477904,Shriners Hospitals for Children,True,HI,https://ClinicalTrials.gov/show/NCT02477904,True,Ketogenic Diet Therapy for Autism Spectrum Disorder,Autism Spectrum Disorder,Other:Ketogenic Diet,[u'Shriners Hospitals for Children - Honolulu'],"June 22, 2015",2,18,Both,True
NCT02454296,University of Hawaii,True,HI,https://ClinicalTrials.gov/show/NCT02454296,True,Paracervical Block for Pain Associated With Laminaria Insertion,Pain,Drug:Paracervical Block with lidocaine; Drug:Sham paracervical block,"[u""University Women's Health Specialists""]","November 30, 2015",18,49,Female,True
NCT02453282,AstraZeneca,False,HI,https://ClinicalTrials.gov/show/NCT02453282,True,Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,Non-Small-Cell Lung Carcinoma (NSCLC),Biological:MEDI4736; Biological:MEDI4736+Tremelimumab; Drug:Paclitaxel + Carboplatin; Drug:Gemcitabine + Cisplatin; Drug:Gemcitabine + Carboplatin; Drug:Pemetrexed + Cisplatin; Drug:Pemetrexed + Carboplatin; Biological:Tremelimumab,[],"January 22, 2016",18,130,Both,False
NCT02441946,Eli Lilly and Company,False,HI,https://ClinicalTrials.gov/show/NCT02441946,True,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma,Drug:Abemaciclib; Drug:Loperamide; Drug:Anastrozole,[],"January 28, 2016",18,9223372036854775807,Female,False
NCT02435433,Eli Lilly and Company,False,HI,https://ClinicalTrials.gov/show/NCT02435433,True,A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein,Hepatocellular Carcinoma,Drug:Ramucirumab; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02422615,Novartis Pharmaceuticals,False,HI,https://ClinicalTrials.gov/show/NCT02422615,True,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,"Breast Neoplasms; Breast Diseases; Neoplasms; Neoplasms by Site; Fulvestrant; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Therapeutic Use",Drug:Ribociclib; Drug:fulvestrant; Drug:Ribociclib placebo,[],"September 14, 2015",18,9223372036854775807,Female,False
NCT02419014,Tripler Army Medical Center,False,HI,https://ClinicalTrials.gov/show/NCT02419014,True,Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome,Restless Legs Syndrome,Device:Active CES Device Alpha-Stim; Device:Sham Device,[u'Tripler Army Medical Center'],"November 2, 2015",18,9223372036854775807,Both,False
NCT02411448,Eli Lilly and Company,False,HI,https://ClinicalTrials.gov/show/NCT02411448,True,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,Metastatic Non-Small Cell Lung Cancer,Drug:Ramucirumab; Drug:Placebo; Drug:Erlotinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02409355,Hoffmann-La Roche,False,HI,https://ClinicalTrials.gov/show/NCT02409355,True,A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Cisplatin; Drug:Gemcitabine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,HI,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02405091,Neurocrine Biosciences,False,HI,https://ClinicalTrials.gov/show/NCT02405091,True,Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia,Drug:NBI-98854,[],"January 7, 2016",18,85,Both,False
NCT02388100,GRADE Study Group,False,HI,https://ClinicalTrials.gov/show/NCT02388100,True,The GRADE Capillary Blood Collection Pilot Study,Type 2 Diabetes,Procedure:Capillary HbA1c collection,"[u'Southwestern American Indian Center', u'University of Colorado', u'Pacific Health Research and Education Institute (VA Pacific Islands)', u'Pennington Biomedical Research Center', u'International Diabetes Center']","December 2, 2015",30,9223372036854775807,Both,False
NCT02383563,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02383563,True,Metformin for HIV Inflammation,HIV; Coronary Artery Disease,Drug:metformin extended release,[u'Hawaii Center for AIDS'],"March 3, 2015",45,9223372036854775807,Both,False
NCT02374671,"Refocus Group, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT02374671,True,A Clinical Trial of The VisAbility Implant System Presbyopic Patients,Presbyopia,Device:VisAbility Implant Model SGP-046,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","September 17, 2015",45,60,Both,True
NCT02367794,Hoffmann-La Roche,False,HI,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02367781,Hoffmann-La Roche,False,HI,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02366143,Hoffmann-La Roche,False,HI,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02352363,Acorda Therapeutics,False,HI,https://ClinicalTrials.gov/show/NCT02352363,True,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,Idiopathic Parkinson's Disease,Drug:CVT-301; Other:Observational cohort,[],"November 17, 2015",30,85,Both,False
NCT02320344,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02320344,True,Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project Partners in Care,Type 2 Diabetes,Behavioral:Partners in Care,"[u'Department of Native Hawaiian Health, University of Hawaii']","December 16, 2014",18,9223372036854775807,Both,False
NCT02320331,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02320331,True,Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project,Obesity,Behavioral:PILI Lifestyle Program,"[u'Department of Native Hawaiian Health, University of Hawaii']","December 16, 2014",13,9223372036854775807,Both,False
NCT02318849,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02318849,True,Online Intervention for ANHPI College Students,Tissue and Organ Procurement,Behavioral:Web intervention,"[u'Cheryl Albright, PhD, MPH']","December 12, 2014",18,29,Both,True
NCT02318368,"AVEO Pharmaceuticals, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT02318368,True,"A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",Non-small Cell Lung Cancer,Drug:Ficlatuzumab; Drug:Erlotinib; Drug:placebo,[],"October 1, 2015",18,9223372036854775807,Both,False
NCT02316847,Acorda Therapeutics,False,HI,https://ClinicalTrials.gov/show/NCT02316847,True,"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures",Epilepsy,Drug:diazepam nasal spray,[],"January 13, 2016",12,65,Both,False
NCT02315469,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02308020,Eli Lilly and Company,False,HI,https://ClinicalTrials.gov/show/NCT02308020,True,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases,Drug:Abemaciclib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02295410,VA Pacific Islands Health Care System,True,HI,https://ClinicalTrials.gov/show/NCT02295410,True,The Effects of Home-Based Telemental Health for Rural Veterans With PTSD,"Stress Disorders, Post-Traumatic",Behavioral:CPT,[u'VA Pacific Island Health Care System'],"November 14, 2014",18,9223372036854775807,Both,False
NCT02288507,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02288507,True,Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer,Hepatocellular Cancer,Drug:Sorafenib; Radiation:yttrium-90 radioembolization,[u'University of Hawaii'],"November 10, 2014",18,9223372036854775807,Both,False
NCT02283060,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02283060,True,Sleep and Cognition After Atripla to Stribild Switch,HIV,Drug:Stribild; Drug:Atripla,[u'Hawaii Center for AIDS'],"November 4, 2014",18,65,Both,True
NCT02278120,Novartis Pharmaceuticals,False,HI,https://ClinicalTrials.gov/show/NCT02278120,True,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","Advanced, Metastatic Breast Cancer",Drug:LEE011; Drug:Tamoxifen; Drug:Letrozole; Drug:Anastrozole; Drug:Goserelin; Drug:LEE011 Placebo,[],"September 29, 2015",18,59,Female,False
NCT02271217,Acorda Therapeutics,False,HI,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02268786,"Illumina, Inc.",True,HI,https://ClinicalTrials.gov/show/NCT02268786,True,Single Embryo TrAnsfeR of Euploid Embryo,Infertility; Aneuploidy,Other:Preimplantation Genetic Screening by NGS,[],"November 14, 2015",25,40,Female,False
NCT02260167,Practitioners Alliance Network,False,HI,https://ClinicalTrials.gov/show/NCT02260167,True,"Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol",Alzheimer's Disease; Dementia,Other:A mix of natural treatments and medications,[u'PAN'],"October 10, 2014",0,9223372036854775807,Both,False
NCT02260141,Practitioners Alliance Network,False,HI,https://ClinicalTrials.gov/show/NCT02260141,True,Treating Alzheimer's and Dementia With D-ribose,Alzheimers; Dementia,Dietary Supplement:d-ribose,[u'PAN'],"October 10, 2014",0,9223372036854775807,Both,False
NCT02257736,"Janssen Research & Development, LLC",False,HI,https://ClinicalTrials.gov/show/NCT02257736,True,An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),Prostatic Neoplasms,Drug:JNJ56021927; Drug:Abiraterone acetate; Drug:Prednisone; Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02252172,"Janssen Research & Development, LLC",False,HI,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02247479,Hoffmann-La Roche,False,HI,https://ClinicalTrials.gov/show/NCT02247479,True,A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,HI,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02200042,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02200042,True,Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery,Stage III Intrahepatic Cholangiocarcinoma; Stage IVA Intrahepatic Cholangiocarcinoma,Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Radiation:Image Guided Radiation Therapy; Other:Laboratory Biomarker Analysis,"[u'University of Alabama at Birmingham Cancer Center', u'Emory University/Winship Cancer Institute', u""Queen's Medical Center"", u'Northwestern University', u'Massachusetts General Hospital Cancer Center', u'Dartmouth Hitchcock Medical Center', u'Ohio State University Comprehensive Cancer Center', u'M D Anderson Cancer Center']","January 29, 2016",18,9223372036854775807,Both,False
NCT02193841,The Hospital for Sick Children,True,HI,https://ClinicalTrials.gov/show/NCT02193841,True,Simple Bone Cysts in Kids,Bone Cyst,Procedure:Curettage with puncture (C & P); Device:Curette; Device:Vitoss morsels,[],"September 4, 2015",2,21,Both,False
NCT02190734,Rehabilitation Institute of Chicago,False,HI,https://ClinicalTrials.gov/show/NCT02190734,True,Pushing Behaviors in Individuals Post-stroke,Stroke,Other:Sitting in wheel chair; Other:Gait training on treadmill; Other:Gait training overground,"[u'Rehabilitation Hospital of the Pacific', u'Rehabilitation Institute of Chicago']","September 8, 2015",18,89,Both,False
NCT02162732,Giselle Sholler,False,HI,https://ClinicalTrials.gov/show/NCT02162732,True,Molecular-Guided Therapy for Childhood Cancer,Neuroblastoma; Medulloblastoma; Glioma; Ependymoma; Choroid Plexus Neoplasms; Craniopharyngioma; Dysembryoplastic Neuroepithelial Tumor; Meningioma; Primitive Neuroectodermal Tumors (PNETs); Germ Cell Tumors; Rhabdomyosarcoma; Non-rhabdomyosarcoma; Ewings Sarcoma; Osteosarcoma; Wilms Tumor; Renal Cell Carcinoma; Malignant Rhabdoid Tumor; Clear Cell Sarcoma; Liver Tumors,Device:Guided Therapy,"[u""Arkansas Children's Hospital"", u""Rady Children's Hospital"", u""Connecticut Children's Hospital"", u'Arnold Palmer Hospital for Children', u'Kapiolani Medical Center for Women and Children', u""Helen DeVos Children's Hospital"", u""Children's Hospital and Clinics on Minnesota"", u""Children's Mercy Hospitals and Clinics"", u""Cardinal Glennon Children's Medical Center"", u""The Children's Hospital at Montefiore"", u""Levine Children's Hospital"", u""Penn State Milton S. Hershey Medical Center and Children's Hospital"", u'Medical University of South Carolina', u""Monroe Carrell Jr. Children's Hospital at Vanderbilt"", u""Dell Children's Blood and Cancer Center"", u""Texas Children's Cancer and Hematology Centers"", u""Primary Children's Hospital""]","January 18, 2016",13,21,Both,False
NCT02159027,University of Hawaii,True,HI,https://ClinicalTrials.gov/show/NCT02159027,True,Maraviroc and NeuroAIDS Pathogenesis,AIDS Dementia Complex,Drug:Maraviroc; Drug:Placebo,"[u'Clint Spencer Clinic, Hawaii Center for AIDS, University of Hawaii', u'Puerto Rico Clinical and Translational Research Consortium']","March 17, 2015",18,70,Both,False
NCT02158429,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02158429,True,Study of Ultrasound To Increase Parental Bonding in Women With Substance Use Disorders,Substance Use Disorders; Pregnancy,Other:2 dimensional vs. 3 dimensional ultrasound,[u'Path Clinic'],"June 8, 2015",18,50,Female,False
NCT02141438,Bayer,False,HI,https://ClinicalTrials.gov/show/NCT02141438,True,Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer,Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223)",[],"February 4, 2016",18,9223372036854775807,Male,False
NCT02138734,Altor Bioscience Corporation,False,HI,https://ClinicalTrials.gov/show/NCT02138734,True,A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer,Non-muscle Invasive Bladder Cancer,Biological:BCG+ALT-803; Biological:BCG,"[u'University of Alabama at Birmingham', u'Alaska Clinical Research Center', u'UCLA Department of Urology', u'University of Hawaii Cancer Center', u'Dartmouth-Hitchcock Medical Center', u'Winthrop University Hospital']","October 21, 2015",18,9223372036854775807,Both,False
NCT02128828,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02128828,True,Effect of Cenicriviroc on HIV Neurocognitive Impairment,AIDS Dementia Complex; HIV-1-Associated Cognitive Motor Complex; Human Immunodeficiency Virus,Drug:cenicriviroc,[u'Clint Spencer Clinic'],"March 17, 2015",18,70,Both,False
NCT02112916,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02101853,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02100787,Jenkins Eye Care,True,HI,https://ClinicalTrials.gov/show/NCT02100787,True,Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears,Dry Eye Syndrome,Other:TheraTears lubricating drops,[u'Jenkins Eye Care'],"March 27, 2014",21,9223372036854775807,Both,False
NCT02096354,"EpicentRx, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT02096354,True,"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",Colorectal Neoplasms,Drug:RRx-001; Drug:Regorafenib; Drug:Irinotecan,"[u'UCSD Moores Cancer Center', u'Stanford University', u'Kaiser Permanete', u'Walter Reed National Military Medical Center', u'Aquilino Cancer Center, Maryland Oncology and Hematology PA']","October 29, 2015",18,9223372036854775807,Both,False
NCT02083809,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT02083809,True,Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation,Abortion; Dilation and Evacuation; Hemorrhage; Blood Loss,Drug:intravenous oxytocin,"[u'University of Hawaii', u'University of Washington']","July 12, 2015",14,50,Female,False
NCT02060630,New England Research Institutes,False,HI,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02054741,Gary Morrow,False,HI,https://ClinicalTrials.gov/show/NCT02054741,True,Geriatric Assessment Intervention for Reducing Chemotherapy Toxicity in Older Patients With Advanced Cancer,Adult Solid Neoplasm; Chemotherapeutic Agent Toxicity; Lymphoma,Other:Comprehensive Geriatric Assessment; Other:Quality-of-Life Assessment; Other:Survey Administration,[],"November 2, 2015",70,9223372036854775807,Both,False
NCT02054715,University of Rochester,False,HI,https://ClinicalTrials.gov/show/NCT02054715,True,Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trial Participation,Malignant Neoplasm,Other:educational intervention; Other:educational intervention; Other:questionnaire administration,"[u'San Diego State University', u'H. Lee Moffitt Cancer Center and Research Institute', u'Hawaii MU-NCORP', u'Heartland NCORP', u'Kansas City Clinical Oncology Program', u'Gulf South MU-NCORP', u'Cancer Research Consortium of West Michigan', u'Metro MN NCORP', u'Nevada NCORP', u'Nevada Cancer Research Foundation NCORP', u'URCC / University of Rochester NCORP Research Base', u'Southeast Clinical Oncology Research Consortium', u'Columbus NCORP', u'Dayton Community Oncology Program', u'Geisinger Cancer Institute NCORP', u'Greenville Health System Cancer Instutite/Greenville NCORP', u'Wisconsin NCORP', u'Aurora NCORP']","November 23, 2015",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02043678,Bayer,False,HI,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02019264,Eisai Inc.,False,HI,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01975389,Pfizer,False,HI,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,HI,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,HI,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01955161,H. Lundbeck A/S,False,HI,https://ClinicalTrials.gov/show/NCT01955161,True,Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Drug:Placebo; Drug:Lu AE58054,[],"December 10, 2015",50,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01922258,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01922258,True,Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases,"Drug:Brexpiprazole, OPC-34712",[],"May 1, 2015",55,90,Both,False
NCT01917721,Hawaii Pacific Health,False,HI,https://ClinicalTrials.gov/show/NCT01917721,True,Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease,Kawasaki Disease; Coronary Aneurysm,Drug:Doxycycline; Drug:Standard care,[u'Kapiolani Medical Center for Women and Children'],"August 8, 2013",1,18,Both,False
NCT01908426,Exelixis,False,HI,https://ClinicalTrials.gov/show/NCT01908426,True,Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,Hepatocellular Carcinoma,Drug:Cabozantinib tablets; Drug:Placebo tablets,[],"May 27, 2015",18,9223372036854775807,Both,False
NCT01881373,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT01881373,True,Children's Healthy Living Program,Obesity,Other:CHL program,[u'University of Hawaii'],"June 18, 2013",2,8,Both,True
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01836471,Novartis Pharmaceuticals,False,HI,https://ClinicalTrials.gov/show/NCT01836471,True,A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients,Asthma,Drug:QAW039; Drug:Placebo; Drug:Inhaled corticosteroid (ICS),[],"November 3, 2014",18,9223372036854775807,Both,False
NCT01828112,Novartis Pharmaceuticals,False,HI,https://ClinicalTrials.gov/show/NCT01828112,True,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT01822522,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01822522,True,Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,Adult Solid Neoplasm; Advanced Malignant Neoplasm; HIV Infection; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Solid Neoplasm; Unresectable Malignant Neoplasm,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,"[u'UCLA / Jonsson Comprehensive Cancer Center', u'University of California San Diego', u'University of Hawaii Cancer Center', u'Louisiana State University', u'Johns Hopkins University/Sidney Kimmel Cancer Center', u'Boston Medical Center', u'Washington University School of Medicine', u'Albert Einstein College of Medicine', u'Ohio State University Comprehensive Cancer Center', u'Baylor College of Medicine', u'Ben Taub General Hospital', u'Virginia Mason Medical Center', u'Fred Hutchinson Cancer Research Center']","November 9, 2015",18,9223372036854775807,Both,False
NCT01796574,Johns Hopkins University,True,HI,https://ClinicalTrials.gov/show/NCT01796574,True,Ketogenic Diet for Refractory Status Epilepticus,Status Epilepticus; Seizure; Epilepsy; Refractory Status Epilepticus; Medically Resistant Status Epilepticus,Dietary Supplement:Ketogenic diet,"[u'Mayo Clinic', u""Queen's Medical Center"", u'Rush University Medical Center', u'Johns Hopkins University', u'Mayo Clinic', u'New York University', u'University of Rochester', u'Oregon Health & Science University', u'Thomas Jefferson University', u'Intermountain Medical Center']","April 27, 2015",18,80,Both,False
NCT01794143,GRADE Study Group,False,HI,https://ClinicalTrials.gov/show/NCT01794143,True,A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes,Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications,Drug:Sulfonylurea (glimepiride); Drug:DPP-4 inhibitor (sitagliptin); Drug:GLP-1 receptor agonist (liraglutide); Drug:Insulin (glargine),[],"December 2, 2015",30,9223372036854775807,Both,False
NCT01730950,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01730950,True,Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Biological:bevacizumab; Radiation:intensity-modulated radiation therapy; Radiation:3-dimensional conformal radiation therapy; Radiation:proton beam radiation therapy,[],"November 19, 2015",18,9223372036854775807,Both,False
NCT01730937,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01730937,True,Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer,Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer,Drug:sorafenib tosylate; Radiation:stereotactic body radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01659411,Actelion,False,HI,https://ClinicalTrials.gov/show/NCT01659411,True,Adult Congenital Heart Disease Registry (QuERI),Pulmonary Arterial Hypertension; Congenital Heart Disease,Other:observational,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01652872,Amgen,False,HI,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01633060,Novartis Pharmaceuticals,False,HI,https://ClinicalTrials.gov/show/NCT01633060,True,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi","Metastatic Breast Cancer HR+, HER2-",Drug:Fulvestrant; Drug:BKM120; Drug:BKM120 matching placebo,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01626079,Evalve,False,HI,https://ClinicalTrials.gov/show/NCT01626079,True,COAPT Clinical Trial,Mitral Regurgitation; Mitral Valve Regurgitation,Device:MitraClip System,[],"October 9, 2015",18,9223372036854775807,Both,False
NCT01621178,Eli Lilly and Company,False,HI,https://ClinicalTrials.gov/show/NCT01621178,True,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes; Chronic Kidney Disease,Drug:Dulaglutide; Drug:Insulin glargine; Drug:Insulin lispro,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT01602666,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01602666,True,Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors,Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma,Procedure:therapeutic conventional surgery; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Drug:carboplatin; Drug:etoposide; Drug:ifosfamide,[],"October 20, 2015",3,21,Both,False
NCT01570036,George E. Peoples,False,HI,https://ClinicalTrials.gov/show/NCT01570036,True,Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,Breast Cancer,Drug:Herceptin; Drug:NeuVax vaccine; Drug:GM-CSF,[],"December 1, 2015",18,9223372036854775807,Female,False
NCT01567722,AIDS Malignancy Consortium,False,HI,https://ClinicalTrials.gov/show/NCT01567722,True,Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies,Anal Cancer; Cervical Cancer; Lung Cancer; Lymphoma; Nonneoplastic Condition,Genetic:DNA analysis; Genetic:RNA analysis; Genetic:gene expression analysis; Genetic:polymorphism analysis; Other:biologic sample preservation procedure; Other:flow cytometry; Other:laboratory biomarker analysis; Other:medical chart review,"[u'Moores UCSD Cancer Center', u'UCLA Clinical AIDS Research and Education (CARE) Center', u'University of Miami', u'Cancer Research Center of Hawaii', u'John H. Stroger Hospital of Cook County', u'Louisiana State University Public Hospital', u'Washington University School of Medicine', u'Albert Einstein Cancer Center at Albert Einstein College of Medicine', u'Memorial Sloan Kettering Cancer Center', u'UNC Lineberger Comprehensive Cancer Center', u'Harborview Madison Clinic', u'Seattle Cancer Care Alliance', u'Virginia Mason Medical Center']","October 1, 2015",18,9223372036854775807,Both,False
NCT01534819,Medtronic Endovascular,False,HI,https://ClinicalTrials.gov/show/NCT01534819,True,ANCHOR (Aneurysm Treatment Using the Heli-FX Aortic Securement System Global Registry),Abdominal Aortic Aneurysm,Device:Heli-FX EndoAnchor System; Procedure:AAA endograft placement; Device:Use of Aptus Heli-FX EndoAnchor System (Heli-FX),[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01524575,University of Hawaii,False,HI,https://ClinicalTrials.gov/show/NCT01524575,True,Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1,Metastatic Pancreatic Cancer; ERCC1,Drug:gemcitabine and oxaliplatin,[u'University of Hawaii'],"January 30, 2012",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01503632,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01492361,Amarin Pharma Inc.,False,HI,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01471340,Merck Sharp & Dohme Corp.,False,HI,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01442194,Novartis,False,HI,https://ClinicalTrials.gov/show/NCT01442194,True,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,Multiple Sclerosis,Drug:Fingolimod; Drug:other disease-modifying therapy,[],"January 15, 2016",0,9223372036854775807,Both,False
NCT01407952,Northwestern University,False,HI,https://ClinicalTrials.gov/show/NCT01407952,True,Hydrogel Endovascular Aneurysm Treatment Trial,Cerebral Aneurysm,Device:HydroCoil Embolic System; Device:Control (bare platinum coils),[],"July 10, 2015",18,75,Both,False
NCT01395030,Queen's Medical Centre,True,HI,https://ClinicalTrials.gov/show/NCT01395030,True,Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer,Liver Cancer,Drug:Fluoromethylcholine (FCH) PET/CT Imaging,"[u""The Queen's Medical Center""]","October 1, 2015",18,9223372036854775807,Both,False
NCT01381718,University of South Florida,False,HI,https://ClinicalTrials.gov/show/NCT01381718,True,Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor,Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment,Drug:modafinil; Other:placebo,[],"July 15, 2015",6,19,Both,False
NCT01372787,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01369212,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),False,HI,https://ClinicalTrials.gov/show/NCT01369212,True,Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B,Hepatitis B,Drug:Tenofovir; Drug:Peginterferon-alfa 2a and tenofovir,"[u'University of California Los Angeles', u'Cedars Sinai Medical Center', u'University of California San Francisco', u'California Pacific Medical Center', u""Queen's Medical Center"", u'NIH Clinical Center', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'University of Michigan Health System', u'University of Minnesota', u'Mayo Clinic', u'Washington University', u'Saint Louis University', u'University of North Carolina', u'Duke University Medical Center', u'Baylor University Medical Center', u'University of Texas Southwestern', u'Virginia Commonwealth University', u'Virginia Mason Medical Center', u'University of Washington Medical Center', u'University of Toronto-Toronto Western Hospital']","October 28, 2015",18,9223372036854775807,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,HI,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01346267,University of South Florida,False,HI,https://ClinicalTrials.gov/show/NCT01346267,True,Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy,"Central Nervous System Tumor, Pediatric; Chemotherapy-induced Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific",Procedure:Real Acupressure Band; Procedure:Placebo Acupressure Band,[],"July 7, 2015",4,18,Both,False
NCT01307579,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01239082,VA Office of Research and Development,True,HI,https://ClinicalTrials.gov/show/NCT01239082,True,Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM),Colorectal Cancer,Procedure:Colonoscopy; Procedure:FIT,[],"January 20, 2016",50,75,Both,True
NCT01194063,Kapiolani Medical Center For Women & Children,True,HI,https://ClinicalTrials.gov/show/NCT01194063,True,Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease,Cholestasis,Drug:Omega-3 fish oil lipid emulsion,[u'Kapiolani Medical Center for Women and Children'],"April 6, 2015",0,9223372036854775807,Both,False
NCT01146990,"Lumara Health, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01146990,True,"A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth",Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial,"Drug:ASQ-3, Bayley III, Neurologic exam",[],"December 9, 2015",22,25,Both,False
NCT01101035,Takeda,True,HI,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01077401,Johns Hopkins University,False,HI,https://ClinicalTrials.gov/show/NCT01077401,True,Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study,Diabetic Macular Edema,Drug:Ranibizumab; Drug:ranibizumab,"[u'Retina Vitreous Associates', u'University of California San Diego', u'Doheny Eye Institute', u'East Bay Retina Institute', u'Retina Macula Institute', u'Retina Group of Florida', u'Retina Institute of Hawaii', u'Illinois Retina Associates', u'University of Kansas', u'Johns Hopkins University Wilmer Eye Institute', u'Eye Care Specialists', u'Black Hills Eye Institute', u'Texas Retina Associates']","March 29, 2010",18,9223372036854775807,Both,False
NCT01052688,"Sequenom, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01052688,True,Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies,Down Syndrome; Aneuploidy,Other:Maternal blood draw of 30 to 50ml,"[u'Perinatal Care Associates', u""St. Joseph's Hospital and medical Center"", u'Sharp Grossmount', u'IGO', u'San Diego Perinatal Center', u""Women's Healthcare at Frost Street"", u'Reiter, Hill, Johnson and Nevin', u'Fetal Diagnostic Institute of the Pacific', u'Spectrum Health', u'Women and Infants Hospital of Rhode Island']","September 15, 2015",0,9223372036854775807,Female,False
NCT01004029,"Lumara Health, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01004029,True,Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery,Preterm Birth,"Drug:Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug:Vehicle",[],"June 29, 2015",18,9223372036854775807,Female,False
NCT00785525,Center for International Blood and Marrow Transplant Research,False,HI,https://ClinicalTrials.gov/show/NCT00785525,True,Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors,Healthy,Drug:Filgrastim,[],"January 26, 2016",18,60,Both,True
NCT00772200,Children's Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00658021,AstraZeneca,False,HI,https://ClinicalTrials.gov/show/NCT00658021,True,Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes,Type 2 Diabetes,Drug:Placebo; Drug:Exenatide; Drug:Exenatide,[],"January 29, 2016",10,17,Both,False
NCT00639782,"On-X Life Technologies, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT00639782,True,Prospective Randomized On-X Versus SJM Evaluation Trial,Heart Valve Disease,Device:On-X Heart valve replacement; Device:SJM Heart valve replacement,"[u'Southern California Permanente Medical Group', u'Kaiser Foundation Hospital', u'Washington University - St Louis', u'Robert Wood Johnson Medical School', u'Sentara Norfolk General Hospital', u""St. Paul's Hospital"", u'Vancouver General Hospital', u'Victoria Heart Institute', u'Jewish General Hospital', u'Erasmus Medical Center', u'University of Bergen', u'Sahlgrenska University Hospital']","September 4, 2015",18,80,Both,False
NCT00628498,Jazz Pharmaceuticals,True,HI,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT00355433,Tripler Army Medical Center,True,HI,https://ClinicalTrials.gov/show/NCT00355433,True,Comparison of Body and Room Temperature Saline in Urodynamics,Urinary Incontinence,Procedure:Urodymanics,[u'Tripler Army Medical Center'],"July 20, 2006",18,9223372036854775807,Female,True
NCT00294242,Tripler Army Medical Center,True,HI,https://ClinicalTrials.gov/show/NCT00294242,True,Safety Study of Membrane Sweeping in Pregnancy,Pregnancy; Prelabor Rupture of Membranes,Procedure:membrane sweeping,[u'Tripler Army Medical Center'],"February 17, 2006",18,50,Female,True
NCT01120249,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01272037,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003222,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01674140,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02003209,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01853748,Dana-Farber Cancer Institute,False,ID,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01516216,Dana-Farber Cancer Institute,False,ID,https://ClinicalTrials.gov/show/NCT01516216,True,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']","January 10, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02134912,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,ID,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02601209,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02388165,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02315469,NRG Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT01968967,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01839864,Family Medicine Residency of Idaho,False,ID,https://ClinicalTrials.gov/show/NCT01839864,True,Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial,Metabolic Syndrome,"Behavioral:Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count","[u'Saint Alphonsus Medical Group Caldwell Clinic', u'Saint Lukes Clinic Jerome', u'St Alphonsus Medical Group Nampa Clinic']","April 22, 2013",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01805076,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,ID,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02674386,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02643251,BioDelivery Sciences International,False,ID,https://ClinicalTrials.gov/show/NCT02643251,True,"The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy",Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,"Drug:Clonidine Hydrochloride Topical Gel, 0.1%; Drug:Clonidine Hydrochloride Gel Comparator",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02563561,"Spectrum Pharmaceuticals, Inc",False,ID,https://ClinicalTrials.gov/show/NCT02563561,True,A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT,Bladder Cancer,Drug:Apaziquone; Other:Placebo,"[u'The Urology Center of Colorado', u'Dr. Lancing C. Patterson', u'North Idaho Urology', u'Idaho Urologic Institute, P.A.', u'Regional Urology, LLC', u'Anne Arundel Urology', u'Adult and Pediatric Urology P.C', u'Accumed Research Associates', u'Manhattan Medical Research Practice PLLC', u'Urologic Consultants of South Eastern Pennsylvania', u'Urology San Antonio Research', u'Integrity Medical Research, LLC']","November 3, 2015",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02480153,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02480153,True,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,ID,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02449239,Viventia Bio,False,ID,https://ClinicalTrials.gov/show/NCT02449239,True,Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG,Bladder Cancer,Biological:Vicinium,"[u'Urology Centers of Alabama', u'Skyline Urology', u'Skyline Urology', u'Urology Associates PC', u'Advanced Urology research', u'Pinellas Urology', u'Private Group Practice', u'North Idaho Urology', u'Idaho Urologic Institute', u'Kansas City Urology Care', u'Coastal Urology Associates', u'Premier Urology Associates', u'AccumetRx/Urology group of New Mexico', u'The Urological Institute of Northeastern New York', u'Premier Medical Group of the Hudson Valley', u'Carolina Clinical Trials', u'PMG Research of Winston-Salem', u'Clinical Research Solutions', u'Urology Consultants of Southeastern Pennsylvania', u'Urology Health Specialists LLC', u'Carolina Urologic Research Center', u'Virginia Urology Center']","October 19, 2015",18,9223372036854775807,Both,False
NCT02446912,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02446912,True,Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus,Active Systemic Lupus Erythematosus,Biological:Anifrolumab; Drug:Placebo,[],"November 9, 2015",18,70,Both,False
NCT02373813,Amgen,False,ID,https://ClinicalTrials.gov/show/NCT02373813,True,Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission,Rheumatoid Arthritis,Drug:etanercept pre-filled syringe sq injection; Drug:Oral methotrexate; Drug:Placebo for etanercept sq injection; Drug:Placebo for methotrexate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02293395,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02293395,True,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:Acetylsalicylic acid; Drug:Rivaroxaban; Drug:Clopidogrel; Drug:Ticagrelor,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02277990,Medtronic Cardiac Rhythm Disease Management,False,ID,https://ClinicalTrials.gov/show/NCT02277990,True,World-wide Randomized Antibiotic Envelope Infection Prevention Trial,CIED Related Infection,Device:TYRX Absorbable Antibacterial Envelope,[],"August 27, 2015",18,9223372036854775807,Both,True
NCT02187159,Daiichi Sankyo Inc.,False,ID,https://ClinicalTrials.gov/show/NCT02187159,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02187055,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02187055,True,An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate,Rhematoid Arthritis,Drug:Tofacitinib with methotrexate; Drug:Tofacitinib without methotrexate; Biological:Adalimumab with methotrexate,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01976364,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01976364,True,Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis,"Arthritis, Psoriatic",Drug:Tofacitinib; Drug:Tofacitinib,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,ID,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01872975,NSABP Foundation Inc,False,ID,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01856192,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,ID,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01621178,Eli Lilly and Company,False,ID,https://ClinicalTrials.gov/show/NCT01621178,True,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes; Chronic Kidney Disease,Drug:Dulaglutide; Drug:Insulin glargine; Drug:Insulin lispro,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,ID,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01535066,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01535066,True,"S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer",Breast Cancer; Pain,Procedure:acupuncture therapy; Procedure:sham acupuncture,[],"September 25, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01471340,Merck Sharp & Dohme Corp.,False,ID,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01359592,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01312909,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01312909,True,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],"February 3, 2016",12,19,Both,False
NCT01286272,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01146990,"Lumara Health, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT01146990,True,"A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth",Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial,"Drug:ASQ-3, Bayley III, Neurologic exam",[],"December 9, 2015",22,25,Both,False
NCT01004029,"Lumara Health, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT01004029,True,Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery,Preterm Birth,"Drug:Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug:Vehicle",[],"June 29, 2015",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02675426,AbbVie,False,ID,https://ClinicalTrials.gov/show/NCT02675426,True,A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,99,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02670434,"Kowa Research Institute, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02670434,True,Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia,Hyperlipidemia; Dyslipidemia,Drug:NK-104-CR; Drug:Placebo; Drug:Livalo,[],"February 2, 2016",18,80,Both,False
NCT02648204,Novo Nordisk A/S,False,ID,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02647320,Daiichi Sankyo Inc.,False,ID,https://ClinicalTrials.gov/show/NCT02647320,True,12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin,Type 2 Diabetes Mellitus,Drug:Sitagliptin 100 mg; Drug:DS-8500a 25mg; Drug:placebo,[],"January 26, 2016",18,70,Both,False
NCT02640612,Boehringer Ingelheim,False,ID,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02638805,Intarcia Therapeutics,False,ID,https://ClinicalTrials.gov/show/NCT02638805,True,Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide,"Diabetes Mellitus, Type 2",Drug:ITCA 650 20/60 mcg/day; Drug:ITCA 650 60 mcg/day,[],"February 3, 2016",18,80,Both,False
NCT02638129,Takeda,False,ID,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02628028,Eli Lilly and Company,False,ID,https://ClinicalTrials.gov/show/NCT02628028,True,A Study of LY3337641 in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:LY3337641; Drug:Placebo,[],"January 8, 2016",18,65,Both,False
NCT02624947,Novavax,False,ID,https://ClinicalTrials.gov/show/NCT02624947,True,A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization,Respiratory Syncytial Virus Infections,Biological:RSV F vaccine with adjuvant; Biological:Formulation buffer,"[u'Research Site US032', u'Research Site US025', u'Research Site US020', u'Research Site AR002', u'Research Site AR003', u'Research Site AR004', u'Research Site AR005', u'Research Site AU010', u'Research Site AU007', u'Research Site AU008', u'Research Site AU009', u'Research Site CL003', u'Research Site CL002', u'Research Site CL001', u'Research Site NZ002', u'Research Site NZ001', u'Research Site ZA003', u'Research Site ZA004', u'Research Site ZA002', u'Research Site ZA001']","January 5, 2016",18,40,Female,True
NCT02614261,Eli Lilly and Company,False,ID,https://ClinicalTrials.gov/show/NCT02614261,True,Evaluation of LY2951742 in the Prevention of Chronic Migraine,Chronic Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02614183,Eli Lilly and Company,False,ID,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02609633,Hoffmann-La Roche,False,ID,https://ClinicalTrials.gov/show/NCT02609633,True,Accu-Chek(R) Connect at School (CATS) Pediatric Study,Type 1 Diabetes,Device:Accu-Chek(R) Connect DMS; Device:DMS,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","November 18, 2015",6,18,Both,False
NCT02607865,Novo Nordisk A/S,False,ID,https://ClinicalTrials.gov/show/NCT02607865,True,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:sitagliptin; Drug:placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,ID,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02583919,"Ionis Pharmaceuticals, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02583919,True,"Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes",Type 2 Diabetes,Drug:ISIS-GCGRRx- Dose Level 1; Drug:ISIS-GCGRRx- Dose Level 2; Drug:Placebo,[],"October 20, 2015",18,75,Both,False
NCT02561078,Eli Lilly and Company,False,ID,https://ClinicalTrials.gov/show/NCT02561078,True,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug:Human regular U-500 insulin (CSII); Drug:Human regular U-500 insulin (MDI),[],"January 7, 2016",18,85,Both,False
NCT02552212,UCB BIOSCIENCES GmbH,False,ID,https://ClinicalTrials.gov/show/NCT02552212,True,Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS,Axial Spondyloarthritis; Nonradiographic Axial Spondyloarthritis; Nr-axSpA,Biological:Certolizumab Pegol; Other:Placebo,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02548351,Intercept Pharmaceuticals,False,ID,https://ClinicalTrials.gov/show/NCT02548351,True,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment,Non Alcoholic Steatohepatitis (NASH),Drug:Obeticholic Acid; Drug:Placebo,[],"November 2, 2015",18,85,Both,False
NCT02547935,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02547935,True,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabestes and CKD3","Type 2 Diabetes Mellitus, CKD3 and Albuminuria",Drug:Dapagliflozin 10 mg; Drug:Dapagliflozin 10mg+Saxagliptin 2.5mg; Drug:Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,[],"December 16, 2015",18,74,Both,False
NCT02546960,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02546960,True,A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860,Healthy,Biological:ExPEC4V (4 : 4 : 4 : 4); Biological:ExPEC4V (4 : 4 : 4 : 8); Biological:ExPEC4V (8 : 8 : 8 : 8); Biological:ExPEC4V (8 : 8 : 8 : 16); Biological:ExPEC4V (16 : 16 : 16 : 16); Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 8, 2016",18,9223372036854775807,Both,True
NCT02542631,"Calibra Medical, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02542631,True,Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents,"Diabetes Mellitus, Type 2 (T2DM)",Device:Bolus Insulin Patch (Calibra Finesse); Device:Insulin Pen (Novo-Nordisk FlexPen),[],"October 19, 2015",22,75,Both,False
NCT02542215,Sucampo AG,False,ID,https://ClinicalTrials.gov/show/NCT02542215,True,Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer,Oral Mucositis,Drug:Cobiprostone; Drug:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02531516,"Aragon Pharmaceuticals, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02531516,True,An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS,Prostatic Neoplasms,Drug:JNJ-56021927; Drug:Bicalutamide; Drug:Bicalutamide Placebo; Drug:JNJ-56021927 Placebo; Drug:GnRH (agonist); Radiation:74-80 Grays (units of radiation),[],"January 27, 2016",18,9223372036854775807,Male,False
NCT02504294,"Hospira, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02504294,True,A Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Drug:Epoetin Hospira Arm; Other:Standard of Care Arm,"[u'CA Institute of Renal Research', u'CA Institute of Renal Research', u'Genesis Clinical Research, Inc', u'Boise Kidney and Hypertension Institute', u'Nephrology Center, PC', u'South Mississippi Medical Research, LLC', u'Southern Renal Research Group, LLC', u'Metrolina Nephrology Associates, PA', u'Durham Nephrology Associates', u'Delaware Valley Nephrology and Hypertension Associates, PC', u'Rhode Island Hospital', u'Knoxville Kidney Center, PLLC', u'Nephrology Associates, PC', u'Research Management Inc', u'Gamma Medical Research, Inc', u'Southwest Houston Research, Ltd', u'Eugenia M. Galindo-Ramos', u'Jose L. Cangiano-Rivera']","November 25, 2015",18,9223372036854775807,Both,False
NCT02504268,Bristol-Myers Squibb,False,ID,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02502669,"Elorac, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02502669,True,Finasteride Treatment of Severe Nodulocystic Acne,NODULOCYSTIC ACNE,Drug:Finasteride 23.5 mg tablets; Drug:Finasteride 33.5 mg tablets; Drug:Placebo tablets,[],"February 3, 2016",18,35,Male,True
NCT02501161,Novo Nordisk A/S,False,ID,https://ClinicalTrials.gov/show/NCT02501161,True,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec/liraglutide; Drug:insulin glargine,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,ID,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02491073,Sunovion,False,ID,https://ClinicalTrials.gov/show/NCT02491073,True,Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL),Epilepsy,Other:blood draw,"[u'Medsol Clinical Research Center', u'Consultans in Epilepsy & Neurology, PLLC', u'Bluegrass Epilepsy Research', u'Minneapolis Clinic of Neurology', u'CliniLabs', u'NeurologicalClinic of Texas, P.A.']","December 10, 2015",18,9223372036854775807,Both,True
NCT02487888,"Proove Bioscience, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02487888,True,A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care,"Pain; Chronic Pain; Mental Disorders; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Arthritis",Other:Unblinded to Genetic Testing Results; Other:Blinded to Genetic Testing Results,[],"July 21, 2015",18,9223372036854775807,Both,False
NCT02487446,Novartis Pharmaceuticals,False,ID,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02485795,"Proove Bioscience, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02485795,True,Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management,"Pain; Chronic Pain; Back Pain; Nociceptive Pain; Neuropathic Pain; Musculoskeletal Pain; Neck Pain; Pain, Intractable",Other:Observational,"[u'Medical Clinic - Steven J. Waltrip M.D. Inc.', u'Coastal Pain & Spinal Diagnostics - Yogesh Patel, M.D.', u'Regional Pain Treatment Medical Center', u'The Helm Center for Pain Management', u'Remedy Pain Solutions', u'Back Bay Medical', u'Pain Management Associates of CT, PC', u'Center for Interventional Pain & Spine', u'Neurospine Institute, LLC', u'South Florida Pain & Wellness Institute', u'Coastal Pain & Neurology', u'Perimeter Orthopedics', u'OrthoGeorgia', u'Roswell Pain Specialists', u'Optim Orthopedics', u'Medical Clinic - Dr. Robert Rust', u'The Kahan Center For Pain Management', u'Medical Centre Pain Mgmt', u'Spine Specialists (Texas Spine & Joint Hospital)', u'National Spine And Pain Centers', u'Northwest Spine and Pain Medicine']","July 21, 2015",18,9223372036854775807,Both,False
NCT02477891,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02477891,True,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02477618,Sage Therapeutics,False,ID,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02465320,"Juniper Pharmaceuticals, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02465320,True,"COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy",Endometrial Biopsy,Drug:COL-1077; Drug:Placebo,"[u'Genesis Center for Clinical Research', u'MCB Clinical Research Centers', u'New Age Medical Research Corporation', u'WR Mount Vernon Clinical Research, LLC', u'Rosemark Women Care Specialist', u""Women's Clinic of Lincoln PC"", u'Lawrence OB-GYN Clinical Research, LLC', u""New York Center for Women's Health Research"", u'Carolina Womens Research Wellness Center', u'Wake Research Associates', u'Hawthorne Medical Research Inc.', u'Clinical Trials of South Carolina', u""North Spokane Women's Health""]","July 15, 2015",40,75,Female,False
NCT02456740,Amgen,False,ID,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,ID,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02437487,"Seres Therapeutics, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02437487,True,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),Clostridium Difficile,Drug:SER-109; Drug:Placebo,[],"December 1, 2015",18,9223372036854775807,Both,False
NCT02435992,"Receptos, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02435992,True,Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Drug:RPC1063; Drug:Placebo,[],"January 20, 2016",18,75,Both,False
NCT02427802,Innocoll,False,ID,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02420262,Novo Nordisk A/S,False,ID,https://ClinicalTrials.gov/show/NCT02420262,True,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec/liraglutide; Drug:insulin glargine; Drug:insulin aspart,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02416973,"Regenesis Biomedical, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02416973,True,Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery,Lumbar Surgery,Device:Provant,"[u'AOC-Research', u'Hope Research', u'Injury Care Research', u'Rockford Orthopedic', u'Hope Research_Las Vegas', u'Tarheel Clinical Research', u'Upstate Clinical', u'Danville Orthopedic']","January 26, 2016",22,9223372036854775807,Both,True
NCT02414958,Boehringer Ingelheim,False,ID,https://ClinicalTrials.gov/show/NCT02414958,True,Empagliflozin as Adjunctive to inSulin thErapy in Type 1 Diabetes Over 52 Weeks (EASE-2),"Diabetes Mellitus, Type 1",Drug:Empagliflozin; Drug:Empagliflozin; Drug:Placebo,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02414854,Sanofi,False,ID,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,ID,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02408523,"UCB BIOSCIENCES, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02408523,True,A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications,Epilepsy,Drug:Lacosamide Tablet; Drug:Lasosamide Oral Solution; Other:Placebo Tablet; Other:Placebo Oral Solution,[],"January 8, 2016",4,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02403401,Bayer,False,ID,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02403323,Hoffmann-La Roche,False,ID,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02394028,Hoffmann-La Roche,False,ID,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,ID,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02376790,Amgen,False,ID,https://ClinicalTrials.gov/show/NCT02376790,True,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Drug:Etanercept + Oral Methotrexate; Drug:Etanercept + Placebo for Methotrexate; Drug:Oral Methotrexate + Placebo for Etanercept,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02375815,Mayo Clinic,False,ID,https://ClinicalTrials.gov/show/NCT02375815,True,Statin Choice Decision Aid Implementation First Phase,Cardiovascular Factor Risk,Other:Statin Choice Implementation,"[u'Kootenai Health', u'Mayo Clinic in Rochester', u'Mosaic Life Care', u'Altru Health System']","February 1, 2016",18,9223372036854775807,Both,False
NCT02367313,"Biota Pharmaceuticals, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02367313,True,A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection,Asthma,Drug:Vapendavir; Drug:Vapendavir; Drug:Placebo,[],"October 16, 2015",18,70,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,ID,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02330445,"Protalex, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02330445,True,6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection,"Arthritis, Rheumatoid",Drug:PRTX-100,[u'Protalex Investigational Site'],"September 30, 2015",18,9223372036854775807,Both,True
NCT02322320,"National Heart, Lung, and Blood Institute (NHLBI)",False,ID,https://ClinicalTrials.gov/show/NCT02322320,True,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",Multiple Myeloma,Drug:Lenalidomide,[],"December 17, 2015",18,70,Both,False
NCT02320149,Warner Chilcott,False,ID,https://ClinicalTrials.gov/show/NCT02320149,True,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Drug:Sarecycline; Drug:Placebo,[],"December 23, 2015",9,45,Both,False
NCT02319837,"Medivation, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02319837,True,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Drug:Enzalutamide; Drug:Placebo; Drug:Leuprolide,[],"December 1, 2015",18,9223372036854775807,Male,False
NCT02308046,"Curatek Pharmaceuticals, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02308046,True,Multi-Center Study of New Medications to Treat Vaginal Infections,Vaginal Infection,Drug:Terconazole; Drug:Placebo,[],"November 17, 2015",12,9223372036854775807,Female,False
NCT02308033,"Curatek Pharmaceuticals, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02308033,True,Multi-Center Study of New Medications to Treat Vaginal Infections,Vaginal Infection,Drug:Metronidazole; Drug:Gel vehicle,[],"November 17, 2015",12,9223372036854775807,Female,False
NCT02308007,"Curatek Pharmaceuticals, LLC",False,ID,https://ClinicalTrials.gov/show/NCT02308007,True,Multi-Center Study of New Medications to Treat Vaginal Infections,Vaginal Infection,Drug:Terconazole; Drug:Metronidazole; Drug:Terconazole/metronidazole,[],"November 17, 2015",12,9223372036854775807,Female,False
NCT02299570,Rebiotix Inc.,True,ID,https://ClinicalTrials.gov/show/NCT02299570,True,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,Recurrent Clostridium Difficile Infection,Biological:RBX2660 (microbiota suspension); Other:Placebo,[],"August 14, 2015",18,9223372036854775807,Both,False
NCT02282397,"DexCom, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02282397,True,Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes,Diabetes Mellitus,Device:Continuous Glucose Monitor; Other:Continuous Subcutaneous insulin infusion,[],"December 17, 2015",25,9223372036854775807,Both,False
NCT02273726,FibroGen,False,ID,https://ClinicalTrials.gov/show/NCT02273726,True,Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects,CKD Anemia in Stable Dialysis Patients,Drug:Epoetin Alfa; Drug:FG-4592,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT02269241,"Laboratories Leon Farma, S.A.",False,ID,https://ClinicalTrials.gov/show/NCT02269241,True,"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles",Contraception,Drug:LF111 (drospirenone),[],"August 11, 2015",15,9223372036854775807,Female,True
NCT02268214,Bristol-Myers Squibb,False,ID,https://ClinicalTrials.gov/show/NCT02268214,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Drug:Dapagliflozin; Drug:Placebo for Dapagliflozin,[],"January 26, 2016",18,75,Both,False
NCT02265744,Bristol-Myers Squibb,False,ID,https://ClinicalTrials.gov/show/NCT02265744,True,Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus,Lupus,Drug:BMS-931699; Drug:Placebo matching BMS-931699,[],"January 26, 2016",18,70,Both,False
NCT02251067,"Vascular Pharmaceuticals, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02251067,True,Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients,Diabetic Nephropathy,Drug:VPI-2690B low dose; Drug:VPI-2690B medium dose; Drug:Placebo to match VPI-2690B; Drug:VPI-2690B high dose,[],"December 18, 2015",21,80,Both,False
NCT02243592,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02243592,True,Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment,Malignant Neoplasm,Other:Laboratory Biomarker Analysis,[],"January 22, 2016",0,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,ID,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02200614,Bayer,False,ID,https://ClinicalTrials.gov/show/NCT02200614,True,Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS),Prostate Cancer Non-Metastatic; Castration-Resistant,Drug:BAY1841788 (ODM-201); Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02196818,Medacta International SA,False,ID,https://ClinicalTrials.gov/show/NCT02196818,True,"A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup",Osteoarthritis; Arthritis; Avascular Necrosis; Fracture of the Femoral Neck or Head; Congenital Hip Dysplasia,Device:Mpact Acetabular Shell,"[u'Vail Orthopedics, P.C.', u'Saint Alphonsus Regional Medical Center', u'Illinois Bone & Joint Institute, LLC']","April 14, 2015",0,9223372036854775807,Both,False
NCT02194699,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02186847,NRG Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02185001,Orthopedic Specialty Institute,True,ID,https://ClinicalTrials.gov/show/NCT02185001,True,Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation,Dislocated Patella; Torn Medial Patellofemoral Ligament,Procedure:Direct Medial Patellofemoral Ligament (MPFL) Repair; Procedure:Physical therapy,[u'The Lyman Knee Clinic'],"December 30, 2014",10,9223372036854775807,Both,False
NCT02182440,AM-Pharma,False,ID,https://ClinicalTrials.gov/show/NCT02182440,True,"A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI",Acute Kidney Injury,Biological:recAP; Other:Placebo,[],"February 3, 2016",18,80,Both,False
NCT02180867,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02177695,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02170558,"Zimmer, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02170558,True,Evaluating Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With Trabecular Metal Implants (TM-Ardis),Degenerartive Disc Disease,Device:TM- Ardis implant and Metal Reduction CT software,[u'St Alphonsus Regional Medical Center'],"January 20, 2015",18,85,Both,False
NCT02166463,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02164916,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,ID,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT02145468,GlaxoSmithKline,False,ID,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02143973,Trevi Therapeutics,False,ID,https://ClinicalTrials.gov/show/NCT02143973,True,Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus,Uremic Pruritus; Pruritus,Drug:nalbuphine HCl ER 60mg BID; Drug:nalbuphine HCl ER 90mg BID; Drug:nalbuphine HCl ER 120mg BID,[],"May 14, 2015",18,9223372036854775807,Both,False
NCT02138916,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02129738,Wellspect HealthCare,False,ID,https://ClinicalTrials.gov/show/NCT02129738,True,Reuse of Intermittent Urethral Catheters,Intermittent Urethral Catheterization,Device:LoFric catheters,"[u'North Idaho Urology', u'University of Pennsylvania, Penn Urology', u'Froedtert Medical College and Specialty Clinic', u'Royal Rehab', u'Prince of Wales Hospital Spinal Unit', u'Princess Alexandra Hospital', u'Caulfield Hospital, Spinal Rehabilitation Unit']","February 4, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02106546,AbbVie,False,ID,https://ClinicalTrials.gov/show/NCT02106546,True,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],"January 13, 2016",18,99,Both,False
NCT02104583,Gilead Sciences,False,ID,https://ClinicalTrials.gov/show/NCT02104583,True,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],"January 8, 2016",18,80,Both,False
NCT02101788,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02100514,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02093221,Grifols Therapeutics Inc.,False,ID,https://ClinicalTrials.gov/show/NCT02093221,True,Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Biological:180 mg/kg Alpha1-PI; Biological:90 mg/kg Alpha1-PI; Biological:Placebo,[],"September 17, 2015",6,35,Both,False
NCT02092467,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02091804,University of Washington,False,ID,https://ClinicalTrials.gov/show/NCT02091804,True,Beginning Relationships in a Native Community,Parent-child Interaction,Behavioral:Immediate Group; Behavioral:Wait-List group,[u'Nimiipuu Health Community Clinic'],"December 4, 2014",0,9223372036854775807,Both,True
NCT02085408,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02054156,Bonnie Ramsey,False,ID,https://ClinicalTrials.gov/show/NCT02054156,True,OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis,Cystic Fibrosis,Drug:azithromycin; Drug:placebo; Drug:Tobramycin solution for inhalation,[],"September 25, 2015",6,18,Both,False
NCT02052310,FibroGen,False,ID,https://ClinicalTrials.gov/show/NCT02052310,True,Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients,Anemia in Incident Dialysis Patients,Drug:FG-4592 (roxadustat); Drug:Epoetin Alfa,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02043678,Bayer,False,ID,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02032277,AbbVie,False,ID,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT02019264,Eisai Inc.,False,ID,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01987895,Actelion,False,ID,https://ClinicalTrials.gov/show/NCT01987895,True,Phase 3 Study With Cadazolid in Clostridium Difficile-associated Diarrhea (CDAD).,Clostridium Difficile Infection,Drug:Cadazolid; Drug:vancomycin,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01960023,NSABP Foundation Inc,False,ID,https://ClinicalTrials.gov/show/NCT01960023,True,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,Colorectal Cancer,Drug:Cetuximab; Drug:Neratinib,"[u'University of Florida', u'MD Anderson Cancer Center Orlando', u""Saint Luke's Mountain States Tumor Institute"", u'Decatur Memorial Hospital', u'Saint Joseph Mercy Hospital', u'Henry Ford Health System', u'Levine Cancer Institute', u'Novant Health Presbyterian Medical Center', u'Thomas Jefferson University Hospital', u'Allegheny General Hospital', u'University of Pittsburgh', u'Reading Hospital and Medical Center']","October 8, 2015",18,9223372036854775807,Both,False
NCT01956812,"Immunomedics, Inc.",True,ID,https://ClinicalTrials.gov/show/NCT01956812,True,Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer,Metastatic Pancreatic Cancer; Pancreatic Cancer,Drug:IMMU-107; Drug:placebo; Drug:Gemcitabine,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,ID,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01888120,Jazz Pharmaceuticals,False,ID,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01885078,Eli Lilly and Company,False,ID,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01881425,InnFocus Inc.,False,ID,https://ClinicalTrials.gov/show/NCT01881425,True,InnFocus MicroShunt Versus Trabeculectomy Study,Primary Open Angle Glaucoma,Procedure:Glaucoma Surgery; Device:InnFocus MicroShunt,"[u'Vold Vision', u'Ophthalmic Consultants of Connecticut', u'Inter-Mountain Eye Care', u'Eugene and Marilyn Glick Eye Institute', u'Stiles Eyecare Excellence', u'Washington Eye Physicians and Surgeons', u'Cincinnati Eye Institute', u'Dean McGee Eye Institute', u'Ophthalmic Partners of Pennsylvania', u'Wills Eye Hospital', u'Glaucoma Associates of Texas', u'The Robert Cizik Eye Clinic', u'Specialty Eye Care']","May 4, 2015",40,85,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01870778,Novartis Pharmaceuticals,False,ID,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01858519,AbbVie,False,ID,https://ClinicalTrials.gov/show/NCT01858519,True,Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy,Cystic Fibrosis,Biological:pancrelipase,[],"December 14, 2015",2,99,Both,False
NCT01855750,"Janssen Research & Development, LLC",False,ID,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01846793,Nymox Corporation,False,ID,https://ClinicalTrials.gov/show/NCT01846793,True,Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022),Benign Prostatic Hyperplasia; BPH; Lower Urinary Tract Symptoms (LUTS); LUTS; Enlarged Prostate,Drug:NX-1207,"[u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.']","April 1, 2014",45,9223372036854775807,Male,False
NCT01824875,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01776424,Bayer,False,ID,https://ClinicalTrials.gov/show/NCT01776424,True,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,Prevention & Control,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Aspirin; Drug:Aspirin placebo; Drug:Rivaroxaban placebo; Drug:Pantoprazole",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01754298,Children's Hospital Boston,False,ID,https://ClinicalTrials.gov/show/NCT01754298,True,Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee,Juvenile Osteochondritis Dissecans,Procedure:Retro-articular drilling; Procedure:Trans-articular drilling,"[u'Kaiser Permanente Los Angeles', u""Rady Children's Hospital"", u'Rocky Mountain Hospital for Children', u""Connecticut Children's Medical Center"", u""St. Luke's Children's Hospital"", u""Children's Hospital Boston"", u'Washington University School of Medicine', u""Cincinnati Children's Hospital Medical Center"", u""The Children's Hopstial of Philadelphia"", u'University of Pennsylvania', u'Tennessee Orthopaedic Alliance', u'Medical College of Wisconsin', u'The Hospital for Sick Children']","September 29, 2014",8,18,Both,False
NCT01750190,FibroGen,False,ID,https://ClinicalTrials.gov/show/NCT01750190,True,A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis,CKD Anemia,Drug:FG-4592; Drug:Placebo,[],"September 24, 2015",18,9223372036854775807,Both,False
NCT01744106,Perrigo Company,False,ID,https://ClinicalTrials.gov/show/NCT01744106,True,A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold,Nasal Congestion Associated With the Common Cold,Drug:pseudoephedrine hydrochloride 30 mg tablets; Drug:Placebo tablets,"[u'Emmaus Research Center', u'WCCT Global, LLC', u'Advanced Clinical Research - Boise', u'Bluegrass Clinical Research', u'Meridian Clinical Research', u'Rapid Medical Research', u'Carolina Ear, Nose and Throat Clinic', u'Meridian Clinical Research - Dakota Dunes', u'ClinPoint Trials, LLC', u'Chrysalis Clinical Research', u'Advanced Clinical Research - West Jordan']","November 19, 2015",6,11,Both,False
NCT02562716,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02474160,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,IL,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02249949,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02249949,True,"Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma",Liposarcoma,Drug:efatutazone; Drug:placebo,[],"June 12, 2015",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,IL,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01575548,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,IL,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00828009,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00828009,True,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,IL,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,IL,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02101788,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01535053,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01101035,Takeda,True,IL,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02106546,AbbVie,False,IL,https://ClinicalTrials.gov/show/NCT02106546,True,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],"January 13, 2016",18,99,Both,False
NCT01835145,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,IL,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT01991795,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT02019264,Eisai Inc.,False,IL,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,IL,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02185599,DySIS Medical Inc.,False,IL,https://ClinicalTrials.gov/show/NCT02185599,True,IMproved PRactice Outcomes and Value Excellence in Colposcopy,High Grade Cervical Intraepithelial Neoplasia,Device:DySIS,[],"November 23, 2015",21,9223372036854775807,Female,False
NCT01870778,Novartis Pharmaceuticals,False,IL,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,IL,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT00316888,Eastern Cooperative Oncology Group,True,IL,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02671981,Radiation Therapy Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02339571,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02339571,True,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma of the Skin; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Biological:Sargramostim,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01805076,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,IL,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,IL,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,IL,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02104817,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01975389,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,IL,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,IL,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01197079,Ann & Robert H Lurie Children's Hospital of Chicago,False,IL,https://ClinicalTrials.gov/show/NCT01197079,True,Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years),Human Papillomavirus (HPV),Other:Survey,"[u'Pediatric Private practice', u'Pediatric Private Practice', u""Children's Memorial Hospital Uptown Clinic"", u'Pediatric Private Practice', u'Erie Family Health Clinic', u'Howard Brown Health Center', u'Private pediatric practice', u'Pediatric Private practice']","July 14, 2011",9,26,Male,True
NCT00430183,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02528188,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,IL,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01715805,Forest Laboratories,False,IL,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,IL,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01652872,Amgen,False,IL,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01096368,Children's Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT00888615,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00772200,Children's Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00736749,Children's Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT02540993,Bayer,False,IL,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,IL,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02367794,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02367781,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,IL,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02319967,University of Illinois at Chicago,False,IL,https://ClinicalTrials.gov/show/NCT02319967,True,Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes,Asthma,Behavioral:CAPE; Behavioral:Home,"[u'Sinai Health System', u""Ann & Robert H. Lurie Children's Hospital of Chicago"", u'Cook County Health & Hospitals System', u'Rush University Medical Center', u'University of Illinois at Chicago', u'University of Chicago']","December 3, 2015",5,11,Both,False
NCT02206334,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02206334,True,"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",Male Breast Carcinoma; Prostate Adenocarcinoma; Recurrent Breast Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Prostate Carcinoma; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Prostate Cancer,Radiation:Stereotactic Radiosurgery,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02142868,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT02142868,True,"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",Advanced Breast Cancer (Female),Drug:Palbociclib; Drug:Letrozole,[],"January 20, 2016",18,9223372036854775807,Female,False
NCT02104947,Boehringer Ingelheim,False,IL,https://ClinicalTrials.gov/show/NCT02104947,True,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Drug:idarucizumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02066636,Bristol-Myers Squibb,False,IL,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02032277,AbbVie,False,IL,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,IL,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01920711,Novartis Pharmaceuticals,False,IL,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01909791,Diabetic Retinopathy Clinical Research Network,False,IL,https://ClinicalTrials.gov/show/NCT01909791,True,Treatment for CI-DME in Eyes With Very Good VA Study,Diabetic Macular Edema,Procedure:Prompt Laser; Drug:Prompt aflibercept; Procedure:Deferred laser; Drug:Deferred aflibercept,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT01827046,Daniel Hanley,False,IL,https://ClinicalTrials.gov/show/NCT01827046,True,Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III,Intracerebral Hemorrhage,Drug:rt-PA,[],"October 23, 2015",18,80,Both,False
NCT01492361,Amarin Pharma Inc.,False,IL,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01345019,Amgen,False,IL,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01087073,University of Chicago,True,IL,https://ClinicalTrials.gov/show/NCT01087073,True,Improving Diabetes Care and Outcomes on the South Side of Chicago,Diabetes Mellitus,Behavioral:Patient Activation; Behavioral:Provider Training; Behavioral:Quality Improvement; Behavioral:Community Outreach,"[u'ACCESS Grand Boulevard Family Health Center', u'Friend Family Health Center', u'Chicago Family Health Center', u'Kovler Diabetes Center', u'University of Chicago, Primary Care Group', u'ACCESS Booker Family Health Center']","October 31, 2014",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,IL,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00628745,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT00628745,True,Transthyretin-Associated Amyloidoses Outcome Survey (THAOS),Transthyretin Mutations; Transthyretin Amyloidosis,Other:None. Observational Study.,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT00628498,Jazz Pharmaceuticals,True,IL,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),True,IL,https://ClinicalTrials.gov/show/NCT00042289,True,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],"September 2, 2015",0,9223372036854775807,Female,False
NCT02674386,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,IL,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,IL,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02493868,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02493868,True,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 2, 2016",18,64,Both,False
NCT02470585,AbbVie,False,IL,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02448342,Sensible Medical Innovations Ltd.,True,IL,https://ClinicalTrials.gov/show/NCT02448342,True,Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients,Heart Failure,Device:Remote Dielectric Sensing (ReDS) Wearable System,"[u'University of Alabama', u'Encore Research Group', u'University of Chicago', u'Elmhurst Memorial Hospital', u'Northshore University HealthSystem', u'Edward Heart Hospital', u""Prairie Heart Institute / St. John's Hospital"", u'St Elizabeth Healthcare', u'Mount Sinai Medical Center', u'Dorothy M. Davis Heart & Lung Research Institute at The Ohio State University Wexner Medical Center', u'The Ohio State University Wexner Medical Center', u'Lancaster General Health Hospital', u'Drexel University Medical Center', u'Centennial Medical Center - Sarah Cannon Research Institute', u""Henrico Doctors' Hospital""]","January 15, 2016",21,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02364557,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02364557,True,Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer,Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer,Radiation:Stereotactic Radiosurgery; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,"[u'University of Alabama at Birmingham Cancer Center', u'UC San Diego Moores Cancer Center', u'University of California Irvine Health', u'Permanente Medical Group - Roseville Radiation Oncology', u'Kaiser Permanente Cancer Treatment Center', u'University of Colorado Cancer Center - Anschutz Cancer Pavilion', u'Memorial Hospital Colorado Springs', u'Emory University Hospital Midtown', u'Piedmont Hospital', u'Emory University/Winship Cancer Institute', u'Northwestern University', u'University of Illinois', u'Decatur Memorial Hospital', u'Loyola University Medical Center', u'Northwestern Medicine Cancer Center Warrenville', u'Saint Vincent Anderson Regional Hospital/Cancer Center', u'Parkview Hospital', u'Memorial Hospital of South Bend', u'Lahey Hosptial and Medical Center', u'NRG Oncology', u'Jewish General Hospital']","December 22, 2015",18,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,IL,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02275533,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02275533,True,Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,Adult Acute Myeloid Leukemia in Remission,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,"[u'City of Hope Comprehensive Cancer Center', u'University of California Davis Comprehensive Cancer Center', u'Smilow Cancer Center/Yale-New Haven Hospital', u'Yale University', u'University of Chicago Comprehensive Cancer Center P2C', u'University of Chicago Comprehensive Cancer Center', u'Decatur Memorial Hospital', u'UC Comprehensive Cancer Center at Silver Cross', u'Illinois CancerCare-Peoria', u'Indiana University/Melvin and Bren Simon Cancer Center', u'University of Maryland/Greenebaum Cancer Center', u'National Institutes of Health Clinical Center', u'NCI - Center for Cancer Research', u'Wayne State University/Karmanos Cancer Institute', u'Case Western Reserve University', u'Penn State Milton S Hershey Medical Center', u'Virginia Commonwealth University/Massey Cancer Center', u'University Health Network-Princess Margaret Hospital']","January 11, 2016",18,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,IL,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02194699,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02186847,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02101853,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02066298,Milton S. Hershey Medical Center,False,IL,https://ClinicalTrials.gov/show/NCT02066298,True,Steroids In Eosinophil Negative Asthma,Asthma,Drug:Mometasone 220mcg BID; Drug:Tiotropium Respimat 5mcg QD; Drug:Placebo,"[u'University of Arizona College of Medicine', u""UCSF Benioff Children's Hospital"", u'National Jewish Health', u""Nemours Children's Clinic"", u""Nemours Children's Clinic"", u'Emory University', u'Northwestern Memorial Hospital', u'Rush University Medical Center', u'University of Illinois at Chicago', u""Ann and Robert H. Lurie Children's Hospital"", u'University of Chicago', u""Brigham and Women's Hospital"", u""Children's Hospital Boston"", u""St. Louis Children's Hospital"", u'Washington University', u'Columbia University Medical Center', u'Duke University School of Medicine', u'North Carolina Clinical Research', u'Wake Forest University Health Sciences', u""Rainbow Babies and Children's Hospital, Case Western Reserve University"", u'Allegheny General Hospital', u'University of Pittsburgh', u""Children's Hospital of Pittsburgh of UPMC"", u'University of Wisconsin-Madison']","April 6, 2015",12,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02060630,New England Research Institutes,False,IL,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT01967173,Milton S. Hershey Medical Center,False,IL,https://ClinicalTrials.gov/show/NCT01967173,True,Best African American Response to Asthma Drugs,Asthma,Drug:Flovent Diskus 100 mcg; Drug:Flovent Diskus 250 mcg; Drug:Flovent Diskus 500 mcg; Drug:Advair Diskus 100/50 mcg; Drug:Advair Diskus 250/50 mcg,[],"April 22, 2015",5,9223372036854775807,Both,False
NCT01947608,Novartis Pharmaceuticals,False,IL,https://ClinicalTrials.gov/show/NCT01947608,True,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:LDK378,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,IL,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01893749,"Benjamin Van Voorhees, MD, MPH",False,IL,https://ClinicalTrials.gov/show/NCT01893749,True,Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health,Major Depression; Depressive Episodes,Behavioral:CATCH-IT,"[u'ACCESS Healthcare Systems', u'University of Illinois', u'Northshore Healthcare Systems', u'Advocate Health Care', u""Children's Clinic"", u'Franciscan St. Margaret Health', u'Wellesley Center for Women']","December 7, 2015",13,18,Both,True
NCT01858532,AbbVie,False,IL,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01751906,Abbott Vascular,False,IL,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01710709,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,IL,https://ClinicalTrials.gov/show/NCT01710709,True,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Bipolar I,Drug:Aripiprazole,[],"October 7, 2015",18,65,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01610284,Novartis Pharmaceuticals,False,IL,https://ClinicalTrials.gov/show/NCT01610284,True,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,Breast Cancer,Drug:BKM120 Matching placebo; Drug:Fulvestrant; Drug:BKM120,[],"January 20, 2016",18,9223372036854775807,Female,False
NCT01595061,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01546038,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01478321,Northwestern University,False,IL,https://ClinicalTrials.gov/show/NCT01478321,True,Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma,Drug:Temozolomide; Radiation:hypofractionated radiation therapy; Biological:bevacizumab; Other:questionnaire administration,"[u'Northwestern University', u'University of Chicago', u'Northwestern Lake Forest Hospital', u'Edward Cancer Center', u'Central Dupage Hospital']","October 14, 2015",18,9223372036854775807,Both,False
NCT01321541,CTI BioPharma,False,IL,https://ClinicalTrials.gov/show/NCT01321541,True,Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant,Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma,Drug:Pixantrone + Rituximab; Drug:Gemcitabine + Rituximab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01307579,Children's Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01200589,GlaxoSmithKline,False,IL,https://ClinicalTrials.gov/show/NCT01200589,True,Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy,Non-Hodgkin's Lymphoma,Biological:Ofatumumab; Biological:Rituximab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01163253,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT00700882,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02648204,Novo Nordisk A/S,False,IL,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,IL,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02551874,Bristol-Myers Squibb,False,IL,https://ClinicalTrials.gov/show/NCT02551874,True,"A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy",Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glargine insulin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02542696,Cynapsus Therapeutics Inc,False,IL,https://ClinicalTrials.gov/show/NCT02542696,True,"An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of ""OFF"" Episodes in Patients With Parkinson's Disease",Parkinson Disease,Drug:APL-130277,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02528253,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,IL,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02492711,MacroGenics,False,IL,https://ClinicalTrials.gov/show/NCT02492711,True,Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,HER-2 Positive Breast Cancer; Metastatic Neoplasm,Biological:Margetuximab; Biological:Trastuzumab; Drug:Capecitabine; Drug:Eribulin; Drug:Gemcitabine; Drug:Vinorelbine,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02477618,Sage Therapeutics,False,IL,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02418754,Regeneron Pharmaceuticals,False,IL,https://ClinicalTrials.gov/show/NCT02418754,True,"Study of Intravitreal REGN2176-3 in Patients With Neovascular (""Wet"") Age-Related Macular Degeneration (AMD)",Neovascular Age-Related Macular Degeneration,Drug:REGN2176-3; Drug:Intravitreal Aflibercept Injection (IAI),[],"January 14, 2016",50,9223372036854775807,Both,False
NCT02418585,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02418585,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 27, 2016",18,64,Both,False
NCT02417064,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02417064,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 3, 2016",18,64,Both,False
NCT02394028,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,IL,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02366143,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02319044,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02319044,True,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck,Drug:MEDI4736; Drug:Tremelimumab; Drug:MEDI4736 + Tremelimumab,[],"January 18, 2016",18,96,Both,False
NCT02316548,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02316548,True,Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer,Stage III Bladder Cancer; Stage IV Bladder Cancer,Other:No radiation; Radiation:Intensity-Modulated Radiation Therapy,"[u'Emory University Hospital Midtown', u""Saint Joseph's Hospital of Atlanta"", u'Decatur Memorial Hospital', u'Pekin Cancer Treatment Center', u'OSF Saint Francis Medical Center', u'OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive Cancer Center', u'McFarland Clinic PC-William R. Bliss Cancer Center', u'University of Oklahoma Health Sciences Center', u'NRG Oncology']","November 19, 2015",18,9223372036854775807,Both,False
NCT02264288,Celgene Corporation,False,IL,https://ClinicalTrials.gov/show/NCT02264288,True,Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease,Peripheral Arterial Disease; Diabetic Foot,Biological:3 x 10^6 cells; Biological:10 x 10^6 cells; Biological:30 x 10^6 cells; Other:Placebo,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02243592,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02243592,True,Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment,Malignant Neoplasm,Other:Laboratory Biomarker Analysis,[],"January 22, 2016",0,9223372036854775807,Both,False
NCT02213744,Merrimack Pharmaceuticals,False,IL,https://ClinicalTrials.gov/show/NCT02213744,True,MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,Breast Cancer; HER2 Positive Breast Cancer,Drug:MM-302; Drug:Gemcitabine; Drug:Capecitabine; Drug:Vinorelbine; Drug:Trastuzumab,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02207530,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02207530,True,Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck (SCCHN),Drug:MEDI4736,[],"January 25, 2016",18,130,Both,False
NCT02207244,"Janssen Research & Development, LLC",False,IL,https://ClinicalTrials.gov/show/NCT02207244,True,A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment,Psoriasis,Drug:Guselkumab 100 mg; Drug:Placebo for guselkumab; Drug:Adalimumab; Drug:Placebo for adalimumab,[],"January 26, 2016",18,99,Both,False
NCT02177695,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,IL,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02135042,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02135042,True,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02118584,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02100696,Hoffmann-La Roche,False,IL,https://ClinicalTrials.gov/show/NCT02100696,True,A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors,Ulcerative Colitis,Drug:etrozulimab; Drug:placebo,[],"February 1, 2016",18,80,Both,False
NCT02092467,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02073279,Chugai Pharmaceutical,False,IL,https://ClinicalTrials.gov/show/NCT02073279,True,Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD,Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD),Drug:SA237; Drug:Placebo,[],"December 8, 2015",18,74,Both,False
NCT02072226,"Genentech, Inc.",False,IL,https://ClinicalTrials.gov/show/NCT02072226,True,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,IL,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02038764,Pfizer,False,IL,https://ClinicalTrials.gov/show/NCT02038764,True,A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Drug:Placebo; Biological:PF-06342674 Dose A; Biological:PF-06342674 Dose B; Biological:PF-06342674 Dose C; Biological:PF-06342674 Dose D,"[u'VA San Diego Healthcare System (Drug Shipment)', u'Veterans Administration San Diego Healthcare System', u'UCSF Gateway Medical Building', u'Barbara Davis Center for Childhood Diabetes', u'Yale New Haven Hospital', u'Yale New Haven Hospital - Investigational Drug Services', u'Yale University School of Medicine', u'Atlanta Diabetes Associates', u'The University of Chicago Medical Center', u'University of Chicago Clinical Resource Center', u'University of Chicago Medical Center', u'Duchossois Center for Advanced Medicine', u'UMass Medical School', u'University Of Minnesota Medical School', u'University Of Minnesota Fairview Pharmacy Services', u'(drug shipment only) Barnes- Jewish HOSP Att: Kathryn Vehe', u'Washington University (study supplies shipping only)', u'Washington University - Center for Advanced Medicine', u'Washington University', u'Duke Clinical Research Unit']","February 4, 2016",18,9223372036854775807,Both,False
NCT02037529,Academic and Community Cancer Research United,False,IL,https://ClinicalTrials.gov/show/NCT02037529,True,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Drug:Eribulin; Drug:Paclitaxel,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00565851,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT00843882,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02115282,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,IN,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02164916,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT00892866,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00892866,True,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02406677,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02065687,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01991795,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02451137,Sanofi,False,IN,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,IN,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01810913,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT00978458,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01872975,NSABP Foundation Inc,False,IN,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02164864,Boehringer Ingelheim,False,IN,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02343952,"Nasser Hanna, M.D.",False,IN,https://ClinicalTrials.gov/show/NCT02343952,True,Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC,"Carcinoma, Non-Small-Cell Lung",Drug:Pembrolizumab,"[u'City of Hope Comprehensive Cancer Center', u'Fort Wayne Oncology & Hematology, Inc.', u'IU Health Goshen Hospital', u'Indiana University Melvin and Bren Simon Cancer Center', u'IU Health Arnett Cancer Center', u'IU Health at Ball Memorial Hospital', u'Oncology Hematology Associates of SW Indiana', u'Northern Indiana Cancer Research Consortium', u'Nebraska Cancer Specialists', u'Rutgers Cancer Institute of New Jersey']","January 13, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,IN,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,IN,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01177683,"Sherif Farag, MB, BS",False,IN,https://ClinicalTrials.gov/show/NCT01177683,True,Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,Multiple Myeloma,Drug:Bendamustine; Drug:Doxorubicin; Drug:Bortezomib; Drug:Bendamustine; Drug:Filgrastim,"[u'Cancer Care Center of Southern Indiana', u'IU Health Goshen Hospital', u'IU Health Central Indiana Cancer Centers', u'Community Regional Cancer Center', u'Indiana University Melvin and Bren Simon Cancer Center', u'IU Health Arnett Cancer Center', u'Floyd Memorial Cancer Center of Indiana', u'Metro Health Cancer Care', u'University Hospitals Seidman Cancer Center']","December 28, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00828009,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00828009,True,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,IN,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02101385,"Bryan Schneider, MD",False,IN,https://ClinicalTrials.gov/show/NCT02101385,True,Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer,Malignant Neoplasm of Breast; Breast Cancer,Drug:Genomically Directed Monotherapy; Other:Observation/Standard Therapy,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01415752,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT00666731,University of Nebraska,False,IN,https://ClinicalTrials.gov/show/NCT00666731,True,A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,Breast Cancer; Precancerous Condition,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:Excess human biological tissue; Procedure:quality-of-life assessment,[],"November 30, 2015",19,120,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,IN,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02648204,Novo Nordisk A/S,False,IN,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02558803,"Regenstrief Institute, Inc.",True,IN,https://ClinicalTrials.gov/show/NCT02558803,True,HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3,Human Papilloma Virus Infection Type 11; Human Papilloma Virus Infection Type 16; Human Papilloma Virus Infection Type 18; Human Papilloma Virus Infection Type 6; Cervical Cancer; Genital Warts; Oropharyngeal Cancer,Behavioral:Simple Reminder,"[u'Eskenazi Health Outpatient Care Center', u'Eskenazi Health Center Blackburn', u'Eskenazi Health Center Forest Manor', u'Eskenazi Health West 38th Street', u'Eskenazi Health Center Pecar']","September 23, 2015",11,17,Both,False
NCT02048813,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01897532,Boehringer Ingelheim,False,IN,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01805076,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01681433,Costantine Albany,True,IN,https://ClinicalTrials.gov/show/NCT01681433,True,OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,Prostate Cancer; Metastatic Castrate-Resistant Prostate Cancer; PSA,Drug:OGX-427; Drug:Abiraterone Acetate; Drug:Prednisone,"[u'Prostate Oncology Specialists, Inc.', u'IU Health Bloomington Hospital', u'IU Health Goshen Hospital', u'Indiana University Melvin and Bren Simon Cancer Center', u'IU Health Central Indiana Cancer Centers', u'Northern Indiana Cancer Research Consortium', u'Dana Farber Cancer Institute', u'Mayo Clinic', u'University of New Mexico Cancer Center: Albuquerque', u'Virginia Oncology Associates', u'Alberta Health Services: Tom Baker Cancer Centre', u'Cross Cancer Institute', u'BC Cancer Agency', u'Cancer Care Manitoba', u'Juravinski Cancer Centre', u""Centre Hospitalier de l'Universit\xe9 de Montr\xe9al""]","January 7, 2016",18,9223372036854775807,Male,False
NCT01663402,Sanofi,False,IN,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00980954,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT02614183,Eli Lilly and Company,False,IN,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02595372,Kathy Miller,False,IN,https://ClinicalTrials.gov/show/NCT02595372,True,Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy,Cancer of the Breast,Drug:Omeprazole,"[u'Indiana University Health North Hospital', u'Indiana University Health Hospital', u'Indiana University Health Melvin and Bren Simon Cancer Center', u'Spring Mill Medical Center']","January 28, 2016",18,9223372036854775807,Both,False
NCT02528253,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,IN,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02443103,Kathy Miller,False,IN,https://ClinicalTrials.gov/show/NCT02443103,True,Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis,Bone Cancer; Metastasis,Drug:Guanabenz acetate,"[u'Indiana University Health Hospital', u'Indiana University Melvin and Bren Simon Cancer Center', u'Sidney & Lois Eskenazi Hospital', u'Spring Mill Medical Center']","January 28, 2016",18,9223372036854775807,Both,False
NCT02369874,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02369874,True,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN).,Drug:MEDI4736; Drug:MEDI4736 + Tremelimumab; Drug:Standard of Care,[],"January 18, 2016",18,96,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,IN,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02320721,Sanofi,False,IN,https://ClinicalTrials.gov/show/NCT02320721,True,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Drug:Insulin glargine U300 HOE901; Drug:Insulin glargine HOE901,[],"February 3, 2016",65,9223372036854775807,Both,False
NCT02231723,"Boston Biomedical, Inc",False,IN,https://ClinicalTrials.gov/show/NCT02231723,True,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug:BBI608; Drug:Nab-paclitaxel; Drug:Gemcitabine; Drug:Oxaliplatin; Drug:Leucovorin; Drug:Irinotecan; Drug:Fluorouracil,"[u'Emory University Winship Cancer Institute', u'Indiana University Health Goshen Center for Cancer Care', u'Indiana University Melvin and Bren Simon Cancer Center', u'Indiana University Health Arnett Hospital', u'Indiana University Health Ball Memorial Hospital', u'Ochsner Medical Center - Baton Rouge', u'Ochsner Medical Center', u'Comprehensive Cancer Centers of Nevada', u'The Ohio State University Comprehensive Cancer Center', u'The University of Tennessee Medical Center', u'Texas Oncology - Austin Midtown', u'Texas Oncology - Baylor Charles A. Sammons Cancer Center', u'Texas Oncology - SAT&BC', u'Virginia Oncology Associates', u'Yakima Valley Memorial Hospital / North Star Lodge']","January 6, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,IN,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02032277,AbbVie,False,IN,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT02024607,"Boston Biomedical, Inc",False,IN,https://ClinicalTrials.gov/show/NCT02024607,True,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,Advanced Gastrointestinal Cancer,Drug:BBI608; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Leucovorin; Drug:Irinotecan; Drug:Bevacizumab; Drug:Capecitabine; Drug:Regorafenib,"[u'Mayo Clinic Campus in Arizona', u'Florida Cancer Specialists', u'Emory University Winship Cancer Institute', u'Indiana University Health Goshen Center for Cancer Care', u'Indiana University Simon Cancer Center', u'Indiana University Health Arnett Hospital', u'Indiana University Health Ball Memorial Hospital', u'Mayo Clinic', u'Oncology Hematology Care, Inc.', u'Medical University of South Carolina', u'Institute for Translational Oncology Research, Greenville Health System', u'Tennessee Oncology - Chattanooga', u'Tennessee Oncology - Nashville', u'Ottawa Hospital Cancer Center']","January 6, 2016",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01874756,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT01874756,True,The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia,Schizophrenia,Drug:LY500307 150mg; Drug:LY500307 75mg; Drug:Placebo,"[u'Indiana University Center for NeuroImaging', u'IU Biostatistics', u'Prevention and Recovery Center for Early Psychosis', u'Larue D Carter Memorial Hospital']","June 15, 2015",18,60,Male,False
NCT01870778,Novartis Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,IN,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,IN,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01414608,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,IN,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,IN,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,IN,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02647320,Daiichi Sankyo Inc.,False,IN,https://ClinicalTrials.gov/show/NCT02647320,True,12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin,Type 2 Diabetes Mellitus,Drug:Sitagliptin 100 mg; Drug:DS-8500a 25mg; Drug:placebo,[],"January 26, 2016",18,70,Both,False
NCT02638805,Intarcia Therapeutics,False,IN,https://ClinicalTrials.gov/show/NCT02638805,True,Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide,"Diabetes Mellitus, Type 2",Drug:ITCA 650 20/60 mcg/day; Drug:ITCA 650 60 mcg/day,[],"February 3, 2016",18,80,Both,False
NCT02427802,Innocoll,False,IN,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02415400,Bristol-Myers Squibb,False,IN,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,IN,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02403323,Hoffmann-La Roche,False,IN,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02364557,NRG Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02364557,True,Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer,Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer,Radiation:Stereotactic Radiosurgery; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,"[u'University of Alabama at Birmingham Cancer Center', u'UC San Diego Moores Cancer Center', u'University of California Irvine Health', u'Permanente Medical Group - Roseville Radiation Oncology', u'Kaiser Permanente Cancer Treatment Center', u'University of Colorado Cancer Center - Anschutz Cancer Pavilion', u'Memorial Hospital Colorado Springs', u'Emory University Hospital Midtown', u'Piedmont Hospital', u'Emory University/Winship Cancer Institute', u'University of Illinois', u'Northwestern University', u'Decatur Memorial Hospital', u'Loyola University Medical Center', u'Northwestern Medicine Cancer Center Warrenville', u'Saint Vincent Anderson Regional Hospital/Cancer Center', u'Parkview Hospital', u'Memorial Hospital of South Bend', u'Lahey Hosptial and Medical Center', u'NRG Oncology', u'Jewish General Hospital']","December 22, 2015",18,9223372036854775807,Both,False
NCT02293395,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02293395,True,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:Acetylsalicylic acid; Drug:Rivaroxaban; Drug:Clopidogrel; Drug:Ticagrelor,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02271217,Acorda Therapeutics,False,IN,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,IN,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02200614,Bayer,False,IN,https://ClinicalTrials.gov/show/NCT02200614,True,Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS),Prostate Cancer Non-Metastatic; Castration-Resistant,Drug:BAY1841788 (ODM-201); Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02180867,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,IN,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02160041,Novartis Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT02160041,True,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,Solid Tumor; Hematologic Malignancies,Drug:BGJ398,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02138916,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02106546,AbbVie,False,IN,https://ClinicalTrials.gov/show/NCT02106546,True,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],"January 13, 2016",18,99,Both,False
NCT02059265,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02003222,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01999738,Endocyte,False,IN,https://ClinicalTrials.gov/show/NCT01999738,True,Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,Solid Tumors; Triple-Negative Breast Cancer (TNBC); Advanced Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer,Drug:EC1456 and etarfolatide (EC20),"[u'Scottsdale Healthcare Research Institute', u'IU Health Goshen Center for Cancer Care', u'Indiana University Cancer Center', u'Horizon BioAdvance', u'University of Maryland']","January 19, 2016",18,9223372036854775807,Both,False
NCT01993550,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT01993550,True,Telephone Support Program for Lung Cancer Patients and Their Family Caregivers,Lung Cancer,Behavioral:Telephone counseling; Behavioral:Education,"[u'Eskenazi Hospital', u'Indiana University Simon Cancer Center', u'Richard L. Roudebush VA Medical Center']","March 23, 2015",18,9223372036854775807,Both,False
NCT01987232,"Onyx Therapeutics, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT01987232,True,"Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer",Extensive-Stage Small-Cell Lung Cancer,Drug:Carfilzomib; Drug:Carboplatin; Drug:Etoposide,"[u'Yale University, Yale Cancer Center', u'UF Health Davis Cancer Pavilion and Shands Med Plaza', u'Goshen Center for Cancer Care', u'Horizon Oncology Research, Inc.', u'Indiana University Health Ball Memorial Hospital', u'Baptist Health Lexington Clinical Research Center', u'Frederick Memorial Hospital', u'John Theurer Cancer Center at Hackensack UMC', u'Levine Cancer Institute', u'Wake Forest Baptist Health', u'The University of Texas MD Anderson Cancer Center', u'Juravinski Cancer Centre', u'Regional Budgetary Healthcare Institution ""Kursk Regional Clinical Oncology Dispensary""', u'State budgetary healthcare institution of Arkhangelsk Region ""Arkhangelsk Clinical Oncological Dispensary""', u'Federal State Budgetary Scientific Institution ""N.N. Blokhin Russian Cancer Research Center""', u'State Budgetary Educational Inslitution of Higher Professional Education ""First St. Petersburg I.P.Pavlov State Medical University""', u'State Budgetary Healthcare Institution of Yaroslavl Region ""Regional Clinical Oncological Hospital""']","December 2, 2015",18,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01939301,Indiana University School of Medicine,False,IN,https://ClinicalTrials.gov/show/NCT01939301,True,Nitric Oxide to Treat Pulmonary Embolism,Pulmonary Embolism,Drug:Nitric Oxide; Drug:Oxygen,"[u'Eskenazi Hospital', u'Indiana University Hospital', u'Methodist Hospital', u'University of Mississippi']","February 16, 2015",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01885078,Eli Lilly and Company,False,IN,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01855750,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01779700,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT01779700,True,Fingolimod in Schizophrenia Patients,Schizophrenia,Drug:Fingolimod; Drug:placebo,"[u'Center for NeuroImaging', u'Prevention and Recovery Center', u'Larue D Carter Memorial Hospital']","June 15, 2015",18,65,Both,False
NCT01774578,NewLink Genetics Corporation,False,IN,https://ClinicalTrials.gov/show/NCT01774578,True,Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer; Progression of Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Recurrent,Drug:Docetaxel; Biological:HyperAcute-Lung Immunotherapy; Drug:Gemcitabine; Drug:Pemetrexed,[],"October 8, 2015",18,9223372036854775807,Both,False
NCT01730950,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01730950,True,Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Biological:bevacizumab; Radiation:intensity-modulated radiation therapy; Radiation:3-dimensional conformal radiation therapy; Radiation:proton beam radiation therapy,[],"November 19, 2015",18,9223372036854775807,Both,False
NCT01699503,Indiana University,True,IN,https://ClinicalTrials.gov/show/NCT01699503,True,Indiana University Dementia Screening Trial,Dementia; Alzheimer's Disease; Mild Cognitive Impairment,Behavioral:Collaborative Dementia Care Program,"[u'IU Health-Primary Care Clinics', u'Wishard Health Services-Primary Care Clinics', u'IU Health Arnett Primary Care Clinics']","August 27, 2015",65,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01494519,Major Extremity Trauma Research Consortium,False,IN,https://ClinicalTrials.gov/show/NCT01494519,True,Assessment of Fixation Strategies for Severe Open Tibia Fractures,Severe Open Fractures of the Tibia (Shin) Bone,Procedure:Surgery with an external ring fixator; Procedure:Definitive fixation with a locked IM nail or plate,[],"September 1, 2015",18,64,Both,False
NCT01471340,Merck Sharp & Dohme Corp.,False,IN,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01345019,Amgen,False,IN,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01312909,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01312909,True,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],"February 3, 2016",12,19,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01163253,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00959296,MedtronicNeuro,False,IN,https://ClinicalTrials.gov/show/NCT00959296,True,Implantable Systems Performance Registry,Spinal Cord Stimulation; Deep Brain Stimulation; Drug Infusion (Implantable Pumps); Sacral Neuromodulation,Device:Various,[],"September 24, 2015",0,9223372036854775807,Both,False
NCT00867815,Bayer,False,IN,https://ClinicalTrials.gov/show/NCT00867815,True,PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION),Anterior Ischemic Optic Neuropathy,Drug:Diagnostic procedures,[],"January 25, 2016",40,9223372036854775807,Male,False
NCT00700882,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00551733,CTI BioPharma,True,IN,https://ClinicalTrials.gov/show/NCT00551733,True,"Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Drug:paclitaxel poliglumex,[],"December 15, 2010",18,9223372036854775807,Female,False
NCT00131313,East Valley Hematology and Oncology Medical Group,False,IN,https://ClinicalTrials.gov/show/NCT00131313,True,"Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.",Chronic Lymphocytic Leukemia,"Drug:Nipent, Cytoxan, Rituxan",[],"August 17, 2005",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02670434,"Kowa Research Institute, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02670434,True,Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia,Hyperlipidemia; Dyslipidemia,Drug:NK-104-CR; Drug:Placebo; Drug:Livalo,[],"February 2, 2016",18,80,Both,False
NCT02663908,Ferring Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT02663908,True,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,Prostate Cancer,Drug:Degarelix; Drug:Leuprolide,[],"January 22, 2016",0,9223372036854775807,Male,False
NCT02645409,Chandru Sundaram,False,IN,https://ClinicalTrials.gov/show/NCT02645409,True,Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma,Renal Cell Carcinoma,Drug:OTL38; Device:Intraoperative fluorescence imaging system,"[u'Indiana University Health Hospital', u'Indiana University Health Melvin and Bren Simon Cancer Center']","December 30, 2015",18,9223372036854775807,Both,False
NCT02632110,"DUSA Pharmaceuticals, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02632110,True,Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face,Actinic Keratosis,Drug:ALA; Drug:Topical Solution Vehicle; Device:IBL 10 mW; Procedure:Microneedle lesion preparation; Device:IBL 20 mW,"[u'UCSD Dermatology', u'Therapeutics Clinical Research', u'MOORE Clinical Research, Inc', u'Altman Dermatology Associates', u'Shideler Clinical Research Center', u'The Indiana Clinical Trials Center, PC', u'Minnesota Clinical Study Center', u'Virginia Clinical Research, Inc.']","December 14, 2015",18,9223372036854775807,Both,False
NCT02630615,Shadia Jalal,False,IN,https://ClinicalTrials.gov/show/NCT02630615,True,Circulating Tumor Cells (CTC) in Lung Cancer,Lung Neoplasms,Other:Blood draw,"[u'Indiana University Health Hospital', u'Indiana University Health Melvin and Bren Simon Cancer Center']","December 11, 2015",18,9223372036854775807,Both,True
NCT02619253,Roberto Pili,False,IN,https://ClinicalTrials.gov/show/NCT02619253,True,Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,Renal Cell Carcinoma; Urinary Bladder Neoplasms,Drug:Pembrolizumab; Drug:Vorinostat,"[u'Indiana University Hospital', u'Indiana University Melvin and Bren Simon Cancer Center']","November 30, 2015",18,9223372036854775807,Both,False
NCT02608450,Cassiopea SpA,False,IN,https://ClinicalTrials.gov/show/NCT02608450,True,"A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)",Acne Vulgaris,"Drug:CB-03-01 cream, 1%; Drug:Vehicle cream",[],"January 20, 2016",9,9223372036854775807,Both,False
NCT02592135,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT02592135,True,High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT),Heart Failure,Other:hsTnT level,"[u'Eskenazi Health', u'IU Health Methodist Hospital', u'Detroit Receiving Hospital', u'University of Cincinnati', u'Vanderbilt University']","January 27, 2016",21,9223372036854775807,Both,False
NCT02589860,Sherif S. Farag,False,IN,https://ClinicalTrials.gov/show/NCT02589860,True,Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant,Mucositis; Multiple Myeloma; Amyloidosis; Oral Mucositis,Other:Melphalan kinetic study; Genetic:Oral bacterial study; Genetic:Gene expression study,"[u'Indiana University Health Hospital', u'Indiana University Melvin and Bren Simon Cancer Center']","October 26, 2015",18,9223372036854775807,Both,False
NCT02589847,Rebiotix Inc.,False,IN,https://ClinicalTrials.gov/show/NCT02589847,True,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,Clostridium Difficile Infection,Biological:RBX2660,"[u'', u'', u'', u'', u'', u'', u'', u'', u'']","November 23, 2015",18,9223372036854775807,Both,False
NCT02589717,"Genentech, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02589717,True,An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy,Urothelial Carcinoma,Drug:Atezolizumab,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02576847,"Cutanea Life Sciences, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02576847,True,Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel,Rosacea,Drug:Omiganan,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","December 23, 2015",18,9223372036854775807,Both,True
NCT02553798,"Dermira, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02553798,True,Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis,Hyperhidrosis,Drug:DRM04 Topical Wipes,[],"January 21, 2016",9,9223372036854775807,Both,False
NCT02549534,Indiana University,True,IN,https://ClinicalTrials.gov/show/NCT02549534,True,Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer,Peripheral Neuropathy,Procedure:Axon Reflexes; Procedure:Axon Flares; Procedure:Self-Reported Signs & Symptoms of CIPN,"[u'Indiana University Melvin and Bren Simon Cancer Center (IUSCC)', u'Syndney & Lois Eskenazi Health Center']","September 15, 2015",18,85,Female,True
NCT02532855,Merck Sharp & Dohme Corp.,False,IN,https://ClinicalTrials.gov/show/NCT02532855,True,A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838),Type 2 Diabetes Mellitus,Drug:Sitagliptin; Drug:Dapagliflozin; Drug:Metformin; Drug:Matching placebo to sitagliptin; Drug:Matching placebo to dapagliflozin,[],"February 2, 2016",25,9223372036854775807,Both,False
NCT02528188,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02525094,MedImmune LLC,False,IN,https://ClinicalTrials.gov/show/NCT02525094,True,Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis,Atopic Dermatitis,Biological:MEDI9929; Biological:Placebo,"[u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site']","October 5, 2015",18,75,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02521493,Children's Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02521493,True,Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,Childhood Acute Myeloid Leukemia; Childhood Myelodysplastic Syndrome; Cytopenia; Down Syndrome; Myeloid Leukemia Associated With Down Syndrome; Myeloproliferative Neoplasm,Drug:Asparaginase; Drug:Asparaginase Erwinia chrysanthemi; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mitoxantrone Hydrochloride; Drug:Thioguanine,[],"January 26, 2016",91,3,Both,False
NCT02519907,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT02519907,True,Surface Electrical Stimulation for Treatment of Phantom Limb Pain,Phantom Limb Pain,Device:Surface Electrical Stimulation,"[u'Indiana University', u'IU Health Neuroscience Center']","October 22, 2015",18,70,Both,False
NCT02502669,"Elorac, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02502669,True,Finasteride Treatment of Severe Nodulocystic Acne,NODULOCYSTIC ACNE,Drug:Finasteride 23.5 mg tablets; Drug:Finasteride 33.5 mg tablets; Drug:Placebo tablets,[],"February 3, 2016",18,35,Male,True
NCT02497469,Takeda,False,IN,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,IN,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02492763,Merck Sharp & Dohme Corp.,False,IN,https://ClinicalTrials.gov/show/NCT02492763,True,A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004),Type II Diabetes Mellitus,Drug:MK-8521; Drug:Placebo; Drug:Liraglutide; Drug:Metformin,[],"February 2, 2016",21,65,Both,False
NCT02492360,Costantine Albany,False,IN,https://ClinicalTrials.gov/show/NCT02492360,True,Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy,Peripheral Nervous System Diseases; Testicular Neoplasms,Procedure:Blood sample collection; Behavioral:Report of peripheral neuropathy after cisplatin therapy,"[u'Indiana University Hospital', u'Indiana University Melvin and Bren Simon Cancer Center']","January 27, 2016",18,9223372036854775807,Male,False
NCT02490345,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT02490345,True,Gabapentin as Adjunctive Treatment for Postoperative Pain Control,Drug Usage,Drug:gabapentin; Drug:Placebo,"[u'Eskenazi Health', u'Eskenazi Hospital']","August 20, 2015",18,9223372036854775807,Female,True
NCT02489318,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02489318,True,A Study of JNJ-56021927 (ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,Prostate Cancer,Drug:JNJ-56021927; Drug:Placebo; Drug:Androgen Deprivation Therapy (ADT),[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02485353,Hamid Sayar,False,IN,https://ClinicalTrials.gov/show/NCT02485353,True,Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML,"Leukemia, Myeloid, Acute",Drug:Vosaroxin and Cytarabine,"[u'Indiana University Health Hospital', u'Indiana University Health Melvin and Bren Simon Cancer Center']","January 27, 2016",60,9223372036854775807,Both,False
NCT02483247,"Boston Biomedical, Inc",False,IN,https://ClinicalTrials.gov/show/NCT02483247,True,A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,Cancer,Drug:BBI503; Drug:Capecitabine; Drug:Doxorubicin; Drug:Nivolumab; Drug:Pembrolizumab; Drug:Paclitaxel; Drug:Sunitinib,"[u'University of California: Los Angeles', u'University of Chicago', u'Indiana University Health Goshen', u'Indiana University -Ball', u'Louisiana State Univesity', u'Massachusetts General Hospital', u'Princess Margaret Cancer Centre']","December 14, 2015",18,9223372036854775807,Both,False
NCT02477800,Biogen,False,IN,https://ClinicalTrials.gov/show/NCT02477800,True,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02477332,Novartis Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT02477332,True,Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU,Chronic Spontaneous Urticaria,Biological:QGE031; Biological:Omalizumab; Other:Placebo,[],"January 5, 2016",18,75,Both,False
NCT02470585,AbbVie,False,IN,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02457819,Sunovion,False,IN,https://ClinicalTrials.gov/show/NCT02457819,True,Dasotraline Pediatric Extension Study,Attention Deficit Hyperactivity Disorder,Drug:Dasotraline,[],"December 16, 2015",6,12,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02436239,Forest Laboratories,False,IN,https://ClinicalTrials.gov/show/NCT02436239,True,A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Vilazodone,[],"December 23, 2015",7,17,Both,False
NCT02428088,Sunovion,False,IN,https://ClinicalTrials.gov/show/NCT02428088,True,Dasotraline Pediatric ADHD Study,Attention Deficit Hyperactivity Disorder,Drug:Dasotraline; Drug:Dasotraline; Drug:Placebo Comparator,[],"January 7, 2016",6,12,Both,False
NCT02425644,Actelion,False,IN,https://ClinicalTrials.gov/show/NCT02425644,True,Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis,Relapsing Multiple Sclerosis,Drug:ponesimod; Drug:teriflunomide,[],"August 26, 2015",18,55,Both,False
NCT02422940,Acorda Therapeutics,False,IN,https://ClinicalTrials.gov/show/NCT02422940,True,"An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study",Post-ischemic Stroke,Drug:dalfampridine-ER 7.5 mg; Drug:dalfampridine-ER 10 mg,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02408315,Indiana University,True,IN,https://ClinicalTrials.gov/show/NCT02408315,True,Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE),Pregnancy,Drug:misoprostol/placebo,"[u'IU Health Methodist Hospital', u'Sidney and Lois Eskenazi Hospital']","September 24, 2015",14,45,Female,False
NCT02407054,Eli Lilly and Company,False,IN,https://ClinicalTrials.gov/show/NCT02407054,True,A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,Prostate Cancer Metastatic,Drug:LY3023414; Drug:Enzalutamide; Drug:Placebo,"[u'Urology Centers of Alabama, P.C.', u'Pinnacle Oncology Hematology', u'Highlands Oncology Group', u'Florida Cancer Specialists', u'Florida Cancer Specialists North', u'Florida Cancer Specialists East', u'Ingalls Memorial Hospital', u'Fort Wayne Oncology and Hematology', u'Indiana Cancer Pavilion', u'Tulane University School of Medicine', u'Dana Farber Cancer Institute', u'Hudson Valley Urology', u'Oncology Hematology Care Inc.', u'Carolina Urologic Research Center', u'SMO Sarah Cannon Research Inst.', u'Tennessee Oncology PLLC', u'Urology Associates', u'Southwestern Medical Center - Dallas', u'University of Virginia Health System', u'Swedish Medical Center']","December 22, 2015",18,9223372036854775807,Male,False
NCT02392624,"Genentech, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02392624,True,A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU),Chronic Idiopathic Urticaria,Drug:Omalizumab,[],"September 1, 2015",12,75,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02372799,Forest Laboratories,False,IN,https://ClinicalTrials.gov/show/NCT02372799,True,Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22),Major Depressive Disorder,Drug:Vilazodone; Drug:Placebo; Drug:Fluoxetine,[],"December 17, 2015",7,17,Both,False
NCT02365636,"Teva Branded Pharmaceutical Products, R&D Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02365636,True,A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN),Postherpetic Neuralgia,Drug:TV-45070; Drug:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02364999,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT02364999,True,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02348723,Boehringer Ingelheim,False,IN,https://ClinicalTrials.gov/show/NCT02348723,True,Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT),Atrial Fibrillation,Drug:Warfarin; Drug:Dabigatran Etexilate 150mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02336451,Novartis Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT02336451,True,A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges.,Drug:LDK378,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02326454,Light Sciences Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02326454,True,A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug:talaporfin sodium; Drug:Saline; Device:Drug Activator 100 J/cm; Device:Drug Activator 200 J/cm,[],"February 1, 2016",40,9223372036854775807,Male,False
NCT02320149,Warner Chilcott,False,IN,https://ClinicalTrials.gov/show/NCT02320149,True,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Drug:Sarecycline; Drug:Placebo,[],"December 23, 2015",9,45,Both,False
NCT02309372,Indiana University,False,IN,https://ClinicalTrials.gov/show/NCT02309372,True,Depression Therapy to Improve Cardiovascular Risk in HIV,Depression; HIV,Behavioral:Beating the Blues,"[u'Indiana University Health University Hospital, Indiana Clinical Research Center', u'Infectious Diseases Research Center']","November 2, 2015",18,9223372036854775807,Both,False
NCT02308111,Intercept Pharmaceuticals,True,IN,https://ClinicalTrials.gov/show/NCT02308111,True,Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis,"Liver Cirrhosis, Biliary",Drug:Obeticholic Acid (OCA); Drug:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02299505,Novartis Pharmaceuticals,False,IN,https://ClinicalTrials.gov/show/NCT02299505,True,Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer.,Drug:ceritinib,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02295865,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02295865,True,A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis,Psoriasis,Drug:JNJ-38518168 60 mg; Drug:JNJ-38518168 30 mg; Drug:JNJ-38518168 3 mg; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 19, 2016",18,9223372036854775807,Both,False
NCT02276209,Sunovion,False,IN,https://ClinicalTrials.gov/show/NCT02276209,True,Dasotraline Adult ADHD Study,Adult Attention Hyperactivity Disorder,Drug:Dasotraline; Drug:Dasotraline; Other:Placebo,[],"January 12, 2016",18,55,Both,False
NCT02274857,"Topera, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02274857,True,Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures,Persistent Atrial Fibrillation,Procedure:Standard PVI Ablation; Procedure:FIRM-Guided Procedure and PVI,"[u'Arizona Heart Rhythm Center', u'Hoag Memorial Hospital Presbyterian', u'Indiana University - Krannert Institute of Cardiology', u'St. Vincent Hospital', u'Weill Medical College at Cornell University', u'The Ohio State University', u'Herz- und Diabeteszentrum Bad Oeynhausen', u'Unfallkrankenhaus Berlin', u'Klinikum Coburg GmbH', u'Zentrum f\xfcr klinische Pr\xfcfungen in der Facharztzentrum Dresden-Neustadt GbR', u'St\xe4dtisches Klinikum Karlsruhe gGmbH', u'Leipzig Heart Institute GmbH', u'Kardiologische Gemeinschaftspraxis am Park Sanssouci']","November 2, 2015",18,80,Both,False
NCT02249949,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02249949,True,"Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma",Liposarcoma,Drug:efatutazone; Drug:placebo,[],"June 12, 2015",18,9223372036854775807,Both,False
NCT02240680,Boehringer Ingelheim,False,IN,https://ClinicalTrials.gov/show/NCT02240680,True,Linagliptin as Add on to Basal Insulin in the Elderly,"Diabetes Mellitus, Type 2",Drug:placebo; Drug:linagliptin,[],"January 26, 2016",60,9223372036854775807,Both,False
NCT02240121,"Valeant Pharmaceuticals International, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT02240121,True,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,IN,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02224755,Thoratec Corporation,False,IN,https://ClinicalTrials.gov/show/NCT02224755,True,MOMENTUM 3 IDE Clinical Study Protocol,Advanced Refractory Left Ventricular Heart Failure,Device:HeartMate 3 LVAS; Device:HeartMate II LVAS,[],"December 11, 2015",18,100,Both,False
NCT02207244,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02207244,True,A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment,Psoriasis,Drug:Guselkumab 100 mg; Drug:Placebo for guselkumab; Drug:Adalimumab; Drug:Placebo for adalimumab,[],"January 26, 2016",18,99,Both,False
NCT02206334,NRG Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02206334,True,"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",Male Breast Carcinoma; Prostate Adenocarcinoma; Recurrent Breast Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Prostate Carcinoma; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Prostate Cancer,Radiation:Stereotactic Radiosurgery,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,IA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,IA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01950390,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02154490,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,IA,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02003209,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02032823,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01415752,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01242800,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01835145,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT00828009,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00828009,True,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00897442,Gynecologic Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT00807768,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02601209,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,IA,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01372787,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT00888615,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01975389,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02528253,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01809691,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01216683,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,IA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00700882,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00316888,Eastern Cooperative Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,IA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01872975,NSABP Foundation Inc,False,IA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01672892,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01041703,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,IA,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,IA,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02451137,Sanofi,False,IA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02425046,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02425046,True,Family Obesity Intervention: Motivational Interviewing and Community Support,Obesity,Behavioral:health coaching; Behavioral:community screening,"[u'Primary Health Care, Inc', u'DMARC food pantries', u'University of Iowa']","April 20, 2015",6,9223372036854775807,Both,True
NCT02180867,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02037529,Academic and Community Cancer Research United,False,IA,https://ClinicalTrials.gov/show/NCT02037529,True,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Drug:Eribulin; Drug:Paclitaxel,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,IA,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01220583,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01220583,True,Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery,Head and Neck Cancer,Drug:cisplatin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01092182,National Cancer Institute (NCI),True,IA,https://ClinicalTrials.gov/show/NCT01092182,True,Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma,"Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive; Plasmablastic Lymphoma",Drug:EPOCH-R; Drug:EPOCH-RR,"[u'Mercy Medical Center-Sioux City', u""Saint Luke's Regional Medical Center"", u'Siouxland Hematology Oncology Associates LLP', u'Providence Medical Center', u'Menorah Medical Center', u""Saint Luke's South Hospital"", u'Kansas City CCOP', u'Shawnee Mission Medical Center-KCCC', u'National Institutes of Health Clinical Center, 9000 Rockville Pike', u'Massachusetts General Hospital', u'Dana Farber Cancer Institute', u'Beth Israel Deaconess Medical Center', u'Heartland Hematology and Oncology Associates Incorporated', u'Liberty Radiation Oncology Clinic', u'North Kansas City Hospital', u'Research Medical Center', u""Saint Luke's Hospital of Kansas City"", u""Saint Luke's East - Lee's Summit"", u'Heartland Regional Medical Center', u'Saint Joseph Oncology Inc', u'Washington University School of Medicine', u'Cleveland Clinic Beachwood', u'Cleveland Clinic', u'Cleveland Clinic Transplantation Clinic', u'Fairview Hospital', u'Cleveland Clinic Independence', u'Hillcrest Hospital', u'Parma Community General Hospital', u'North Coast Cancer Care', u'Cleveland Clinic Strongsville', u'Cleveland Clinic Wooster', u'MD Anderson Cancer Center']","May 5, 2015",18,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00666731,University of Nebraska,False,IA,https://ClinicalTrials.gov/show/NCT00666731,True,A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,Breast Cancer; Precancerous Condition,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:Excess human biological tissue; Procedure:quality-of-life assessment,[],"November 30, 2015",19,120,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00074282,Eastern Cooperative Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02528188,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02470585,AbbVie,False,IA,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02367794,Hoffmann-La Roche,False,IA,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02367781,Hoffmann-La Roche,False,IA,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02320721,Sanofi,False,IA,https://ClinicalTrials.gov/show/NCT02320721,True,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Drug:Insulin glargine U300 HOE901; Drug:Insulin glargine HOE901,[],"February 3, 2016",65,9223372036854775807,Both,False
NCT02285062,Celgene Corporation,False,IA,https://ClinicalTrials.gov/show/NCT02285062,True,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,"Lymphoma, Large B-Cell, Diffuse",Drug:lenalidomide; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:prednisone; Drug:vincristine,[],"December 23, 2015",18,80,Both,False
NCT02190604,Novartis Pharmaceuticals,False,IA,https://ClinicalTrials.gov/show/NCT02190604,True,"Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients",Cystic Fibrosis,Drug:Placebo; Drug:QBW251,[],"March 10, 2015",18,55,Both,True
NCT02185599,DySIS Medical Inc.,False,IA,https://ClinicalTrials.gov/show/NCT02185599,True,IMproved PRactice Outcomes and Value Excellence in Colposcopy,High Grade Cervical Intraepithelial Neoplasia,Device:DySIS,[],"November 23, 2015",21,9223372036854775807,Female,False
NCT02164513,GlaxoSmithKline,False,IA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02145468,GlaxoSmithKline,False,IA,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02055781,CTI BioPharma,False,IA,https://ClinicalTrials.gov/show/NCT02055781,True,Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia,Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis,Drug:Pacritinib; Drug:Best Available Therapy,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,IA,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01968967,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01966419,Ocera Therapeutics,False,IA,https://ClinicalTrials.gov/show/NCT01966419,True,Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE),Acute Episode of Overt Hepatic Encephalopathy; Hepatic Encephalopathy,Drug:ornithine phenylacetate; Drug:placebo intravenous infusion,[],"January 14, 2016",18,75,Both,False
NCT01921751,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01921751,True,High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01909791,Diabetic Retinopathy Clinical Research Network,False,IA,https://ClinicalTrials.gov/show/NCT01909791,True,Treatment for CI-DME in Eyes With Very Good VA Study,Diabetic Macular Edema,Procedure:Prompt Laser; Drug:Prompt aflibercept; Procedure:Deferred laser; Drug:Deferred aflibercept,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,IA,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,IA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01776424,Bayer,False,IA,https://ClinicalTrials.gov/show/NCT01776424,True,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,Prevention & Control,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Aspirin; Drug:Aspirin placebo; Drug:Rivaroxaban placebo; Drug:Pantoprazole",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,IA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,IA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01693120,Medtronic Atrial Fibrillation Solutions,False,IA,https://ClinicalTrials.gov/show/NCT01693120,True,Evaluation of the Phased Radio Frequency Ablation System,Persistent Atrial Fibrillation,Device:Medtronic Phased RF Ablation System,[],"December 3, 2015",18,75,Both,False
NCT01614652,"CardioKinetix, Inc",False,IA,https://ClinicalTrials.gov/show/NCT01614652,True,A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System,Congestive Heart Failure; Left Ventricular (LV) Systolic Dysfunction,Device:CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT),[],"December 7, 2015",18,79,Both,False
NCT01503632,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01406756,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01345019,Amgen,False,IA,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01307579,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01227967,National Institute of Allergy and Infectious Diseases (NIAID),True,IA,https://ClinicalTrials.gov/show/NCT01227967,True,"Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications",Influenza,"Drug:Amantadine, Ribavirin, Oseltamivir; Drug:Oseltamivir",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01096368,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT00980954,Radiation Therapy Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00959296,MedtronicNeuro,False,IA,https://ClinicalTrials.gov/show/NCT00959296,True,Implantable Systems Performance Registry,Spinal Cord Stimulation; Deep Brain Stimulation; Drug Infusion (Implantable Pumps); Sacral Neuromodulation,Device:Various,[],"September 24, 2015",0,9223372036854775807,Both,False
NCT00772200,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00736749,Children's Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT00244686,GlaxoSmithKline,False,IA,https://ClinicalTrials.gov/show/NCT00244686,True,Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES),Hypereosinophilic Syndrome,Drug:mepolizumab,[],"January 28, 2016",12,9223372036854775807,Both,False
NCT02668809,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02668809,True,Oral Hygiene Intervention Pilot Study,Dental Caries; Gingivitis,Other:oral health assessment; Other:Questionnaires; Other:Clinical Exam; Other:Microbiological sampling; Other:Monitoring Adherence; Other:Varnish application; Other:Consent; Other:Educational Program,[u'UIowa'],"January 26, 2016",21,120,Both,True
NCT02668289,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02668289,True,Periodontal Phenotype Study,Tooth Extraction Status Nos,Other:consent; Other:Screening; Other:Xray; Other:PVS Impressions; Other:Photographs; Other:CBCT; Other:Anesthesia; Procedure:Extraction; Other:Clinical measurements,[u'UIowa'],"January 26, 2016",18,75,Both,True
NCT02663908,Ferring Pharmaceuticals,False,IA,https://ClinicalTrials.gov/show/NCT02663908,True,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,Prostate Cancer,Drug:Degarelix; Drug:Leuprolide,[],"January 22, 2016",0,9223372036854775807,Male,False
NCT02655354,University of Washington,False,IA,https://ClinicalTrials.gov/show/NCT02655354,True,A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity,Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life; Pain; Wounds and Injury; Brain Injuries; Chronic Disease,Behavioral:Motivational Interviewing; Behavioral:Cognitive Behavioral Therapy Elements; Behavioral:Care Management; Drug:Fluoxetine; Drug:Fluvoxamine; Drug:Paroxetine; Drug:Setraline; Drug:Citalopram; Drug:Venlafaxine; Drug:Duloxetine; Drug:Mirtazapine; Drug:Diphenhydramine; Drug:Trazodone; Drug:Prazosin,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02632552,VA Office of Research and Development,False,IA,https://ClinicalTrials.gov/show/NCT02632552,True,A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD,CHF; COPD,Behavioral:Technology-assisted care transition intervention; Behavioral:Active attention control,"[u'VA Palo Alto Health Care System, Palo Alto, CA', u'Iowa City VA Health Care System, Iowa City, IA', u'Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA', u'VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA']","December 11, 2015",18,9223372036854775807,Both,False
NCT02628405,Academic and Community Cancer Research United,False,IA,https://ClinicalTrials.gov/show/NCT02628405,True,R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Transformed Recurrent Non-Hodgkin Lymphoma,Drug:Carboplatin; Drug:Etoposide; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,"[u'Illinois CancerCare-Peoria', u'University of Iowa/Holden Comprehensive Cancer Center', u'Academic and Community Cancer Research United', u'Mayo Clinic', u'Coborn Cancer Center at Saint Cloud Hospital', u'Metro Minnesota Community Oncology Research Consortium', u'University of Nebraska Medical Center', u'Dartmouth Hitchcock Medical Center', u'State University of New York Upstate Medical University', u'Geisinger Medical Center', u'Rapid City Regional Hospital', u'Marshfield Clinic']","December 30, 2015",18,9223372036854775807,Both,False
NCT02624219,National Institute of Allergy and Infectious Diseases (NIAID),False,IA,https://ClinicalTrials.gov/show/NCT02624219,True,H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults,Avian Influenza; Influenza,Drug:AS03; Drug:MF59; Biological:Monovalent Influenza A/H5N8 vaccine,"[u'University of Iowa - Vaccine Research and Education Unit', u'Saint Louis University - Center for Vaccine Development', u""Cincinnati Children's Hospital Medical Center - Infectious Diseases"", u'Baylor College of Medicine - Molecular Virology and Microbiology']","December 3, 2015",19,64,Both,True
NCT02623426,JHSPH Center for Clinical Trials,True,IA,https://ClinicalTrials.gov/show/NCT02623426,True,Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial,Uveitis; Macular Edema,Drug:Dexamethasone intravitreal implant 0.7 mg; Drug:Intravitreal Methotrexate 400 g; Drug:Intravitreal Ranibizumab 0.5 mg,[],"December 4, 2015",18,9223372036854775807,Both,False
NCT02622295,University of Iowa,True,IA,https://ClinicalTrials.gov/show/NCT02622295,True,Musculoskeletal Plasticity After Spinal Cord Injury,Spinal Cord Injuries,Behavioral:Single-session high-frequency active-resisted stance; Behavioral:Single-session low-frequency active-resisted stance; Behavioral:High-frequency active-resisted stance training; Behavioral:Low-frequency active-resisted stance training,[u'University of Iowa'],"December 3, 2015",21,60,Both,False
NCT02614183,Eli Lilly and Company,False,IA,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02603562,"aTyr Pharma, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02603562,True,Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy,Facioscapulohumeral Muscular Dystrophy (FSHD),Biological:ATYR1940; Biological:Placebo,"[u'Stanford University', u""University of Iowa Children's Hospital"", u'University of Utah', u'Institut de Myologie', u'Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta']","January 6, 2016",12,25,Both,False
NCT02602561,Metabolic Technologies Inc.,False,IA,https://ClinicalTrials.gov/show/NCT02602561,True,Effects of HMB Supplementation on Recovery Following ACL Surgery,ACL Injury,Dietary Supplement:HMB; Dietary Supplement:Placebo,[u'Iowa State University'],"November 10, 2015",18,49,Both,True
NCT02597933,Boehringer Ingelheim,False,IA,https://ClinicalTrials.gov/show/NCT02597933,True,A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis,"Scleroderma, Systemic",Drug:Nintedanib; Drug:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02593773,"Horizon Pharma Ireland, Ltd., Dublin Ireland",False,IA,https://ClinicalTrials.gov/show/NCT02593773,True,"Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study",Friedreich's Ataxia,Drug:Interferon -1b,"[u'University of California, Los Angeles Neurology Clinic', u'University of Florida - Clinical Research Center', u""University of Iowa Children's Hospital"", u""Children's Hospital of Philadelphia""]","October 29, 2015",10,26,Both,False
NCT02593305,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02593305,True,Dietary Nitrate and Physiological Aging,Aging,Dietary Supplement:Super Beets; Dietary Supplement:Super Beets Placebo,[u'University of Iowa'],"October 29, 2015",60,85,Both,True
NCT02589717,"Genentech, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02589717,True,An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy,Urothelial Carcinoma,Drug:Atezolizumab,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02585713,Academic and Community Cancer Research United,False,IA,https://ClinicalTrials.gov/show/NCT02585713,True,Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism,Deep Vein Thrombosis; Malignant Neoplasm; Portal Vein Thrombosis; Pulmonary Embolism; Renal Vein Thrombosis; Venous Thromboembolism,Drug:Apixaban; Drug:Dalteparin; Other:Questionnaire Administration,"[u'Illinois Cancer Care, PC', u'Siouxland Hematology - Oncology Associates, LLP', u'Mayo Clinic', u'Academic and Community Cancer Research United', u'Metro Minnesota Community Oncology Research Consortium', u'Coborn Cancer Center / CentraCare Clinic', u'NH Oncology - Hematology, PA', u'Columbus NCORP', u'Guthrie Medical Group, P.C/Robert Packer Hospital', u'Rapid City Regional Hospital']","January 29, 2016",18,9223372036854775807,Both,False
NCT02584855,Eli Lilly and Company,False,IA,https://ClinicalTrials.gov/show/NCT02584855,True,A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02584660,"Janssen Scientific Affairs, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02584660,True,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,Pulmonary Embolism,Drug:Rivaroxaban; Drug:Standard-of-care,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02579187,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02579187,True,"Socket Study, Pilot Clinical Trial",Tooth Extraction Status Nos,Procedure:tooth extraction; Radiation:CBCT scan; Drug:Anesthesia; Other:clinical measurements; Drug:Biodegradable sponge (type I bovine collagen); Drug:miR-200C plasmids in a biodegradable sponge; Procedure:cross mattress suture,[u'UIowa'],"January 22, 2016",18,75,Both,True
NCT02577484,Acist Medical Systems,True,IA,https://ClinicalTrials.gov/show/NCT02577484,True,Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement,Coronary Artery Disease,Device:RXi System; Device:Pressure Wire,"[u'Scripps Green Hospital', u'Long Beach VA Medical Center', u'Stanford School of Medicine', u'University of Chicago Medicine', u'Iowa Heart Center', u'Metropolitan Cardiology Heart and Vascular Institute', u'University of Minnesota', u'Saint Louis University', u'Columbia University Medical Center / New York Presbyterian Hospital', u'Lindner Research Center at The Christ Hospital', u'Cleveland Cllinic Foundation']","January 26, 2016",18,9223372036854775807,Both,False
NCT02572817,National Institute of Allergy and Infectious Diseases (NIAID),False,IA,https://ClinicalTrials.gov/show/NCT02572817,True,Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A,Influenza A Virus Infection,Biological:High-titer anti-influenza plasma; Biological:Low-titer (control) anti-influenza plasma,"[u""Arkansas Children's Hospital"", u'University of Iowa Hospitals & Clinics', u'Johns Hopkins University', u'NIH Clinical Center', u'Massachusetts General Hospital', u'University of Massachusetts Medical School', u'University of Michigan']","February 3, 2016",0,9223372036854775807,Both,False
NCT02561078,Eli Lilly and Company,False,IA,https://ClinicalTrials.gov/show/NCT02561078,True,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug:Human regular U-500 insulin (CSII); Drug:Human regular U-500 insulin (MDI),[],"January 7, 2016",18,85,Both,False
NCT02557828,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02557828,True,Target Sign vs Palpation for Radial Arterial Line Placement,Evaluating the Success Rates of Palpation Versus a New Ultrasound Technique for Radial Artery Cannulation,Procedure:arterial line placement,[u'University of Iowa'],"September 22, 2015",18,9223372036854775807,Both,True
NCT02555878,"Janssen Research & Development, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02555878,True,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,Cancer,Drug:Rivaroxaban; Drug:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02548455,St. Jude Medical,False,IA,https://ClinicalTrials.gov/show/NCT02548455,True,St Jude Medical LV Lead - Quartet 1457Q IDE,Heart Failure,Device:Left Ventricular Lead,"[u'Iowa Heart Center', u'Thoracic Cardiovascular Healthcare Foundation']","October 30, 2015",18,9223372036854775807,Both,False
NCT02547922,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT02547922,True,Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis,Lupus Nephritis,Biological:Anifrolumab; Drug:Placebo,[],"December 17, 2015",18,70,Both,False
NCT02545049,Bayer,False,IA,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02542631,"Calibra Medical, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02542631,True,Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents,"Diabetes Mellitus, Type 2 (T2DM)",Device:Bolus Insulin Patch (Calibra Finesse); Device:Insulin Pen (Novo-Nordisk FlexPen),[],"October 19, 2015",22,75,Both,False
NCT02540993,Bayer,False,IA,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02535533,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02535533,True,SLM + Axitinib for Clear Cell RCC,Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC),Drug:Selenomethionine (SLM); Drug:Axitinib; Drug:Selenomethionine (SLM); Drug:Axitinib,[u'University of Iowa Hospitals and Clinics'],"January 25, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02523911,"Mercy Medical Center, Des Moines, Iowa",True,IA,https://ClinicalTrials.gov/show/NCT02523911,True,Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening,Colorectal Cancer,Drug:Simethicone; Drug:Placebo; Drug:sodium sulfate/potassium sulfate/magnesium sulfate solution,"[u'UF Health Jacksonville', u'Iowa Endoscopy Center']","September 9, 2015",18,9223372036854775807,Both,True
NCT02514473,Vertex Pharmaceuticals Incorporated,False,IA,https://ClinicalTrials.gov/show/NCT02514473,True,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug:VX-809; Drug:Placebo; Drug:VX-770,[],"September 1, 2015",6,11,Both,False
NCT02508389,"Galera Therapeutics, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02508389,True,A Study of GC4419 Protection Against Radiation Induced Oral Mucositis in Patients With Head & Neck Cancer,Radiation Induced Oral Mucositis,Drug:Low Dose GC4419: 30mg/day; Drug:High Dose GC4419: 90mg/day; Drug:Placebo,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02508376,National Institute of Allergy and Infectious Diseases (NIAID),False,IA,https://ClinicalTrials.gov/show/NCT02508376,True,"Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects",Tuberculosis,Other:AP10-602; Biological:ID93; Biological:GLA-SE,[u'University of Iowa - Vaccine Research and Education Unit'],"October 22, 2015",18,49,Both,True
NCT02508194,MedImmune LLC,False,IA,https://ClinicalTrials.gov/show/NCT02508194,True,A Study to Evaluate the Efficacy of MEDI7510 in Older Adults,Respiratory Syncytial Virus (RSV),Biological:MEDI7510; Biological:IIV; Other:Placebo,[],"January 22, 2016",60,99,Both,True
NCT02500381,Sarepta Therapeutics,False,IA,https://ClinicalTrials.gov/show/NCT02500381,True,Study of SRP-4045 and SRP-4053 in DMD Patients,Duchenne Muscular Dystrophy; DMD; Muscular Dystrophy,Drug:SRP-4045; Drug:SRP-4053; Drug:Placebo,[],"January 12, 2016",7,16,Male,False
NCT02497469,Takeda,False,IA,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02497287,"Janssen Research & Development, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02497287,True,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Duloxetine; Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02496767,Cytokinetics,False,IA,https://ClinicalTrials.gov/show/NCT02496767,True,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,Amyotrophic Lateral Sclerosis,Drug:tirasemtiv; Drug:Placebo tablets,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02495402,RTI International,False,IA,https://ClinicalTrials.gov/show/NCT02495402,True,Substance Abuse Treatment to HIV Care (SAT2HIV),Substance Use,Behavioral:Motivational Interviewing,"[u'Champaign-Urbana Public Health District (Collaborating Organization)', u'The Project of the Quad Cities (Collaborating Organization)', u'Health Emergency Lifeline Programs (Collaborating Organization)', u'Community Health Awareness Group (Collaborating Organization)', u'Community AIDS Resources and Education Services (Collaborating Organization)', u'Minnesota AIDS Project (Collaborating Organization)', u'Burrell Behavioral Health (Collaborating Organization)', u'Doorways (Collaborating Organization)', u'Places for People (Collaborating Organization)', u'St. Louis Effort for AIDS (Collaborating Organization)', u'Nebraska AIDS Project (Collaborating Organization )', u'Caracole House (Collaborating Organization)', u'ARC Ohio (Collaborating Organization)']","January 29, 2016",18,99,Both,True
NCT02493868,"Janssen Research & Development, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02493868,True,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 2, 2016",18,64,Both,False
NCT02487498,Novartis Pharmaceuticals,False,IA,https://ClinicalTrials.gov/show/NCT02487498,True,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol ); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02485808,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),True,IA,https://ClinicalTrials.gov/show/NCT02485808,True,Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Prospective Observational Cohort Study Protocol,Lower Urinary Tract Symptoms,Other:None-observational,"[u'Northwestern University', u'University of Iowa', u'University of Michigan', u'Washington University', u'Duke University', u'University of Washington']","June 29, 2015",18,9223372036854775807,Both,False
NCT02483520,University of Iowa,True,IA,https://ClinicalTrials.gov/show/NCT02483520,True,Supporting Family Caregivers With Technology for Dementia Home Care,Dementia,Behavioral:FamTechCare,[u'University of Iowa College of Nursing'],"June 24, 2015",18,9223372036854775807,Both,False
NCT02481817,Vanderbilt University,False,IA,https://ClinicalTrials.gov/show/NCT02481817,True,Treatment Alternatives in iSGS (NoAAC PR-02 Study),Idiopathic Subglottic Stenosis (iSGS),Procedure:Endoscopic dilation of subglottic stenosis; Procedure:Endoscopic resection of the stenosis; Procedure:Tracheal Resection,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02481674,Vaccinex Inc.,True,IA,https://ClinicalTrials.gov/show/NCT02481674,True,VX15/2503 Treatment for Huntington's Disease,Huntington's Disease,Drug:VX15/2503; Drug:Placebo,"[u'University of Alabama at Birmingham', u'University of California, San Diego', u'University of Colorado - Denver', u'Georgetown University', u'Emory University School of Medicine', u'University of Iowa', u'University of Louisville', u'Massachusetts General Hospital', u'University of Michigan', u'Washington University', u'Columbia University', u'University of Rochester', u'Duke University Health Center', u'Wake Forest University', u'University of Cincinnati', u'Ohio State University', u'University of Toledo', u'Vanderbilt University', u'University of Vermont']","January 26, 2016",21,9223372036854775807,Both,False
NCT02480153,Pfizer,False,IA,https://ClinicalTrials.gov/show/NCT02480153,True,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02477891,"Janssen Research & Development, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02477891,True,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02475850,Brigham and Women's Hospital,False,IA,https://ClinicalTrials.gov/show/NCT02475850,True,Strategies to Reduce Injuries and Develop Confidence in Elders,Accidental Falls; Wounds and Injuries,Other:Evidence-based tailored fall prevention; Other:Usual care,"[u'Healthcare Partners', u'University of Iowa Health Alliance', u'Johns Hopkins Medicine', u'Partners Healthcare', u'Reliant Medical Group', u'University of Michigan', u'Essentia Health', u'Mt Sinai Health System', u'University of Pittsburgh', u'University of Texas Medical Branch at Galveston']","November 16, 2015",75,9223372036854775807,Both,False
NCT02467270,Ariad Pharmaceuticals,False,IA,https://ClinicalTrials.gov/show/NCT02467270,True,Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses,"Myeloid Leukemia, Chronic, Chronic Phase",Drug:ponatinib 45 mg; Drug:ponatinib 30 mg; Drug:ponatinib 15 mg,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02465515,GlaxoSmithKline,False,IA,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02456740,Amgen,False,IA,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02456298,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02456298,True,Comparing Behavioral Assessments Using Telehealth for Children With Autism,Autism Spectrum Disorder,Behavioral:Standard FA+FCT; Behavioral:Pragmatic FA+FCT,[u'University of Iowa'],"November 30, 2015",18,83,Both,False
NCT02453191,"Milhem, Mohammed M",False,IA,https://ClinicalTrials.gov/show/NCT02453191,True,TVEC and Preop Radiation for Sarcoma,Soft Tissue Sarcoma,Drug:talimogene laherparepvec; Radiation:Radiotherapy,[u'University of Iowa Hospitals and Clinics'],"August 11, 2015",18,9223372036854775807,Both,False
NCT02453178,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02453178,True,Effects of a Bicycling Intervention on Cognitive Skills and Cardiovascular Health,Sedentary Lifestyle,Behavioral:Cycling,[u'HBC Lab'],"August 6, 2015",60,80,Both,True
NCT02450383,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02450383,True,Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness,Tooth Loss; Peri-implant Mucosa Defect,Procedure:Surgical endosseous dental implant placement with simultaneous buccal autologous subepithelial connective tissue graft; Procedure:Surgical endosseous dental implant placement with simultaneous buccal soft tissue allograft (Alloderm); Device:Alloderm; Device:autologous subepithelial connective tissue graft,[u'University of Iowa College of Dentistry - Craniofacial Clinical Research Center and Department of Periodontics'],"December 2, 2015",18,80,Both,True
NCT02450331,Hoffmann-La Roche,False,IA,https://ClinicalTrials.gov/show/NCT02450331,True,"A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]","Bladder Cancer, Cancer","Drug:Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02445040,"Draeger Medical Systems, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02445040,True,Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates,Respiratory Distress Syndrome In Premature Infants,Device:Babylog VN500 in HFOV Mode,"[u""Arkansas Children's Hospital"", u'University of Arkansas for Medical Sciences', u'Sharp Mary Birch Hospital for Women and Newborns', u'University of Iowa Hospitals and Clinics', u""Children's Hospitals and Clinics of Minnesota"", u""St. Paul Children's Hospital"", u'New Hanover Regional Medical Center', u'Women & Infants Hospital of Rhode Island', u'Medical University of South Carolina', u'University of Texas Health Science Center at San Antonio', u'University of Utah Health Science Center']","January 25, 2016",23,30,Both,False
NCT02441088,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02441088,True,Theranostics: 68GaDOTATOC and 90YDOTATOC,Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma,Drug:90Y-DOTA-tyr3-Octreotide; Radiation:Dosimetry-Guided Peptide Receptor Radiotherapy; Drug:Aminosyn II,[u'University of Iowa Hospitals and Clinics'],"August 3, 2015",6,9223372036854775807,Both,False
NCT02441062,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02441062,True,Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors,Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma,Drug:68Ga-DOTATOC PET/CT,[u'University of Iowa Hospitals and Clinics'],"January 15, 2016",6,9223372036854775807,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,IA,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02437188,University of Iowa,True,IA,https://ClinicalTrials.gov/show/NCT02437188,True,Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT,Persistent Post-surgical Pain; Acceptance and Commitment Therapy; Substance Use Disorder,Behavioral:ACT (Acceptance and Commitment Therapy),[u'Iowa City VAMC'],"May 4, 2015",18,9223372036854775807,Both,False
NCT02433834,"Pearl Therapeutics, Inc.",False,IA,https://ClinicalTrials.gov/show/NCT02433834,True,Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma,Asthma,Drug:Glycopyrronium MDI; Drug:Serevent Diskus 50 g; Drug:Placebo,[],"May 4, 2015",18,70,Both,False
NCT02426164,Miller Orthopedic Specialists,False,IA,https://ClinicalTrials.gov/show/NCT02426164,True,Liposomal Bupivacaine in Total Knee Arthroplasty,"Pain, Postoperative; Arthroplasty, Replacement, Knee; Osteoarthritis","Drug:Liposomal bupivacaine; Drug:bupivacaine HCl, morphine, epinephrine, methylprednisolone",[u'Miller Orthopedic Specialists'],"April 21, 2015",18,90,Both,False
NCT02422186,"Janssen Research & Development, LLC",False,IA,https://ClinicalTrials.gov/show/NCT02422186,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral Antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (New Antidepressant),[],"February 4, 2016",65,9223372036854775807,Both,False
NCT02420379,Sarepta Therapeutics,False,IA,https://ClinicalTrials.gov/show/NCT02420379,True,Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy,Duchenne Muscular Dystrophy (DMD),Drug:eteplirsen,"[u'Neuromuscular Research Center of Arizona', u'Ronald Reagan UCLA Medical Center', u'University of California, Davis Medical Center', u'Stanford University Medical Center', u'University of Florida, Shands Hospital', u""Children's Hospital of Atlanta"", u""University of Iowa Children's Hospital"", u""St. Louis Children's Hospital"", u""Nationwide Children's Hospital"", u'Shriners Hospital for Children', u""Children's Hospital of Philadelphia"", u""Seattle Children's Hospital""]","November 13, 2015",4,6,Male,False
NCT02420314,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT02420314,True,Pharmacological Ascorbate for Lung Cancer,"Carcinoma, Non-Small-Cell Lung",Drug:Paclitaxel; Drug:Carboplatin; Drug:Ascorbic Acid,[u'Holden Comprehensive Cancer Center'],"December 1, 2015",18,9223372036854775807,Both,False
NCT02418754,Regeneron Pharmaceuticals,False,IA,https://ClinicalTrials.gov/show/NCT02418754,True,"Study of Intravitreal REGN2176-3 in Patients With Neovascular (""Wet"") Age-Related Macular Degeneration (AMD)",Neovascular Age-Related Macular Degeneration,Drug:REGN2176-3; Drug:Intravitreal Aflibercept Injection (IAI),[],"January 14, 2016",50,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,KS,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,KS,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01649089,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01575548,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01372787,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,KS,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00700882,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT00840177,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00840177,True,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],"September 25, 2015",18,9223372036854775807,Both,False
NCT00316888,Eastern Cooperative Oncology Group,True,KS,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,KS,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02474160,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT00888615,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT02152982,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02595320,University of Kansas Medical Center,True,KS,https://ClinicalTrials.gov/show/NCT02595320,True,Capecitabine in Metastatic Breast and GI Cancers,Breast Cancer; Gastrointestinal Cancer,Drug:Capecitabine,"[u'Newman Regional Health', u'University of Kansas Cancer Center - CRC', u'St. Catherine Hospital - Central Care Cancer Center', u'Heartland Cancer Center - Central Care Cancer Center', u'Hays Medical Center Dreiling-Schmidt Cancer Institute', u'University of Kansas Cancer Center - West', u'Olathe Medical Center', u'University of Kansas Cancer Center - Overland Park', u'Via Christi Cancer Center', u'Salina Regional Health', u'St. Francis Comprehensive Cancer Center', u'University of Kansas Cancer Center - Westwood', u'Truman Medical Center', u'University of Kansas Cancer Center - South', u'University of Kansas Cancer Center - North', u""University of Kansas Cancer Center - Lee's Summit""]","November 1, 2015",18,9223372036854775807,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,KS,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02180867,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02100514,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,KS,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01546038,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01092182,National Cancer Institute (NCI),True,KS,https://ClinicalTrials.gov/show/NCT01092182,True,Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma,"Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive; Plasmablastic Lymphoma",Drug:EPOCH-R; Drug:EPOCH-RR,"[u'Mercy Medical Center-Sioux City', u""Saint Luke's Regional Medical Center"", u'Siouxland Hematology Oncology Associates LLP', u'Providence Medical Center', u'Menorah Medical Center', u""Saint Luke's South Hospital"", u'Kansas City CCOP', u'Shawnee Mission Medical Center-KCCC', u'National Institutes of Health Clinical Center, 9000 Rockville Pike', u'Massachusetts General Hospital', u'Dana Farber Cancer Institute', u'Beth Israel Deaconess Medical Center', u'North Kansas City Hospital', u'Liberty Radiation Oncology Clinic', u'Research Medical Center', u""Saint Luke's Hospital of Kansas City"", u'Heartland Hematology and Oncology Associates Incorporated', u""Saint Luke's East - Lee's Summit"", u'Heartland Regional Medical Center', u'Saint Joseph Oncology Inc', u'Washington University School of Medicine', u'Cleveland Clinic Beachwood', u'Cleveland Clinic Transplantation Clinic', u'Cleveland Clinic', u'Fairview Hospital', u'Cleveland Clinic Independence', u'Hillcrest Hospital', u'Parma Community General Hospital', u'North Coast Cancer Care', u'Cleveland Clinic Strongsville', u'Cleveland Clinic Wooster', u'MD Anderson Cancer Center']","May 5, 2015",18,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00892866,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00892866,True,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02590432,Forest Laboratories,False,KS,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02393794,Priyanka Sharma,False,KS,https://ClinicalTrials.gov/show/NCT02393794,True,Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),Triple-Negative Breast Cancer; Breast Cancer,Drug:Romidepsin; Drug:Cisplatin,"[u'University of Kansas Cancer Center - Clinical Research Center', u'University of Kansas Cancer Center - West', u'University of Kansas Cancer Center - Overland Park', u'University of Kansas Cancer Center - Westwood', u'University of Kansas Cancer Center - South', u'University of Kansas Cancer Center - North', u""University of Kansas Cancer Center - Lee's Summit""]","September 28, 2015",18,9223372036854775807,Female,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,KS,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01872975,NSABP Foundation Inc,False,KS,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01810913,Radiation Therapy Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,KS,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,KS,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02674386,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,KS,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02413320,University of Kansas Medical Center,False,KS,https://ClinicalTrials.gov/show/NCT02413320,True,Neoadjuvant Carboplatin and Docetaxel in TNBC,Triple-negative Breast Cancer,Drug:Paclitaxel; Drug:Carboplatin; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel,"[u'University of Kansas Cancer Center - CRC', u'Hays Medical Center', u'University of Kansas Cancer Center - Westwood', u'Truman Medical Center']","July 9, 2015",18,70,Female,False
NCT02164513,GlaxoSmithKline,False,KS,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01947608,Novartis Pharmaceuticals,False,KS,https://ClinicalTrials.gov/show/NCT01947608,True,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:LDK378,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,KS,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01442194,Novartis,False,KS,https://ClinicalTrials.gov/show/NCT01442194,True,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,Multiple Sclerosis,Drug:Fingolimod; Drug:other disease-modifying therapy,[],"January 15, 2016",0,9223372036854775807,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT00980954,Radiation Therapy Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00351611,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,KS,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02670434,"Kowa Research Institute, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02670434,True,Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia,Hyperlipidemia; Dyslipidemia,Drug:NK-104-CR; Drug:Placebo; Drug:Livalo,[],"February 2, 2016",18,80,Both,False
NCT02648204,Novo Nordisk A/S,False,KS,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02647320,Daiichi Sankyo Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02647320,True,12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin,Type 2 Diabetes Mellitus,Drug:Sitagliptin 100 mg; Drug:DS-8500a 25mg; Drug:placebo,[],"January 26, 2016",18,70,Both,False
NCT02614261,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02614261,True,Evaluation of LY2951742 in the Prevention of Chronic Migraine,Chronic Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02561754,University of Kansas Medical Center,False,KS,https://ClinicalTrials.gov/show/NCT02561754,True,Weight Management for Adolescents With IDD,Developmental Disabilities; Weight Loss; Body Weight; Down Syndrome; Body Weight Changes; Intellectual Disability,Dietary Supplement:Enhanced Stop Light Diet (eSLD); Dietary Supplement:Conventional Diet (CD); Behavioral:Face-to-face (FTF); Behavioral:Technology (TECH); Other:iPad with FaceTime,"[u'University of Kansas Medical Center', u'Energy Balance Lab, The University of Kansas']","September 25, 2015",11,21,Both,False
NCT02538666,Bristol-Myers Squibb,False,KS,https://ClinicalTrials.gov/show/NCT02538666,True,"A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy",Lung Cancer,Biological:Nivolumab; Biological:Ipilimumab; Other:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02536833,Samumed LLC,False,KS,https://ClinicalTrials.gov/show/NCT02536833,True,"A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects",Osteoarthritis,Drug:SM04690; Drug:Placebo,[],"January 12, 2016",40,80,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02508194,MedImmune LLC,False,KS,https://ClinicalTrials.gov/show/NCT02508194,True,A Study to Evaluate the Efficacy of MEDI7510 in Older Adults,Respiratory Syncytial Virus (RSV),Biological:MEDI7510; Biological:IIV; Other:Placebo,[],"January 22, 2016",60,99,Both,True
NCT02505035,University of Pennsylvania,False,KS,https://ClinicalTrials.gov/show/NCT02505035,True,Randomized Evaluation of Default Access to Palliative Services,COPD; ESRD; Dementia,Behavioral:Default ordering of palliative consult,"[u""St. Vincent's Medical Center"", u""St. Vincent's Medical Center, Southside"", u""St. Vincent's Medical Center, Riverside"", u'Via Christi Hospital, St. Francis', u'Via Christi Hospital, St. Joseph', u'Borgess Medical Center', u'Our Lady of Lourdes Memorial Hospital', u'St. Thomas West Hospital', u'University Medical Center Brackenridge', u""Columbia St. Mary's, Ozaukee"", u""Columbia St. Mary's, North Lake""]","October 28, 2015",45,9223372036854775807,Both,False
NCT02497287,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02497287,True,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Duloxetine; Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02493868,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02493868,True,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 2, 2016",18,64,Both,False
NCT02477891,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02477891,True,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02477800,Biogen,False,KS,https://ClinicalTrials.gov/show/NCT02477800,True,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02456740,Amgen,False,KS,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02451137,Sanofi,False,KS,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02418585,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02418585,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 27, 2016",18,64,Both,False
NCT02417064,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02417064,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 3, 2016",18,64,Both,False
NCT02403401,Bayer,False,KS,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02371980,Takeda,False,KS,https://ClinicalTrials.gov/show/NCT02371980,True,"Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder",Major Depressive Disorder,Drug:Vortioxetine; Drug:Placebo,[],"November 24, 2015",18,75,Both,False
NCT02367820,Nektar Therapeutics,False,KS,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02362672,Nektar Therapeutics,False,KS,https://ClinicalTrials.gov/show/NCT02362672,True,Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181; Drug:Placebo,[],"September 10, 2015",18,75,Both,False
NCT02348619,Jazz Pharmaceuticals,False,KS,https://ClinicalTrials.gov/show/NCT02348619,True,"""Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Obstructive Sleep Apnea,Drug:JZP-110,[],"December 9, 2015",18,75,Both,False
NCT02322320,"National Heart, Lung, and Blood Institute (NHLBI)",False,KS,https://ClinicalTrials.gov/show/NCT02322320,True,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",Multiple Myeloma,Drug:Lenalidomide,[],"December 17, 2015",18,70,Both,False
NCT02319837,"Medivation, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02319837,True,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Drug:Enzalutamide; Drug:Placebo; Drug:Leuprolide,[],"December 1, 2015",18,9223372036854775807,Male,False
NCT02312037,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT02312037,True,Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy,CD33 Positive Acute Myelogenous Leukemia,Biological:Antibody Drug Conjugate Chemotherapeutic,[],"January 5, 2016",3,9223372036854775807,Both,False
NCT02301234,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02301234,True,"Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg; Drug:Celecoxib 100 mg; Drug:Celecoxib 100 mg Matching Placebo,[],"January 20, 2016",18,99,Both,False
NCT02284568,Teva Pharmaceutical Industries,False,KS,https://ClinicalTrials.gov/show/NCT02284568,True,"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo",Primary Progressive Multiple Sclerosis,Drug:Laquinimod; Drug:Placebo,[],"January 6, 2016",25,55,Both,False
NCT02267525,"Theravance Biopharma R & D, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02267525,True,"The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study",Gastroparesis,Drug:Velusetrag; Drug:Placebo,[],"December 10, 2015",18,75,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02187159,Daiichi Sankyo Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02187159,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02186847,NRG Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02174731,AstraZeneca,False,KS,https://ClinicalTrials.gov/show/NCT02174731,True,"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis",Anemia,Drug:Roxadustat; Drug:Epoetin alfa,[],"February 2, 2016",18,130,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02152631,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02152631,True,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,Non Small Cell Lung Cancer,Drug:Abemaciclib; Drug:Erlotinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02128659,"Megha Ramaswamy, PhD, MPH",False,KS,https://ClinicalTrials.gov/show/NCT02128659,True,Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention,Cervical Cancer,Behavioral:SHE Project,"[u'Wyandotte County Detention Center', u'University of Kansas Medical Center', u'Jackson County Detention/Regional Correctional Center']","January 10, 2016",21,9223372036854775807,Female,True
NCT02111577,Sotio a.s.,False,KS,https://ClinicalTrials.gov/show/NCT02111577,True,Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,Metastatic Castrate Resistant Prostate Cancer,Biological:Dendritic Cells DCVAC; Biological:Placebo; Drug:Docetaxel; Drug:Taxotere,[],"January 5, 2016",18,9223372036854775807,Male,False
NCT02107443,Gary Morrow,False,KS,https://ClinicalTrials.gov/show/NCT02107443,True,Improving Communication in Older Cancer Patients and Their Caregivers,Adult Solid Neoplasm; Lymphoma,Other:Informational Intervention; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,"[u'City of Hope Comprehensive Cancer Center', u'Delaware/Christiana Care NCORP', u'University of Chicago Comprehensive Cancer Center', u'Heartland NCORP', u'Kansas City NCORP', u'Wichita NCORP', u'Metro-Minnesota NCORP', u'Nevada NCORP', u'North Shore LIJ Health System NCORP', u'University of Rochester', u'Southeast Clinical ONcology Research Consortium', u'Columbus NCORP', u'Dayton NCORP', u'Pacific Cancer Research Consortium Ncorp', u'Geisinger Cancer Institute NCORP', u'Greenville NCORP', u'Northwest NCORP', u'Wisconsin NCORP', u'Aurora NCORP']","November 2, 2015",70,9223372036854775807,Both,True
NCT02104817,AstraZeneca,False,KS,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02092467,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02080364,vTv Therapeutics,False,KS,https://ClinicalTrials.gov/show/NCT02080364,True,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02073279,Chugai Pharmaceutical,False,KS,https://ClinicalTrials.gov/show/NCT02073279,True,Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD,Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD),Drug:SA237; Drug:Placebo,[],"December 8, 2015",18,74,Both,False
NCT02066636,Bristol-Myers Squibb,False,KS,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02054741,Gary Morrow,False,KS,https://ClinicalTrials.gov/show/NCT02054741,True,Geriatric Assessment Intervention for Reducing Chemotherapy Toxicity in Older Patients With Advanced Cancer,Adult Solid Neoplasm; Chemotherapeutic Agent Toxicity; Lymphoma,Other:Comprehensive Geriatric Assessment; Other:Quality-of-Life Assessment; Other:Survey Administration,[],"November 2, 2015",70,9223372036854775807,Both,False
NCT02027428,Celgene Corporation,False,KS,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02027025,Sun Pharma Advanced Research Company Limited,False,KS,https://ClinicalTrials.gov/show/NCT02027025,True,Action of Baclofen Capsules in Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen dose 1; Drug:Baclofen dose 2; Drug:Placebo,"[u'Collaborative Neuroscience Network, Inc.', u'Pacific Research Network Inc', u'University of Colorado Health Sciences Center', u'Jacksonville Center For Clinical Research', u'Ocean Blue Medical Research Center Inc', u'Compass Research', u'Suncoast Neuroscience Associates Inc', u'Meridien Research', u'West Georgia Sleep Disorder Center and Neurology Associates', u'University of Kansas Medical center', u'Midamerica Neuroscience Institute - Rowe Neurology Institute', u'Quest Research Institute', u'Neurological Institute PA', u'Rapid Medical Research Inc', u'Zain Research LLC']","December 5, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02003924,"Medivation, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02003924,True,Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,Nonmetastatic Castration-Resistant Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Drug:Enzalutamide; Drug:Placebo,[],"December 1, 2015",18,9223372036854775807,Male,False
NCT01968967,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01890265,FibroGen,True,KS,https://ClinicalTrials.gov/show/NCT01890265,True,Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Drug:FG-3019; Drug:Placebo,[],"December 16, 2015",40,80,Both,False
NCT01872689,Hoffmann-La Roche,False,KS,https://ClinicalTrials.gov/show/NCT01872689,True,A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Drug:lebrikizumab; Drug:pirfenidone; Drug:placebo,[],"February 1, 2016",40,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01797185,Sun Pharma Advanced Research Company Limited,False,KS,https://ClinicalTrials.gov/show/NCT01797185,True,"A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial",Spasticity,Drug:Baclofen,[],"September 15, 2015",18,90,Both,False
NCT01746212,Kansas Joint and Spine Institute,False,KS,https://ClinicalTrials.gov/show/NCT01746212,True,Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft,Degenerative Disc Disease,Procedure:One-level or two-level anterior lumbar interbody fusion; Biological:InQu Bone Graft Extender and Substitute mixed with BMAC; Device:Synthes Spinal Instrumentation,"[u'Kansas Joint and Spine Institute', u'National Center of Innovation for Biomaterials in Orthopaedic Research']","December 6, 2012",18,70,Both,False
NCT01652872,Amgen,False,KS,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01644877,"Ansun Biopharma, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT01644877,True,"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen",Parainfluenza,"Drug:DAS181 dry powder, formulation F02; Drug:Lactose Placebo",[],"January 7, 2016",12,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,KS,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01621178,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT01621178,True,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes; Chronic Kidney Disease,Drug:Dulaglutide; Drug:Insulin glargine; Drug:Insulin lispro,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,KS,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,KS,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01457352,Sun Pharma Advanced Research Company Limited,False,KS,https://ClinicalTrials.gov/show/NCT01457352,True,Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen ER Capsules; Drug:Placebo GRS,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01371305,Biogen,False,KS,https://ClinicalTrials.gov/show/NCT01371305,True,STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis (IPF),Drug:BG00011; Drug:Placebo,"[u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site']","October 23, 2015",18,84,Both,False
NCT01321541,CTI BioPharma,False,KS,https://ClinicalTrials.gov/show/NCT01321541,True,Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant,Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma,Drug:Pixantrone + Rituximab; Drug:Gemcitabine + Rituximab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01302080,Pfizer,False,KS,https://ClinicalTrials.gov/show/NCT01302080,True,Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES),Obsessive Compulsive Disorder,Drug:sertraline; Behavioral:psychotherapy,[],"January 16, 2016",6,16,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01201356,Novartis Pharmaceuticals,False,KS,https://ClinicalTrials.gov/show/NCT01201356,True,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Relapsing Forms of Multiple Sclerosis,Drug:FTY720,[],"October 27, 2015",18,9223372036854775807,Both,False
NCT01118026,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01118026,True,Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma,Lymphoma,Drug:ABVD; Drug:BEACOPP; Radiation:radiation therapy,[],"August 25, 2015",18,60,Both,False
NCT00858364,Amgen,False,KS,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00547469,Dynogen Pharmaceuticals,False,KS,https://ClinicalTrials.gov/show/NCT00547469,True,A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females,Irritable Bowel Syndrome,Drug:DDP733,[],"April 7, 2008",18,65,Female,False
NCT02675023,Baxalta US Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02675023,True,"Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects",Healthy,Biological:M923,"[u'QOPK Phase 1 Clinic', u'QLON Phase 1 Clinic']","February 2, 2016",18,55,Both,True
NCT02674347,Wockhardt,False,KS,https://ClinicalTrials.gov/show/NCT02674347,True,"MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults",Healthy Subjects,Drug:3 g or 6 g Zidebactam; Drug:Placebo,[u'Quintiles'],"February 1, 2016",18,55,Both,True
NCT02673229,"Dhaval Bhavsar, MD",False,KS,https://ClinicalTrials.gov/show/NCT02673229,True,Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns,"Burn, Partial Thickness",Drug:Collagenase Santyl; Drug:Bacitracin,[u'University of Kansas Medical Center'],"February 2, 2016",2,75,Both,False
NCT02670083,Hoffmann-La Roche,False,KS,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02666742,"Dhanunjaya Lakkireddy, MD, FACC",False,KS,https://ClinicalTrials.gov/show/NCT02666742,True,Safety and Efficacy of Post Ablation Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation,Ventricular Tachycardia,Drug:Apixaban; Drug:Aspirin,[u'University of Kansas Medical Center'],"January 25, 2016",18,80,Both,False
NCT02666729,"Dhanunjaya Lakkireddy, MD, FACC",False,KS,https://ClinicalTrials.gov/show/NCT02666729,True,Use of a Novel Contact Force Sensing Catheter for AF Ablation - Impact of TactiCath on Dormant Conduction Across the Pulmonary Veins,Atrial Fibrillation,Procedure:AF Ablation with contact force information; Procedure:AF Ablation without contact force information,[u'University of Kansas Medical Center'],"January 27, 2016",18,80,Both,False
NCT02661893,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02661893,True,A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922,Healthy,Drug:JNJ-42847922; Drug:Rifampin,[u''],"January 19, 2016",18,60,Both,True
NCT02655549,"Pfenex, Inc",False,KS,https://ClinicalTrials.gov/show/NCT02655549,True,A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects,Anthrax,"Biological:Px563L, RPA563, or placebo",[u'Quintiles Phase One Services'],"January 13, 2016",18,55,Both,True
NCT02654418,Cosmo Technologies Ltd,False,KS,https://ClinicalTrials.gov/show/NCT02654418,True,Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm,Adenomas,Procedure:Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size),"[u'Mayo Clinic', u'Indiana University Hospital', u'University of Kansas Medical Center']","January 11, 2016",18,9223372036854775807,Both,True
NCT02651584,Braeburn Pharmaceuticals,False,KS,https://ClinicalTrials.gov/show/NCT02651584,True,"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence",Opioid Use Disorders,Drug:CAM2038 subcutaneous injection; Drug:SL BPN tablets; Drug:placebo subcutaneous (SC) injections; Drug:SL placebo tablets,[],"February 3, 2016",18,65,Both,True
NCT02641899,Intarcia Therapeutics,False,KS,https://ClinicalTrials.gov/show/NCT02641899,True,Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs,Healthy,Drug:ITCA 650 20/60 mcg/day; Drug:Acetaminophen; Drug:Atorvastatin; Drug:Lisinopril; Drug:Warfarin; Drug:Digoxin,[u'Quintiles'],"December 24, 2015",18,65,Both,True
NCT02641028,Cerecor Inc,False,KS,https://ClinicalTrials.gov/show/NCT02641028,True,A Study in a Human Laboratory Model of Smoking Behavior,Smoking,Drug:CERC-501; Drug:Placebo,"[u'Vince and Associates', u'University of Kentucky', u'Columbia University']","December 28, 2015",21,60,Both,False
NCT02640612,Boehringer Ingelheim,False,KS,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02638805,Intarcia Therapeutics,False,KS,https://ClinicalTrials.gov/show/NCT02638805,True,Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide,"Diabetes Mellitus, Type 2",Drug:ITCA 650 20/60 mcg/day; Drug:ITCA 650 60 mcg/day,[],"February 3, 2016",18,80,Both,False
NCT02638129,Takeda,False,KS,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02636907,Boehringer Ingelheim,False,KS,https://ClinicalTrials.gov/show/NCT02636907,True,Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe,"Arthritis, Rheumatoid",Drug:BI 695501 Autoinjector; Drug:BI 695501 Prefilled syringe,[],"February 2, 2016",18,80,Both,False
NCT02635204,"Promius Pharma, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02635204,True,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Psoriasis,Drug:DFD06 Cream; Drug:Vehicle Cream,[],"December 21, 2015",18,9223372036854775807,Both,False
NCT02634073,ViiV Healthcare,False,KS,https://ClinicalTrials.gov/show/NCT02634073,True,"A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers","Infection, Human Immunodeficiency Virus",Drug:Lamivudine; Drug:Sorbitol,[u'GSK Investigational Site'],"January 25, 2016",18,65,Both,True
NCT02632266,"Mitzi Go, M.D.",True,KS,https://ClinicalTrials.gov/show/NCT02632266,True,Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants,Complication of Prematurity,Dietary Supplement:Powder HMF; Dietary Supplement:Liquid HMF,[u'University of Kansas Medical Center'],"December 11, 2015",28,34,Both,True
NCT02628028,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02628028,True,A Study of LY3337641 in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:LY3337641; Drug:Placebo,[],"January 8, 2016",18,65,Both,False
NCT02626299,University of Kansas Medical Center,False,KS,https://ClinicalTrials.gov/show/NCT02626299,True,Assessment of DHA On Reducing Early Preterm Birth,Preterm Birth,Drug:Docosahexaenoic acid - 800mg/day; Drug:Docosahexaenoic acid - 200mg/day; Other:Placebo,[u'University of Kansas Medical Center'],"December 8, 2015",18,36,Female,True
NCT02622373,"Vishal Pandey, M.D.",True,KS,https://ClinicalTrials.gov/show/NCT02622373,True,Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition,Premature Birth; Preterm Birth,Device:PEA POD Infant Body Composition System,[u'University of Kansas Medical Center'],"December 2, 2015",23,42,Both,True
NCT02622282,University of Kansas Medical Center,False,KS,https://ClinicalTrials.gov/show/NCT02622282,True,Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease,Peripheral Arterial Disease,Other:Text Messages; Other:Phone Calls; Other:Handout,"[u'KU School of Medicine - Wichita', u'University of Texas Health Science Center in San Antonio']","December 3, 2015",50,9223372036854775807,Both,True
NCT02617810,"Janssen Research & Development, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02617810,True,A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants,Healthy,Drug:JNJ-42847922; Drug:Midazolam; Drug:Warfarin,[u''],"January 12, 2016",18,60,Both,True
NCT02617589,Bristol-Myers Squibb,False,KS,https://ClinicalTrials.gov/show/NCT02617589,True,"Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",Brain Cancer,Drug:Nivolumab; Drug:Temozolomide; Radiation:Radiotherapy,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02614612,Incyte Corporation,False,KS,https://ClinicalTrials.gov/show/NCT02614612,True,Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute GVHD,Acute Graft Versus Host Disease,Drug:INCB039110 (200 mg); Drug:INCB039110 (300 mg); Drug:prednisone or methylprednisolone (corticosteroids),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02614196,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02614196,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-2 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02614183,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02608034,"Genentech, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02608034,True,A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State,"Metastatic Melanoma, BRAF V600 Mutation Positive",Drug:Itraconazole; Drug:Rifampin; Drug:Vemurafenib,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","February 1, 2016",18,9223372036854775807,Both,False
NCT02607865,Novo Nordisk A/S,False,KS,https://ClinicalTrials.gov/show/NCT02607865,True,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:sitagliptin; Drug:placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02604407,Shire,False,KS,https://ClinicalTrials.gov/show/NCT02604407,True,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),"Drug:SHP465 12.5mg capsules (one capsule daily); Other:Placebo; Drug:SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)",[],"December 8, 2015",18,55,Both,False
NCT02597933,Boehringer Ingelheim,False,KS,https://ClinicalTrials.gov/show/NCT02597933,True,A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis,"Scleroderma, Systemic",Drug:Nintedanib; Drug:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02597049,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02597049,True,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug:Dulaglutide; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,KS,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02596451,Glenmark Pharmaceuticals Ltd. India,False,KS,https://ClinicalTrials.gov/show/NCT02596451,True,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Osteoarthritis,"Drug:Diclofenac Sodium gel, 1%; Drug:Voltaren Gel; Drug:Placebo",[],"December 11, 2015",35,9223372036854775807,Both,False
NCT02596399,"Genentech, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02596399,True,"A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers",Healthy Volunteer,Drug:DSTA4637S; Drug:Placebo,[u''],"February 1, 2016",18,65,Both,True
NCT02593760,Hoffmann-La Roche,False,KS,https://ClinicalTrials.gov/show/NCT02593760,True,A Study to Evaluate Efficacy and Safety of Vismodegib (Erivedge) in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF),Myelofibrosis,Other:Placebo; Drug:Ruxolitinib; Drug:Vismodegib,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02593318,"Russell Swerdlow, MD",False,KS,https://ClinicalTrials.gov/show/NCT02593318,True,Trial of Oxaloacetate in Alzheimer's Disease (TOAD),Alzheimer's Disease (AD),Drug:Oxaloacetate (OAA),[u'University of Kansas Medical Center'],"October 30, 2015",50,85,Both,False
NCT02591199,Urigen,False,KS,https://ClinicalTrials.gov/show/NCT02591199,True,Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome,Interstitial Cystitis; Bladder Pain Syndrome,Drug:URG101; Drug:Placebo; Drug:Lidocaine; Drug:Heparin,"[u'IC Study, LLC', u'University of California San Diego', u'Scripps Clinic', u'Georgia Urology', u'The Urogynecology Center', u'The Arthur Smith Institue for Urology- North Shore Long Island Jewish Health System', u'Wake Forest University Health Sciences', u'MetroHealth System, Center for Advanced Gynecology', u'Medical University of South Carolina', u'Sanford Research', u'Urology of Virginia, PLLC']","February 2, 2016",18,9223372036854775807,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02584855,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02584855,True,A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02584660,"Janssen Scientific Affairs, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02584660,True,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,Pulmonary Embolism,Drug:Rivaroxaban; Drug:Standard-of-care,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02578459,Flowonix Medical,False,KS,https://ClinicalTrials.gov/show/NCT02578459,True,A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain,Pain Management; Cancer Pain,Device:Intrathecal Drug Delivery System; Other:Conventional Medical Management,[u'Menorah Medical Center'],"October 20, 2015",22,9223372036854775807,Both,False
NCT02575482,Suven Life Sciences Limited,False,KS,https://ClinicalTrials.gov/show/NCT02575482,True,"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects",Cognitive Disorders,Drug:SUVN-D4010; Drug:Placebo,[u'PRA Health Sciences'],"October 13, 2015",18,45,Male,True
NCT02567773,GlaxoSmithKline,False,KS,https://ClinicalTrials.gov/show/NCT02567773,True,"Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078",Cachexia,Drug:GSK2881078; Drug:Placebo; Drug:Itraconazole,[u'GSK Investigational Site'],"October 1, 2015",18,75,Both,True
NCT02564588,Sunovion,False,KS,https://ClinicalTrials.gov/show/NCT02564588,True,Dasotraline Binge Eating Disorder Study,Binge Eating Disorder,Drug:Dasotraline; Drug:Placebo,[],"January 12, 2016",18,55,Both,False
NCT02561923,"Janssen Scientific Affairs, LLC",False,KS,https://ClinicalTrials.gov/show/NCT02561923,True,A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants,Healthy,"Drug:Rivaroxaban; Drug:Tranexamic acid; Drug:Kcentra, a 4-factor PCC; Drug:Saline",[u''],"January 6, 2016",18,55,Both,True
NCT02561078,Eli Lilly and Company,False,KS,https://ClinicalTrials.gov/show/NCT02561078,True,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug:Human regular U-500 insulin (CSII); Drug:Human regular U-500 insulin (MDI),[],"January 7, 2016",18,85,Both,False
NCT02559973,Indivior Inc.,False,KS,https://ClinicalTrials.gov/show/NCT02559973,True,"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder",Opioid Use Disorder,Drug:RBP-6000; Drug:SUBOXONE Sublingual Film,[u'Vince & Associates Clinical Research'],"December 28, 2015",18,65,Both,False
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02558595,University of Kansas Medical Center,False,KS,https://ClinicalTrials.gov/show/NCT02558595,True,Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2),Polycystic Kidney Disease,Dietary Supplement:Niacinamide; Other:Placebo,[u'University of Kansas Medical Center'],"October 1, 2015",18,60,Both,False
NCT02553798,"Dermira, Inc.",False,KS,https://ClinicalTrials.gov/show/NCT02553798,True,Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis,Hyperhidrosis,Drug:DRM04 Topical Wipes,[],"January 21, 2016",9,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT02315469,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02154490,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02451137,Sanofi,False,KY,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02164916,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,KY,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT02601209,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01872975,NSABP Foundation Inc,False,KY,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01808573,"Puma Biotechnology, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,KY,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02048917,University of Kentucky,False,KY,https://ClinicalTrials.gov/show/NCT02048917,True,Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients,Lung Cancer; Head and Neck Cancer,Drug:High Intensity Counseling + Long Acting NRT + PRN NRT; Drug:High Intensity Counseling + bupropion + PRN NRT; Drug:High Intensity Counseling + varenicline + PRN NRT; Drug:High Intensity Counseling + Long Acting NRT; Drug:High Intensity Counseling + bupropion; Drug:High Intensity Counseling + varenicline; Drug:Low Intensity Counseling + Long Acting NRT + PRN NRT; Drug:Low Intensity Counseling + bupropion + PRN NRT; Drug:Low Intensity Counseling + varenicline + PRN NRT; Drug:Low Intensity Counseling + Long Acting NRT; Drug:Low Intensity Counseling + bupropion; Drug:Low Intensity Counseling + varenicline,"[u""King's Daughters Medical Center"", u'Hardin Memorial Health Cancer Care Center', u'ARH Cancer Center', u'Kentucky Cancer Clinic', u'University Of Kentucky, Markey Cancer Center', u'University of Louisville, James Graham Brown Cancer Center', u'St. Claire Regional Medical Center']","January 6, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01845025,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01389596,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01389596,True,A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years,"Epilepsy, Partial Seizures",Drug:Pregabalin add-on therapy; Drug:Pregabalin add-on therapy; Drug:Pregabalin add-on therapy,[],"January 8, 2016",4,16,Both,False
NCT02072226,"Genentech, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02072226,True,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,KY,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01663402,Sanofi,False,KY,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01649089,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01594333,Brigham and Women's Hospital,False,KY,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01463306,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01463306,True,A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures,"Epilepsy, Partial Seizures; Epilepsy, Primary Generalized Tonic-Clonic Seizures",Drug:Pregabalin,[],"January 20, 2016",1,65,Both,False
NCT01312909,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01312909,True,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],"February 3, 2016",12,19,Both,False
NCT01274338,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02671981,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,KY,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02152631,Eli Lilly and Company,False,KY,https://ClinicalTrials.gov/show/NCT02152631,True,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,Non Small Cell Lung Cancer,Drug:Abemaciclib; Drug:Erlotinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02027428,Celgene Corporation,False,KY,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,KY,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01975389,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,KY,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01543087,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01543087,True,Duration of Immunity Study,Meningococcal Infection,Procedure:blood sampling; Drug:bivalent rLP2086,[],"January 25, 2016",10,18,Both,True
NCT01101035,Takeda,True,KY,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00955708,Boston Scientific Corporation,False,KY,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00843882,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02559570,Forest Laboratories,False,KY,https://ClinicalTrials.gov/show/NCT02559570,True,A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC),Functional Constipation in Children Ages 6-17 Years,Drug:Linaclotide Dose A; Drug:Linaclotide Dose B; Drug:Linaclotide Dose C; Drug:Linaclotide Approved Adult Dose; Drug:Matching Placebo,[],"October 30, 2015",6,17,Both,False
NCT02504216,Bayer,False,KY,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02499120,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT02499120,True,Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Drug:palbociclib; Drug:Cetuximab; Drug:Placebo,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02497469,Takeda,False,KY,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02470585,AbbVie,False,KY,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02461589,Novo Nordisk A/S,False,KY,https://ClinicalTrials.gov/show/NCT02461589,True,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:liraglutide; Drug:placebo,[],"October 29, 2015",18,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,KY,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02392624,"Genentech, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02392624,True,A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU),Chronic Idiopathic Urticaria,Drug:Omalizumab,[],"September 1, 2015",12,75,Both,False
NCT02388165,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02367781,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02367781,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02332889,University of Louisville,False,KY,https://ClinicalTrials.gov/show/NCT02332889,True,Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,"Gliomas; Medulloblastoma; Neuroectodermal Tumors, Primitive",Biological:Vaccine (autologous dendritic cells); Drug:Decitabine and Hiltonol,"[u'Pediatric Hematology/Oncology University of Louisville', u""University of Louisville, Kosair Children's Charities Pediatric Clinical Research Unit"", u'University of Louisville']","November 30, 2015",2,25,Both,False
NCT02186847,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,KY,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,KY,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02138916,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,KY,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02072824,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT02072824,True,"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.",Partial Onset Seizures,Drug:Pregabalin Dose Level 1; Drug:Pregabalin Dose Level 2; Drug:Placebo,[],"January 8, 2016",1,3,Both,False
NCT02066636,Bristol-Myers Squibb,False,KY,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02032823,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01870778,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01805076,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01747915,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01747915,True,"A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.",Generalized Tonic Clonic Seizures,Drug:Pregabalin Dose Level 1; Drug:Pregabalin Dose Level 2; Drug:Placebo,[],"January 19, 2016",5,65,Both,False
NCT01546571,Polynoma LLC,False,KY,https://ClinicalTrials.gov/show/NCT01546571,True,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",Melanoma,Biological:POL-103A; Biological:POL-103A without API,[],"December 8, 2015",18,80,Both,False
NCT01439711,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01439711,True,Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:letrozole; Procedure:MRI; Procedure:conventional surgery,[],"September 18, 2015",18,9223372036854775807,Female,False
NCT01414608,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01169337,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01163253,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01163253,True,"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00897442,Gynecologic Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT02675426,AbbVie,False,KY,https://ClinicalTrials.gov/show/NCT02675426,True,A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,99,Both,False
NCT02638129,Takeda,False,KY,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02614183,Eli Lilly and Company,False,KY,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02607865,Novo Nordisk A/S,False,KY,https://ClinicalTrials.gov/show/NCT02607865,True,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:sitagliptin; Drug:placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02583256,Novartis Vaccines,False,KY,https://ClinicalTrials.gov/show/NCT02583256,True,"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)",Influenza,Biological:aQIV-aQIV; Biological:aQIV-QIV; Biological:QIV-aQIV; Biological:QIV-QIV,[],"January 15, 2016",18,85,Both,True
NCT02562716,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02528253,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02499770,"G1 Therapeutics, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02499770,True,G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),Small Cell Lung Cancer,Drug:G1T28 + carboplatin/ etoposide; Drug:Placebo + carboplatin/ etoposide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02487498,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT02487498,True,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol ); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02477332,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT02477332,True,Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU,Chronic Spontaneous Urticaria,Biological:QGE031; Biological:Omalizumab; Other:Placebo,[],"January 5, 2016",18,75,Both,False
NCT02469857,Atox Bio Ltd,False,KY,https://ClinicalTrials.gov/show/NCT02469857,True,Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections,Necrotizing Soft Tissue Infections; Necrotizing Fasciitis; Fournier's Gangrene,Drug:AB103 0.5 mg/kg; Other:NaCl 0.9%,[],"December 12, 2015",12,9223372036854775807,Both,False
NCT02460991,"CeloNova BioSciences, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02460991,True,A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,Hepatocellular Carcinoma; Hepatoma; Liver Cell Carcinoma,Device:DEB-TACE; Drug:Sorafenib,"[u'University of Alabama Hospital', u'University of Southern California', u'University of California Los Angeles', u'Yale Cancer Center', u'University of Miami Hospital', u'University of Kentucky', u'University of Louisville', u'University of Maryland Medical Center', u'Memorial Sloan Kettering Cancer Center', u'Oregon Health & Science University', u'Medical University of South Carolina', u'UT Southwestern Medical Center', u'MD Anderson Cancer Center']","December 22, 2015",18,9223372036854775807,Both,False
NCT02460978,Bristol-Myers Squibb,False,KY,https://ClinicalTrials.gov/show/NCT02460978,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Diabetes,Drug:Dapagliflozin; Drug:Insulin; Other:Placebo,[],"January 26, 2016",18,75,Both,False
NCT02450331,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02450331,True,"A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]","Bladder Cancer, Cancer","Drug:Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02431806,Forest Laboratories,False,KY,https://ClinicalTrials.gov/show/NCT02431806,True,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],"December 23, 2015",12,17,Both,False
NCT02418754,Regeneron Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT02418754,True,"Study of Intravitreal REGN2176-3 in Patients With Neovascular (""Wet"") Age-Related Macular Degeneration (AMD)",Neovascular Age-Related Macular Degeneration,Drug:REGN2176-3; Drug:Intravitreal Aflibercept Injection (IAI),[],"January 14, 2016",50,9223372036854775807,Both,False
NCT02414854,Sanofi,False,KY,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02409355,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02409355,True,A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Cisplatin; Drug:Gemcitabine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02403323,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02394028,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02376790,Amgen,False,KY,https://ClinicalTrials.gov/show/NCT02376790,True,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Drug:Etanercept + Oral Methotrexate; Drug:Etanercept + Placebo for Methotrexate; Drug:Oral Methotrexate + Placebo for Etanercept,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02369874,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT02369874,True,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN).,Drug:MEDI4736; Drug:MEDI4736 + Tremelimumab; Drug:Standard of Care,[],"January 18, 2016",18,96,Both,False
NCT02367794,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02344290,National Institute of Allergy and Infectious Diseases (NIAID),False,KY,https://ClinicalTrials.gov/show/NCT02344290,True,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,HIV Infections; Cardiovascular Diseases,Drug:Pitavastatin; Drug:Placebo,[],"February 1, 2016",40,75,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,KY,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02317549,"Leading BioSciences, Inc",False,KY,https://ClinicalTrials.gov/show/NCT02317549,True,Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148,Septic Shock,Drug:LB1148; Drug:Placebo,[],"January 6, 2016",18,75,Both,False
NCT02296125,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT02296125,True,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,Drug:AZD9291 80 mg/40 mg + placebo; Drug:Placebo Erlotinib 150/100mg; Drug:Placebo Gefitinib 250 mg; Drug:Erlotinib 150/100 mg; Drug:Gefitinib 250 mg; Drug:Placebo AZD9291 80 mg/ 40 mg,[],"January 18, 2016",18,130,Both,False
NCT02289950,Morphotek,False,KY,https://ClinicalTrials.gov/show/NCT02289950,True,A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,Platinum-Sensitive Ovarian Cancer in First Relapse,Drug:Farletuzumab; Drug:Placebo,[],"January 8, 2016",18,9223372036854775807,Female,False
NCT02271217,Acorda Therapeutics,False,KY,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02267525,"Theravance Biopharma R & D, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02267525,True,"The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study",Gastroparesis,Drug:Velusetrag; Drug:Placebo,[],"December 10, 2015",18,75,Both,False
NCT02250651,Allergan,False,KY,https://ClinicalTrials.gov/show/NCT02250651,True,Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",Drug:Bimatoprost sustained-release; Other:Sham; Drug:Timolol; Drug:Timolol Vehicle (placebo),[],"January 15, 2016",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,KY,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,KY,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02206334,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02206334,True,"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",Male Breast Carcinoma; Prostate Adenocarcinoma; Recurrent Breast Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Prostate Carcinoma; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Prostate Cancer,Radiation:Stereotactic Radiosurgery,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02190604,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT02190604,True,"Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients",Cystic Fibrosis,Drug:Placebo; Drug:QBW251,[],"March 10, 2015",18,55,Both,True
NCT02180867,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02163538,University of Louisville,False,KY,https://ClinicalTrials.gov/show/NCT02163538,True,Articulating Enseal Versus Ligasure Energy Devices,Task Performance,Device:articulating Enseal; Device:Ligasure device,"[u'University of Louisville Health Care Outpatient Center', u'University of Louisville Hospital']","September 18, 2015",18,9223372036854775807,Female,True
NCT02156518,Vrushali Angadi,False,KY,https://ClinicalTrials.gov/show/NCT02156518,True,The Efficacy of Vocal Function Exercises for Early Glottic Cancers,Vocal Folds,Procedure:Vocal Function Exercises; Procedure:Vocal Hygiene,"[u'University of Kentucky, Markey Cancer Center', u'University of Kentucky']","December 6, 2015",40,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02143050,James Graham Brown Cancer Center,False,KY,https://ClinicalTrials.gov/show/NCT02143050,True,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",Melanoma,Drug:Dabrafenib; Drug:Trametinib; Drug:Metformin,"[u'James Graham Brown Cancer Center-Universityof Louisville', u'James Graham Brown Cancer Center']","September 29, 2014",18,9223372036854775807,Both,False
NCT02131389,"Iconacy Orthopedic Implants, LLC.",False,KY,https://ClinicalTrials.gov/show/NCT02131389,True,"Multi-Site, Post-Market Study of the ICONACY I-Hip System",Degenerative Joint Disease,Device:Iconacy Hip System,"[u'Baptist Health Louisville', u'Sts. Mary & Elizabeth Hospital - KentuckyOne Health']","May 2, 2014",30,80,Both,False
NCT02130934,Majd Makhoul,False,KY,https://ClinicalTrials.gov/show/NCT02130934,True,Cardiac 3D MRI in Pediatric Cancer Patients,Childhood Cancer,Procedure:Cardiac 3D MRI,"[u'UK Medical Center', u'University of Kentucky Medical Center']","June 26, 2015",8,26,Both,False
NCT02128100,James Graham Brown Cancer Center,False,KY,https://ClinicalTrials.gov/show/NCT02128100,True,Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer,Pancreatic Cancer Non-resectable,Drug:Folfirinox; Radiation:Stereotactic Body Radiation Therapy,"[u'James Graham Brown Cancer Center', u'James Graham Brown Cancer Center']","May 12, 2015",18,9223372036854775807,Both,False
NCT02127112,University of Louisville,False,KY,https://ClinicalTrials.gov/show/NCT02127112,True,Ridge Augmentation Comparing a Block Allograft to a Demineralized Bone Matrix Allograft.,Alveolar Process Defect,Procedure:Block Allograft plus Matrix Allograft; Procedure:Moldable Matrix Allograft,"[u'Graduate Periodontics Clinic, University of Louisville', u'U of L Dental School']","September 3, 2014",18,9223372036854775807,Both,True
NCT02126943,Actelion,False,KY,https://ClinicalTrials.gov/show/NCT02126943,True,OPsumit USers Registry,Pulmonary Arterial Hypertension; PAH,Drug:Opsumit (macitentan),[],"February 24, 2015",0,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02106546,AbbVie,False,KY,https://ClinicalTrials.gov/show/NCT02106546,True,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],"January 13, 2016",18,99,Both,False
NCT02100228,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT02100228,True,"Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",Atrial Fibrillation,Drug:Apixaban; Drug:Parenteral heparin and/or oral Vitamin K antagonist,[],"January 16, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02047097,Biogen,False,KY,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02034058,Stryker Neurovascular,False,KY,https://ClinicalTrials.gov/show/NCT02034058,True,Post Market Surveillance Study of the Wingspan Stent System,Intracranial Atherosclerosis,Device:Wingspan Stent System,[],"January 12, 2016",0,9223372036854775807,Both,False
NCT02032004,Teva Pharmaceutical Industries,False,KY,https://ClinicalTrials.gov/show/NCT02032004,True,The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure.,Chronic Heart Failure,Biological:Allogeneic Mesenchymal Precursor Cells (MPC); Other:Sham Comparator,[],"February 4, 2016",18,80,Both,False
NCT01981603,Catherine Sullivan,False,KY,https://ClinicalTrials.gov/show/NCT01981603,True,Transplant Navigator Dissemination,Kidney Transplant; Renal Failure Chronic Requiring Hemodialysis,Other:navigator,"[u'Lutheran Hospital', u'University of Kentucky', u'Jewish Hospital', u'MetroHealth Medical Center', u'The Ohio State University']","October 2, 2015",18,70,Both,False
NCT01969799,Cardeas Pharma,False,KY,https://ClinicalTrials.gov/show/NCT01969799,True,Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin fosfomycin inhalation solution; Drug:Aerosolized placebo,[],"January 28, 2016",18,80,Both,False
NCT01950390,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01941316,Cancer Research and Biostatistics Clinical Trials Consortium,False,KY,https://ClinicalTrials.gov/show/NCT01941316,True,Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients,Small Cell Lung Carcinoma; Non Small Cell Lung Carcinoma; Irinotecan Sensitive Cancers,Drug:Carfilzomib; Drug:Irinotecan,"[u'Cancer Treatment Centers of America, Western Regional Medical Center', u'Cedars-Sinai Medical Center', u'UCLA', u'University of Kentucky Markey Cancer Center', u'Norton Cancer Institute', u'Washington University School of Medicine', u'Providence Portland Medical Center | Earle A. Chiles Research Institute', u'Virginia Mason Cancer Institute', u'Aurora Research Institute | Aurora Cancer Care']","January 26, 2016",18,9223372036854775807,Both,False
NCT01934192,GlaxoSmithKline,False,KY,https://ClinicalTrials.gov/show/NCT01934192,True,Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study,Gastroparesis,Drug:GSK962040 50 mg; Drug:Metoclopramide 10 mg; Drug:Placebo NG; Drug:Placebo IV,"[u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site', u'GSK Investigational Site']","February 4, 2016",18,85,Both,False
NCT01920711,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,KY,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01917747,"Matthew Bush, MD",False,KY,https://ClinicalTrials.gov/show/NCT01917747,True,Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators,Congenital Hearing Loss,Behavioral:Patient Navigator; Behavioral:Standard scheduling and follow-up,"[u'University of Kentucky', u'Commission for Children with Special Health Care Needs']","December 2, 2015",0,9223372036854775807,Both,True
NCT01909791,Diabetic Retinopathy Clinical Research Network,False,KY,https://ClinicalTrials.gov/show/NCT01909791,True,Treatment for CI-DME in Eyes With Very Good VA Study,Diabetic Macular Edema,Procedure:Prompt Laser; Drug:Prompt aflibercept; Procedure:Deferred laser; Drug:Deferred aflibercept,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,KY,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01897272,Christine M. Kleinert Institute for Hand and Microsurgery,False,KY,https://ClinicalTrials.gov/show/NCT01897272,True,Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study,Carpal Tunnel Syndrome,Behavioral:Splinting,"[u'Christine M. Kleinert Institute for Hand and Microsurgery', u'Kleinert, Kutz & Associates']","July 9, 2013",18,9223372036854775807,Both,False
NCT01883869,University of Kentucky,False,KY,https://ClinicalTrials.gov/show/NCT01883869,True,Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor,Pneumonia; Community Acquired Pneumonia; Hospital Acquired Pneumonia; Acute Lung Injury,Drug:ticagrelor; Drug:placebo,"[u'University of Kentucky Hospitals', u'University of Kentucky Hospital']","December 4, 2015",18,9223372036854775807,Both,False
NCT01882218,University of Louisville,False,KY,https://ClinicalTrials.gov/show/NCT01882218,True,Direct Peritoneal Resuscitation Plus Conventional Resuscitation,Hepatic Cancer,Drug:Galactose; Drug:Standard Treatment,"[u'Norton Hospital', u'University of Louisville Hospital']","June 17, 2013",18,75,Both,False
NCT01858532,AbbVie,False,KY,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01854229,Flowonix Medical,True,KY,https://ClinicalTrials.gov/show/NCT01854229,True,Prometra Post-Approval Study,Chronic Pain; Cancer Pain; Intractable Pain; Back Pain,Device:Prometra Programmable Intrathecal Infusion Pump,[],"February 2, 2016",22,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01838161,Elisia Cohen,False,KY,https://ClinicalTrials.gov/show/NCT01838161,True,Improving Adolescent Vaccination in Appalachian Kentucky,Adolescent Immunization,Behavioral:Part II; Behavioral:Part III,"[u'University of Kentucky', u'University of Kentucky']","December 3, 2014",11,70,Both,True
NCT01810913,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01772472,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01771809,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01771809,True,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],"January 16, 2016",18,65,Both,False
NCT01766817,Bristol-Myers Squibb,False,KY,https://ClinicalTrials.gov/show/NCT01766817,True,Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Drug:BMS-986020; Drug:Placebo matching with BMS-986020,[],"August 11, 2015",40,90,Both,False
NCT01757535,Celgene Corporation,False,KY,https://ClinicalTrials.gov/show/NCT01757535,True,Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission,"Leukemia, Myeloid, Acute",Drug:300 mg Oral Azacitidine; Drug:Placebo,[],"January 20, 2016",55,9223372036854775807,Both,False
NCT01733017,University of Kentucky,False,KY,https://ClinicalTrials.gov/show/NCT01733017,True,Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure,Heart Failure,Behavioral:Sodium reduction; Dietary Supplement:omega 3 and lycopene supplements,"[u'University of Kentucky, College of Nursing', u'Norton Health Care']","December 1, 2014",21,9223372036854775807,Both,False
NCT01716754,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01716754,True,Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma,Asthma,Drug:QGE031; Drug:Omalizumab; Drug:Placebo to QGE031; Drug:Placebo to omalizumab,[],"January 15, 2015",18,75,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,KY,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01652872,Amgen,False,KY,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01622868,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01602666,Children's Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01602666,True,Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors,Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma,Procedure:therapeutic conventional surgery; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Drug:carboplatin; Drug:etoposide; Drug:ifosfamide,[],"October 20, 2015",3,21,Both,False
NCT01529034,Upsher-Smith Laboratories,False,KY,https://ClinicalTrials.gov/show/NCT01529034,True,Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters,Epilepsy,Drug:USL261,[],"January 20, 2016",12,9223372036854775807,Both,False
NCT01471522,New York University School of Medicine,True,KY,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT01446965,"University of California, San Francisco",False,KY,https://ClinicalTrials.gov/show/NCT01446965,True,Vest Prevention of Early Sudden Death Trial and VEST Registry,Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation,Device:wearable defibrillator,[],"April 7, 2015",18,9223372036854775807,Both,False
NCT01442194,Novartis,False,KY,https://ClinicalTrials.gov/show/NCT01442194,True,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,Multiple Sclerosis,Drug:Fingolimod; Drug:other disease-modifying therapy,[],"January 15, 2016",0,9223372036854775807,Both,False
NCT01407952,Northwestern University,False,KY,https://ClinicalTrials.gov/show/NCT01407952,True,Hydrogel Endovascular Aneurysm Treatment Trial,Cerebral Aneurysm,Device:HydroCoil Embolic System; Device:Control (bare platinum coils),[],"July 10, 2015",18,75,Both,False
NCT01406756,Children's Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01393405,"University of North Carolina, Chapel Hill",True,KY,https://ClinicalTrials.gov/show/NCT01393405,True,Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis,Ulcerative Colitis,Drug:Methotrexate,[],"July 20, 2015",18,70,Both,False
NCT01390220,Upsher-Smith Laboratories,False,KY,https://ClinicalTrials.gov/show/NCT01390220,True,Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters,Epilepsy,Drug:USL261; Drug:Placebo,[],"January 19, 2016",12,9223372036854775807,Both,False
NCT01371656,Children's Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01371656,True,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,Acute Leukemias of Ambiguous Lineage; Bacterial Infection; Diarrhea; Fungal Infection; Musculoskeletal Complications; Neutropenia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:levofloxacin,[],"August 28, 2015",6,21,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,KY,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01314911,National Institute of Allergy and Infectious Diseases (NIAID),True,KY,https://ClinicalTrials.gov/show/NCT01314911,True,Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults,"Influenza, Human",Drug:Oseltamivir; Drug:Oseltamivir Placebo,[],"December 15, 2014",18,64,Both,False
NCT01307579,Children's Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01298570,UNC Lineberger Comprehensive Cancer Center,False,KY,https://ClinicalTrials.gov/show/NCT01298570,True,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,Colorectal Cancer Metastatic,Drug:Regorafenib (BAY 73-4506); Drug:FOLFIRI; Drug:Placebo; Drug:FOLFIRI,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01283009,VA Office of Research and Development,False,KY,https://ClinicalTrials.gov/show/NCT01283009,True,Extended Steroid in CAP(e),Community Acquired Respiratory Disease Syndrome,Drug:Methylprednisolone,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01220583,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01220583,True,Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery,Head and Neck Cancer,Drug:cisplatin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01146990,"Lumara Health, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT01146990,True,"A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth",Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial,"Drug:ASQ-3, Bayley III, Neurologic exam",[],"December 9, 2015",22,25,Both,False
NCT01131104,Eli Lilly and Company,False,KY,https://ClinicalTrials.gov/show/NCT01131104,True,A Study to Determine if There is a Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 (PDE5) Inhibitors,Nonarteritic Anterior Ischemic Optic Neuropathy,Drug:PDE5 Inhibitors,[],"November 12, 2015",18,9223372036854775807,Male,False
NCT01096368,Children's Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT01064648,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01004029,"Lumara Health, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT01004029,True,Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery,Preterm Birth,"Drug:Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug:Vehicle",[],"June 29, 2015",18,9223372036854775807,Female,False
NCT00978458,Eastern Cooperative Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00922974,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00922974,True,Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis,Metastatic Cancer; Pain,Radiation:external beam radiation therapy; Radiation:image-guided radiation therapy; Radiation:radiosurgery; Radiation:stereotactic body radiation therapy,[],"November 19, 2015",18,120,Both,False
NCT01272037,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,LA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01966107,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01594333,Brigham and Women's Hospital,False,LA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,LA,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02164513,GlaxoSmithKline,False,LA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,LA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,LA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01845025,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01652872,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02164916,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,LA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01663402,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,LA,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02528188,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01877915,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01870778,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,LA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02545049,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02497469,Takeda,False,LA,https://ClinicalTrials.gov/show/NCT02497469,True,An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis,"Colitis, Ulcerative",Drug:Vedolizumab; Drug:Adalimumab placebo; Drug:Adalimumab; Drug:Vedolizumab placebo,[],"December 1, 2015",18,80,Both,False
NCT02415400,Bristol-Myers Squibb,False,LA,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02400905,Veryan Medical Ltd.,False,LA,https://ClinicalTrials.gov/show/NCT02400905,True,Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System,Peripheral Arterial Disease,Device:BioMimics 3D Stent System,[],"January 21, 2016",19,85,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,LA,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02285062,Celgene Corporation,False,LA,https://ClinicalTrials.gov/show/NCT02285062,True,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,"Lymphoma, Large B-Cell, Diffuse",Drug:lenalidomide; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:prednisone; Drug:vincristine,[],"December 23, 2015",18,80,Both,False
NCT02257736,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02257736,True,An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),Prostatic Neoplasms,Drug:JNJ56021927; Drug:Abiraterone acetate; Drug:Prednisone; Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02145468,GlaxoSmithKline,False,LA,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,LA,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01633060,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01633060,True,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi","Metastatic Breast Cancer HR+, HER2-",Drug:Fulvestrant; Drug:BKM120; Drug:BKM120 matching placebo,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01575548,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00074282,Eastern Cooperative Oncology Group,True,LA,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,LA,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02542215,Sucampo AG,False,LA,https://ClinicalTrials.gov/show/NCT02542215,True,Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer,Oral Mucositis,Drug:Cobiprostone; Drug:Placebo,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02509078,Massachusetts General Hospital,False,LA,https://ClinicalTrials.gov/show/NCT02509078,True,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02487446,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02461589,Novo Nordisk A/S,False,LA,https://ClinicalTrials.gov/show/NCT02461589,True,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:liraglutide; Drug:placebo,[],"October 29, 2015",18,9223372036854775807,Both,False
NCT02420262,Novo Nordisk A/S,False,LA,https://ClinicalTrials.gov/show/NCT02420262,True,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec/liraglutide; Drug:insulin glargine; Drug:insulin aspart,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02367820,Nektar Therapeutics,False,LA,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02362672,Nektar Therapeutics,False,LA,https://ClinicalTrials.gov/show/NCT02362672,True,Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181; Drug:Placebo,[],"September 10, 2015",18,75,Both,False
NCT02311933,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02104947,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02104947,True,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Drug:idarucizumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02100514,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02043678,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02032823,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003209,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01997333,Celldex Therapeutics,False,LA,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01855750,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01846611,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT01846611,True,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms,Drug:Trabectedin; Drug:DOXIL; Drug:Dexamethasone; Drug:DOXIL,[],"January 19, 2016",18,9223372036854775807,Female,False
NCT01751906,Abbott Vascular,False,LA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,LA,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01668719,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01614652,"CardioKinetix, Inc",False,LA,https://ClinicalTrials.gov/show/NCT01614652,True,A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System,Congestive Heart Failure; Left Ventricular (LV) Systolic Dysfunction,Device:CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT),[],"December 7, 2015",18,79,Both,False
NCT01584557,Cardiovascular Clinical Science Foundation,False,LA,https://ClinicalTrials.gov/show/NCT01584557,True,"Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management",Heart Failure,Drug:Tolvaptan or Samsca; Drug:placebo or sugar pill,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,LA,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01371656,Children's Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01371656,True,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,Acute Leukemias of Ambiguous Lineage; Bacterial Infection; Diarrhea; Fungal Infection; Musculoskeletal Complications; Neutropenia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:levofloxacin,[],"August 28, 2015",6,21,Both,False
NCT01307579,Children's Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01101035,Takeda,True,LA,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00719303,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00316888,Eastern Cooperative Oncology Group,True,LA,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),True,LA,https://ClinicalTrials.gov/show/NCT00042289,True,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],"September 2, 2015",0,9223372036854775807,Female,False
NCT02674386,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02640482,AbbVie,False,LA,https://ClinicalTrials.gov/show/NCT02640482,True,A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection,Chronic Hepatitis C Virus (HCV) Infection,Drug:ABT-493/ABT-530; Drug:Placebo for ABT-493/ABT-530,[],"January 20, 2016",18,99,Both,False
NCT02605837,Shire,False,LA,https://ClinicalTrials.gov/show/NCT02605837,True,A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved,Eosinophilic Esophagitis (EoE) Dysphagia,Drug:Oral Budesonide Suspension; Drug:Placebo,"[u'Arkansas Gastroenterology', u'GW Research, Inc.', u'Accord Clinical Research LLC', u'Gastroenterology Associates LLC', u'Louisiana Research Center LLC']","November 24, 2015",11,55,Both,False
NCT02596893,Celgene Corporation,False,LA,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02583256,Novartis Vaccines,False,LA,https://ClinicalTrials.gov/show/NCT02583256,True,"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)",Influenza,Biological:aQIV-aQIV; Biological:aQIV-QIV; Biological:QIV-aQIV; Biological:QIV-QIV,[],"January 15, 2016",18,85,Both,True
NCT02551874,Bristol-Myers Squibb,False,LA,https://ClinicalTrials.gov/show/NCT02551874,True,"A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy",Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Dapagliflozin; Drug:Glargine insulin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02532855,Merck Sharp & Dohme Corp.,False,LA,https://ClinicalTrials.gov/show/NCT02532855,True,A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838),Type 2 Diabetes Mellitus,Drug:Sitagliptin; Drug:Dapagliflozin; Drug:Metformin; Drug:Matching placebo to sitagliptin; Drug:Matching placebo to dapagliflozin,[],"February 2, 2016",25,9223372036854775807,Both,False
NCT02531516,"Aragon Pharmaceuticals, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02531516,True,An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS,Prostatic Neoplasms,Drug:JNJ-56021927; Drug:Bicalutamide; Drug:Bicalutamide Placebo; Drug:JNJ-56021927 Placebo; Drug:GnRH (agonist); Radiation:74-80 Grays (units of radiation),[],"January 27, 2016",18,9223372036854775807,Male,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02520284,Gilead Sciences,False,LA,https://ClinicalTrials.gov/show/NCT02520284,True,Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis,Biological:GS-5745; Biological:Placebo,[],"January 15, 2016",18,75,Both,False
NCT02513641,Pennington Biomedical Research Center,False,LA,https://ClinicalTrials.gov/show/NCT02513641,True,Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes,Type 2 Diabetes,Device:Hypoxico Altitude Training Systems,"[u'Pennington Biomedical Research Center', u'Pennington Biomedical Research Center']","January 8, 2016",20,45,Both,True
NCT02510014,Indivior Inc.,False,LA,https://ClinicalTrials.gov/show/NCT02510014,True,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Opioid Use Disorder; Opioid-related Disorders,Drug:SUBOXONE sublingual film; Drug:high dose RBP-6000; Drug:low dose RBP-6000,[],"December 10, 2015",18,65,Both,False
NCT02503631,Exact Sciences Corporation,False,LA,https://ClinicalTrials.gov/show/NCT02503631,True,Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers,Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer,Device:Stool Sample Collection Kit,"[u'', u'Medical Research Center of Connecticut', u'Endoscopic Research, Inc.', u'Rush University Medical Center', u'New Orleans Research Institute', u'Louisiana Research Center, LLC', u'Chevy Chase Clinical Research', u'Commonwealth Clinical Studies', u'Sundance Clinical Research, LLC', u'Asheville Gastroenterology Associates, PA', u'Cumberland Research Associates, LLC', u'Northwest Gastroenterology Clinic, LLC', u'Main Line Gastroenterology Associates', u'Radiant Research, Inc.', u'Gastro One', u'Blue Ridge Medical Researcj', u'Digestive and Liver Disease Specialists', u'Forzani & MacPhali Colon Cancer Screening Centre']","January 21, 2016",40,90,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02456740,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT02456740,True,Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention,Migraine,Drug:AMG 334; Drug:AMG 334; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02438007,Tokai Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT02438007,True,A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,Prostate Cancer,Drug:Galeterone; Drug:Enzalutamide,[],"January 22, 2016",18,9223372036854775807,Male,False
NCT02407236,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02405442,Gilead Sciences,False,LA,https://ClinicalTrials.gov/show/NCT02405442,True,Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease,Crohn's Disease,Drug:GS-5745; Drug:Placebo,[],"January 6, 2016",18,75,Both,False
NCT02403323,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02394028,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02388165,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02379390,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT02379390,True,Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz,Prostate Cancer Metastatic,Drug:CABAZITAXEL XRP6258; Drug:Enzalutamide; Drug:Abiraterone acetate; Drug:Prednisone,"[u'840002', u'840006', u'840001', u'840017', u'840012', u'840016']","November 26, 2015",18,9223372036854775807,Male,False
NCT02373813,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT02373813,True,Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission,Rheumatoid Arthritis,Drug:etanercept pre-filled syringe sq injection; Drug:Oral methotrexate; Drug:Placebo for etanercept sq injection; Drug:Placebo for methotrexate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02369653,Bristol-Myers Squibb,False,LA,https://ClinicalTrials.gov/show/NCT02369653,True,Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase,Lymphoma; Acute Lymphoblastic Leukemia,Drug:Apixaban; Other:No systemic anticoagulant prophylaxis,[],"January 26, 2016",1,17,Both,False
NCT02360748,Ochsner Health System,True,LA,https://ClinicalTrials.gov/show/NCT02360748,True,A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients,End-Stage Renal Disease; Malnutrition,Dietary Supplement:Plant based high protein food items,"[u'OCHSNER', u'Fresenius Home Program']","October 14, 2015",18,90,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02348723,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02348723,True,Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT),Atrial Fibrillation,Drug:Warfarin; Drug:Dabigatran Etexilate 150mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,LA,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02326454,Light Sciences Oncology,False,LA,https://ClinicalTrials.gov/show/NCT02326454,True,A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug:talaporfin sodium; Drug:Saline; Device:Drug Activator 100 J/cm; Device:Drug Activator 200 J/cm,[],"February 1, 2016",40,9223372036854775807,Male,False
NCT02320721,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT02320721,True,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Drug:Insulin glargine U300 HOE901; Drug:Insulin glargine HOE901,[],"February 3, 2016",65,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02280824,"National Heart, Lung, and Blood Institute (NHLBI)",True,LA,https://ClinicalTrials.gov/show/NCT02280824,True,Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access,Aortic Valve Stenosis,Procedure:CA-TAVR,"[u'Medstar Washington Hospital Center', u'University of Florida', u'Emory University', u'NorthShore University HealthSystem, Evanston Hospital', u'Advocate Heart Institute', u'Cardiovascular Institute of the South', u'Ochsner Health System', u'Henry Ford Hospital', u'Wake Forest University', u'Good Samaritan Hospital', u'Oklahoma Heart Institute', u'York Hospital', u'Vanderbilt Heart and Vascular Institute', u'University of Virginia Medical Center']","November 24, 2015",21,99,Both,False
NCT02243293,AbbVie,False,LA,https://ClinicalTrials.gov/show/NCT02243293,True,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],"February 4, 2016",18,100,Both,False
NCT02240108,"Valeant Pharmaceuticals International, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02240108,True,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02231723,"Boston Biomedical, Inc",False,LA,https://ClinicalTrials.gov/show/NCT02231723,True,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug:BBI608; Drug:Nab-paclitaxel; Drug:Gemcitabine; Drug:Oxaliplatin; Drug:Leucovorin; Drug:Irinotecan; Drug:Fluorouracil,"[u'Emory University Winship Cancer Institute', u'Indiana University Health Goshen Center for Cancer Care', u'Indiana University Melvin and Bren Simon Cancer Center', u'Indiana University Health Arnett Hospital', u'Indiana University Health Ball Memorial Hospital', u'Ochsner Medical Center - Baton Rouge', u'Ochsner Medical Center', u'Comprehensive Cancer Centers of Nevada', u'The Ohio State University Comprehensive Cancer Center', u'The University of Tennessee Medical Center', u'Texas Oncology - Austin Midtown', u'Texas Oncology - Baylor Charles A. Sammons Cancer Center', u'Texas Oncology - SAT&BC', u'Virginia Oncology Associates', u'Yakima Valley Memorial Hospital / North Star Lodge']","January 6, 2016",18,9223372036854775807,Both,False
NCT02187471,Daiichi Sankyo Inc.,False,LA,https://ClinicalTrials.gov/show/NCT02187471,True,Treatment of Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:DS-5565 15mg tablet; Drug:150mg pregabalin capsule; Drug:placebo tablet; Drug:placebo capsule; Drug:75mg pregabalin capsule,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02187055,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT02187055,True,An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate,Rhematoid Arthritis,Drug:Tofacitinib with methotrexate; Drug:Tofacitinib without methotrexate; Biological:Adalimumab with methotrexate,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02181673,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02181673,True,A Study of Golimumab in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Placebo; Drug:Golimumab,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02156336,Horizons International Peripheral Group,True,LA,https://ClinicalTrials.gov/show/NCT02156336,True,Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP),Diabetic Peripheral Neuropathic Pain,Drug:Ranolazine; Drug:Placebo,"[u'Cardiology Associates', u'Cardiovascular Institute of the South', u'Cardiovascular Institute of the South']","August 18, 2015",18,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02153645,Osmotica Pharmaceutical Corp.,False,LA,https://ClinicalTrials.gov/show/NCT02153645,True,Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.,Parkinson's Disease; Levodopa Induced Dyskinesias (LID),Drug:Amantadine ER Tablets; Drug:Placebo Tablets for Amantadine ER Tablets,[],"October 14, 2015",30,85,Both,False
NCT02153632,Osmotica Pharmaceutical Corp.,False,LA,https://ClinicalTrials.gov/show/NCT02153632,True,Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias,Parkinson's Disease; Levodopa Induced Dyskinesia (LID),Drug:Amantadine HCl ER (ALLAY-LID II); Drug:Placebo,[],"October 14, 2015",30,85,Both,False
NCT02151149,Celgene Corporation,False,LA,https://ClinicalTrials.gov/show/NCT02151149,True,Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly,"Non-Small Cell Lung Cancer; Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma; Carcinoma, Large Cell; Lung Neoplasm",Drug:nab-paclitaxel; Drug:Carboplatin,[],"October 19, 2015",70,9223372036854775807,Both,False
NCT02138253,Conatus Pharmaceuticals Inc.,False,LA,https://ClinicalTrials.gov/show/NCT02138253,True,A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV,Liver Fibrosis; Hepatic Fibrosis; Liver Cirrhosis; Hepatic Cirrhosis,Drug:IDN-6556; Drug:Placebo,[],"September 25, 2015",18,9223372036854775807,Both,False
NCT02118584,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02100696,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT02100696,True,A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors,Ulcerative Colitis,Drug:etrozulimab; Drug:placebo,[],"February 1, 2016",18,80,Both,False
NCT02089217,"Thomas G. Brott, M.D.",False,LA,https://ClinicalTrials.gov/show/NCT02089217,True,Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial,Carotid Stenosis,Procedure:Carotid endarterectomy; Device:Carotid stenting,[],"January 27, 2016",35,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02060630,New England Research Institutes,False,LA,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02051608,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT02051608,True,A Study of Gantenerumab in Patients With Mild Alzheimer Disease,Alzheimer Disease,Drug:florbetapir; Drug:gantenerumab; Drug:placebo,[],"February 1, 2016",50,90,Both,False
NCT02047097,Biogen,False,LA,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02034552,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT02034552,True,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo,BAY88-8223); Drug:Abiraterone acetate; Drug:Prednisone; Drug:Enzalutamide",[],"January 4, 2016",18,9223372036854775807,Male,False
NCT02025751,Evoke Pharma,False,LA,https://ClinicalTrials.gov/show/NCT02025751,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Male,False
NCT02025725,Evoke Pharma,False,LA,https://ClinicalTrials.gov/show/NCT02025725,True,Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis,Diabetic Gastroparesis,Drug:Metoclopramide Nasal Spray; Drug:Placebo Nasal Spray,[],"December 28, 2015",18,75,Female,False
NCT02019264,Eisai Inc.,False,LA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01996345,Obstetrix Medical Group,False,LA,https://ClinicalTrials.gov/show/NCT01996345,True,Vaginal Pessary Versus Expectant Management for Placenta Previa,Placenta Previa,Procedure:Cervical Pessary Placement,"[u'University of South Alabama Medical Center', u'Long Beach Memorial Medical Center', u'Good Samaritan Hospital', u""Presbyterian/St Luke's Hospital"", u'Denver Health and Hospital Authority', u""Norton Kosair Children's Hospital"", u'Tulane - Lakeside Hospital for Women and Children', u'Touro Infirmary', u'Swedish Medical Center']","November 4, 2015",18,54,Female,False
NCT01968967,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01966419,Ocera Therapeutics,False,LA,https://ClinicalTrials.gov/show/NCT01966419,True,Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE),Acute Episode of Overt Hepatic Encephalopathy; Hepatic Encephalopathy,Drug:ornithine phenylacetate; Drug:placebo intravenous infusion,[],"January 14, 2016",18,75,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01942694,Tufts Medical Center,False,LA,https://ClinicalTrials.gov/show/NCT01942694,True,Vitamin D and Type 2 Diabetes Study,Prediabetes; Type 2 Diabetes,Dietary Supplement:Vitamin D (Cholecalciferol); Other:Placebo,[],"November 6, 2015",30,9223372036854775807,Both,False
NCT01922011,Cubist Pharmaceuticals LLC,False,LA,https://ClinicalTrials.gov/show/NCT01922011,True,Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006),Acute Hematogenous Osteomyelitis,Drug:Daptomycin; Drug:Vancomycin (or equivalent); Drug:Nafcillin (or equivalent),[],"February 4, 2016",1,17,Both,False
NCT01903811,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01858519,AbbVie,False,LA,https://ClinicalTrials.gov/show/NCT01858519,True,Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy,Cystic Fibrosis,Biological:pancrelipase,[],"December 14, 2015",2,99,Both,False
NCT01856192,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01854229,Flowonix Medical,True,LA,https://ClinicalTrials.gov/show/NCT01854229,True,Prometra Post-Approval Study,Chronic Pain; Cancer Pain; Intractable Pain; Back Pain,Device:Prometra Programmable Intrathecal Infusion Pump,[],"February 2, 2016",22,9223372036854775807,Both,False
NCT01832480,Tulane University Health Sciences Center,True,LA,https://ClinicalTrials.gov/show/NCT01832480,True,Trichomonas Vaginalis Repeat Infections Among HIV Negative Women,Vaginitis Trichomonal or Due to Trichomonas,Drug:MTZ 500 mg BID x 7 days; Drug:MTZ 2 g,"[u'Jefferson County Dept of Health/STD Specialty Clinic', u'ILH LSU OB/GYN Clinic', u'CrescentCare Health and Wellness Center', u'Crossroads Clinic']","December 3, 2015",18,9223372036854775807,Female,False
NCT01824875,Eastern Cooperative Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01797185,Sun Pharma Advanced Research Company Limited,False,LA,https://ClinicalTrials.gov/show/NCT01797185,True,"A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial",Spasticity,Drug:Baclofen,[],"September 15, 2015",18,90,Both,False
NCT01794663,Opsona Therapeutics Ltd.,False,LA,https://ClinicalTrials.gov/show/NCT01794663,True,Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function,Delayed Graft Function,Drug:OPN-305 or Placebo,[],"October 30, 2015",18,9223372036854775807,Both,False
NCT01757535,Celgene Corporation,False,LA,https://ClinicalTrials.gov/show/NCT01757535,True,Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission,"Leukemia, Myeloid, Acute",Drug:300 mg Oral Azacitidine; Drug:Placebo,[],"January 20, 2016",55,9223372036854775807,Both,False
NCT01750190,FibroGen,False,LA,https://ClinicalTrials.gov/show/NCT01750190,True,A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis,CKD Anemia,Drug:FG-4592; Drug:Placebo,[],"September 24, 2015",18,9223372036854775807,Both,False
NCT01737814,"Mast Therapeutics, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT01737814,True,Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC),Vaso-occlusive Crisis; Sickle Cell Disease,Drug:Saline; Drug:MST-188,[],"January 9, 2016",4,65,Both,False
NCT01727154,Dendreon,False,LA,https://ClinicalTrials.gov/show/NCT01727154,True,Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T,Prostate Cancer,Biological:Sipuleucel-T,[],"December 18, 2015",18,9223372036854775807,Male,False
NCT01714817,Bristol-Myers Squibb,False,LA,https://ClinicalTrials.gov/show/NCT01714817,True,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Lupus Nephritis,Biological:BMS-188667; Drug:Mycophenolate mofetil; Drug:Prednisone; Biological:Placebo matching with BMS-188667,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01660451,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT01660451,True,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","Lymphoma, Non-Hodgkin",Drug:Copanlisib (BAY80-6946),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01632241,"Human Genome Sciences Inc., a GSK Company",False,LA,https://ClinicalTrials.gov/show/NCT01632241,True,Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Drug:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01621243,"Momenta Pharmaceuticals, Inc.",False,LA,https://ClinicalTrials.gov/show/NCT01621243,True,M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug:nab-paclitaxel; Drug:gemcitabine; Drug:placebo; Drug:Necuparanib,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01503632,Children's Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01457352,Sun Pharma Advanced Research Company Limited,False,LA,https://ClinicalTrials.gov/show/NCT01457352,True,Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis,Spasticity,Drug:Baclofen ER Capsules; Drug:Placebo GRS,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,LA,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01236547,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01227967,National Institute of Allergy and Infectious Diseases (NIAID),True,LA,https://ClinicalTrials.gov/show/NCT01227967,True,"Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications",Influenza,"Drug:Amantadine, Ribavirin, Oseltamivir; Drug:Oseltamivir",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01200589,GlaxoSmithKline,False,LA,https://ClinicalTrials.gov/show/NCT01200589,True,Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy,Non-Hodgkin's Lymphoma,Biological:Ofatumumab; Biological:Rituximab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01193842,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01193842,True,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,Adult Grade III Lymphomatoid Granulomatosis; AIDS-Related Diffuse Large Cell Lymphoma; HIV Infection; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Adult Contiguous Immunoblastic Lymphoma; Stage II Adult Non-Contiguous Immunoblastic Lymphoma; Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Contiguous Mantle Cell Lymphoma; Stage II Grade 3 Contiguous Follicular Lymphoma; Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Mantle Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02155296,RAND,False,ME,https://ClinicalTrials.gov/show/NCT02155296,True,RCT of the Restorative Practices Intervention,Intervention Schools (Schools Receiving RPI); Control Schools (Schools Not Receiving RPI),Behavioral:Restorative Practices Intervention,"[u'Bath Middle School', u'Boothbay school', u'Bucksport school', u'Bonny Eagle school', u'Ridge View school', u'Hall-Dale school', u'Molly Ockett', u'Gorham school', u'Hope school', u'Jefferson Village school', u'Mt. Jefferson school', u'Libby school', u'Maranacook school', u'Oak Hill school', u'Skowhegan school', u'Windham school']","October 27, 2015",12,9223372036854775807,Both,True
NCT02194738,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,ME,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02115282,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,ME,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01663402,Sanofi,False,ME,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,ME,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02488967,NRG Oncology,False,ME,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01950390,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT02562716,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02438722,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02164916,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01903811,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01772472,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01311336,University of Vermont,False,ME,https://ClinicalTrials.gov/show/NCT01311336,True,Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain,Pegfilgrastim-induced Back and Leg Pain,Drug:Loratadine; Drug:placebo,"[u'Cancer Care of Maine', u'Maine Center for Cancer Medicine', u'York Hospital', u'CR Wood Cancer Center', u'Mountainview Medical Center', u'Vermont Cancer Center', u'Vermont Center for Cancer Medicine']","January 23, 2013",18,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,ME,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02670083,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02406677,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02180867,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,ME,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02027428,Celgene Corporation,False,ME,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01858532,AbbVie,False,ME,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01856192,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,ME,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01190930,Children's Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01169337,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,ME,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00892866,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00892866,True,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,ME,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02675426,AbbVie,False,ME,https://ClinicalTrials.gov/show/NCT02675426,True,A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone,Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,99,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02670434,"Kowa Research Institute, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT02670434,True,Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia,Hyperlipidemia; Dyslipidemia,Drug:NK-104-CR; Drug:Placebo; Drug:Livalo,[],"February 2, 2016",18,80,Both,False
NCT02643251,BioDelivery Sciences International,False,ME,https://ClinicalTrials.gov/show/NCT02643251,True,"The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy",Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy,"Drug:Clonidine Hydrochloride Topical Gel, 0.1%; Drug:Clonidine Hydrochloride Gel Comparator",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,ME,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02617667,Novaliq GmbH,False,ME,https://ClinicalTrials.gov/show/NCT02617667,True,CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED),Dry Eye Syndromes,Drug:Cyclosporine A; Drug:Placebo,"[u'CYS-002 Investigational Site', u'CYS-002 Investigational Site', u'CYS-002 Investigational Site']","January 11, 2016",18,99,Both,False
NCT02608697,Catabasis Pharmaceuticals,False,ME,https://ClinicalTrials.gov/show/NCT02608697,True,A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia,Hypercholesterolemia,Drug:CAT-2054; Drug:Placebo; Drug:Atorvastatin,[],"December 23, 2015",18,74,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02574078,Bristol-Myers Squibb,False,ME,https://ClinicalTrials.gov/show/NCT02574078,True,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02566889,"Janssen Scientific Affairs, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02566889,True,An Efficacy and Safety Study of Infliximab in Pediatric Participants With Inflammatory Bowel Disease,Inflammatory Bowel Disease,Drug:Infliximab,[],"January 20, 2016",6,16,Both,False
NCT02547935,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02547935,True,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabestes and CKD3","Type 2 Diabetes Mellitus, CKD3 and Albuminuria",Drug:Dapagliflozin 10 mg; Drug:Dapagliflozin 10mg+Saxagliptin 2.5mg; Drug:Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,[],"December 16, 2015",18,74,Both,False
NCT02545049,Bayer,False,ME,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,ME,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02536339,"Genentech, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT02536339,True,Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,Metastatic Breast Cancer,Drug:Pertuzumab; Drug:Trastuzumab,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","February 1, 2016",18,9223372036854775807,Both,False
NCT02509078,Massachusetts General Hospital,False,ME,https://ClinicalTrials.gov/show/NCT02509078,True,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,ME,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02492711,MacroGenics,False,ME,https://ClinicalTrials.gov/show/NCT02492711,True,Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,HER-2 Positive Breast Cancer; Metastatic Neoplasm,Biological:Margetuximab; Biological:Trastuzumab; Drug:Capecitabine; Drug:Eribulin; Drug:Gemcitabine; Drug:Vinorelbine,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02477891,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02477891,True,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02477618,Sage Therapeutics,False,ME,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02470585,AbbVie,False,ME,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02465515,GlaxoSmithKline,False,ME,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02459899,Lexicon Pharmaceuticals,False,ME,https://ClinicalTrials.gov/show/NCT02459899,True,Dose-ranging Study in Patients With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Drug:Placebo; Drug:Sotagliflozin; Drug:Sotagliflozin; Drug:Sotagliflozin,"[u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site']","January 22, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,ME,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02450331,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02450331,True,"A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]","Bladder Cancer, Cancer","Drug:Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02422615,Novartis Pharmaceuticals,False,ME,https://ClinicalTrials.gov/show/NCT02422615,True,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,"Breast Neoplasms; Breast Diseases; Neoplasms; Neoplasms by Site; Fulvestrant; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Therapeutic Use",Drug:Ribociclib; Drug:fulvestrant; Drug:Ribociclib placebo,[],"September 14, 2015",18,9223372036854775807,Female,False
NCT02421588,PharmaMar,False,ME,https://ClinicalTrials.gov/show/NCT02421588,True,Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients,Ovarian Cancer,Drug:Lurbinectedin (PM01183); Drug:Pegylated liposomal doxorubicin (PLD); Drug:Topotecan,[],"January 14, 2016",18,9223372036854775807,Both,False
NCT02414854,Sanofi,False,ME,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02410278,Biogen,False,ME,https://ClinicalTrials.gov/show/NCT02410278,True,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,Multiple Sclerosis,Drug:dimethyl fumarate; Drug:montelukast; Drug:Placebo,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT02400476,"Puma Biotechnology, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT02400476,True,A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,Early Stage HER2+ Breast Cancer,Drug:Neratinib; Drug:Loperamide,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02394509,Dartmouth-Hitchcock Medical Center,False,ME,https://ClinicalTrials.gov/show/NCT02394509,True,HOBSCOTCH Phase II,Epilepsy,Behavioral:Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH),"[u'Maine Medical Center', u'University of Massachusetts Medical School', u'Dartmouth-Hitchcock Medical Center in Lebanon, NH', u'University of Vermont Medical Center']","January 7, 2016",18,65,Both,False
NCT02392676,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02392676,True,Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,Platinum Sensitive Relapsed Ovarian Cancer,Drug:OLAPARIB; Drug:PLACEBO,[],"October 26, 2015",18,96,Female,False
NCT02389023,University of Vermont Medical Center,True,ME,https://ClinicalTrials.gov/show/NCT02389023,True,Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery,Peripheral Artery Disease; Critical Limb Ischemia; Claudication,Other:standard gauze dressing; Other:Prevena Incision Management system,"[u'Maine Medical Center', u""Brigham and Women's Hospital"", u'Beth Isreal Deaconess Medical Center', u'University of Vermont Medical Center']","February 2, 2016",18,9223372036854775807,Both,False
NCT02383940,Lexicon Pharmaceuticals,False,ME,https://ClinicalTrials.gov/show/NCT02383940,True,Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C,Type 1 Diabetes Mellitus,Drug:Sotagliflozin; Drug:Placebo,"[u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site', u'Lexicon Investigational Site']","January 22, 2016",18,30,Both,False
NCT02367794,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02366143,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02366143,True,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02352948,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02343445,Parion Sciences,False,ME,https://ClinicalTrials.gov/show/NCT02343445,True,Clearing Lungs With ENAC Inhibition in Cystic Fibrosis,Cystic Fibrosis,Drug:P-1037; Drug:Hypertonic Saline; Drug:Saline,[],"November 17, 2015",12,80,Both,False
NCT02315469,NRG Oncology,False,ME,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02293395,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02293395,True,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:Acetylsalicylic acid; Drug:Rivaroxaban; Drug:Clopidogrel; Drug:Ticagrelor,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02290028,Biotronik SE & Co. KG,False,ME,https://ClinicalTrials.gov/show/NCT02290028,True,Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads,Heart Failure,Device:Sentus QP left ventricular lead,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02279394,Dana-Farber Cancer Institute,False,ME,https://ClinicalTrials.gov/show/NCT02279394,True,Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,Smoldering Myeloma; Smoldering Multiple Myeloma,Drug:Elotuzumab; Drug:Lenalidomide; Drug:Dexamethasone,"[u'Colorado Blood Cancer Institute', u'St Francis Hospital and Medical Center', u'Lawrence and Memorial Hospital', u'Eastern Maine Medical Center', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Newton-Wellesley Hospital', u'Barbara Ann Karmanos Cancer Institute']","October 22, 2015",18,9223372036854775807,Both,False
NCT02277990,Medtronic Cardiac Rhythm Disease Management,False,ME,https://ClinicalTrials.gov/show/NCT02277990,True,World-wide Randomized Antibiotic Envelope Infection Prevention Trial,CIED Related Infection,Device:TYRX Absorbable Antibacterial Envelope,[],"August 27, 2015",18,9223372036854775807,Both,True
NCT02273960,Bristol-Myers Squibb,False,ME,https://ClinicalTrials.gov/show/NCT02273960,True,Study to Evaluate Safety and Efficacy in Adult Subjects With ITP,Immune Thrombocytopenic Purpura,Drug:BMS-986004,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02268851,Dana-Farber Cancer Institute,False,ME,https://ClinicalTrials.gov/show/NCT02268851,True,A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma,Drug:TGR-1202; Drug:Ibrutinib,"[u'Pacific Cancer Care', u'St. Francis Hospital and Cancer Center', u'Northside Hospital and Cancer Center', u'Eastern Maine Medical Center', u'Dana Farber Cancer Institute', u'Beth Israel Deaconness Medical Center', u'Kadlec Clinic Hematology Oncology']","September 23, 2015",18,9223372036854775807,Both,False
NCT02268214,Bristol-Myers Squibb,False,ME,https://ClinicalTrials.gov/show/NCT02268214,True,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Drug:Dapagliflozin; Drug:Placebo for Dapagliflozin,[],"January 26, 2016",18,75,Both,False
NCT02258542,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02257736,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02257736,True,An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),Prostatic Neoplasms,Drug:JNJ56021927; Drug:Abiraterone acetate; Drug:Prednisone; Drug:Placebo,[],"February 2, 2016",18,9223372036854775807,Male,False
NCT02251548,Dana-Farber Cancer Institute,False,ME,https://ClinicalTrials.gov/show/NCT02251548,True,"A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",Chronic Lymphocytic Leukemia; Leukemia,Drug:Ibrutinib; Drug:Fludarabine; Drug:Cyclophosphamide; Drug:Rituximab,"[u'Eastern Maine Medical Center', u'Massachusetts General Hospital', u'Dana Farber Cancer Institute', u'Duke University Medical Center']","November 2, 2015",18,65,Both,False
NCT02247479,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02247479,True,A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02243592,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02243592,True,Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment,Malignant Neoplasm,Other:Laboratory Biomarker Analysis,[],"January 22, 2016",0,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,ME,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02230969,Biogen,False,ME,https://ClinicalTrials.gov/show/NCT02230969,True,Plegridy Observational Program,Relapsing Forms of Multiple Sclerosis,Drug:peginterferon beta-1a,[],"September 10, 2015",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02228681,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02228681,True,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"Advanced, Persistent, or Recurrent Endometrial Cancer",Drug:Everolimus; Drug:Tamoxifen; Drug:Letrozole; Drug:Medroxyprogesterone Acetate,[],"November 18, 2015",18,9223372036854775807,Female,False
NCT02195232,Dana-Farber Cancer Institute,False,ME,https://ClinicalTrials.gov/show/NCT02195232,True,Cancer Associated Thrombosis and Isoquercetin (CAT IQ),Thromboembolism of Vein VTE in Colorectal Cancer; Thromboembolism of Vein in Pancreatic Cancer; Thromboembolism of Vein in Non-small Cell Lung Cancer,Drug:Isoquercetin,"[u'USC/Norris Comprehensive Cancer Center and Hospital', u'UC Davis Health System', u'Veteran Affairs Medical Center', u'Georgetown University', u'York Hospital', u'VA Boston Healthcare System', u'Beth Israel Deaconess Medical Center', u'Mount Auburn Hospital', u'Washington University']","November 17, 2015",18,9223372036854775807,Both,False
NCT02188758,Dartmouth-Hitchcock Medical Center,True,ME,https://ClinicalTrials.gov/show/NCT02188758,True,Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment,Cystic Fibrosis,Other:Adults - CFPE Treatment,"[u'Maine Medical Center', u'Dartmouth-Hitchcock Medical Center', u'University of Vermont']","August 14, 2015",18,65,Both,False
NCT02177695,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02164864,Boehringer Ingelheim,False,ME,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,ME,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT02159521,EKOS Corporation,False,ME,https://ClinicalTrials.gov/show/NCT02159521,True,Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic Endovascular System,Deep Vein Thrombosis; Post-thrombotic Syndrome,Device:EkoSonic Endovascular System,"[u'Pima Vascular, Tucson Medical Center', u'UCLA Medical Center', u'Yale-New haven Hospital', u'Christiana Hospital', u'Tampa General Hospital', u'Florida Hospital at Tampa', u'Medical Center of Central Georgia', u'St. Vincent Hospital', u'University of Louisville Research Foundation', u'Maine Medical Center', u'University of Michigan Medical Center', u'Hackensack Medical Center', u'Saint Barnabas Medical Center', u'Holy Name Medical Center', u'Aultman Hospital', u'Fairfield Medical Center', u'Oregon Health & Science University', u'DFW Vascular Group/ Methodist Dallas Medical Ctr', u'Inova Alexandria Hospital', u'Sentara Norfolk General Hospital']","January 26, 2015",18,75,Both,False
NCT02150343,Circassia Limited,False,ME,https://ClinicalTrials.gov/show/NCT02150343,True,Phase II HDM-SPIRE Safety and Efficacy Study,Rhinoconjunctivitis,Drug:HDM-SPIRE; Drug:Placebo,[],"June 11, 2015",18,65,Both,False
NCT02145468,GlaxoSmithKline,False,ME,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104947,Boehringer Ingelheim,False,ME,https://ClinicalTrials.gov/show/NCT02104947,True,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Drug:idarucizumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02101853,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02101788,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02100722,Stanford University,True,ME,https://ClinicalTrials.gov/show/NCT02100722,True,A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease,Coronary Disease; Coronary Stenosis,Procedure:FFR guided PCI; Procedure:CABG,[],"September 22, 2015",21,9223372036854775807,Both,False
NCT02097849,Biogen,False,ME,https://ClinicalTrials.gov/show/NCT02097849,True,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,Relapsing Forms of Multiple Sclerosis,Drug:dimethyl fumarate; Biological:tetanus diphtheria toxoids vaccine; Biological:23-valent pneumococcal polysaccharide vaccine; Biological:meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent); Drug:non-pegylated interferon,"[u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site']","December 3, 2015",18,55,Both,False
NCT02089217,"Thomas G. Brott, M.D.",False,ME,https://ClinicalTrials.gov/show/NCT02089217,True,Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial,Carotid Stenosis,Procedure:Carotid endarterectomy; Device:Carotid stenting,[],"January 27, 2016",35,9223372036854775807,Both,False
NCT02073565,OrbusNeich,False,ME,https://ClinicalTrials.gov/show/NCT02073565,True,"HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt",Coronary Arteriosclerosis; Non ST Segment Elevation Acute Coronary Syndrome,Device:OrbusNeich Combo stent; Device:Everolimus Eluting Stent (EES),[],"July 27, 2015",20,9223372036854775807,Both,False
NCT02070250,Ohio State University Comprehensive Cancer Center,False,ME,https://ClinicalTrials.gov/show/NCT02070250,True,Stress Management for Cancer Patients: How Well Does it Work? (C2H-D),"Mood; Stress, Psychological",Behavioral:From Cancer to Health (C2H-D),"[u'Cancer Center of East Alabama Medical Center', u'Tahoe Forest Cancer Center', u'Cancer Wellness Center', u'IU Health Ball Memorial Hospital', u'Christine Gray, PsyD, Private Practice', u'Josephine Ford Cancer Institute-Henry Ford Hospital', u'Urology Center of Raleigh', u'OSU Stephanie Spielman Comprehensive Breast Center', u'Seton UT Southwestern', u'Baylor Regional Medical Center at Plano, Texas']","November 17, 2015",21,80,Both,False
NCT02066636,Bristol-Myers Squibb,False,ME,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02064439,Bayer,False,ME,https://ClinicalTrials.gov/show/NCT02064439,True,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Pulmonary Embolism; Thromboembolism; Thrombosis; Venous Thrombosis; Venous Thromboembolism,Drug:BAY 59-7939; Drug:BAY 59-7939; Drug:ASA,[],"January 14, 2016",18,9223372036854775807,Both,False
NCT02060630,New England Research Institutes,False,ME,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02054156,Bonnie Ramsey,False,ME,https://ClinicalTrials.gov/show/NCT02054156,True,OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis,Cystic Fibrosis,Drug:azithromycin; Drug:placebo; Drug:Tobramycin solution for inhalation,[],"September 25, 2015",6,18,Both,False
NCT02047097,Biogen,False,ME,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02042898,"St. Michael's Hospital, Toronto",False,ME,https://ClinicalTrials.gov/show/NCT02042898,True,Transfusion Requirements in Cardiac Surgery III,"Disorder; Heart, Functional, Postoperative, Cardiac Surgery",Other:Restrictive Transfusion Strategy; Other:Liberal transfusion strategy,[],"December 2, 2015",18,9223372036854775807,Both,False
NCT02037529,Academic and Community Cancer Research United,False,ME,https://ClinicalTrials.gov/show/NCT02037529,True,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Drug:Eribulin; Drug:Paclitaxel,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02036970,"Reata Pharmaceuticals, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT02036970,True,Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Drug:Bardoxolone methyl; Drug:Placebo,[],"September 24, 2015",18,75,Both,False
NCT02032277,AbbVie,False,ME,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT02030522,University of South Florida,True,ME,https://ClinicalTrials.gov/show/NCT02030522,True,Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma,Post-traumatic Stress Disorder (PTSD),Behavioral:Accelerated Resolution Therapy (ART),"[u'Homeless Emergency Project (HEP)', u'Veterans Alternative Therapy Center', u'Life Renewal Counseling', u'Pasco County Detention Center', u'Supportive Services for Veterans Families', u'Gilstrap & Associates', u'University of South Florida', u'Cornerstone Counseling']","December 18, 2014",18,9223372036854775807,Both,True
NCT02025621,"Tenax Therapeutics, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT02025621,True,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,Coronary Artery Bypass Grafting; Mitral Valve Surgery; Low Cardiac Output Syndrome,Drug:Levosimendan; Drug:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01976728,Ferring Pharmaceuticals,False,ME,https://ClinicalTrials.gov/show/NCT01976728,True,LutrePulse Hypogonadotropic Hypogonadism,Primary Amenorrhea With Hypogonadotropic Hypogonadism,Drug:Gonadorelin acetate 10g/pulse; Drug:Gonadorelin acetate 15g/pulse; Drug:Gonadorelin acetate 20g/pulse; Drug:Placebo,[],"October 8, 2015",18,40,Female,False
NCT01968967,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01958476,Tufts Medical Center,True,ME,https://ClinicalTrials.gov/show/NCT01958476,True,Improving Outcomes in Neonatal Abstinence Syndrome,Neonatal Abstinence Syndrome; Neonatal Opioid Withdrawal,Drug:Neonatal Morphine Solution; Drug:Methadone; Drug:Phenobarbital,"[u'Shands Jacksonville Medical Center', u'Maine Medical Center', u'Tufts Medical Center', u'Boston Medical Center', u'Baystate Medical Center', u'University of Pittsburgh Medical Center', u""Women and Infant's Hospital of Rhode Island"", u'Vanderbilt University']","May 15, 2015",0,9223372036854775807,Both,False
NCT01955161,H. Lundbeck A/S,False,ME,https://ClinicalTrials.gov/show/NCT01955161,True,Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Drug:Placebo; Drug:Lu AE58054,[],"December 10, 2015",50,9223372036854775807,Both,False
NCT01942694,Tufts Medical Center,False,ME,https://ClinicalTrials.gov/show/NCT01942694,True,Vitamin D and Type 2 Diabetes Study,Prediabetes; Type 2 Diabetes,Dietary Supplement:Vitamin D (Cholecalciferol); Other:Placebo,[],"November 6, 2015",30,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,ME,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,ME,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01872975,NSABP Foundation Inc,False,ME,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01872689,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT01872689,True,A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Drug:lebrikizumab; Drug:pirfenidone; Drug:placebo,[],"February 1, 2016",40,9223372036854775807,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,ME,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01827787,Dana-Farber Cancer Institute,False,ME,https://ClinicalTrials.gov/show/NCT01827787,True,Eribulin in HER2 Negative Metastatic BrCa,Breast Cancer,Drug:Eribulin,"[u'Eastern Maine Medical Center', u'Dana-Farber Cancer Institute at Faulkner Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'DF/BWCC at Milford Regional Cancer Center', u'South Shore Hospital', u'Dana-Farber/New Hampshire Oncology-Hematology']","January 26, 2016",18,9223372036854775807,Both,False
NCT01827046,Daniel Hanley,False,ME,https://ClinicalTrials.gov/show/NCT01827046,True,Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III,Intracerebral Hemorrhage,Drug:rt-PA,[],"October 23, 2015",18,80,Both,False
NCT01822509,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01822509,True,Ipilimumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,"Myeloproliferative Neoplasm; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Plasma Cell Myeloma",Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,"[u'UC San Diego Moores Cancer Center', u'Colorado Blood Cancer Institute', u'Northside Hospital', u'Maine Center for Cancer Medicine-Scarborough', u'Dana-Farber/Harvard Cancer Center', u'Beth Israel Deaconess Medical Center', u'Massachusetts General Hospital']","January 11, 2016",18,9223372036854775807,Both,False
NCT01817660,Boston University,False,ME,https://ClinicalTrials.gov/show/NCT01817660,True,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u""Brigham and Women's Hospital"", u'BI-Deaconess Hospital', u'Boston Medical Center', u'Massachusetts General Hospital', u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']","March 28, 2013",35,9223372036854775807,Both,False
NCT01812174,"On-X Life Technologies, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT01812174,True,On-X Heart Valve - 17mm Aortic and 23mm Mitral,Heart Valve Disease,Device:17 or 23 mm valve (On-X ),"[u'Maine Medical Center', u""Children's Heart Center Nevada"", u""Cincinnati Children's Medical Center"", u""University of Oklahoma/Children's Hospital"", u""University of Texas Southwestern Medical Center - Dallas Children's"", u'University of Virginia', u""Mary Bridge Children's - Tacoma General Hospital"", u'Mayaguez Medical Center', u'Hospital Clinico Provincial', u'University Hospital Salamanca']","September 4, 2015",0,9223372036854775807,Both,False
NCT01810679,"Sorin Group USA, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT01810679,True,Perceval S Aortic Heart Valve Study- North America,"Aortic Valve Stenosis; Aortic Valve Stenosis With Insufficiency; Regurgitation, Aortic Valve; Aortic Valve Incompetence",Device:Perceval S Aortic Heart Valve,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01799993,Bayer,False,ME,https://ClinicalTrials.gov/show/NCT01799993,True,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin Inhalation Solution (BAY41-6551); Drug:Aerosolized Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01734928,Celgene Corporation,False,ME,https://ClinicalTrials.gov/show/NCT01734928,True,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:Pomalidomide; Drug:Bortezomib; Drug:Dexamethasone,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT01730950,Radiation Therapy Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01730950,True,Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Biological:bevacizumab; Radiation:intensity-modulated radiation therapy; Radiation:3-dimensional conformal radiation therapy; Radiation:proton beam radiation therapy,[],"November 19, 2015",18,9223372036854775807,Both,False
NCT01703481,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT01703481,True,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma",Tumor or Lymphoma,Drug:JNJ-42756493: Part 1; Drug:JNJ-42756493: Part 2; Drug:JNJ-42756493: Part 3; Drug:JNJ-42756493: Part 4,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,ME,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01660451,Bayer,False,ME,https://ClinicalTrials.gov/show/NCT01660451,True,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","Lymphoma, Non-Hodgkin",Drug:Copanlisib (BAY80-6946),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01659411,Actelion,False,ME,https://ClinicalTrials.gov/show/NCT01659411,True,Adult Congenital Heart Disease Registry (QuERI),Pulmonary Arterial Hypertension; Congenital Heart Disease,Other:observational,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01656616,Maine Medical Center,False,ME,https://ClinicalTrials.gov/show/NCT01656616,True,Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis,Cyanide Poisoning,Drug:Cyanide antidote administration,[u'Maine Medical Center Department of Emergency Medicine'],"August 2, 2012",0,9223372036854775807,Both,False
NCT01652872,Amgen,False,ME,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01627041,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01627041,True,"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Decitabine; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,"[u'Lafayette Family Cancer Center-EMMC', u'Albert Einstein College of Medicine', u'Montefiore Medical Center - Moses Campus', u'Roswell Park Cancer Institute', u'Columbia University/Herbert Irving Cancer Center', u'Memorial Sloan-Kettering Cancer Center', u'Weill Medical College of Cornell University', u'Case Western Reserve University', u'Ohio State University Comprehensive Cancer Center']","January 11, 2016",18,65,Both,False
NCT01626079,Evalve,False,ME,https://ClinicalTrials.gov/show/NCT01626079,True,COAPT Clinical Trial,Mitral Regurgitation; Mitral Valve Regurgitation,Device:MitraClip System,[],"October 9, 2015",18,9223372036854775807,Both,False
NCT01623492,Actelion,False,ME,https://ClinicalTrials.gov/show/NCT01623492,True,Eisenmenger Quality Enhancement Research Initiative,Eisenmenger,Other:subjects with diagnosis of Eisenmenger Syndrome,[],"April 20, 2015",18,9223372036854775807,Both,False
NCT01621178,Eli Lilly and Company,False,ME,https://ClinicalTrials.gov/show/NCT01621178,True,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes; Chronic Kidney Disease,Drug:Dulaglutide; Drug:Insulin glargine; Drug:Insulin lispro,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,ME,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01372787,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01345019,Amgen,False,ME,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01327027,Bowdoin College,False,ME,https://ClinicalTrials.gov/show/NCT01327027,True,Vasopressin Effects on Human Social Communication,Healthy,Drug:Vasopressin; Drug:Placebo,"[u'Maine Medical Center, McGeachey Hall, OP Psych']","January 29, 2015",18,30,Both,True
NCT01307579,Children's Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01269736,Yale University,True,ME,https://ClinicalTrials.gov/show/NCT01269736,True,Implementation of Practice Standards for ECG Monitoring,Cardiovascular Disease,Behavioral:Education,"[u'Long Beach Memorial Medical Center', u'University of California, San Francisco Medical Center', u'Yale-New Haven Hospital', u'Maine Medical Center', u'Baystate Medical Center', u'United Hospital', u'Erie County Medical Center', u'University of North Carolina Hospitals', u'Aultman Hospital', u'Hospital of the University of Pennsylvania', u'Thomas Jefferson University Hospital', u'Seton Medical Center', u'Baylor University Medical Center', u'Meriter Heart Hospital', u'University of Ottawa Heart Institute, Ottawa, Canada', u'Hong Kong Sanatorium & Hospital']","January 3, 2011",0,9223372036854775807,Both,True
NCT01208662,"Paul G. Richardson, MD",False,ME,https://ClinicalTrials.gov/show/NCT01208662,True,"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65",Multiple Myeloma,Drug:Lenalidomide; Drug:Bortezomib; Drug:Dexamethasone; Procedure:Autologous Stem Cell Transplant,[],"January 21, 2016",18,65,Both,False
NCT01200589,GlaxoSmithKline,False,ME,https://ClinicalTrials.gov/show/NCT01200589,True,Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy,Non-Hodgkin's Lymphoma,Biological:Ofatumumab; Biological:Rituximab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01066702,Histogenics Corporation,True,ME,https://ClinicalTrials.gov/show/NCT01066702,True,Confirmatory Study of NeoCart in Knee Cartilage Repair,Articular Cartilage Defects in the Knee Joint,Biological:NeoCart; Procedure:Microfracture,[],"December 3, 2015",18,55,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00897442,Gynecologic Oncology Group,True,ME,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT00807768,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00792454,Maine Medical Center,False,ME,https://ClinicalTrials.gov/show/NCT00792454,True,Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program,Chronic Kidney Disease; End Stage Kidney Disease; Cardiovascular Disease,Behavioral:exercise training,[u'Maine Nephrology Associates'],"October 25, 2012",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,MD,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,MD,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,MD,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT01991795,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,MD,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02115282,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02364999,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02364999,True,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02254577,Shady Grove Fertility Reproductive Science Center,True,MD,https://ClinicalTrials.gov/show/NCT02254577,True,Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer,Infertility,Drug:Endometrin Only; Drug:Endometrin plus Progesterone in Oil (PIO); Drug:Progesterone in Oil (PIO) Only,"[u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center']","November 17, 2015",18,48,Female,False
NCT02032823,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01872975,NSABP Foundation Inc,False,MD,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02111564,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02075047,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT01663402,Sanofi,False,MD,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01101035,Takeda,True,MD,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00351611,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02251366,Johns Hopkins University,False,MD,https://ClinicalTrials.gov/show/NCT02251366,True,NVAMD Satellite Study,Neovascular Age Related Macular Degeneration,Procedure:Physician-guided diagnostic,"[u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute']","September 7, 2015",18,9223372036854775807,Both,True
NCT02187003,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02187003,True,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug:Rivipansel; Other:Placebo,[],"January 8, 2016",6,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02125461,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02125461,True,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Drug:MEDI4736; Other:PLACEBO,[],"January 11, 2016",18,130,Both,False
NCT02114203,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02114203,True,"Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease",Phase 1 Sickle Cell,Drug:PDE9i; Drug:PDE9i; Drug:placebo for PDE9i; Drug:PDE9i,[],"February 1, 2016",18,65,Both,False
NCT02066636,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,MD,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,MD,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01855750,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,MD,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01470612,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,MD,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01345019,Amgen,False,MD,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT00980954,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00499330,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT00499330,True,Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer,Lung Cancer,Procedure:lobectomy; Procedure:segmentectomy or wedge resection,[],"August 28, 2015",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02574078,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT02574078,True,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,MD,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,MD,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02365649,AbbVie,False,MD,https://ClinicalTrials.gov/show/NCT02365649,True,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Anti-TNF Therapy (Celest Study)",Crohn's Disease,Drug:ABT-494; Drug:Placebo,[],"February 3, 2016",18,75,Both,False
NCT02352948,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02285062,Celgene Corporation,False,MD,https://ClinicalTrials.gov/show/NCT02285062,True,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,"Lymphoma, Large B-Cell, Diffuse",Drug:lenalidomide; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:prednisone; Drug:vincristine,[],"December 23, 2015",18,80,Both,False
NCT02247531,Hoffmann-La Roche,False,MD,https://ClinicalTrials.gov/show/NCT02247531,True,A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02243293,AbbVie,False,MD,https://ClinicalTrials.gov/show/NCT02243293,True,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],"February 4, 2016",18,100,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02152982,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02092467,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02043678,Bayer,False,MD,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02003209,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01897532,Boehringer Ingelheim,False,MD,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01858532,AbbVie,False,MD,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01856192,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01846793,Nymox Corporation,False,MD,https://ClinicalTrials.gov/show/NCT01846793,True,Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022),Benign Prostatic Hyperplasia; BPH; Lower Urinary Tract Symptoms (LUTS); LUTS; Enlarged Prostate,Drug:NX-1207,"[u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.', u'For information concerning this clinical site, please contact Nymox at 800-936-9669.']","April 1, 2014",45,9223372036854775807,Male,False
NCT01772472,Hoffmann-La Roche,False,MD,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,MD,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01610284,Novartis Pharmaceuticals,False,MD,https://ClinicalTrials.gov/show/NCT01610284,True,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,Breast Cancer,Drug:BKM120 Matching placebo; Drug:Fulvestrant; Drug:BKM120,[],"January 20, 2016",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01492361,Amarin Pharma Inc.,False,MD,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01458574,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01367002,Yale University,True,MD,https://ClinicalTrials.gov/show/NCT01367002,True,Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,Endometrial Cancer,Drug:Carboplatin/Paclitaxel; Drug:Trastuzumab,"[u""St. Joseph's Hospital and Medical Center"", u'University of Arizona Cancer Center', u'University of Arizona Cancer Center', u'John Muir Clinical Research Center', u'University of California at Los Angeles', u'Penrose St. Francis Hospital', u'The Hospital of Central Connecticut', u'Smilow Cancer Hospital at Yale New Haven', u'The University of Chicago Medicine', u'Greater Baltimore Medical Center', u'Walter Reed National Military Medical Center', u'University of Maryland Medical Center', u'Holy Cross Hospital', u'Jersey Shore University Medical Center', u'Montefiore Medical Center', u'Duke University School of Medicine', u'The Ohio State University']","August 20, 2015",0,9223372036854775807,Female,False
NCT01190930,Children's Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01013649,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00628745,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT00628745,True,Transthyretin-Associated Amyloidoses Outcome Survey (THAOS),Transthyretin Mutations; Transthyretin Amyloidosis,Other:None. Observational Study.,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT00243425,Agency for Healthcare Research and Quality (AHRQ),True,MD,https://ClinicalTrials.gov/show/NCT00243425,True,Patient-Centered Depression Care for African Americans,Major Depressive Disorder,Procedure:Standard Quality Improvement; Procedure:Patient-centered Intervention,"[u'Christiana Care Health Services', u'Johns Hopkins Community Phsyicians', u'Sinai Hospital', u'Baltimore Medical Systems, Middlesex Health Center', u'Johns Hopkins School of Medicine']","October 21, 2005",18,75,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02623426,JHSPH Center for Clinical Trials,True,MD,https://ClinicalTrials.gov/show/NCT02623426,True,Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial,Uveitis; Macular Edema,Drug:Dexamethasone intravitreal implant 0.7 mg; Drug:Intravitreal Methotrexate 400 g; Drug:Intravitreal Ranibizumab 0.5 mg,[],"December 4, 2015",18,9223372036854775807,Both,False
NCT02601209,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02552212,UCB BIOSCIENCES GmbH,False,MD,https://ClinicalTrials.gov/show/NCT02552212,True,Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS,Axial Spondyloarthritis; Nonradiographic Axial Spondyloarthritis; Nr-axSpA,Biological:Certolizumab Pegol; Other:Placebo,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02533934,"University of California, San Francisco",False,MD,https://ClinicalTrials.gov/show/NCT02533934,True,Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre or Post Liver Transplant,HIV; Hepatitis C; Cirrhosis,Drug:Harvoni,"[u'University of California, San Francisco', u'Georgetown University', u'University of Maryland', u'Johns Hopkins Medical Center', u'National Institutes of Health Clinical Center', u'Mt. Sinai Medical Center', u'Columbia University', u'University of Pennsylvania']","August 25, 2015",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02521493,Children's Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02521493,True,Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,Childhood Acute Myeloid Leukemia; Childhood Myelodysplastic Syndrome; Cytopenia; Down Syndrome; Myeloid Leukemia Associated With Down Syndrome; Myeloproliferative Neoplasm,Drug:Asparaginase; Drug:Asparaginase Erwinia chrysanthemi; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mitoxantrone Hydrochloride; Drug:Thioguanine,[],"January 26, 2016",91,3,Both,False
NCT02501902,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02501902,True,Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,Metastatic Pancreatic Ductal Adenocarcinoma,Drug:Palbociclib; Drug:Nab-Paclitaxel,"[u'Scottsdale Healthcare Hospitals DBA HonorHealth', u'Virginia G. Piper Cancer Pharmacy', u'Oncology Investigational Drug Services (Drug Shipment Only)', u'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', u'John Hopkins Hospital', u'Siteman Cancer Center - West County', u'Siteman Cancer Center - South County', u'Barnes-Jewish Hospital', u'Washington University Infusion Center Pharmacy', u'Washington University School of Medicine, Siteman Cancer Center', u'Siteman Cancer Center', u""Hospital Universitari Vall D'Hebron""]","January 4, 2016",18,9223372036854775807,Both,False
NCT02489318,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT02489318,True,A Study of JNJ-56021927 (ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,Prostate Cancer,Drug:JNJ-56021927; Drug:Placebo; Drug:Androgen Deprivation Therapy (ADT),[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02470585,AbbVie,False,MD,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02451137,Sanofi,False,MD,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02437487,"Seres Therapeutics, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02437487,True,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),Clostridium Difficile,Drug:SER-109; Drug:Placebo,[],"December 1, 2015",18,9223372036854775807,Both,False
NCT02436239,Forest Laboratories,False,MD,https://ClinicalTrials.gov/show/NCT02436239,True,A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Vilazodone,[],"December 23, 2015",7,17,Both,False
NCT02418819,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02418819,True,"A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia",Schizophrenia,Drug:PF-06412562 3mg BID; Drug:PF-06412562 9mg BID; Drug:PF-06412562 45mg BID; Other:Placebo,"[u'Arcadia MRI & Imaging Center', u'California Clinical Trials Medical Group', u'Glendale Adventist Medical Center', u'Maryland Psychiatric Research Center', u'CBH Health, LLC', u'Foers Long Term Care Pharmacy LLC']","January 11, 2016",18,45,Both,False
NCT02414854,Sanofi,False,MD,https://ClinicalTrials.gov/show/NCT02414854,True,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Drug:dupilumab SAR231893 (REGN668); Drug:placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT02403401,Bayer,False,MD,https://ClinicalTrials.gov/show/NCT02403401,True,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,Contraception,Drug:Levonorgestrel (BAY98-7196),[],"January 22, 2016",18,35,Female,False
NCT02374060,JHSPH Center for Clinical Trials,True,MD,https://ClinicalTrials.gov/show/NCT02374060,True,PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial,Macular Edema; Uveitis,Drug:Periocular triamcinolone 40 mg; Drug:Intravitreal triamcinolone 4 mg; Drug:Dexamethasone intravitreal implant,[],"October 2, 2015",18,9223372036854775807,Both,True
NCT02372799,Forest Laboratories,False,MD,https://ClinicalTrials.gov/show/NCT02372799,True,Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22),Major Depressive Disorder,Drug:Vilazodone; Drug:Placebo; Drug:Fluoxetine,[],"December 17, 2015",7,17,Both,False
NCT02362503,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT02362503,True,Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients,HIV/AIDS,Drug:BMS-663068; Other:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02349295,Eli Lilly and Company,False,MD,https://ClinicalTrials.gov/show/NCT02349295,True,A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02310763,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02310763,True,"A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy",Duchenne Muscular Dystrophy,Biological:PF-06252616; Drug:Placebo,[],"January 19, 2016",6,9,Male,False
NCT02284217,HeadSense Medical,False,MD,https://ClinicalTrials.gov/show/NCT02284217,True,An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an External Ventricular Drainage (EVD) Device,Intracranial Pressure,Device:EVD; Device:HS-1000,"[u'University of Miami Hospital', u'University of Maryland Medical Center', u'Sinai Hospital', u'The Johns Hopkins Hospital', u'Metro Health', u'Erlangen University', u'Klinikum Stuttgart']","November 4, 2014",18,9223372036854775807,Both,False
NCT02275533,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02275533,True,Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,Adult Acute Myeloid Leukemia in Remission,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,"[u'City of Hope Comprehensive Cancer Center', u'University of California Davis Comprehensive Cancer Center', u'Yale University', u'Smilow Cancer Center/Yale-New Haven Hospital', u'University of Chicago Comprehensive Cancer Center P2C', u'University of Chicago Comprehensive Cancer Center', u'Decatur Memorial Hospital', u'UC Comprehensive Cancer Center at Silver Cross', u'Illinois CancerCare-Peoria', u'Indiana University/Melvin and Bren Simon Cancer Center', u'University of Maryland/Greenebaum Cancer Center', u'National Institutes of Health Clinical Center', u'NCI - Center for Cancer Research', u'Wayne State University/Karmanos Cancer Institute', u'Case Western Reserve University', u'Penn State Milton S Hershey Medical Center', u'Virginia Commonwealth University/Massey Cancer Center', u'University Health Network-Princess Margaret Hospital']","January 11, 2016",18,9223372036854775807,Both,False
NCT02252172,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT02252172,True,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug:Daratumumab; Drug:Lenalidomide; Drug:Dexamethasone,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,MD,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02224664,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02224664,True,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease",Parkinson`s Disease,Drug:PF-06649751; Drug:PF-06649751; Drug:PF-06649751; Drug:PF-06649751,"[u'Orange Coast Memorial Medical Center', u""The Parkinson's and Movement Disorder Institute"", u'Collaborative Neuroscience Network, LLC', u'Rocky Mountain Movement Disorders Center', u'Davita Clinical Research Center', u'MD Clinical', u'Compass Research, LLC', u'Atlanta Center for Medical Research', u'SNBL Clinical Pharmacology Center (Pharmacy Shipping Address)', u'SNBL Clinical Pharmacology Center', u""Parkinson's and Movement Disorders Center of Maryland"", u'Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY', u'Massachusetts General Hospital', u'QUEST Research Institute', u'PRA International', u'Carolina Phase I Research, LLC', u'Lynn Health Science Institute', u'Neurology Consultants of Dallas, PA', u'Walnut Hill Medical Center']","February 1, 2016",30,80,Both,False
NCT02180867,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02164864,Boehringer Ingelheim,False,MD,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02141438,Bayer,False,MD,https://ClinicalTrials.gov/show/NCT02141438,True,Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer,Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223)",[],"February 4, 2016",18,9223372036854775807,Male,False
NCT02104817,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02104583,Gilead Sciences,False,MD,https://ClinicalTrials.gov/show/NCT02104583,True,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],"January 8, 2016",18,80,Both,False
NCT02101853,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02032277,AbbVie,False,MD,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT02008773,Indiana University,False,MD,https://ClinicalTrials.gov/show/NCT02008773,True,A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia,Schizophrenia,Drug:Valacyclovir HCI 500 mg tablets; Drug:placebo,"[u'C.I. Trials, Inc.-Los Angeles County', u'University of California, Los Angeles', u'University of California, Riverside at C.I. Trials, Inc.-Inland Empire', u'C.I. Trials, Inc.-Orange County', u'Yale University', u'Innovative Clinical Research, Inc.', u'Indiana University Psychotic Disorders Clinic', u'Prevention and Recovery Center for Early Psychosis', u'University of Kansas Medical Center-Witchita', u'Maryland Psychiatric Research Center', u'Centers for Behavioral Health, LLC', u'Sheppard Pratt Health System', u'Laureate Institute for Brain Research']","December 16, 2015",18,40,Both,False
NCT02003222,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01996865,Celgene Corporation,False,MD,https://ClinicalTrials.gov/show/NCT01996865,True,"Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.","Lymphoma, Non-Hodgkin",Drug:Lenalidomide; Drug:Rituximab,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01966419,Ocera Therapeutics,False,MD,https://ClinicalTrials.gov/show/NCT01966419,True,Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE),Acute Episode of Overt Hepatic Encephalopathy; Hepatic Encephalopathy,Drug:ornithine phenylacetate; Drug:placebo intravenous infusion,[],"January 14, 2016",18,75,Both,False
NCT01920711,Novartis Pharmaceuticals,False,MD,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01890434,Bayer,False,MD,https://ClinicalTrials.gov/show/NCT01890434,True,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),Coronary Artery Disease,"Drug:Gadobutrol (Gadovist, BAY86-4875)",[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01878292,Forest Laboratories,False,MD,https://ClinicalTrials.gov/show/NCT01878292,True,Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Placebo; Drug:Vilazodone; Drug:Vilazodone,[],"December 17, 2015",12,17,Both,False
NCT01870778,Novartis Pharmaceuticals,False,MD,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01864174,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT01864174,True,Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug:Metformin XR; Drug:Metformin IR; Drug:Placebo matching with Metformin XR; Drug:Placebo matching with Metformin IR,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,MD,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,MD,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01734928,Celgene Corporation,False,MD,https://ClinicalTrials.gov/show/NCT01734928,True,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:Pomalidomide; Drug:Bortezomib; Drug:Dexamethasone,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT01716754,Novartis Pharmaceuticals,False,MD,https://ClinicalTrials.gov/show/NCT01716754,True,Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma,Asthma,Drug:QGE031; Drug:Omalizumab; Drug:Placebo to QGE031; Drug:Placebo to omalizumab,[],"January 15, 2015",18,75,Both,False
NCT01715805,Forest Laboratories,False,MD,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01645891,"Electrochemical Oxygen Concepts, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT01645891,True,"A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers",Diabetic Foot Ulcer,Device:CDO electrochemical tissue oxygenation system; Device:Moist Wound Therapy,"[u'Clinical Trials of Texas, Inc., dba Clinical Trials of Arizona, Inc.', u'Associated Foot and Ankle Specialists', u'Southern Arizona VA Health Care System', u'Roy O. Kroeker, DPM , Inc.', u'Doctors Research Network', u'Foot and Ankle Specialists of the Mid-Atlantic', u'Foot and Ankle Specialists of the Mid-Atlantic', u'Foot and Ankle Specialists of the Mid-Atlantic', u'PMG Research of Wilmington, LLC', u'Richard C. Galperin, DPM, PA', u'William Blake Partners, LLC', u'Complete Family Foot Care', u'Alamo Clinical Research', u'Clinical Trials of Texas', u'The University of Texas Health Science Center at San Antonio']","August 9, 2013",30,90,Both,False
NCT01643902,Johns Hopkins University,False,MD,https://ClinicalTrials.gov/show/NCT01643902,True,Safety of Intravenous Thrombolytics in Stroke on Awakening,Stroke,Drug:rt-PA,"[u'Anne Arundel Medical Center', u'The Johns Hopkins Hospital', u'Johns Hopkins Bayview Medical Center']","January 16, 2014",18,9223372036854775807,Both,False
NCT01570036,George E. Peoples,False,MD,https://ClinicalTrials.gov/show/NCT01570036,True,Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,Breast Cancer,Drug:Herceptin; Drug:NeuVax vaccine; Drug:GM-CSF,[],"December 1, 2015",18,9223372036854775807,Female,False
NCT01529034,Upsher-Smith Laboratories,False,MD,https://ClinicalTrials.gov/show/NCT01529034,True,Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters,Epilepsy,Drug:USL261,[],"January 20, 2016",12,9223372036854775807,Both,False
NCT01492504,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT01492504,True,Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial,Hepatitis C,Drug:Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052),[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01479283,McMaster University,True,MD,https://ClinicalTrials.gov/show/NCT01479283,True,Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY),Infection; Bone Neoplasms,Drug:24-Hour Prophylactic Cefazolin* Antibiotic Regimen; Drug:5-Days Prophylactic Cefazolin* Antibiotic Regimen,[],"April 28, 2015",12,9223372036854775807,Both,False
NCT01471522,New York University School of Medicine,True,MD,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01393405,"University of North Carolina, Chapel Hill",True,MD,https://ClinicalTrials.gov/show/NCT01393405,True,Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis,Ulcerative Colitis,Drug:Methotrexate,[],"July 20, 2015",18,70,Both,False
NCT01307579,Children's Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01302197,Baltimore VA Medical Center,False,MD,https://ClinicalTrials.gov/show/NCT01302197,True,"Muscle Atrophy, Physical Performance and Glucose Tolerance Post Stroke",Stroke,Other:No intervention,"[u'University of Maryland Medical System', u'VA Maryland Health Care System, Baltimore', u'Kernan Hospital']","July 21, 2015",21,9223372036854775807,Both,False
NCT01211418,University of Maryland,False,MD,https://ClinicalTrials.gov/show/NCT01211418,True,Integrative Meditation (IM) for Cocaine Addiction,Cocaine Addiction,Behavioral:Integrative Meditation; Behavioral:Supportive Counseling,"[u'Alcohol and Drug Abuse Program (ADAP)', u'Outpatient Addiction Treatment Service (OATS)', u'University of Maryland Methadone Treatment Program']","September 28, 2010",18,9223372036854775807,Both,False
NCT01174706,Johns Hopkins University,False,MD,https://ClinicalTrials.gov/show/NCT01174706,True,Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients,Patient Compliance; Medication Adherence; Medication Non-Adherence,Behavioral:Information prescriptions,"[u'Johns Hopkins Hospital', u'Johns Hopkins Bayview Medical Center', u'Howard County General Hospital']","June 24, 2011",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01116648,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01116648,True,"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",Estrogen Receptor Negative; HER2/Neu Negative; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Triple-Negative Breast Carcinoma,Drug:Cediranib Maleate; Other:Laboratory Biomarker Analysis; Drug:Olaparib; Other:Pharmacological Study,"[u'Cedars-Sinai Medical Center', u'University of Chicago Comprehensive Cancer Center', u'NorthShore University HealthSystem-Evanston Hospital', u'Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard', u'Fort Wayne Medical Oncology and Hematology Inc-Parkview', u'Johns Hopkins University/Sidney Kimmel Cancer Center', u'National Institutes of Health Clinical Center', u'National Cancer Institute', u'Massachusetts General Hospital Cancer Center', u'Dana-Farber/Harvard Cancer Center', u'Beth Israel Deaconess Medical Center', u'Massachusetts General Hospital', u'University of Michigan Comprehensive Cancer Center']","January 11, 2016",18,9223372036854775807,Female,False
NCT01101451,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01096368,Children's Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01042522,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01042522,True,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01041703,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00959296,MedtronicNeuro,False,MD,https://ClinicalTrials.gov/show/NCT00959296,True,Implantable Systems Performance Registry,Spinal Cord Stimulation; Deep Brain Stimulation; Drug Infusion (Implantable Pumps); Sacral Neuromodulation,Device:Various,[],"September 24, 2015",0,9223372036854775807,Both,False
NCT00736749,Children's Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT00628498,Jazz Pharmaceuticals,True,MD,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00131313,East Valley Hematology and Oncology Medical Group,False,MD,https://ClinicalTrials.gov/show/NCT00131313,True,"Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.",Chronic Lymphocytic Leukemia,"Drug:Nipent, Cytoxan, Rituxan",[],"August 17, 2005",18,9223372036854775807,Both,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,MD,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),True,MD,https://ClinicalTrials.gov/show/NCT00042289,True,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],"September 2, 2015",0,9223372036854775807,Female,False
NCT02675244,Icahn School of Medicine at Mount Sinai,False,MD,https://ClinicalTrials.gov/show/NCT02675244,True,Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery,Mild Tricuspid Regurgitation; Moderate Tricuspid Regurgitation; Tricuspid Regurgitation,Procedure:TV Annuloplasty; Procedure:MVS Alone,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02658981,Sidney Kimmel Comprehensive Cancer Center,False,MD,https://ClinicalTrials.gov/show/NCT02658981,True,Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma,Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Biological:Anti-LAG-3 Monoclonal Antibody BMS 986016; Biological:Anti-PD-1; Other:Pharmacological Study; Other:Laboratory Biomarker Analysis; Biological:Anti-CD137,"[u'UAB Comprehensive Cancer Center', u'Jonsson Comprehensive Cancer Center at UCLA', u'University of California San Francisco Medical Center', u'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', u'Johns Hopkins Oncology Center', u'Memorial Sloan-Kettering Cancer Center', u'Wake Forest University Comprehensive Cancer Center', u'Cleveland Clinic Taussig Cancer Center', u'Abrams Cancer Center of the University of Pennsylvania', u'Hillman Cancer Center at University of Pittsburgh Cancer Institute']","January 19, 2016",18,9223372036854775807,Both,False
NCT02653482,Saint Luke's Health System,False,MD,https://ClinicalTrials.gov/show/NCT02653482,True,Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure,Chronic Heart Failure With Reduced Systolic Function,Drug:Dapagliflozin; Drug:Dapagliflozin matching placebo,"[u'University of Colorado', u'Emory University', u'Advocate Health and Hospitals', u'University of Maryland', u'Walter Reed National Military Medical Center', u""Brigham & Women's Hospital"", u'Henry Ford Health System', u'Mayo Clinic', u""Saint Luke's Hospital of Kansas City"", u'Truman Medical Center', u'Washington University', u'New York University', u'Duke University', u'Cleveland Clinic', u'University of Pennsylvania', u'Vanderbilt University', u'University of Texas Southwestern']","January 9, 2016",19,74,Both,False
NCT02648204,Novo Nordisk A/S,False,MD,https://ClinicalTrials.gov/show/NCT02648204,True,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:Dulaglutide,[],"January 7, 2016",18,9223372036854775807,Both,False
NCT02640612,Boehringer Ingelheim,False,MD,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02639338,Gilead Sciences,False,MD,https://ClinicalTrials.gov/show/NCT02639338,True,Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Hepatitis C Virus Infection,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02639247,Gilead Sciences,False,MD,https://ClinicalTrials.gov/show/NCT02639247,True,Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Hepatitis C Virus Infection,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02635009,NRG Oncology,False,MD,https://ClinicalTrials.gov/show/NCT02635009,True,Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Carcinoma; Limited Stage Small Cell Lung Carcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Other:Cognitive Assessment; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,"[u'Cadence Cancer Center in Warrenville', u'University of Maryland Medical Center', u'Upper Chesapeake Medical Center']","December 16, 2015",18,9223372036854775807,Both,False
NCT02619552,University of Maryland,False,MD,https://ClinicalTrials.gov/show/NCT02619552,True,Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease,Crohn's Disease; IBD,Drug:Anti-TNF; Drug:Anti-TNF; Drug:Steroids,"[u'Mercy Medical Center', u'University of Maryland Medical Center', u'Penn State Hershey Medical Center', u'Vanderbilt University']","November 30, 2015",18,9223372036854775807,Both,False
NCT02615002,Neurim Pharmaceuticals Ltd.,False,MD,https://ClinicalTrials.gov/show/NCT02615002,True,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug:Piromelatine; Drug:Placebo,[],"January 26, 2016",60,85,Both,False
NCT02609659,AbbVie,False,MD,https://ClinicalTrials.gov/show/NCT02609659,True,Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection,Chronic Hepatitis C Infection,Drug:Ombitasvir/paritaprevir/ritonavir; Drug:Dasabuvir; Drug:Ribavirin,"[u'Site Reference ID/Investigator# 144661', u'Site Reference ID/Investigator# 144667', u'Site Reference ID/Investigator# 144659', u'Site Reference ID/Investigator# 144665', u'Site Reference ID/Investigator# 144655', u'Site Reference ID/Investigator# 144656', u'Site Reference ID/Investigator# 144666', u'Site Reference ID/Investigator# 144664', u'Site Reference ID/Investigator# 144660']","November 18, 2015",18,100,Both,False
NCT02607800,Gilead Sciences,False,MD,https://ClinicalTrials.gov/show/NCT02607800,True,Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Drug:SOF/VEL/GS-9857; Drug:SOF/VEL,[],"January 18, 2016",18,9223372036854775807,Both,False
NCT02607735,Gilead Sciences,False,MD,https://ClinicalTrials.gov/show/NCT02607735,True,Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Drug:SOF/VEL/GS-9857; Drug:Placebo,[],"January 18, 2016",18,9223372036854775807,Both,False
NCT02603341,Abramson Cancer Center of the University of Pennsylvania,False,MD,https://ClinicalTrials.gov/show/NCT02603341,True,Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial,Breast Cancer,Radiation:Photon; Radiation:Proton,[],"January 28, 2016",21,65,Both,False
NCT02598661,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT02598661,True,Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),Myelodysplastic Syndromes,Drug:Imetelstat; Drug:Placebo,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,MD,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02592967,"Janssen Research & Development, LLC",True,MD,https://ClinicalTrials.gov/show/NCT02592967,True,"Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",Biological:JNJ-64041757 (Cohort 1A and 1B); Biological:JNJ-64041757 (Cohort 2A and 2B),"[u'', u'', u'', u'', u'', u'', u'']","January 8, 2016",18,9223372036854775807,Both,False
NCT02584855,Eli Lilly and Company,False,MD,https://ClinicalTrials.gov/show/NCT02584855,True,A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug:Ixekizumab; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02572817,National Institute of Allergy and Infectious Diseases (NIAID),False,MD,https://ClinicalTrials.gov/show/NCT02572817,True,Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A,Influenza A Virus Infection,Biological:High-titer anti-influenza plasma; Biological:Low-titer (control) anti-influenza plasma,"[u""Arkansas Children's Hospital"", u'University of Iowa Hospitals & Clinics', u'Johns Hopkins University', u'NIH Clinical Center', u'Massachusetts General Hospital', u'University of Massachusetts Medical School', u'University of Michigan']","February 3, 2016",0,9223372036854775807,Both,False
NCT02559206,"Ironwood Pharmaceuticals, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02559206,True,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"January 12, 2016",18,9223372036854775807,Both,False
NCT02556203,Bayer,False,MD,https://ClinicalTrials.gov/show/NCT02556203,True,Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes,Transcatheter Aortic Valve Replacement,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Acetylsalicylic acid; Drug:Clopidogrel",[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02548351,Intercept Pharmaceuticals,False,MD,https://ClinicalTrials.gov/show/NCT02548351,True,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment,Non Alcoholic Steatohepatitis (NASH),Drug:Obeticholic Acid; Drug:Placebo,[],"November 2, 2015",18,85,Both,False
NCT02541838,University of Maryland,False,MD,https://ClinicalTrials.gov/show/NCT02541838,True,Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy,Diabetes Complications; Diabetic Neuropathies,Other:Muscle power; Other:balance perturbation; Other:aerobic exercise,"[u'PTRS Research Lab', u'VA Maryland Health Care System']","September 3, 2015",55,80,Both,False
NCT02536339,"Genentech, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02536339,True,Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,Metastatic Breast Cancer,Drug:Pertuzumab; Drug:Trastuzumab,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","February 1, 2016",18,9223372036854775807,Both,False
NCT02531113,"Receptos, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02531113,True,Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease,Crohn's Disease,Drug:RPC1063,"[u'Receptos Study Site 116', u'Receptos Study Site 199', u'Receptos Study Site 184', u'Receptos Study Site 144', u'Receptos Study Site 207', u'Receptos Study Site 126', u'Receptos Study Site 192', u'Receptos Study Site 211', u'Receptos Study Site 112', u'Receptos Study Site 114', u'Receptos Study Site 119', u'Receptos Study Site 103', u'Receptos Study Site 189', u'Receptos Study Site 121', u'Receptos Study Site 142', u'Receptos Study Site 183', u'Receptos Study Site 179', u'Receptos Study Site 217', u'Receptos Study Site 150', u'Receptos Study Site 115']","January 12, 2016",18,75,Both,False
NCT02528253,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02527460,National Institute of Neurological Disorders and Stroke (NINDS),True,MD,https://ClinicalTrials.gov/show/NCT02527460,True,"Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection",HIV Infections; Neurologic Disorders,Drug:Anakinra,"[u'Johns Hopkins University', u'National Institutes of Health Clinical Center, 9000 Rockville Pike']","August 22, 2015",18,61,Both,False
NCT02517996,Johns Hopkins University,True,MD,https://ClinicalTrials.gov/show/NCT02517996,True,Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS),Interstitial Cystitis; Painful Bladder Syndrome,Drug:Lidocaine; Drug:Placebo,"[u'Greater Baltimore Medical Center', u'Johns Hopkins Bayview Medical Center']","August 25, 2015",18,9223372036854775807,Female,False
NCT02511106,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02511106,True,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",Stage IB-IIIA Non-small Cell Lung Carcinoma,Drug:AZD9291 80 mg/40 mg; Drug:Placebo AZD9291 80 mg/40 mg,[],"January 29, 2016",18,130,Both,False
NCT02510794,"Genentech, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT02510794,True,Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration,Macular Degeneration,Drug:Ranibizumab ITV injection; Drug:Ranibizumab through RPDS Implant,[],"December 31, 2015",50,9223372036854775807,Both,False
NCT02501161,Novo Nordisk A/S,False,MD,https://ClinicalTrials.gov/show/NCT02501161,True,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec/liraglutide; Drug:insulin glargine,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02498821,C. R. Bard,False,MD,https://ClinicalTrials.gov/show/NCT02498821,True,Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation,"Catheterization, Central Venous",Device:X-ray; Device:Sherlock 3CG TCS; Procedure:Peripherally Inserted Central Catheter (PICC),"[u'Florida Hospital', u'University of Maryland - Baltimore', u'Peninsula Regional Medical Center', u'Unity Hospital']","November 23, 2015",22,9223372036854775807,Both,False
NCT02493452,Synergy Pharmaceuticals Inc.,False,MD,https://ClinicalTrials.gov/show/NCT02493452,True,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 14, 2016",18,85,Both,False
NCT02492711,MacroGenics,False,MD,https://ClinicalTrials.gov/show/NCT02492711,True,Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,HER-2 Positive Breast Cancer; Metastatic Neoplasm,Biological:Margetuximab; Biological:Trastuzumab; Drug:Capecitabine; Drug:Eribulin; Drug:Gemcitabine; Drug:Vinorelbine,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02484690,Hoffmann-La Roche,False,MD,https://ClinicalTrials.gov/show/NCT02484690,True,AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD),"Macular Degeneration, Choroidal Neovascularization",Drug:RG7716; Drug:Ranibizumab,[],"September 9, 2015",50,9223372036854775807,Both,False
NCT02482298,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02482298,True,A Study to Evaluate the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease,Sickle Cell Disease,Drug:Ticagrelor; Drug:Placebo; Drug:Analgesic,"[u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site', u'Research Site']","January 8, 2016",18,30,Both,False
NCT01272037,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02154490,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01238588,Brigham and Women's Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01238588,True,The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan,Dialysis; Cardiovascular Disease; Atherosclerosis; Inflammation; Hyperphosphatemia,Drug:Sevelamer Carbonate (Renvela),"[u""Brigham and Women's Hospital"", u'BWH/FH/DCI Outpatient Dialysis Unit', u'Fresenius Boston-TKC', u'Fresenius Framingham (#1109)', u'Fresenius Marlborough (#3448)', u'Fresenius Medford Dialysis (#1246)', u'Fresenius Quincy (#1610)', u'Fresenius Roxbury (#1630)', u'DCI Dialysis Unit-Somerville', u'Fresenius QCDC-Weymouth (#9144)']","October 5, 2015",50,9223372036854775807,Both,False
NCT00251875,Agency for Healthcare Research and Quality (AHRQ),False,MA,https://ClinicalTrials.gov/show/NCT00251875,True,Shared Online Health Records for Patient Safety and Care,Diabetes,Device:online health information journal,"[u'Beacon Hill/Downtown Primary Care', u'Bulfinch Medical Group', u""Massachusetts General Hospital Women's Health Associates"", u'Charlestown Health Center', u""Brigham & Women's Hospital Women's Health Center"", u""Brigham & Women's Physicians Group"", u'Brigham Primary Physicians at Faulkner', u'Southern Jamaica Plain Health Center', u""Brigham & Women's Hospital at Norwood"", u'Revere Health Center']","November 9, 2005",18,9223372036854775807,Both,True
NCT02060630,New England Research Institutes,False,MA,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01817660,Boston University,False,MA,https://ClinicalTrials.gov/show/NCT01817660,True,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u'BI-Deaconess Hospital', u""Brigham and Women's Hospital"", u'Boston Medical Center', u'Massachusetts General Hospital', u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']","March 28, 2013",35,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02359084,Boston University,False,MA,https://ClinicalTrials.gov/show/NCT02359084,True,"Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children",Autism; Developmental Delay Disorders,Behavioral:Family Navigation; Behavioral:Conventional Care Management,"[u'Yale University School of Medicine', u'Boston University School of Public Health', u'South End Community Health Center', u'Dorchester House Multi-Service Center', u'Codman Square Health Center', u'East Boston Neighborhood Health Center', u'Boston Medical Center', u'MGH Chelsea', u""Children's Hospital of Philadelphia""]","July 28, 2015",15,27,Both,False
NCT02019264,Eisai Inc.,False,MA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01947283,Cambridge Health Alliance,False,MA,https://ClinicalTrials.gov/show/NCT01947283,True,"Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation",Mental Disorders,Behavioral:DECIDE-PA; Behavioral:DECIDE-PC,"[u'South Cove Community Health Center', u""Children's Hospital Boston (Martha Elliot Health Center)"", u'Beth Israel Deaconess Medical Center (Ambulatory Psychiatry Unit)', u'Beth Israel Deaconess Medical Center (Latino Mental Health)', u'Cambridge Health Alliance (Windsor Clinic, Macht Building, Central Street, Malden Primary Care Mental Health)', u'Harbor Health Services, Inc. (Geiger Gibson Community Health Center and Neponset Health Center)', u'Edward M Kennedy Health Center (Great Brook Valley Health Center)']","May 4, 2015",18,80,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01672892,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01516216,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01516216,True,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']","January 10, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02509078,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02509078,True,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,MA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,MA,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01858532,AbbVie,False,MA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT00858364,Amgen,False,MA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),True,MA,https://ClinicalTrials.gov/show/NCT00042289,True,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],"September 2, 2015",0,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02477618,Sage Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,MA,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02233946,Children's Hospital Boston,True,MA,https://ClinicalTrials.gov/show/NCT02233946,True,Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care,Prevention Harmful Effects,Behavioral:computer-facilitated brief intervention,"[u'Tufts Medical Center', u'Boston Childrens Primary Care Center', u'Longwood Pediatrics', u'East Boston Neighborhood Health Center', u'Lexington Pediatrics']","February 5, 2015",9,18,Both,True
NCT02065687,Gynecologic Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02047097,Biogen,False,MA,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01870778,Novartis Pharmaceuticals,False,MA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01827787,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01827787,True,Eribulin in HER2 Negative Metastatic BrCa,Breast Cancer,Drug:Eribulin,"[u'Eastern Maine Medical Center', u'Dana-Farber Cancer Institute at Faulkner Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'DF/BWCC at Milford Regional Cancer Center', u'South Shore Hospital', u'Dana-Farber/New Hampshire Oncology-Hematology']","January 26, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,MA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01674842,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01674842,True,Cisplatin + RT for Triple Negative Breast Cancer,Breast Cancer,Radiation:Radiation Therapy; Drug:Cisplatin,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Dana-Farber at Milford', u'Dana Farber at South Shore Hospital']","January 19, 2016",18,9223372036854775807,Both,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,MA,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01208662,"Paul G. Richardson, MD",False,MA,https://ClinicalTrials.gov/show/NCT01208662,True,"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65",Multiple Myeloma,Drug:Lenalidomide; Drug:Bortezomib; Drug:Dexamethasone; Procedure:Autologous Stem Cell Transplant,[],"January 21, 2016",18,65,Both,False
NCT01169337,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00628498,Jazz Pharmaceuticals,True,MA,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT00585195,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT00585195,True,"A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",Non-Small Cell Lung Cancer (ALK-positive); Non-Small Cell Lung Cancer (c-Met Dependent); Non-Small Cell Lung Cancer (ROS Marker Positive); Systemic Anaplastic Large-Cell Lymphoma; Advanced Malignancies (Except Leukemia),Drug:PF-02341066; Drug:Rifampin; Drug:Itraconazole,"[u'University of California, Irvine Medical Center Pharmacy', u'University of California, Irvine Medical Center', u'Drug Shipment: Anschutz Cancer Pavilion', u'University of Colorado Hospital', u'University of Chicago', u'Beth Israel Deaconess Medical Center', u'Ophthalmic Consultants of Boston Inc.', u'Dana Farber Cancer Center', u'Joslin Beetham Eye Institute', u'Massachusetts General Hospital', u'Karmanos Cancer Institute', u'Kresge Eye Institute', u'Memorial Sloan Kettering Cancer Center', u'Memorial Sloan-Kettering Rockefeller Outpatient Pavillion', u'Memorial Sloan-Kettering Cancer Center', u'UNC Hospitals', u'Ohio State Eye and Ear Institute', u'The James Cancer Hospital and Solove Research Institute', u'The Ohio State University Martha Morehouse Medical Plaza', u'UPMC Hillman Cancer Center', u'Henry-Joyce Cancer Clinic', u'Vanderbilt Eye Institute', u'Vanderbilt Oncology Pharmacy', u'Peter MacCallum Cancer Centre', u'Seoul National University Hospital']","January 4, 2016",18,9223372036854775807,Both,False
NCT02559895,"Alder Biopharmaceuticals, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02559895,True,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,Migraine Disorders,Drug:ALD403; Drug:Placebo,[],"January 28, 2016",18,75,Both,False
NCT02477800,Biogen,False,MA,https://ClinicalTrials.gov/show/NCT02477800,True,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02439658,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02439658,True,Genetics of QT Prolongation With Antiarrhythmics,Long QT Syndrome; Drug Toxicity,Drug:Dofetilide and/or sotalol,"[u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Brigham and Womens Hospital', u'West Roxbury VA Medical Center']","May 8, 2015",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02344290,National Institute of Allergy and Infectious Diseases (NIAID),False,MA,https://ClinicalTrials.gov/show/NCT02344290,True,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,HIV Infections; Cardiovascular Diseases,Drug:Pitavastatin; Drug:Placebo,[],"February 1, 2016",40,75,Both,False
NCT02339090,Versartis Inc.,False,MA,https://ClinicalTrials.gov/show/NCT02339090,True,Comparison of Long-acting Growth Hormone Somavaratan (VRS-317) to Daily Growth Hormone in Pediatric GHD Patients,Growth Disorders,Drug:somavaratan; Drug:Daily rhGH,[],"January 14, 2016",3,11,Both,False
NCT02320253,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02320253,True,REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes,Type 2 Diabetes Mellitus; Obesity,Behavioral:In Person Group (IP); Behavioral:Telephone Conference Call Group (TCC); Behavioral:Medical Nutrition Therapy (MNT),"[u'Massachusetts General Hospital', u'Charlestown HealthCare Center', u'Chelsea HealthCare Center', u'Revere HealthCare Center']","September 21, 2015",18,9223372036854775807,Both,True
NCT02317432,Cambridge Health Alliance,False,MA,https://ClinicalTrials.gov/show/NCT02317432,True,Building Community Capacity for Disability Prevention for Minority Elders (Positive Minds - Strong Bodies),Depression; Anxiety; Physical Disability,Behavioral:Comparison of a combined CBT + exercise intervention and enhanced usual care,"[u'Greater Boston Chinese Golden Age Center', u'La Alianza Hispana', u'Kit Clark Senior Services', u'Spanish American Center', u""Central Harlem Senior Citizens' Center"", u'Hamilton Madison City Hall Senior Center']","September 16, 2015",60,9223372036854775807,Both,True
NCT02279394,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02279394,True,Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,Smoldering Myeloma; Smoldering Multiple Myeloma,Drug:Elotuzumab; Drug:Lenalidomide; Drug:Dexamethasone,"[u'Colorado Blood Cancer Institute', u'St Francis Hospital and Medical Center', u'Lawrence and Memorial Hospital', u'Eastern Maine Medical Center', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Newton-Wellesley Hospital', u'Barbara Ann Karmanos Cancer Institute']","October 22, 2015",18,9223372036854775807,Both,False
NCT02247479,Hoffmann-La Roche,False,MA,https://ClinicalTrials.gov/show/NCT02247479,True,A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02235077,Duke University,False,MA,https://ClinicalTrials.gov/show/NCT02235077,True,Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure,Heart Failure,Drug:Spironolactone; Drug:Placebo,"[u'Emory University School of Medicine', u'Johns Hopkins Hospital', u""Brigham and Women's Hospital"", u'Massachusetts General Hospital', u'Tufts Medical Center', u'Boston VA Healtcare System', u'Mayo Clinic', u'Washington University', u'Saint Louis University Hospital', u'Stony Brook University Medical Center', u'Duke University', u'Southeastern Regional Medical Center', u'Metro Health System', u'Cleveland Clinic', u'University Hospitals - Case Medical Center', u'Lancaster General Hospital', u'Jefferson Medical College', u'University of Pennsylvania', u'Michael Debakey VA Medical Center', u'University of Utah School of Medicine', u'Utah VA Medical Center', u'The University of Vermont- Fletcher Allen Health Care']","January 19, 2016",21,9223372036854775807,Both,False
NCT02235038,Children's Hospital Boston,True,MA,https://ClinicalTrials.gov/show/NCT02235038,True,Metabolic Fuels Study,Obesity,Behavioral:Low carbohydrate diet; Behavioral:Moderate carbohydrate diet; Behavioral:High carbohydrate diet,"[u""Boston Children's Hospital"", u""Brigham & Women's Hospital"", u'Boston Medical Center', u'Framingham State University']","February 4, 2015",18,65,Both,True
NCT02234583,Daiichi Sankyo Inc.,False,MA,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02231749,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02231749,True,Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma,Biological:Nivolumab; Biological:Ipilimumab; Drug:Sunitinib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02230969,Biogen,False,MA,https://ClinicalTrials.gov/show/NCT02230969,True,Plegridy Observational Program,Relapsing Forms of Multiple Sclerosis,Drug:peginterferon beta-1a,[],"September 10, 2015",18,9223372036854775807,Both,False
NCT02227251,"Karyopharm Therapeutics, Inc",False,MA,https://ClinicalTrials.gov/show/NCT02227251,True,Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL),Diffuse Large B-cell Lymphoma,Drug:Selinexor,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT02175225,Beth Israel Deaconess Medical Center,True,MA,https://ClinicalTrials.gov/show/NCT02175225,True,Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial,Intracerebral Hemorrhage,Drug:Deferoxamine Mesylate; Drug:Placebo (for Deferoxamine Mesylate),[],"July 20, 2015",18,80,Both,False
NCT02164916,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,MA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02162719,"Genentech, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02162719,True,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,Breast Cancer,Drug:Ipatasertib; Drug:Paclitaxel; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Female,False
NCT02133742,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT02133742,True,"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",Renal Cell Carcinoma,Drug:Axitinib; Drug:MK-3475,"[u'Georgetown University Medical Center', u'H. Lee Moffitt Cancer Center & Research Institute, Inc.', u'Massachusetts General Hospital', u""Brigham & Women's Hospital"", u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Karmanos Cancer Institute', u'Roswell Park Cancer Institute', u'Attn. Alicia Sammarco, RPh, NYU Investigational Pharmacy', u'NYU Langone Medical Center', u'NYU Langone', u'Investigational Drug Services (Drug Management Only)', u'James Cancer Hospital', u'The James Cancer Hospital', u'Martha Morehouse Medical Plaza', u'Fox Chase Cancer Center', u'Henry-Joyce Cancer Clinic', u'Texas Oncology - Baylor Charles A. Sammons Cancer Center']","January 5, 2016",18,9223372036854775807,Both,False
NCT02114203,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT02114203,True,"Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease",Phase 1 Sickle Cell,Drug:PDE9i; Drug:PDE9i; Drug:placebo for PDE9i; Drug:PDE9i,[],"February 1, 2016",18,65,Both,False
NCT02112916,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02104947,Boehringer Ingelheim,False,MA,https://ClinicalTrials.gov/show/NCT02104947,True,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Drug:idarucizumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,MA,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02052882,Memorial Sloan Kettering Cancer Center,False,MA,https://ClinicalTrials.gov/show/NCT02052882,True,Study of Romiplostim Versus Observation for Chemotherapy Induced Thrombocytopenia,Isolated Chemotherapy-induced Thrombocytopenia,"Biological:romiplostim,; Other:Control cohort","[u'Massachusetts General Hospital Cancer Center', u""Brigham and Women's Hospital"", u'Dana Farber Cancer Institute', u'Beth Israel Deaconess Medical Center', u'Memorial Sloan Kettering at Basking Ridge', u'Memorial Sloan Kettering Cancer Center @ Suffolk', u'Memorial Sloan Kettering Cancer Center', u'Memorial Sloan Kettering at Mercy Medical Center', u'Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center', u'Memorial Sloan Kettering West Harrison']","August 17, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01970865,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01970865,True,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug:PF-06463922; Drug:Crizotinib,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950819,Novartis Pharmaceuticals,False,MA,https://ClinicalTrials.gov/show/NCT01950819,True,Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM),End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis; Renal Replacement Therapy; Renal Transplantation,Biological:Induction therapy; Drug:Corticosteroids; Drug:EVR+rCNI; Drug:MPA+sCNI,[],"January 19, 2015",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01942837,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01942837,True,Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling,Prostate Cancer,Drug:Enzalutamide,"[u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Beth Israel Deaconess Medical Center', u'South Shore Hospital', u'University of Washington Medical Center/Seattle Cancer Care Alliance']","June 2, 2015",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01854034,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01854034,True,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,Non Small Cell Lung Cancer,Drug:AUY922,"[u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute']","August 7, 2015",18,9223372036854775807,Both,False
NCT01829217,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01829217,True,Sunitinib in Never-Smokers With Lung Adenocarcinoma,Lung Cancer,Drug:Sunitinib,"[u'Massachusetts General Hospital', u'Beth Isreal Deaconess Medical Center', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute']","August 4, 2015",18,9223372036854775807,Both,False
NCT01681225,Beth Israel Deaconess Medical Center,True,MA,https://ClinicalTrials.gov/show/NCT01681225,True,EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures,Acute Respiratory Distress Syndrome,Other:Esophageal-pressure guided mechanical ventilation; Other:High PEEP mechanical ventilation,"[u'University of California at San Diego', u'Stanford University Medical Center', u'Orlando Health', u'Shock-Trauma University of Maryland Medical Center', u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Beth Israel Deaconess Medical Center', u'University of Massachusets Medical Center', u'University of Michigan', u'Montefiore Medical Center', u'University of Cincinnati', u'Vancouver General Hospital', u""St Joseph's Healthcare"", u'University Health Network', u'Laval University']","December 24, 2015",16,9223372036854775807,Both,False
NCT01670500,Beth Israel Deaconess Medical Center,False,MA,https://ClinicalTrials.gov/show/NCT01670500,True,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,Breast Cancer,Drug:Cisplatin; Drug:Cyclophosphamide; Drug:Doxorubicin,"[u'University of Colorado Cancer Center', u'Yale School of Medicine', u'Georgetown University Medical Center', u'Johns Hopkins', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute at Faulkner Hospital', u'Dana-Farber Cancer Institute', u'Massachusetts General Hospital', u'New Hampshire Oncology-Hematology', u'Rutgers Cancer Institute of New Jersey', u'Memorial Sloan-Kettering Cancer Center', u'University of Pennsylvania Abramson Cancer Center', u'Women and Infants Hospital', u'MD Anderson Cancer Center']","January 20, 2016",18,9223372036854775807,Both,False
NCT01663090,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01663090,True,Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas,Soft Tissue Sarcoma,Drug:Ferumoxytol,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u""Children's Hospital Boston"", u'Dana-Farber Cancer Institute']","August 3, 2015",12,9223372036854775807,Both,False
NCT01652079,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01652079,True,CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Drug:CRLX101,"[u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute']","January 22, 2014",18,9223372036854775807,Female,False
NCT01649089,Gynecologic Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01595061,Gynecologic Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01584557,Cardiovascular Clinical Science Foundation,False,MA,https://ClinicalTrials.gov/show/NCT01584557,True,"Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management",Heart Failure,Drug:Tolvaptan or Samsca; Drug:placebo or sugar pill,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT01581619,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01581619,True,External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks,Breast Cancer,Radiation:External Beam Partial-Breast Irradiation,"[u'Beth Isreal Deaconness Medical Center', u""Brigham and Women's Hosptial"", u'Dana-Farber Cancer Institute', u'Massachusetts General Hospital']","May 12, 2014",18,9223372036854775807,Female,False
NCT01560416,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01560416,True,Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,Breast Cancer,Drug:Fulvestrant; Drug:Ganetespib,"[u'DFCI at Faulkner Hospital', u'Beth Israel Deaconess Medical Center', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'New Hampshire Oncology and Hematology, P.A.', u'University of North Carolina']","November 25, 2015",18,9223372036854775807,Both,False
NCT01546038,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01471522,New York University School of Medicine,True,MA,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT01446965,"University of California, San Francisco",False,MA,https://ClinicalTrials.gov/show/NCT01446965,True,Vest Prevention of Early Sudden Death Trial and VEST Registry,Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation,Device:wearable defibrillator,[],"April 7, 2015",18,9223372036854775807,Both,False
NCT01442194,Novartis,False,MA,https://ClinicalTrials.gov/show/NCT01442194,True,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,Multiple Sclerosis,Drug:Fingolimod; Drug:other disease-modifying therapy,[],"January 15, 2016",0,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01345019,Amgen,False,MA,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01282242,Lee Schwamm,False,MA,https://ClinicalTrials.gov/show/NCT01282242,True,MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients,Acute Stroke,Drug:IV rt-PA,"[u'University of Arizona', u'Cedars Sinai Medical Center', u'Ronald Reagan UCLA Medical Center', u'Rush University Medical Center', u'University of Iowa', u'NIH/ NINDS, Washington Hospital, Suburban Hospital', u'Massachusetts General Hospital', u'Boston Medical Center', u'Beth Israel Deaconess Medical Center', u'University of Massachusetts', u'Washington University School of Medicine/Barnes Jewish Hospital', u'University of Tennessee Health Science Center', u'Seton/UT Southwestern Medical Center', u'Intermountain Healthcare']","June 25, 2015",18,85,Both,False
NCT01227967,National Institute of Allergy and Infectious Diseases (NIAID),True,MA,https://ClinicalTrials.gov/show/NCT01227967,True,"Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications",Influenza,"Drug:Amantadine, Ribavirin, Oseltamivir; Drug:Oseltamivir",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01116648,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01116648,True,"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",Estrogen Receptor Negative; HER2/Neu Negative; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Triple-Negative Breast Carcinoma,Drug:Cediranib Maleate; Other:Laboratory Biomarker Analysis; Drug:Olaparib; Other:Pharmacological Study,"[u'Cedars-Sinai Medical Center', u'University of Chicago Comprehensive Cancer Center', u'NorthShore University HealthSystem-Evanston Hospital', u'Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard', u'Fort Wayne Medical Oncology and Hematology Inc-Parkview', u'Johns Hopkins University/Sidney Kimmel Cancer Center', u'National Institutes of Health Clinical Center', u'National Cancer Institute', u'Massachusetts General Hospital Cancer Center', u'Dana-Farber/Harvard Cancer Center', u'Beth Israel Deaconess Medical Center', u'Massachusetts General Hospital', u'University of Michigan Comprehensive Cancer Center']","January 11, 2016",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,MA,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00903968,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT00903968,True,Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,Multiple Myeloma,Drug:Plerixafor (AMD3100); Drug:bortezomib,"[u'Dana-Farber Cancer Institute', u'Cape Cod Hospital', u'Milford Hospital', u'Newton-Wellesley Hospital', u'Cancer Treatment Centers of America (Eastern Regional Medical Center)']","August 7, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00830531,"Soul, Janet , M.D.",True,MA,https://ClinicalTrials.gov/show/NCT00830531,True,Pilot Study of Bumetanide for Newborn Seizures,Seizures,Drug:Bumetanide; Drug:Normal Saline as Placebo,"[u'Tufts Floating Hospital for Children at Tufts Medical Center', u'Massachusetts General Hospital', u""Boston Children's Hospital"", u""Brigham and Women's Hospital""]","October 12, 2015",0,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02665429,"University of Massachusetts, Worcester",False,MA,https://ClinicalTrials.gov/show/NCT02665429,True,A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department,"Analgesics, Opioid; Delivery of Health Care; Drug Prescribing; Over Prescribing; Prescribing Patterns, Physician; Practice Management, Medical; Practice Guidelines as Topic",Behavioral:Individual prescribing data profile and self-assessment,"[u'UMass Clinton Hospital', u'UMass Memorial Marlborough Hospital', u'UMass Memorial Medical Center']","January 22, 2016",0,9223372036854775807,Both,False
NCT02661997,VA Office of Research and Development,False,MA,https://ClinicalTrials.gov/show/NCT02661997,True,Novel Interventions for Gulf War Veterans' Illnesses,Gulf War Veteran's Illness,Behavioral:Tai Chi Intervention; Behavioral:Wellness Intervention,"[u'Tuft Medical Center', u'Boston University, School of Medicine', u'VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA']","January 20, 2016",40,9223372036854775807,Both,False
NCT02617589,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02617589,True,"Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",Brain Cancer,Drug:Nivolumab; Drug:Temozolomide; Radiation:Radiotherapy,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,MA,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02589717,"Genentech, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02589717,True,An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy,Urothelial Carcinoma,Drug:Atezolizumab,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02581384,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02581384,True,"Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors",Ewing Sarcoma; Rhabdomyosarcoma; Wilms Tumor,Radiation:Stereotactic Body Radiotherapy (SBRT),"[u""Boston Children's Hospital"", u'Dana Farber Cancer Institute', u'Dana Farber Cancer Institute']","October 19, 2015",8,19,Both,False
NCT02528253,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02504424,"AirXpanders, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02504424,True,AirXpanders AeroForm Tissue Expander System for Breast Reconstruction,Breast Cancer,Device:AeroForm Tissue Expander,"[u'Marin General Hospital', u'Good Samaritan Hospital, San Jose', u'Broward Health Medical Center', u'Massachusetts General Hospital', u'Faulkner Hospital', u'University of Massachusetts Memorial Medical Center', u'Columbia University', u'Presbyterian Medical Center']","October 26, 2015",18,70,Female,True
NCT02504216,Bayer,False,MA,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02493868,"Janssen Research & Development, LLC",False,MA,https://ClinicalTrials.gov/show/NCT02493868,True,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 2, 2016",18,64,Both,False
NCT02493751,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT02493751,True,A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100),Renal Cell Cancer,Drug:Avelumab (MSB0010718C); Drug:Axitinib (AG-013736),"[u'Oncology Research Associates, PLLC d/b/a Pinnacle Oncology Hematology', u""Brigham & Women's Hospital"", u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Kinki University Hospital', u'Keio University Hospital', u'The Royal Marsden NHS Foundation Trust', u'The Christie NHS Foundation Trust']","January 13, 2016",18,9223372036854775807,Both,False
NCT02489526,"Vivozon, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02489526,True,Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery,Post-Operative Pain,Drug:VVZ-149 Injections; Drug:Placebo,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Beth Israel Deaconess Medical Center']","February 4, 2016",18,70,Both,False
NCT02488759,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02488759,True,A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),Various Advanced Cancer,Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02454972,PharmaMar,False,MA,https://ClinicalTrials.gov/show/NCT02454972,True,Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,Advanced Solid Tumors,Drug:lurbinectedin (PM01183),"[u'1', u'3', u'2', u'6', u'7', u'4', u'5']","December 4, 2015",18,9223372036854775807,Both,False
NCT02450331,Hoffmann-La Roche,False,MA,https://ClinicalTrials.gov/show/NCT02450331,True,"A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]","Bladder Cancer, Cancer","Drug:Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02447003,Merck Sharp & Dohme Corp.,False,MA,https://ClinicalTrials.gov/show/NCT02447003,True,Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),Breast Cancer,Biological:Pembrolizumab,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02446704,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02446704,True,Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,Small Cell Lung Cancer,Drug:Olaparib; Drug:Temozolomide,"[u'Massachusetts General Hospital', u'Dana Farber Cancer Institute', u'Beth Israel Deaconess Medical Center']","December 6, 2015",18,9223372036854775807,Both,False
NCT02446444,University of Sydney,False,MA,https://ClinicalTrials.gov/show/NCT02446444,True,"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer",Prostatic Neoplasms,Drug:Enzalutamide; Drug:Conventional NSAA; Drug:LHRHA; Radiation:External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost),[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02441686,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02441686,True,"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",Multiple Myeloma,Drug:Bortezomib; Drug:Lenalidomide; Drug:Dexamethasone,"[u'Massachusetts General Hosptial', u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Virgina Piper Cancer Institute']","January 15, 2016",18,9223372036854775807,Both,False
NCT02425891,Hoffmann-La Roche,False,MA,https://ClinicalTrials.gov/show/NCT02425891,True,A Study of Atezolizumab (MPDL3280A) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130),Metastatic Breast Cancer,Drug:Atezolizumab; Drug:Nab-Paclitaxel; Drug:Placebo,[],"December 31, 2015",18,9223372036854775807,Female,False
NCT02420821,Hoffmann-La Roche,False,MA,https://ClinicalTrials.gov/show/NCT02420821,True,"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]",Renal Cell Carcinoma,Drug:Atezolizumab; Drug:Bevacizumab; Drug:Sunitinib,[],"December 31, 2015",18,9223372036854775807,Both,False
NCT02418585,"Janssen Research & Development, LLC",False,MA,https://ClinicalTrials.gov/show/NCT02418585,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"January 27, 2016",18,64,Both,False
NCT02417064,"Janssen Research & Development, LLC",False,MA,https://ClinicalTrials.gov/show/NCT02417064,True,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Drug:Esketamine; Drug:Placebo; Drug:Duloxetine (Oral Antidepressant); Drug:Escitalopram (Oral antidepressant); Drug:Sertraline (Oral Antidepressant); Drug:Venlafaxine Extended Release (XR) (Oral Antidepressant),[],"February 3, 2016",18,64,Both,False
NCT02406677,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02375880,"HealthCare Pharmaceuticals, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02375880,True,Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder,Carcinoma of Intrahepatic and Extra-hepatic Biliary System; Carcinoma of Gallbladder; Bile Duct Cancer; Cholangiocarcinoma,Drug:DKN-01; Drug:gemcitabine; Drug:cisplatin,"[u'University of Southern California', u'Yale University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Columbia University Medical Center', u'University Hospitals, Case Medical Center']","December 10, 2015",30,9223372036854775807,Both,False
NCT02362997,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02362997,True,Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL,Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma,Drug:Pembrolizumab,"[u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute']","December 14, 2015",18,9223372036854775807,Both,False
NCT02340585,Stryker Neurovascular,False,MA,https://ClinicalTrials.gov/show/NCT02340585,True,Neuroform ATLAS IDE Study,Intracranial Aneurysm,Device:Next Generation Neuroform Stent System,"[u'Radiology Imaging Associates', u'Christiana Care Health Services', u'Lyerly Neurosurgery', u'WellStar Kennestone Hospital', u'Tufts Medical Center', u'Beth Israel Deaconess Medical Center', u'University of Massachusetts Medical School', u'SSM DePaul Health Center', u'University at Buffalo Neurosurgery/Gates Vascular Institute', u'The Cleveland Clinic Foundation', u'Hospital of the University of Pennsylvania', u'University of Pittsburgh Medical Center', u'Medical University of South Carolina', u'Methodist Healthcare - Memphis Hospitals', u'Houston Methodist Hospital', u'Virginia Commonwealth University', u'Harborview Medical Center']","December 9, 2015",18,80,Both,False
NCT02336815,"Karyopharm Therapeutics, Inc",False,MA,https://ClinicalTrials.gov/show/NCT02336815,True,"Phase 2b Open-Label Single-Arm Study of Selinexor & Dexamethasone in Patients Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide",Multiple Myeloma,Drug:Selinexor; Drug:Dexamethasone,[],"November 9, 2015",18,9223372036854775807,Both,False
NCT02326974,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02326974,True,T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,HER-2 Positive Breast Cancer; Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer,Drug:T-DM1; Drug:Pertuzumab; Procedure:Excision of tumor/mastectomy,"[u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Vanderbilt-Ingram Cancer Center']","January 19, 2016",18,9223372036854775807,Both,False
NCT02320058,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02320058,True,A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204),Melanoma,Drug:Ipilimumab; Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02319005,Alnylam Pharmaceuticals,False,MA,https://ClinicalTrials.gov/show/NCT02319005,True,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC); Amyloidosis, Hereditary; Amyloid Neuropathies, Familial; Amyloid Neuropathies; Amyloidosis, Hereditary, Transthyretin-Related; Familial Transthyretin Cardiac Amyloidosis",Drug:Revusiran (ALN-TTRSC); Drug:Sterile Normal Saline (0.9% NaCl),[],"December 23, 2015",18,90,Both,False
NCT02316847,Acorda Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT02316847,True,"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures",Epilepsy,Drug:diazepam nasal spray,[],"January 13, 2016",12,65,Both,False
NCT02313909,Bayer,False,MA,https://ClinicalTrials.gov/show/NCT02313909,True,Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS),Stroke,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Aspirin (Acetylsalicylic acid, BAY1019036); Other:Rivaroxaban-Placebo; Other:Aspirin-Placebo",[],"February 3, 2016",50,9223372036854775807,Both,False
NCT02291237,Gilead Sciences,False,MA,https://ClinicalTrials.gov/show/NCT02291237,True,Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy,Hypertrophic Cardiomyopathy,Drug:Eleclazine; Drug:Placebo,[],"January 29, 2016",18,65,Both,False
NCT02271217,Acorda Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02253992,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02253992,True,Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,Advanced Solid Tumors; Advanced B-cell NHL,Biological:Urelumab; Biological:Nivolumab,"[u'Stanford University School Of Medicine', u'H. Lee Moffitt Cancer Center', u'University Of Chicago', u'Johns Hopkins Sidney Kimmel Comprehensive Cancer Center', u'Dana-Farber Cancer Institute', u'Local Institution', u'Local Institution', u'Memorial Sloan Kettering Cancer Center', u'Providence Portland Medical Center', u'Upmc Eye And Ear Institute', u'Md Anderson', u'Local Institution', u'Local Institution', u'Local Institution', u'Local Institution', u'Universitaetsklinikum Essen', u'Local Institution']","February 1, 2016",18,9223372036854775807,Both,False
NCT02253394,Brigham and Women's Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02253394,True,The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study,Pulmonary Arterial Hypertension,Drug:Ambrisentan plus Spironolactone; Drug:Ambrisentan plus Placebo,"[u""Brigham & Women's Hospital"", u'Tufts-New England Medical Center', u'Boston Medical Center']","September 27, 2014",16,75,Both,False
NCT02240030,Acorda Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT02240030,True,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Drug:CVT-301,[],"November 12, 2015",30,85,Both,False
NCT02228772,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02228772,True,Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults,Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia,Drug:MLN 9708; Drug:Vincristine; Drug:Cytarabine; Drug:Doxorubicin; Drug:Mercaptopurine; Drug:Cyclophosphamide; Drug:Methotrexate,"[u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute']","September 21, 2015",51,75,Both,False
NCT02219724,"Genentech, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02219724,True,"A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors",Solid Cancers,Drug:MOXR0916,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02198690,Beth Israel Deaconess Medical Center,False,MA,https://ClinicalTrials.gov/show/NCT02198690,True,Trial of a Mammography Decision Aid for Women Aged 75 and Older,Breast Cancer Screening,Other:Mammography decision aid; Other:Home safety pamphlet,"[u'Affiliated Physicians Group', u'Beth Israel Deaconess Medical Center', u'Harvard Vanguard Medical Associates', u'University of North Carolina Medical Center']","January 12, 2016",75,89,Female,False
NCT02195232,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02195232,True,Cancer Associated Thrombosis and Isoquercetin (CAT IQ),Thromboembolism of Vein VTE in Colorectal Cancer; Thromboembolism of Vein in Pancreatic Cancer; Thromboembolism of Vein in Non-small Cell Lung Cancer,Drug:Isoquercetin,"[u'USC/Norris Comprehensive Cancer Center and Hospital', u'UC Davis Health System', u'Veteran Affairs Medical Center', u'Georgetown University', u'York Hospital', u'VA Boston Healthcare System', u'Beth Israel Deaconess Medical Center', u'Mount Auburn Hospital', u'Washington University']","November 17, 2015",18,9223372036854775807,Both,False
NCT02191137,Bayer,False,MA,https://ClinicalTrials.gov/show/NCT02191137,True,"MOTION, Measuring Outcomes in Treatment Naive Patients",Pulmonary,"Drug:Riociguat (Adempas,BAY63-2521)",[],"January 22, 2016",18,80,Both,False
NCT02188784,Adrian Hernandez,False,MA,https://ClinicalTrials.gov/show/NCT02188784,True,Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure,Chronic Heart Failure,Drug:Polysaccharide Iron Complex 150 mg; Drug:Placebo (for Polysaccharide Iron Complex),"[u'Emory University School of Medicine', u'Johns Hopkins Hospital', u'Tufts Medical Center', u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Mayo Clinic', u'Saint Louis University Hospital', u'Washington University School of Medicine', u'Duke University Medical Center', u'University Hospitals-Case Medical Center', u'Metor Health System', u'Cleveland Clinic Foundation', u'Lancaster General Hospital', u'Hospital of the University of Pennsylvania', u'University of Utah Hospitals and Clinics', u'The University of Vermont - Fletcher Allen Health Care']","December 30, 2015",18,9223372036854775807,Both,False
NCT02181738,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02181738,True,Study of Nivolumab in Subjects With Classical Hodgkin's Lymphoma (Registrational),Hodgkin Disease,Drug:Nivolumab; Drug:Doxorubicin; Drug:Vinblastine; Drug:Dacarbazine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,MA,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,MA,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02157519,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02157519,True,Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer,Adherence to Medication Regime; Cancer,Other:Mobile Application Intervention,"[u'Massachusetts General Hospital/North Shore Cancer Center', u'Massachusetts General Hospital', u'Massachusetts General Hospital At Emerson Hospital-Bethke']","July 20, 2015",18,9223372036854775807,Both,True
NCT02142530,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02142530,True,Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Peripheral T-cell Lymphoma,Drug:Carfilzomib; Drug:Belinostat,"[u'Massachusetts General Hospital', u'Beth-Israel Deaconess Medical Center', u'Dana Farber Cancer Institute']","January 19, 2016",18,9223372036854775807,Both,False
NCT02135133,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02135133,True,"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:Idelalisib; Drug:Ofatumumab,"[u'Massachusetts General Hospital', u'Beth Isreal Deaconess Medical Center', u'Dana-Farber Cancer Institute']","September 2, 2015",18,9223372036854775807,Both,False
NCT02130986,University of Pittsburgh,True,MA,https://ClinicalTrials.gov/show/NCT02130986,True,Procalcitonin Antibiotic Consensus Trial (ProACT),Lower Respiratory Tract Infection (LRTI),Other:Procalcitonin level; Other:Results of procalcitonin (PCT) level to treating clinician; Other:Provide procalcitonin guideline to treating clinician; Other:Telephone Visit,"[u'University of Alabama at Birmingham', u'Maricopa Medical Center', u'University of California at Irvine Medical Center', u'Norwalk Hospital', u'University of Maryland/Baltimore', u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Beth Israel Deaconess Medical Center', u'Wayne State University/Sanal Grace Hospital', u'Essentia Institute of Rural Health', u'The Ohio State University, College of Medicine', u'Penn State Hershey College of Medicine; Milton S. Hershey Medical Center', u'University of Pittsburgh Medical Center']","October 30, 2015",18,9223372036854775807,Both,False
NCT02128763,University of Pennsylvania,False,MA,https://ClinicalTrials.gov/show/NCT02128763,True,Dry Eye Assessment and Management Study,Dry Eye,Drug:Omega-3 supplements; Drug:Placebo,[],"October 8, 2015",18,9223372036854775807,Both,False
NCT02125695,Biogen,False,MA,https://ClinicalTrials.gov/show/NCT02125695,True,Pilot Tape Harvesting Study,Atopic Dermatitis; Healthy; Discoid Lupus Erythematosus; Subacute Cutaneous Lupus Erythematosus; Systemic Sclerosis,Procedure:Skin Taping; Procedure:Blood Sampling; Procedure:Skin Biopsy,"[u'Research Site', u'Research Site', u'Research Site']","October 16, 2015",18,9223372036854775807,Both,True
NCT02109939,Assurex Health Inc.,False,MA,https://ClinicalTrials.gov/show/NCT02109939,True,Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic,Major Depressive Disorder (MDD),Genetic:GeneSight Psychotropic,[],"December 4, 2015",18,9223372036854775807,Both,False
NCT02086513,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02086513,True,Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT,Graft Versus Host Disease,Drug:LDE225,"[u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Massachusetts General Hospital']","January 28, 2016",18,9223372036854775807,Both,False
NCT02080364,vTv Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT02080364,True,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02071862,"Calithera Biosciences, Inc",False,MA,https://ClinicalTrials.gov/show/NCT02071862,True,Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,Solid Tumors; Triple-Negative Breast Cancer; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Mesothelioma; Fumarate Hydratase (FH)-Deficient Tumors; Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST); Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors; Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations; Tumors Harboring Amplifications in the cMyc Gene,Drug:CB-839; Drug:Pac-CB; Drug:CBE; Drug:CB-Erl; Drug:CBD,"[u'UCSF Helen Diller Family Comprehensive Cancer Center', u'Stanford University Medical Center', u'Florida Cancer Specialists', u'Winship Cancer Institute of Emory School of Medicine', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Columbia University Medical Center', u'Memorial Sloan Kettering Cancer Center', u'University of Pennsylvania, Abramson Cancer Center', u'Tennessee Oncology, PLLC', u'University of Texas MD Anderson Cancer Center']","January 27, 2016",18,9223372036854775807,Both,False
NCT02043678,Bayer,False,MA,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT02039674,Merck Sharp & Dohme Corp.,False,MA,https://ClinicalTrials.gov/show/NCT02039674,True,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),Non-small Cell Lung Carcinoma,Drug:Pembrolizumab; Drug:Paclitaxel; Drug:Carboplatin; Biological:Bevacizumab; Drug:Pemetrexed; Biological:Ipilimumab; Drug:Erlotinib; Drug:Gefitinib,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02038946,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02038946,True,Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),Lymphoma,Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02036970,"Reata Pharmaceuticals, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT02036970,True,Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT,Pulmonary Arterial Hypertension; Pulmonary Hypertension,Drug:Bardoxolone methyl; Drug:Placebo,[],"September 24, 2015",18,75,Both,False
NCT02028988,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT02028988,True,Enzalutamide + External Beam Rt For Prostate,Intermediate Risk Prostate Cancer,Drug:Enzalutamide; Radiation:External Beam Radiation,"[u'Beth Israel Deaconess Medical Center', u""Brigham and Women's Hospital"", u'Dana Farber Cancer Institute']","October 14, 2015",18,9223372036854775807,Male,False
NCT02017717,Bristol-Myers Squibb,False,MA,https://ClinicalTrials.gov/show/NCT02017717,True,A Study of the Efficacy and Safety of Nivolumab Versus Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment,Recurrent Glioblastoma,Biological:Nivolumab; Biological:Bevacizumab; Biological:Ipilimumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02017171,Alessandro Doria,True,MA,https://ClinicalTrials.gov/show/NCT02017171,True,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,Diabetic Nephropathies; Coronary Artery Disease,Drug:Allopurinol; Drug:Placebo,[],"September 17, 2015",18,70,Both,False
NCT02009644,Bolton Medical,False,MA,https://ClinicalTrials.gov/show/NCT02009644,True,Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms,Abdominal Aortic Aneurysm (AAA),Device:Subjects who receive the Treovance stent-graft,[],"August 21, 2015",18,85,Both,False
NCT02003222,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01982448,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01982448,True,Cisplatin vs Paclitaxel for Triple Neg,Triple Negative Breast Cancer,Drug:Cisplatin; Drug:Paclitaxel,"[u'University of Alabama', u'Indiana University- Simon Cancer Center', u'Johns Hopkins University', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'South Shore Hospital', u'Memorial Sloan Kettering Cancer Center-Basking Ridge', u'Memorial Sloan Kettering Cancer Center-Commack', u'Memorial Sloan Kettering Cancer Center', u'Memorial Sloan Kettering Cancer Center-Rockville Centre', u'Memorial Sloan Kettering Cancer Center-Sleepy Hollow', u'Memorial Sloan Kettering Cancer Center-West Harrison', u'University of North Carolina- Lineberger Cancer Center', u'Duke University', u'Universtiy of Pittsburgh- Magee-Womens Hospital', u'Vanderbilt-Ingram Cancer Center', u'Baylor College of Medicine']","January 19, 2016",18,9223372036854775807,Female,False
NCT01976364,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01976364,True,Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis,"Arthritis, Psoriatic",Drug:Tofacitinib; Drug:Tofacitinib,[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01969799,Cardeas Pharma,False,MA,https://ClinicalTrials.gov/show/NCT01969799,True,Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin fosfomycin inhalation solution; Drug:Aerosolized placebo,[],"January 28, 2016",18,80,Both,False
NCT01965353,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01965353,True,A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,Multiple Myeloma in Relapse,Drug:Panobinostat; Drug:Dexamethasone; Drug:Lenalidomide; Drug:Bortezomib,"[u""Brigham and Women's Hospital"", u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Duke University Medical Center']","August 28, 2015",18,9223372036854775807,Both,False
NCT01964430,Celgene Corporation,False,MA,https://ClinicalTrials.gov/show/NCT01964430,True,"Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)","Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic",Drug:nab-Paclitaxel 125 mg/m2; Drug:gemcitabine 1000 mg/m2; Drug:gemcitabine 1000 mg/m2,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT01958476,Tufts Medical Center,True,MA,https://ClinicalTrials.gov/show/NCT01958476,True,Improving Outcomes in Neonatal Abstinence Syndrome,Neonatal Abstinence Syndrome; Neonatal Opioid Withdrawal,Drug:Neonatal Morphine Solution; Drug:Methadone; Drug:Phenobarbital,"[u'Shands Jacksonville Medical Center', u'Maine Medical Center', u'Tufts Medical Center', u'Boston Medical Center', u'Baystate Medical Center', u'University of Pittsburgh Medical Center', u""Women and Infant's Hospital of Rhode Island"", u'Vanderbilt University']","May 15, 2015",0,9223372036854775807,Both,False
NCT01955395,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01955395,True,Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma,Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma,Behavioral:Relaxation Response Resiliency Program (3RP),"[u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Massachusetts General Hospital']","October 22, 2013",18,9223372036854775807,Both,False
NCT01953926,"Puma Biotechnology, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT01953926,True,"An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",Solid Tumors,Drug:Neratinib,"[u'University of Southern California (USC)', u'UCLA', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana Farber Cancer Institute', u'University of Michigan', u'Washington University', u'Memorial Sloan-Kettering Cancer Center', u'Vanderbilt-Ingram Cancer Center', u'MD Anderson Cancer Center', u'Peter MacCallum Cancer Centre', u'Helsinki University Central Hospital', u'Rabin Medical Center', u'Kaplan Medical Center', u'Oncologia Medica-Istituti Ospitalieri di Cremona', u'University and San Giovanni Battista Hospital', u'Hospital Universitario Quiron Dexeus', u""Hospital Universitario Vall d'Hebron"", u'Hospital Universitario Fundacion Jimenez Diaz', u'Hospital Universitario Madrid Sanchinarro (START Madrid)', u'Hospital Universitario Quiron Madrid', u'Instituto Valenciano de Oncologia', u'Hospital Clinico Universitario de Valencia']","January 26, 2016",18,9223372036854775807,Both,False
NCT01922440,Shire,False,MA,https://ClinicalTrials.gov/show/NCT01922440,True,PARADIGHM A Natural History Registry for Patients With Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,Other:None [Natural history registry],[],"February 4, 2016",0,9223372036854775807,Both,False
NCT01915615,University of Virginia,False,MA,https://ClinicalTrials.gov/show/NCT01915615,True,HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy,Hypertrophic Cardiomyopathy,Other:None - this is an observational study,[],"October 21, 2015",18,65,Both,False
NCT01898494,Eastern Cooperative Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01898494,True,Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,Human Papilloma Virus Infection; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Oropharynx,Procedure:therapeutic conventional surgery; Radiation:intensity-modulated radiation therapy; Drug:cisplatin; Drug:carboplatin; Radiation:intensity-modulated radiation therapy; Other:laboratory biomarker analysis; Other:quality-of-life assessment,[],"November 19, 2015",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,MA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01858168,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01858168,True,Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma,Ewing Sarcoma,Drug:Olaparib; Drug:Temozolomide,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute']","March 26, 2014",18,9223372036854775807,Both,False
NCT01855750,"Janssen Research & Development, LLC",False,MA,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01849588,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01849588,True,Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C,Hepatocellular Cancer,Drug:Sorafenib,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute']","March 19, 2014",18,9223372036854775807,Both,False
NCT01839487,Halozyme Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT01839487,True,PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug:PEGPH20+nab-paclitaxel+gemcitabine; Drug:nab-paclitaxel + gemcitabine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01834235,"Precision Biologics, Inc",False,MA,https://ClinicalTrials.gov/show/NCT01834235,True,A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer,"Pancreatic Cancer, Adult",Drug:Gemcitabine; Drug:nab-paclitaxel; Drug:NPC-1C,"[u'California Pacific Medical Center', u'Smilow Cancer Hospital- Yale', u'University of Miami', u'National Cancer Institute', u'Beht Isreal Deaconess Medical Center', u'Dana Farber Cancer Institute', u'Massachusetts General Hospital', u'Washington University in St. Louis', u'Cancer Institute of New Jersey', u'University of North Carolina at Chapel Hill', u'Duke University', u'Thomas Jefferson University Hospital', u'UT Southwestern Medical Center']","November 25, 2015",18,9223372036854775807,Both,False
NCT01822509,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01822509,True,Ipilimumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,"Myeloproliferative Neoplasm; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Plasma Cell Myeloma",Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,"[u'UC San Diego Moores Cancer Center', u'Colorado Blood Cancer Institute', u'Northside Hospital', u'Maine Center for Cancer Medicine-Scarborough', u'Dana-Farber/Harvard Cancer Center', u'Beth Israel Deaconess Medical Center', u'Massachusetts General Hospital']","January 11, 2016",18,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01806064,Tracon Pharmaceuticals Inc.,False,MA,https://ClinicalTrials.gov/show/NCT01806064,True,A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma,Renal Cell Carcinoma,Drug:TRC105 and Axitinib,[],"July 27, 2015",18,9223372036854775807,Both,False
NCT01788631,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01788631,True,A Phase II Trial of Regadenoson in Sickle Cell Anemia,Sickle Cell Anemia,Drug:Regadenoson; Drug:Placebo,"[u""Children's Hospital and Research Center at Oakland"", u'University of Illinois at Chicago', u'Johns Hopkins University', u""Boston Children's Hospital"", u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Wayne State University/Karmanos Cancer Institute', u'Washington University in St. Louis', u'Duke University', u""Cincinnati Children's Hospital Medical Center"", u'Baylor College of Medicine', u'Medical College of Wisconsin']","December 14, 2015",10,70,Both,False
NCT01786096,"Seattle Genetics, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT01786096,True,A Safety Study of SGN-CD19A for Leukemia and Lymphoma,Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma,Drug:SGN-CD19A,"[u""Children's Hospital of Alabama / University of Alabama at Birmingham"", u'University of Alabama at Birmingham', u'Mayo Clinic Arizona', u'City of Hope National Medical Center', u'Mayo Clinic Florida', u""All Children's Hospital"", u'H. Lee Moffitt Cancer Center & Research Institute', u""Children's Healthcare of Atlanta / Emory University"", u'Massachusetts General Hospital', u""Boston Children's Hospital"", u'Dana Farber Cancer Institute', u'Memorial Sloan Kettering Cancer Center', u""Cincinnati Children's Hospital Medical Center""]","January 28, 2016",1,9223372036854775807,Both,False
NCT01775501,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01775501,True,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,Hepatocellular Cancer,Drug:Leucovorin; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Sorafenib,"[u'Massachusetts General Hospital', u'Dana-Farber Cancer Institute', u""Brigham and Women's Hospital""]","October 30, 2014",18,9223372036854775807,Both,False
NCT01773395,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01773395,True,GVAX vs. Placebo for MDS/AML After Allo HSCT,Myelodysplastic Syndrome; Acute Myeloid Leukemia,Biological:GVAX; Biological:Placebo Vaccine; Procedure:Allogeneic Hematopoietic Stem Cell Transplant; Drug:Busulfan; Drug:Fludarabine; Drug:Tacrolimus; Drug:Methotrexate,"[u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Beth Israel Deaconess Medical Center']","January 26, 2016",18,9223372036854775807,Both,False
NCT01767311,Eisai Inc.,False,MA,https://ClinicalTrials.gov/show/NCT01767311,True,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Alzheimer's Disease,Drug:BAN2401 2.5 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg,[],"November 29, 2015",50,90,Both,False
NCT01762046,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01762046,True,Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans,"Diabetes Mellitus, Type 2",Drug:Glipizide; Drug:Metformin; Other:Oral Glucose Tolerance Test,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Joslin Diabetes Center']","December 24, 2015",18,85,Both,True
NCT01734928,Celgene Corporation,False,MA,https://ClinicalTrials.gov/show/NCT01734928,True,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:Pomalidomide; Drug:Bortezomib; Drug:Dexamethasone,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT01728805,"Kyowa Hakko Kirin Pharma, Inc.",False,MA,https://ClinicalTrials.gov/show/NCT01728805,True,Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL,Cutaneous T-Cell Lymphoma,Biological:KW-0761; Drug:Vorinostat,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02488967,NRG Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,MI,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01622868,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00843882,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01101451,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,MI,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02019264,Eisai Inc.,False,MI,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01359592,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,MI,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01372787,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT02180867,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01975376,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,MI,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT02134912,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02315469,NRG Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02152982,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT02474160,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,MI,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01124695,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00499330,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT00499330,True,Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer,Lung Cancer,Procedure:lobectomy; Procedure:segmentectomy or wedge resection,[],"August 28, 2015",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,MI,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01835145,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,MI,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,MI,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,MI,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01511562,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01511562,True,Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma,Lymphoma,Drug:carmustine; Drug:cytarabine; Drug:etoposide; Drug:thiotepa; Procedure:stem cell transplant; Drug:G-CSF,[],"October 20, 2015",18,75,Both,False
NCT00840177,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00840177,True,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],"September 25, 2015",18,9223372036854775807,Both,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02339571,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02339571,True,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma of the Skin; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Biological:Sargramostim,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01884090,University of Michigan,True,MI,https://ClinicalTrials.gov/show/NCT01884090,True,Youth Empowerment Solutions for Positive Youth Development,Violence; Child or Adolescent Antisocial Behavior,Behavioral:Youth Empowerment Solutions (YES),"[u'Bentley Schools', u'Atherton Middle School', u'Bendle Middle School', u'Northwestern High School', u'Northern High School', u'Kearsley Schools', u'Carman-Ainsworth Middle School', u'Hamady Middle School', u'Genesee School District', u'Mt. Morris Junior High', u'Beecher Middle School']","December 1, 2015",10,15,Both,True
NCT01781468,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01470612,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01458574,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,MI,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,MI,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00807768,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02671981,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02112916,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,MI,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01877915,"Janssen Research & Development, LLC",False,MI,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01533207,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01414608,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01307579,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01101035,Takeda,True,MI,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT02293395,"Janssen Research & Development, LLC",False,MI,https://ClinicalTrials.gov/show/NCT02293395,True,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:Acetylsalicylic acid; Drug:Rivaroxaban; Drug:Clopidogrel; Drug:Ticagrelor,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,MI,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02173379,Abbott Vascular,False,MI,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01582971,Michigan State University,False,MI,https://ClinicalTrials.gov/show/NCT01582971,True,Home-Based Symptom Management Via Reflexology for Breast Cancer Patients,Breast Cancer,Other:Reflexology,"[u'Northwestern', u'Hurley Medical Center', u'Lemmon-Holton Cancer Center', u'Breslin Cancer Center', u'Sparrow Cancer Center', u'McLaren Macomb', u'St. Joseph Mercy Oakland Hospital', u'Beaumont Hospital', u'St. Johns Providence']","April 6, 2015",21,9223372036854775807,Female,False
NCT01535066,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01535066,True,"S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer",Breast Cancer; Pain,Procedure:acupuncture therapy; Procedure:sham acupuncture,[],"September 25, 2015",18,9223372036854775807,Female,False
NCT00888615,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,MI,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02389946,"Biotronik, Inc.",True,MI,https://ClinicalTrials.gov/show/NCT02389946,True,Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions,"Coronary Artery Disease; Atherosclerosis, Coronary; Myocardial Ischemia; Ischemic Heart Disease; Acute Coronary Syndrome; Angina Pectoris",Device:Orsiro DES; Device:Xience DES,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02135042,NRG Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02135042,True,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,MI,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01834534,University of Michigan,False,MI,https://ClinicalTrials.gov/show/NCT01834534,True,Telemonitoring Enhanced Support for Depression Self Management,Depression,Behavioral:CarePartners for depression,"[u'Alcona Health Centers', u'University of Michigan', u'Dua Family Practice', u'Morang Chester', u'Hamilton Community Health Network, Inc.', u'Cherry Street Health Services', u'Muskegon Family Care']","January 25, 2016",21,9223372036854775807,Both,False
NCT01822496,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01772472,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01652872,Amgen,False,MI,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01471522,New York University School of Medicine,True,MI,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT01236547,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00700882,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02415400,Bristol-Myers Squibb,False,MI,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02403323,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT02403323,True,Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,Crohn Disease,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02373813,Amgen,False,MI,https://ClinicalTrials.gov/show/NCT02373813,True,Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission,Rheumatoid Arthritis,Drug:etanercept pre-filled syringe sq injection; Drug:Oral methotrexate; Drug:Placebo for etanercept sq injection; Drug:Placebo for methotrexate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02360319,Vanguard Research Group,False,MI,https://ClinicalTrials.gov/show/NCT02360319,True,Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics,Schizophrenia,Drug:Any FDA approved antipsychotic agent; Drug:aripiprazole long acting injectable formulation,[],"December 7, 2015",18,35,Both,False
NCT02145468,GlaxoSmithKline,False,MI,https://ClinicalTrials.gov/show/NCT02145468,True,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Drug:Losmapimod 7.5 mg twice daily; Drug:Placebo twice daily,[],"February 4, 2016",35,9223372036854775807,Both,False
NCT02104947,Boehringer Ingelheim,False,MI,https://ClinicalTrials.gov/show/NCT02104947,True,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Drug:idarucizumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02104583,Gilead Sciences,False,MI,https://ClinicalTrials.gov/show/NCT02104583,True,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],"January 8, 2016",18,80,Both,False
NCT02092467,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02089217,"Thomas G. Brott, M.D.",False,MI,https://ClinicalTrials.gov/show/NCT02089217,True,Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial,Carotid Stenosis,Procedure:Carotid endarterectomy; Device:Carotid stenting,[],"January 27, 2016",35,9223372036854775807,Both,False
NCT01960075,University of Virginia,False,MI,https://ClinicalTrials.gov/show/NCT01960075,True,Established Status Epilepticus Treatment Trial,Benzodiazepine Refractory Status Epilepticus,Drug:Fosphenytoin; Drug:Levetiracetam; Drug:Valproic acid,[],"October 30, 2015",2,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,MI,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,MI,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01805076,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01805076,True,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer,Procedure:Breast surgery; Procedure:Magnetic resonance imaging; Procedure:Mammography,[],"December 9, 2015",18,9223372036854775807,Female,False
NCT01684709,University of Michigan,False,MI,https://ClinicalTrials.gov/show/NCT01684709,True,Enhancing Informal Caregiving to Support Diabetes Self-Management,Type 2 Diabetes Mellitus,Behavioral:Telemonitoring + self-management support,"[u'University of Michigan', u'Hamilton Health Center', u'Center for Family Health', u'Alcona Health Center', u'Muskegon Family Care', u'St. John Masonic Medical Center']","January 25, 2016",21,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01633112,Novartis Pharmaceuticals,False,MI,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01525550,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01525550,True,A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors,Well-differentiated Pancreatic Neuroendocrine Tumor,Drug:sunitinib,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01503632,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01503632,True,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,Childhood Acute Lymphoblastic Leukemia in Remission,Behavioral:behavioral intervention; Drug:mercaptopurine; Procedure:standard follow-up care; Behavioral:compliance monitoring; Other:questionnaire administration; Other:laboratory biomarker analysis,[],"September 1, 2015",1,21,Both,False
NCT01369069,University of Virginia,False,MI,https://ClinicalTrials.gov/show/NCT01369069,True,Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial,Acute Ischemic Stroke; Diabetes; Hyperglycemia,Drug:IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug:Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL,[],"December 1, 2014",18,9223372036854775807,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT01351545,Center for International Blood and Marrow Transplant Research,False,MI,https://ClinicalTrials.gov/show/NCT01351545,True,A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs),Hematologic Malignancies; Certain:; Inherited Disorders of Metabolism; Inherited Abnormalities of Erythrocyte Differentiation or Function; Inherited Abnormalities of Platelets; Disorders of the Immune System; Histiocytic Disorders; X-linked Lymphoproliferative Syndrome; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia,Drug:A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs),[],"October 20, 2015",0,9223372036854775807,Both,False
NCT01096368,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01096368,True,Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma,Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma,Drug:liposomal vincristine sulfate; Other:clinical observation; Radiation:3-dimensional conformal radiation therapy; Drug:carboplatin; Drug:cyclophosphamide; Drug:etoposide; Drug:cisplatin; Other:laboratory biomarker analysis,[],"August 28, 2015",1,21,Both,False
NCT01042522,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01042522,True,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00980954,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00980954,True,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,Cervical Cancer,Drug:carboplatin; Drug:cisplatin; Drug:paclitaxel,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00978458,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00955708,Boston Scientific Corporation,False,MI,https://ClinicalTrials.gov/show/NCT00955708,True,Longitudinal Surveillance Registry (LSR) of ACUITY Spiral,Heart Failure,Device:ACUITY Spiral Left Ventricular Lead,[],"November 10, 2015",0,9223372036854775807,Both,False
NCT00772200,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00772200,True,Neuropsychological and Behavioral Testing in Younger Patients With Cancer,Chemotherapeutic Agent Toxicity; Childhood Cancer; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity,Procedure:psychosocial assessment and care; Procedure:cognitive assessment; Other:quality-of-life assessment; Other:questionnaire administration,[],"September 21, 2015",1,21,Both,False
NCT00316888,Eastern Cooperative Oncology Group,True,MI,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT02584660,"Janssen Scientific Affairs, LLC",False,MI,https://ClinicalTrials.gov/show/NCT02584660,True,A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department,Pulmonary Embolism,Drug:Rivaroxaban; Drug:Standard-of-care,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02407236,"Janssen Research & Development, LLC",False,MI,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02394028,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT02394028,True,A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug:Etrolizumab 210 mg; Drug:Etrolizumab 105 mg; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02060630,New England Research Institutes,False,MI,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,MI,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01909791,Diabetic Retinopathy Clinical Research Network,False,MI,https://ClinicalTrials.gov/show/NCT01909791,True,Treatment for CI-DME in Eyes With Very Good VA Study,Diabetic Macular Edema,Procedure:Prompt Laser; Drug:Prompt aflibercept; Procedure:Deferred laser; Drug:Deferred aflibercept,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,MI,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01799993,Bayer,False,MI,https://ClinicalTrials.gov/show/NCT01799993,True,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Drug:Amikacin Inhalation Solution (BAY41-6551); Drug:Aerosolized Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01358266,Santen Inc.,False,MI,https://ClinicalTrials.gov/show/NCT01358266,True,Study Assessing Double-masked Uveitis Treatment,"Uvea; Posterior, Disorder",Drug:DE-109; Drug:DE-109; Drug:DE-109,[],"January 21, 2015",18,9223372036854775807,Both,False
NCT00892866,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00892866,True,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00858364,Amgen,False,MI,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00828009,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00828009,True,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00545532,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT00545532,True,A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.,Influenza,Drug:oseltamivir; Drug:oseltamivir,[],"February 1, 2016",1,9223372036854775807,Both,False
NCT02653170,Michigan State University,False,MI,https://ClinicalTrials.gov/show/NCT02653170,True,Michigan Stroke Transitions Trial,Acute Stroke,Other:SCM; Other:SCM and VSSP,"[u'University of Michigan', u'McLaren Health Care', u'Sparrow Health System', u'Saint Joseph Mercy Health System']","January 8, 2016",18,9223372036854775807,Both,False
NCT02532283,"Janssen Research & Development, LLC",False,MI,https://ClinicalTrials.gov/show/NCT02532283,True,"A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection",Influenza A Virus,Drug:JNJ-63623872; Drug:Placebo; Drug:Oseltamivir,[],"February 2, 2016",18,85,Both,False
NCT02506153,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,MI,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02277990,Medtronic Cardiac Rhythm Disease Management,False,MI,https://ClinicalTrials.gov/show/NCT02277990,True,World-wide Randomized Antibiotic Envelope Infection Prevention Trial,CIED Related Infection,Device:TYRX Absorbable Antibacterial Envelope,[],"August 27, 2015",18,9223372036854775807,Both,True
NCT02271217,Acorda Therapeutics,False,MI,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02271022,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02271022,True,Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry,Acute Coronary Syndromes,Other:Non-Interventional Study,[],"January 21, 2016",18,99,Both,False
NCT02258542,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02247479,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT02247479,True,A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA),Geographic Atrophy,Drug:Lampalizumab; Other:Sham,[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02226965,"ProNAi Therapeutics, Inc",False,MI,https://ClinicalTrials.gov/show/NCT02226965,True,Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL,"Lymphoma, Diffuse Large B-Cell",Drug:PNT2258,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02206334,NRG Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02206334,True,"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",Male Breast Carcinoma; Prostate Adenocarcinoma; Recurrent Breast Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Prostate Carcinoma; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IV Prostate Cancer,Radiation:Stereotactic Radiosurgery,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02205359,Medtronic Cardiac Rhythm Disease Management,False,MI,https://ClinicalTrials.gov/show/NCT02205359,True,AdaptResponse Clinical Trial,Heart Failure With Left Bundle Branch Block,Device:aCRT ON; Device:aCRT OFF,[],"October 16, 2015",18,9223372036854775807,Both,False
NCT02165215,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT02165215,True,A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug:Etrolizumab; Drug:Placebo,[],"February 1, 2016",18,80,Both,False
NCT02164864,Boehringer Ingelheim,False,MI,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02163694,AbbVie,False,MI,https://ClinicalTrials.gov/show/NCT02163694,True,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",Metastatic Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Other:Placebo,[],"January 26, 2016",18,99,Both,False
NCT02161757,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT02160145,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT02160145,True,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease,Drug:Tolvaptan (OPC-41061); Drug:Placebo,[],"January 4, 2016",18,65,Both,False
NCT02118584,Hoffmann-La Roche,False,MI,https://ClinicalTrials.gov/show/NCT02118584,True,Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies,Ulcerative Colitis,Drug:etrolizumab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02101853,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02072226,"Genentech, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT02072226,True,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02055781,CTI BioPharma,False,MI,https://ClinicalTrials.gov/show/NCT02055781,True,Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia,Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis,Drug:Pacritinib; Drug:Best Available Therapy,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02043678,Bayer,False,MI,https://ClinicalTrials.gov/show/NCT02043678,True,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",Prostatic Neoplasms,"Drug:Radium-223 dichloride (Xofigo, BAY88-8223); Drug:Matching placebo (normal saline); Drug:Abiraterone; Drug:Prednisone/Prednisolone",[],"January 11, 2016",18,9223372036854775807,Male,False
NCT01885078,Eli Lilly and Company,False,MI,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01811550,Temple University,False,MI,https://ClinicalTrials.gov/show/NCT01811550,True,Study of Procoagulation Markers in Stroke Patients,Stroke; Hyperglycemia; Procoagulation Markers,Other:Glycemic Control,[],"August 24, 2015",18,9223372036854775807,Both,False
NCT01767311,Eisai Inc.,False,MI,https://ClinicalTrials.gov/show/NCT01767311,True,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Alzheimer's Disease,Drug:BAN2401 2.5 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg,[],"November 29, 2015",50,90,Both,False
NCT01734928,Celgene Corporation,False,MI,https://ClinicalTrials.gov/show/NCT01734928,True,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:Pomalidomide; Drug:Bortezomib; Drug:Dexamethasone,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT01693120,Medtronic Atrial Fibrillation Solutions,False,MI,https://ClinicalTrials.gov/show/NCT01693120,True,Evaluation of the Phased Radio Frequency Ablation System,Persistent Atrial Fibrillation,Device:Medtronic Phased RF Ablation System,[],"December 3, 2015",18,75,Both,False
NCT01595061,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01483027,BTG International Inc.,False,MI,https://ClinicalTrials.gov/show/NCT01483027,True,Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer,Colorectal Cancer Metastatic,Device:TheraSphere,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01470599,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT01470599,True,"A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease",Crohn's Disease,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,76,Both,False
NCT01286272,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01220583,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01220583,True,Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery,Head and Neck Cancer,Drug:cisplatin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT00736749,Children's Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00736749,True,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Acute Lymphoblastic Leukemia; Brain Neoplasm; Healthy Stem Cell Donor; Hodgkin Lymphoma; Long-Term Effects Secondary to Cancer Therapy in Children,Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications,[],"September 21, 2015",0,9223372036854775807,Both,False
NCT00628498,Jazz Pharmaceuticals,True,MI,https://ClinicalTrials.gov/show/NCT00628498,True,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Drug:Defibrotide; Drug:Defibrotide,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT02674386,Pfizer,False,MI,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02597933,Boehringer Ingelheim,False,MI,https://ClinicalTrials.gov/show/NCT02597933,True,A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis,"Scleroderma, Systemic",Drug:Nintedanib; Drug:Placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02582203,Wayne State University,False,MI,https://ClinicalTrials.gov/show/NCT02582203,True,Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA,"Skin Diseases, Infectious; Staphylococcal Skin Infections",Drug:Ceftaroline; Drug:Vancomycin,"[u'Detroit Medical Center', u'St. John Hospital and Medical Center', u'Henry Ford Hospital']","December 8, 2015",18,89,Both,True
NCT02568267,"Ignyta, Inc.",False,MI,https://ClinicalTrials.gov/show/NCT02568267,True,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)","Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor",Drug:Entrectinib,"[u'City of Hope Cancer Center', u'University of California Irvine College of Medicine', u'Scripps Clinic Medical Group', u'University of California San Diego Moores Cancer Center', u'Southern California Kaiser Permanente', u'UCSF Mount Zion Medical Center', u'Sarcoma Oncology Research Center LLC', u'University of Colorado Cancer Center', u'Georgetown University - Lombardi Comprehensive Cancer Center', u'H. Lee Moffitt Cancer Center and Research Institute, Inc.', u'Winship Cancer Institute', u'Beth Israel Deaconess Medical Center / MGH', u'University of Michigan Comprehensive Cancer Center', u'Karmanos Cancer Center', u'Henry Ford Health System', u'Washington University School of Medicine', u'North Shore Hematology Oncology Associates, PC', u'Memorial Sloan Kettering Cancer Center', u'Cleveland Clinic', u'OSU - James Comprehensive Cancer Center', u'Oregon Health & Science University', u'University of Washington - Seattle Cancer Care Alliance']","January 25, 2016",18,9223372036854775807,Both,False
NCT02542696,Cynapsus Therapeutics Inc,False,MI,https://ClinicalTrials.gov/show/NCT02542696,True,"An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of ""OFF"" Episodes in Patients With Parkinson's Disease",Parkinson Disease,Drug:APL-130277,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,MN,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003209,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01903811,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,MN,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01649089,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01372787,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,MN,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00700882,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00074282,Eastern Cooperative Oncology Group,True,MN,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT00316888,Eastern Cooperative Oncology Group,True,MN,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01236547,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessm